0001048477-24-00012610-Q BIOMARIN PHARMACEUTICAL INC 20240805202408051635151635151635163515 0 0001048477-24-000126 10-Q 79 20240630 20240805 20240805 BIOMARIN PHARMACEUTICAL INC 0001048477 2834 680397820 DE 1231 10-Q 34 000-26727 241175335 105 DIGITAL DRIVE NOVATO CA 94949 4155066700 105 DIGITAL DRIVE NOVATO CA 94949 10-Q 1 bmrn-20240630.htm 10-Q bmrn-20240630false2024Q20001048477--12-31P1YP1Yxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:purebmrn:segmentbmrn:employee00010484772024-01-012024-06-300001048477 2024-07-310001048477us-gaap:ProductMember2024-04-012024-06-300001048477us-gaap:ProductMember2023-04-012023-06-300001048477us-gaap:ProductMember2024-01-012024-06-300001048477us-gaap:ProductMember2023-01-012023-06-300001048477bmrn:RoyaltyAndOtherMember2024-04-012024-06-300001048477bmrn:RoyaltyAndOtherMember2023-04-012023-06-300001048477bmrn:RoyaltyAndOtherMember2024-01-012024-06-300001048477bmrn:RoyaltyAndOtherMember2023-01-012023-06-300001048477 2024-04-012024-06-300001048477 2023-04-012023-06-300001048477 2024-01-012024-06-300001048477 2023-01-012023-06-300001048477 2023-04-012023-06-300001048477us-gaap:CommonStockMember2024-03-310001048477us-gaap:CommonStockMember2023-03-310001048477us-gaap:CommonStockMember2023-12-310001048477us-gaap:CommonStockMember2022-12-310001048477us-gaap:CommonStockMember2024-04-012024-06-300001048477us-gaap:CommonStockMember2023-04-012023-06-300001048477us-gaap:CommonStockMember2024-01-012024-06-300001048477us-gaap:CommonStockMember2023-01-012023-06-300001048477us-gaap:CommonStockMember2024-06-300001048477us-gaap:CommonStockMember2023-06-300001048477 2024-03-310001048477 2023-03-310001048477 2022-12-310001048477us-gaap:AdditionalPaidInCapitalMember2024-03-310001048477us-gaap:AdditionalPaidInCapitalMember2023-03-310001048477us-gaap:AdditionalPaidInCapitalMember2023-12-310001048477us-gaap:AdditionalPaidInCapitalMember2022-12-310001048477us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001048477us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001048477us-gaap:AdditionalPaidInCapitalMember2024-01-012024-06-300001048477us-gaap:AdditionalPaidInCapitalMember2023-01-012023-06-300001048477us-gaap:AdditionalPaidInCapitalMember2024-06-300001048477us-gaap:AdditionalPaidInCapitalMember2023-06-300001048477us-gaap:DeferredCompensationShareBasedPaymentsMember2024-03-310001048477us-gaap:DeferredCompensationShareBasedPaymentsMember2023-03-310001048477us-gaap:DeferredCompensationShareBasedPaymentsMember2023-12-310001048477us-gaap:DeferredCompensationShareBasedPaymentsMember2022-12-310001048477us-gaap:DeferredCompensationShareBasedPaymentsMember2024-04-012024-06-300001048477us-gaap:DeferredCompensationShareBasedPaymentsMember2023-04-012023-06-300001048477us-gaap:DeferredCompensationShareBasedPaymentsMember2024-01-012024-06-300001048477us-gaap:DeferredCompensationShareBasedPaymentsMember2023-01-012023-06-300001048477us-gaap:DeferredCompensationShareBasedPaymentsMember2024-06-300001048477us-gaap:DeferredCompensationShareBasedPaymentsMember2023-06-300001048477us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001048477us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001048477us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001048477us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001048477us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001048477us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001048477us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-06-300001048477us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-06-300001048477us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001048477us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001048477us-gaap:RetainedEarningsMember2024-03-310001048477us-gaap:RetainedEarningsMember2023-03-310001048477us-gaap:RetainedEarningsMember2023-12-310001048477us-gaap:RetainedEarningsMember2022-12-310001048477us-gaap:RetainedEarningsMember2024-04-012024-06-300001048477us-gaap:RetainedEarningsMember2023-04-012023-06-300001048477us-gaap:RetainedEarningsMember2024-01-012024-06-300001048477us-gaap:RetainedEarningsMember2023-01-012023-06-300001048477us-gaap:RetainedEarningsMember2024-06-300001048477us-gaap:RetainedEarningsMember2023-06-300001048477 2023-06-300001048477srt:RestatementAdjustmentMember2024-04-012023-06-300001048477srt:RestatementAdjustmentMember2023-01-012023-06-300001048477us-gaap:FairValueInputsLevel1Member2024-06-300001048477us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2024-06-300001048477us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2024-06-300001048477us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2024-06-300001048477us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Member2024-06-300001048477us-gaap:FairValueInputsLevel2Member2024-06-300001048477us-gaap:FairValueInputsLevel1Member2023-12-310001048477us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2023-12-310001048477us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001048477us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001048477us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Member2023-12-310001048477us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001048477us-gaap:FairValueInputsLevel2Member2023-12-310001048477srt:MaximumMember2023-01-012023-12-310001048477srt:MaximumMember2024-01-012024-06-300001048477srt:MinimumMember2024-01-012024-06-300001048477srt:MinimumMember2023-01-012023-12-310001048477us-gaap:FairValueMeasurementsRecurringMemberbmrn:StrategicInvestmentMember2024-06-300001048477us-gaap:FairValueMeasurementsRecurringMemberbmrn:StrategicInvestmentMember2023-12-310001048477bmrn:StrategicInvestmentMemberus-gaap:FairValueMeasurementsNonrecurringMember2024-04-012024-06-300001048477 2023-01-012023-03-310001048477 2024-01-012024-03-310001048477us-gaap:FairValueInputsLevel3Member2023-12-310001048477us-gaap:FairValueInputsLevel3Member2024-06-300001048477us-gaap:FairValueMeasurementsRecurringMemberbmrn:NonqualifiedDeferredCompensationPlanAssetsMemberus-gaap:FairValueInputsLevel2Member2024-06-300001048477us-gaap:FairValueMeasurementsRecurringMemberbmrn:NonqualifiedDeferredCompensationPlanAssetsMemberus-gaap:FairValueInputsLevel2Member2023-12-310001048477bmrn:RestrictedInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-06-300001048477bmrn:RestrictedInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001048477us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-06-300001048477us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001048477bmrn:NonqualifiedDeferredCompensationPlanLiabilityMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-06-300001048477bmrn:NonqualifiedDeferredCompensationPlanLiabilityMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001048477us-gaap:DesignatedAsHedgingInstrumentMember2024-06-300001048477us-gaap:NondesignatedMember2024-06-300001048477us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:ShortMember2024-06-300001048477us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:ShortMember2023-12-310001048477us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:LongMember2024-06-300001048477us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:LongMember2023-12-310001048477us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMemberus-gaap:ShortMember2024-06-300001048477us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMemberus-gaap:ShortMember2023-12-310001048477us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMemberus-gaap:LongMember2024-06-300001048477us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMemberus-gaap:LongMember2023-12-310001048477us-gaap:OtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueInputsLevel2Member2024-06-300001048477us-gaap:OtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueInputsLevel2Member2023-12-310001048477us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueInputsLevel2Memberus-gaap:OtherNoncurrentAssetsMember2024-06-300001048477us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueInputsLevel2Memberus-gaap:OtherNoncurrentAssetsMember2023-12-310001048477us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueInputsLevel2Member2024-06-300001048477us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueInputsLevel2Member2023-12-310001048477us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:FairValueInputsLevel2Member2024-06-300001048477us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001048477us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel2Member2024-06-300001048477us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001048477us-gaap:OtherCurrentAssetsMemberus-gaap:NondesignatedMemberus-gaap:FairValueInputsLevel2Member2024-06-300001048477us-gaap:OtherCurrentAssetsMemberus-gaap:NondesignatedMemberus-gaap:FairValueInputsLevel2Member2023-12-310001048477us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:NondesignatedMemberus-gaap:FairValueInputsLevel2Member2024-06-300001048477us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:NondesignatedMemberus-gaap:FairValueInputsLevel2Member2023-12-310001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ProductMember2024-04-012024-06-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ProductMember2023-04-012023-06-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ProductMember2024-01-012024-06-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ProductMember2023-01-012023-06-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OperatingExpenseMember2024-04-012024-06-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OperatingExpenseMember2023-04-012023-06-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OperatingExpenseMember2024-01-012024-06-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OperatingExpenseMember2023-01-012023-06-300001048477us-gaap:NondesignatedMember2024-04-012024-06-300001048477us-gaap:NondesignatedMember2023-04-012023-06-300001048477us-gaap:NondesignatedMember2024-01-012024-06-300001048477us-gaap:NondesignatedMember2023-01-012023-06-300001048477bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember2024-06-300001048477bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember2023-12-310001048477bmrn:OnePointTwoFivePercentSeniorSubordinatedConvertibleNotesDueInMay2027Member2024-06-300001048477bmrn:OnePointTwoFivePercentSeniorSubordinatedConvertibleNotesDueInMay2027Member2023-12-310001048477bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMemberus-gaap:SubsequentEventMember2024-08-012024-08-010001048477us-gaap:ConvertibleDebtMember2024-04-012024-06-300001048477us-gaap:ConvertibleDebtMember2023-04-012023-06-300001048477us-gaap:ConvertibleDebtMember2024-01-012024-06-300001048477us-gaap:ConvertibleDebtMember2023-01-012023-06-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-03-310001048477us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-03-310001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-04-012024-06-300001048477us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-04-012024-06-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-06-300001048477us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-06-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-03-310001048477us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-03-310001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-04-012023-06-300001048477us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-04-012023-06-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-06-300001048477us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-06-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310001048477us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-12-310001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-06-300001048477us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-01-012024-06-300001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310001048477us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310001048477us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-06-300001048477us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-06-300001048477bmrn:VOXZOGOMember2024-01-012024-06-300001048477bmrn:VOXZOGOMember2023-01-012023-06-300001048477bmrn:VOXZOGOMember2024-04-012024-06-300001048477bmrn:VOXZOGOMember2023-04-012023-06-300001048477bmrn:VIMIZIMMember2024-04-012024-06-300001048477bmrn:VIMIZIMMember2023-04-012023-06-300001048477bmrn:VIMIZIMMember2024-01-012024-06-300001048477bmrn:VIMIZIMMember2023-01-012023-06-300001048477bmrn:NAGLAZYMEMember2024-04-012024-06-300001048477bmrn:NAGLAZYMEMember2023-04-012023-06-300001048477bmrn:NAGLAZYMEMember2024-01-012024-06-300001048477bmrn:NAGLAZYMEMember2023-01-012023-06-300001048477bmrn:PALYNZIQMember2024-04-012024-06-300001048477bmrn:PALYNZIQMember2023-04-012023-06-300001048477bmrn:PALYNZIQMember2024-01-012024-06-300001048477bmrn:PALYNZIQMember2023-01-012023-06-300001048477bmrn:BRINEURAMember2024-04-012024-06-300001048477bmrn:BRINEURAMember2023-04-012023-06-300001048477bmrn:BRINEURAMember2024-01-012024-06-300001048477bmrn:BRINEURAMember2023-01-012023-06-300001048477bmrn:ALDURAZYMEMember2024-04-012024-06-300001048477bmrn:ALDURAZYMEMember2023-04-012023-06-300001048477bmrn:ALDURAZYMEMember2024-01-012024-06-300001048477bmrn:ALDURAZYMEMember2023-01-012023-06-300001048477bmrn:KUVANMember2024-04-012024-06-300001048477bmrn:KUVANMember2023-04-012023-06-300001048477bmrn:KUVANMember2024-01-012024-06-300001048477bmrn:KUVANMember2023-01-012023-06-300001048477bmrn:ROCTAVIANMember2024-04-012024-06-300001048477bmrn:ROCTAVIANMember2023-04-012023-06-300001048477bmrn:ROCTAVIANMember2024-01-012024-06-300001048477bmrn:ROCTAVIANMember2023-01-012023-06-300001048477country:USus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingALDURAZYMEMember2024-04-012024-06-300001048477country:USus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingALDURAZYMEMember2023-04-012023-06-300001048477country:USus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingALDURAZYMEMember2024-01-012024-06-300001048477country:USus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingALDURAZYMEMember2023-01-012023-06-300001048477us-gaap:SalesChannelDirectlyToConsumerMembersrt:EuropeMemberbmrn:ProductsExcludingALDURAZYMEMember2024-04-012024-06-300001048477us-gaap:SalesChannelDirectlyToConsumerMembersrt:EuropeMemberbmrn:ProductsExcludingALDURAZYMEMember2023-04-012023-06-300001048477us-gaap:SalesChannelDirectlyToConsumerMembersrt:EuropeMemberbmrn:ProductsExcludingALDURAZYMEMember2024-01-012024-06-300001048477us-gaap:SalesChannelDirectlyToConsumerMembersrt:EuropeMemberbmrn:ProductsExcludingALDURAZYMEMember2023-01-012023-06-300001048477srt:LatinAmericaMemberus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingALDURAZYMEMember2024-04-012024-06-300001048477srt:LatinAmericaMemberus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingALDURAZYMEMember2023-04-012023-06-300001048477srt:LatinAmericaMemberus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingALDURAZYMEMember2024-01-012024-06-300001048477us-gaap:MiddleEastMemberus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingALDURAZYMEMember2024-04-012024-06-300001048477us-gaap:MiddleEastMemberus-

gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingALDURAZYMEMember2023-04-012023-06-300001048477us-gaap:MiddleEastMemberus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingALDURAZYMEMember2024-01-012024-06-300001048477us-gaap:MiddleEastMemberus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingALDURAZYMEMember2023-01-012023-06-300001048477bmrn:RestOfWorldMemberus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingALDURAZYMEMember2024-04-012024-06-300001048477bmrn:RestOfWorldMemberus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingALDURAZYMEMember2023-04-012023-06-300001048477bmrn:RestOfWorldMemberus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingALDURAZYMEMember2024-01-012024-06-300001048477bmrn:RestOfWorldMemberus-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingALDURAZYMEMember2023-01-012023-06-300001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingALDURAZYMEMember2024-04-012024-06-300001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingALDURAZYMEMember2023-04-012023-06-300001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingALDURAZYMEMember2024-01-012024-06-300001048477us-gaap:SalesChannelDirectlyToConsumerMemberbmrn:ProductsExcludingALDURAZYMEMember2023-01-012023-06-300001048477us-gaap:SalesChannelThroughIntermediaryMemberbmrn:ALDURAZYMEMember2024-04-012024-06-300001048477us-gaap:SalesChannelThroughIntermediaryMemberbmrn:ALDURAZYMEMember2023-04-012023-06-300001048477us-gaap:SalesChannelThroughIntermediaryMemberbmrn:ALDURAZYMEMember2024-01-012024-06-300001048477us-gaap:SalesChannelThroughIntermediaryMemberbmrn:ALDURAZYMEMember2023-01-012023-06-300001048477bmrn:CustomerOneMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-04-012024-06-300001048477bmrn:CustomerOneMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-04-012023-06-300001048477bmrn:CustomerOneMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-300001048477bmrn:CustomerOneMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-300001048477us-gaap:SalesRevenueNetMemberbmrn:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMember2024-04-012024-06-300001048477us-gaap:SalesRevenueNetMemberbmrn:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMember2023-04-012023-06-300001048477us-gaap:SalesRevenueNetMemberbmrn:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-300001048477us-gaap:SalesRevenueNetMemberbmrn:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-300001048477bmrn:CustomerThreeMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-04-012024-06-300001048477bmrn:CustomerThreeMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-04-012023-06-300001048477bmrn:CustomerThreeMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-300001048477bmrn:CustomerThreeMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-300001048477bmrn:CustomerOneTwoAndThreeMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-04-012024-06-300001048477bmrn:CustomerOneTwoAndThreeMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-04-012023-06-300001048477bmrn:CustomerOneTwoAndThreeMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-300001048477bmrn:CustomerOneTwoAndThreeMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-300001048477bmrn:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember2024-01-012024-06-300001048477us-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMemberbmrn:CustomerTwoMember2024-01-012024-06-300001048477us-gaap:AccountsReceivableMemberbmrn:CustomerThreeMemberus-gaap:CreditConcentrationRiskMember2024-01-012024-06-300001048477bmrn:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember2023-01-012023-12-310001048477us-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMemberbmrn:CustomerTwoMember2023-01-012023-12-310001048477bmrn:CustomersMember2024-06-300001048477bmrn:CustomersMember2023-12-310001048477us-gaap:CostOfSalesMember2024-04-012024-06-300001048477us-gaap:CostOfSalesMember2023-04-012023-06-300001048477us-gaap:CostOfSalesMember2024-01-012024-06-300001048477us-gaap:CostOfSalesMember2023-01-012023-06-300001048477us-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300001048477us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001048477us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300001048477us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001048477us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-04-012024-06-300001048477us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-04-012023-06-300001048477us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-06-300001048477us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-06-300001048477bmrn:A2024WorkforceReductionPlanMember2024-01-012024-06-300001048477bmrn:A2024WorkforceReductionPlanMember2024-06-300001048477bmrn:A2024WorkforceReductionPlanMember2024-04-012024-06-300001048477us-gaap:EmployeeSeveranceMemberbmrn:A2024WorkforceReductionPlanMember2023-12-310001048477us-gaap:OtherRestructuringMemberbmrn:A2024WorkforceReductionPlanMember2023-12-310001048477bmrn:A2024WorkforceReductionPlanMember2023-12-310001048477us-gaap:EmployeeSeveranceMemberbmrn:A2024WorkforceReductionPlanMember2024-01-012024-06-300001048477us-gaap:OtherRestructuringMemberbmrn:A2024WorkforceReductionPlanMember2024-01-012024-06-300001048477us-gaap:EmployeeSeveranceMemberbmrn:A2024WorkforceReductionPlanMember2024-06-300001048477us-gaap:OtherRestructuringMemberbmrn:A2024WorkforceReductionPlanMember2024-06-300001048477us-gaap:StockCompensationPlanMember2024-04-012024-06-300001048477us-gaap:StockCompensationPlanMember2023-04-012023-06-300001048477us-gaap:StockCompensationPlanMember2024-01-012024-06-300001048477us-gaap:StockCompensationPlanMember2023-01-012023-06-300001048477bmrn:CommonStockIssuableUnderConvertibleDebtMember2024-04-012024-06-300001048477bmrn:CommonStockIssuableUnderConvertibleDebtMember2023-04-012023-06-300001048477bmrn:CommonStockIssuableUnderConvertibleDebtMember2024-01-012024-06-300001048477bmrn:CommonStockIssuableUnderConvertibleDebtMember2023-01-012023-06-300001048477us-gaap:ConvertibleDebtMemberbmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember2024-01-012024-06-300001048477us-gaap:ConvertibleDebtMemberbmrn:OnePointTwoFivePercentSeniorSubordinatedConvertibleNotesDueInMay2027Member2024-01-012024-06-30Table of Contents UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549Â _____Form 10-QÂ _____(Mark One)â˜’QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended JuneÂ 30, 2024 Orâ˜TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from Â Â Â

2.Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations19Item 3.Quantitative and Qualitative Disclosures about Market Risk30Item 4.Controls and Procedures30PART II.OTHER INFORMATION31Item 1.Legal Proceedings31Item 1A.Risk Factors31Item 2.Unregistered Sales of Equity Securities and Use of Proceeds59Item 3.Defaults Upon Senior Securities59Item 4.Mine Safety Disclosures59Item 5.Other Information59Item 6.Exhibits61SIGNATURES632PART I. FINANCIAL INFORMATIONItemÂ 1.Â Â Â Â Financial StatementsBIOMARIN PHARMACEUTICAL INC.CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOMEThree and Six Months Ended JuneÂ 30, 2024 and 2023 (In thousands, except per share amounts)(unaudited)Â Three Months EndedJune 30,Six Months EndedJune 30,Â 20242023202420232REVENUES:Net product revenues$702,129Â $584,698Â $1,339,944Â $1,171,124Â Royalty and other revenues9,900Â 10,577Â 20,918Â 20,566Â Total revenues712,029Â 595,275Â 1,360,862Â 1,191,690Â OPERATING EXPENSES:Cost of sales 130,459Â 130,619Â 255,639Â 266,091Â Research and development183,787Â 177,363Â 388,774Â 349,209Â Selling, general and administrative263,032Â 206,103Â 488,938Â 417,126Â Intangible asset amortization14,299Â 15,624Â 28,597Â 31,294Â Gain on sale of nonfinancial assetsâ€”Â â€”Â (10,000)â€”Â Total operating expenses591,577Â 529,709Â 1,151,948Â 1,063,720Â INCOME FROM OPERATIONS120,452Â 65,566Â 208,914Â 127,970Â Interest income19,785Â 12,612Â 39,150Â 24,555Â Interest expense(3,574)(3,755)(7,121)(7,458)Other expense, net(4,527)(3,613)(3,260)(17,500)INCOME BEFORE INCOME TAXES132,136Â 70,810Â 237,683Â 127,567Â Provision for income taxes24,962Â 14,770Â 41,847Â 20,675Â NET INCOME$107,174Â $56,040Â $195,836Â $106,892Â EARNINGS PER SHARE, BASIC$0.56Â $0.30Â $1.03Â $0.57Â EARNINGS PER SHARE, DILUTED$0.55Â $0.29Â $1.01Â $0.56Â Weighted average common shares outstanding, basic190,114Â 187,948Â 189,490Â 187,311Â Weighted average common shares outstanding, diluted200,505Â 194,998Â 200,137Â 194,756Â COMPREHENSIVE INCOME$135,019Â $48,145Â $251,423Â $92,142Â Â The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.3BIOMARIN PHARMACEUTICAL INC.CONDENSED CONSOLIDATED BALANCE SHEETSJuneÂ 30, 2024 and DecemberÂ 31, 2023 (In thousands, except share amounts)June 30, 2024December 31, 2023 â½Â¹â¾ASSETS(unaudited)Â Current assets:Cash and cash equivalents$972,150Â $755,127Â Short-term investments252,201Â 318,683Â Accounts receivable, net691,232Â 633,704Â Inventory1,183,621Â 1,107,183Â Other current assets160,426Â 141,391Â Total current assets3,259,630Â 2,956,088Â Noncurrent assets:Long-term investments557,083Â 611,135Â Property, plant and equipment, net1,052,898Â 1,066,133Â Intangible assets, net265,533Â 294,701Â Goodwill196,199Â 196,199Â Deferred tax assets1,545,006Â 1,545,809Â Other assets190,772Â 171,538Â Total assets$7,067,121Â $6,841,603Â LIABILITIES AND STOCKHOLDERSâ€™ EQUITYCurrent liabilities:Accounts payable and accrued liabilities$572,500Â $683,147Â Short-term convertible debt, net494,837Â 493,877Â Total current liabilities1,067,337Â 1,177,024Â Noncurrent liabilities:Long-term convertible debt, net594,116Â 593,095Â Other long-term liabilities119,369Â 119,935Â Total liabilities1,780,822Â 1,890,054Â Stockholdersâ€™ equity:Common stock, $0.001 par value: 500,000,000 shares authorized; 190,355,517 and 188,598,154 shares issued and outstanding, respectively190Â 189Â Additional paid-in capital5,696,701Â 5,611,562Â Company common stock held by the Nonqualified Deferred Compensation Plan(11,673)(9,860)Accumulated other comprehensive income (loss)26,799Â (28,788)Accumulated deficit(425,718)(621,554)Total stockholdersâ€™ equity5,286,299Â 4,951,549Â Total liabilities and stockholdersâ€™ equity$7,067,121Â $6,841,603Â Â Â Â Â (1)DecemberÂ 31, 2023 balances were derived from the audited Consolidated Financial Statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, filed with the SEC on FebruaryÂ 26, 2024.The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.4BIOMARIN PHARMACEUTICAL INC.CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ EQUITYThree and Six Months Ended JuneÂ 30, 2024 and 2023 (In thousands)(unaudited)Three Months EndedJune 30,Six Months EndedJune 30,Â 20242023202420232Shares of common stock, beginning balances (1)189,777Â 187,601Â 188,598Â 186,251Â Issuances under equity incentive plans579Â 551Â 1,758Â 1,901Â Shares of common stock, ending balances190,356Â 188,152Â 190,356Â 188,152Â Total stockholders' equity, beginning balances (1)$5,073,816Â $4,659,043Â $4,951,549Â $4,603,156Â Common stock:Beginning balances (1)190Â 188Â 189Â 186Â Issuances under equity incentive plans, net of taxâ€”Â â€”Â 1Â 2Â Ending balances190Â 188Â 190Â 188Â Additional paid-in capital:Beginning balances (1)5,619,264Â 5,417,873Â 5,611,562Â 5,404,895Â Issuances under equity incentive plans, net of tax25,326Â 24,489Â (30,343)(17,951)Stock-based compensation52,138Â 51,150Â 113,669Â 105,478Â Change in Common stock held by the Nonqualified Deferred Compensation plan (NQDC)(27)444Â 1,813Â 1,534Â Ending balances5,696,701Â 5,493,956Â 5,696,701Â 5,493,956Â Company common stock held by the NQDC:Beginning balances (1)(11,700)(9,949)(9,860)(8,859)Common stock held by the NQDC27Â (444)(1,813)(1,534)Ending balances(11,673)(10,393)(11,673)(10,393)Accumulated other comprehensive income (loss):Beginning balances (1)(1,046)(10,722)(28,788)(3,867)Other comprehensive income (loss)27,845Â (7,895)55,587Â (14,750)Ending balances26,799Â (18,617)26,799Â (18,617)Accumulated Deficit:Beginning balances (1)(532,892)(738,347)(621,554)(789,199)Net income107,174Â 56,040Â 195,836Â 106,892Â Ending balances(425,718)(682,307)(425,718)(682,307)Total stockholders' equity, ending balances$5,286,299Â $4,782,827Â $5,286,299Â $4,782,827Â (1)The beginning balances for the six-month periods were derived from the audited Consolidated Financial Statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023 filed with the SEC on FebruaryÂ 26, 2024.The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.Â 5BIOMARIN PHARMACEUTICAL INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSSix Months Ended JuneÂ 30, 2024 and 2023 (In thousands)(unaudited)Six Months EndedJune 30,20242023CASH FLOWS FROM OPERATING ACTIVITIES:Net income$195,836Â $106,892Â Adjustments to reconcile net income to net cash used in operating activities:Depreciation and amortization53,813Â 51,840Â Non-cash interest expense1,981Â 2,058Â Accretion of discount on investments(4,678)(4,533)Stock-based compensation106,163Â 103,857Â Gain on sale of nonfinancial assets(10,000)â€”Â Impairment of assets and other non-cash adjustments14,204Â 12,650Â Deferred income taxes1,537Â (5,108)Unrealized foreign exchange loss (gain)(19,958)7,455Â Other(858)361Â Changes in operating assets and liabilities:Accounts receivable, net(56,081)(145,831)Inventory(47,409)(56,476)Other current assets1,615Â (53,430)Other assets(22,880)(5,616)Accounts payable and other short-term liabilities(54,261)(25,093)Other long-term liabilities6,709Â 7,104Â Net cash provided by (used in) operating activities165,733Â (3,870)CASH FLOWS FROM INVESTING ACTIVITIES:Purchases of property, plant and equipment(47,431)(46,039)Maturities and sales of investments317,649Â 491,063Â Purchases of investments(195,462)(444,049)Proceeds from sale of nonfinancial assets10,000Â â€”Â Purchase of intangible assets(8,512)(1,457)Net cash provided by (used in) investing activities76,244Â (482)CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from exercises of awards under equity incentive plans36,618Â 50,193Â Taxes paid related to net share settlement of equity awards(66,739)(67,862)Payments of contingent considerationâ€”Â (9,475)Principal repayments of financing leases(60)(1,635)Net cash used in financing activities(30,181)(28,779)Effect of exchange rate changes on cash5,227Â 2,981Â NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS217,023Â (30,150)Cash and cash equivalents:Beginning of period$755,127Â $724,531Â End of period$972,150Â $694,381Â SUPPLEMENTAL CASH FLOW DISCLOSURES:Cash paid for interest$5,126Â $5,175Â Cash paid for income taxes$22,884Â $28,183Â SUPPLEMENTAL CASH FLOW DISCLOSURES FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:Increase in accounts payable and accrued liabilities related to fixed assets$11,941Â $8,669Â Decrease in accounts payable and accrued liabilities related to intangible assets$8,290Â $2,344Â The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.6Table of ContentsBIOMARIN PHARMACEUTICAL INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)(1) BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIESNature of OperationsFounded in 1997, BioMarin Pharmaceutical Inc. (the Company or BioMarin) is a global biotechnology company dedicated to transforming lives through genetic discovery. The Company develops and commercializes targeted therapies that address the root cause of genetic conditions. The Company's robust research and development (R&D) capabilities have resulted in multiple innovative commercial therapies for patients with rare genetic disorders. The Company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. Basis of PresentationThese Condensed Consolidated Financial Statements have been prepared pursuant to U.S. generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the SEC for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. GAAP for complete financial statements, although management believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended DecemberÂ 31, 2023 included in the Companyâ€™s Annual Report on Form 10-K. The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions have been eliminated. The results of operations for the three and six months ended JuneÂ 30, 2024 are not necessarily indicative of the results that may be expected for the fiscal year ending DecemberÂ 31, 2024 or any other period.Change in Presentation Effective January 1, 2024, the Company changed its presentation for foreign currency transaction gains and losses resulting from remeasurement and idle plant costs within its Condensed Consolidated Statements of Comprehensive Income. Effective with this change in presentation, foreign currency transaction gains and losses resulting from remeasurement are presented in Other Expense, Net and idle plant costs are presented in Cost of Sales. Prior to this change in presentation, both foreign currency transaction gains and losses resulting from remeasurement and idle plant costs were presented in Selling, General and Administrative (SG&A) expense. The Company believes that this change in presentation is preferable because the revised presentation is more consistent with how management measures the Companyâ€™s operating performance.Prior period amounts were revised to conform to current period presentation. The following table reflects the impacts of the change in presentation for the prior periods presented. The change in presentation had no impact to Net Income, Total Stockholdersâ€™ Equity or earnings per share for the three and six months ended JuneÂ 30, 2023.Three Months ended JuneÂ 30, 2023Six Months ended JuneÂ 30, 2023Cost of sales$2,537Â $11,460Â SG&A$(9,233)$(21,213)Total operating expenses$(6,696)$(9,753)Other expense, net$6,696Â $9,753Â Use of EstimatesU.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on managementâ€™s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods.Management performed an evaluation of the Companyâ€™s activities through the date of filing of this Quarterly Report on Form 10-Q to determine if there were any subsequent events that occurred subsequent to the balance sheet date and prior to filing this Quarterly Report on Form 10-Q, that would require recognition or disclosure in the Condensed Consolidated Financial Statements. Further to this evaluation, the Company has included a subsequent event noted relating to the maturity and settlement of the Companyâ€™s convertible notes due in August 2024 that is discussed in Note 6 - Debt.7Table of ContentsBIOMARIN PHARMACEUTICAL INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)Significant Accounting PoliciesThere have been no material changes to the Companyâ€™s significant accounting policies during the six months ended JuneÂ 30, 2024, as compared to the significant accounting policies disclosed in Note 1 â€“ Business Overview and Significant Accounting Policies to the Companyâ€™s Consolidated Financial Statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023.Recent Accounting PronouncementsThere have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board (FASB) during the six months ended JuneÂ 30, 2024, as compared to the recent accounting pronouncements described in Note 1 to the Companyâ€™s Consolidated Financial Statements of the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, that the Company believes are of significance or potential significance to the Company. The following paragraphs discuss new accounting pronouncements issued by the FASB, but not yet adopted by the Company.In November 2023, the FASB issued Accounting Standards Update (ASU) 2023-07, Segment Reporting Topic 280, Improvements to Reportable Segment Disclosures, to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. ASU 2023-07 expands public entitiesâ€™ segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items and interim disclosures of a reportable segmentâ€™s profit or loss and assets. The effective date for the update is for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024 and should be applied on a retrospective basis to all periods presented. The Company is currently evaluating the effect of adopting the update on its related disclosures.In December 2023, the FASB issued ASU 2023-09, Income Taxes Topic 740, Improvements to Income Tax Disclosures. The guidance requires disclosure of disaggregated information about the Companyâ€™s effective tax rate reconciliation as well as information on income taxes paid. The disclosure requirements will be applied on a prospective basis, with the option to apply it retrospectively. The effective date for the update is for fiscal years beginning after December 15, 2024. The Company is currently evaluating the effect of the update on its related disclosures.(2) FINANCIAL INSTRUMENTSAll marketable securities were classified as available-for-sale as of JuneÂ 30, 2024 and DecemberÂ 31, 2023.The following tables show the Companyâ€™s cash, cash equivalents and available-for-sale securities by significant investment category for each period presented:June 30, 2024Amortized CostGrossUnrealizedGainsGrossUnrealizedLossesAggregate Fair ValueCash and Cash EquivalentsShort-termMarketableSecurities (1)Long-termMarketableSecurities (2)Level 1:Cash$285,666Â $â€”Â $â€”Â $285,666Â $285,666Â $â€”Â $â€”Â Level 2:Money market instruments676,505Â â€”Â â€”Â 676,505Â 676,505Â â€”Â â€”Â Corporate debt securities537,626Â 670Â (1,460)536,836Â â€”Â 162,959Â 373,877Â U.S. government agency securities184,487Â 39Â (966)183,560Â 9,979Â 88,310Â 85,271Â Asset-backed securities98,958Â 105Â (196)98,867Â 932Â 97,935Â Subtotal1,497,576Â 814Â (2,622)1,495,768Â 686,484Â 252,201Â 557,083Â Total$1,783,242Â $814Â $(2,622)$1,781,434Â $972,150Â $252,2(of ContentsBIOMARIN PHARMACEUTICAL INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)December 31, 2023Amortized CostGrossUnrealizedGainsGrossUnrealizedLossesAggregate Fair ValueCash and Cash EquivalentsShort-termMarketableSecurities (1)Long-termMarketableSecurities (2)Level 1:Cash$229,676Â $â€”Â $â€”Â $229,676Â $229,676Â $â€”Â $â€”Â Level 2:Money market instruments499,483Â â€”Â â€”Â 499,483Â 499,483Â â€”Â â€”Â Corporate debt securities587,896Â 3,476Â (1,996)589,376Â â€”Â 193,251Â 396,125Â U.S. government agency securities251,952Â 556Â (1,140)251,368Â 19,976Â 111,343Â 120,049Â Commercial paper20,076Â 5Â â€”Â 20,081Â 5,992Â 14,089Â â€”Â Asset-backed securities94,744Â 351Â (134)94,961Â â€”Â â€”Â 94,961Â Subtotal1,454,151Â 4,388Â (3,270)1,455,269Â 525,451Â 318,683Â 611,135Â Total$1,683,827Â $4,388Â $(3,270)$1,684,945Â $755,127(Companyâ€™s short-term marketable securities mature in one year or less.(2)Â Â Â Â The Companyâ€™s long-term marketable securities mature between one and five years.As of JuneÂ 30, 2024, the Company had the ability and intent to hold all investments that were in an unrealized loss position until maturity. The Company considered its intent and ability to hold the securities until recovery of amortized cost basis, the extent to which fair value is less than amortized cost basis, conditions specifically related to the securityâ€™s industry and geography, payment structure and history and changes to the ratings (if any) in determining that the decline in fair value compared to carrying value is not related to a credit loss.The Company has certain investments in non-marketable equity securities, measured using unobservable valuation inputs and remeasured on a nonrecurring basis, which are collectively considered strategic investments. As of JuneÂ 30, 2024 and DecemberÂ 31, 2023, the fair value of the Companyâ€™s strategic investments was $6.7 million and $11.3 million, respectively. These investments were recorded to Other Assets in the Companyâ€™s Condensed Consolidated Balance Sheets. In the second quarter of 2024, based on new developments, the Company became aware of factors that indicated a $4.5Â million decline in the fair value of one of its strategic investments. In the first quarter of 2023, the Company concluded that factors existed indicating it would no longer realize a $12.6Â million equity investment in its non-marketable securities. The losses on the Companyâ€™s non-marketable equity investments were recorded to Other Expense, Net on the Companyâ€™s Condensed Consolidated Statements of Comprehensive Income for the respective periods. See Note 1 - Business Overview and Significant Accounting Policies included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023 for additional information related to the Companyâ€™s non-marketable securities policy.(3) SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATIONSupplemental Balance Sheet InformationInventory consisted of the following:June 30,2024December 31,2023Raw materials$154,153Â $155,704Â Work-in-process605,770Â 571,107Â Finished goods423,698Â 380,372Â Total inventory$1,183,621Â $1,107,183Â 9Table of ContentsBIOMARIN PHARMACEUTICAL INC.NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(In thousands of U.S. Dollars, except per share amounts or as otherwise

disclosed)Property, Plant and Equipment, Net consisted of the following:June 30,2024December 31,2023Property, plant and equipment, gross$1,962,948Â $1,933,222Â Accumulated depreciation(910,050)(867,089)Total property, plant and equipment, net$1,052,898Â $1,066,133Â Depreciation expense, net of amounts capitalized into inventory, for the three and six months ended JuneÂ 30, 2024 was $11.5 million and $24.1 million, respectively. Depreciation expense, net of amounts capitalized into inventory, for the three and six months ended JuneÂ 30, 2023 was $9.4 million and $19.7 million, respectively. Intangible Assets, Net consisted of the following:June 30,2024December 31,2023Finite-lived intangible assets$710,533Â $710,011Â Accumulated amortization(445,000)(415,310)Net carrying value$265,533Â $294,701Â In the first quarter of 2024, the Company received $10.0Â million due to the achievement of a regulatory approval milestone by a third party related to previously sold intangible assets, which the Company recorded as a Gain on Sale of Nonfinancial Assets in the Condensed Consolidated Statements of Comprehensive Income.Accounts Payable and Accrued Liabilities consisted of the following:June 30,2024December 31,2023Accounts payable and accrued operating expenses$257,412Â $315,509Â Accrued compensation expense147,737Â 201,067Â Accrued rebates payable113,432Â 96,179Â Accrued income taxes 18,864Â 2,651Â Lease liability10,689Â 8,779Â Foreign currency exchange forward contracts7,684Â 33,853Â Accrued royalties payable7,667Â 14,299Â Deferred revenue1,912Â 4,620Â Other7,103Â 6,190Â Total accounts payable and accrued liabilities$572,500Â $683,147Â (4) FAIR VALUE MEASUREMENTSThe Company measures certain financial assets and liabilities at fair value in accordance with the policy described in Note 1 â€“ Business Overview and Significant Accounting Policies to the Companyâ€™s Consolidated Financial Statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023.Other than the Companyâ€™s fixed-rate convertible debt disclosed in Note 6 â€“ Debt, there were no financial assets or liabilities that were remeasured using quoted prices in active markets for identical assets (Level 1) as of JuneÂ 30, 2024 or 10Table of ContentsBIOMARIN PHARMACEUTICAL INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)DecemberÂ 31, 2023. The Company had no financial assets or liabilities that are remeasured on a recurring basis using unobservable inputs that reflect estimates and assumptions (Level 3) as of JuneÂ 30, 2024 or DecemberÂ 31, 2023.Level 2 assets and liabilities that are remeasured using significant observable inputs consisted of the following:Â June 30, 2024December 31, 2023Assets:Other current assets:NQDC Plan assets$2,649Â $2,026Â Other assets:NQDC Plan assets33,112Â 28,119Â Restricted investments (1)2,419Â 2,393Â Total other assets35,531Â 30,512Â Total assets$38,180Â $32,538Â Liabilities:Current liabilities:NQDC Plan liability$2,649Â $2,026Â Other long-term liabilities:NQDC Plan liability33,112Â 28,119Â Total liabilities$35,761Â $30,145Â (1)Â Â Â Â The restricted investments as of JuneÂ 30, 2024 and DecemberÂ 31, 2023 secure the Company's irrevocable standby letters of credit obtained in connection with certain commercial agreements.There were no transfers between levels during the three and six months ended JuneÂ 30, 2024.(5) DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIESThe Company uses foreign currency exchange forward contracts (forward contracts) to protect against the impact of changes in the value of forecasted foreign currency cash flows resulting from revenues and operating expenses denominated in currencies other than the U.S. Dollar (USD), primarily the Euro. Certain of these forward contracts are designated as cash flow hedges and have maturities of up to 24 months. The Company also enters into forward contracts to manage foreign exchange risk related to asset or liability positions denominated in currencies other than USD. Such forward contracts are considered to be economic hedges, are not designated as hedging instruments and have maturities of up to three months. The Company does not use derivative instruments for speculative trading purposes. The Company is exposed to counterparty credit risk on its derivatives. The Company has established and maintains strict counterparty credit guidelines and enters into hedging agreements with financial institutions that are investment grade or better to minimize the Companyâ€™s exposure to potential defaults. The Company is not required to pledge collateral under these agreements.The following table summarizes the aggregate notional amounts for the Companyâ€™s derivatives outstanding as of the periods presented.Forward ContractsJune 30,2024December 31,2023Derivatives designated as hedging instruments:Sell$1,086,980Â $1,249,662Â Purchase$192,162Â $198,408Â Derivatives not designated as hedging instruments:Sell$281,438Â $350,269Â Purchase$28,824Â $90,102Â 11Table of ContentsBIOMARIN PHARMACEUTICAL INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)The fair value carrying amounts of the Companyâ€™s derivatives, which are classified as Level 2 within the fair value hierarchy, were as follows:Balance Sheet LocationJune 30,2024December 31,2023Derivatives designated as hedging instruments:Asset DerivativesOtherÂ currentÂ assets$27,599Â $6,663Â Other assets8,236Â 1,855Â Subtotal$35,835Â $8,518Â Liability DerivativesAccountsÂ payableÂ and accruedÂ liabilities$6,407Â $30,005Â OtherÂ long-termÂ liabilities1,257Â 8,171Â Subtotal$7,664Â $38,176Â Derivatives not designated as hedging instruments:Asset DerivativesOtherÂ currentÂ assets$2,352Â $547Â Liability DerivativesAccountsÂ payableÂ and accruedÂ liabilities$1,277Â $3,848Â Total Derivatives Assets$38,187Â $9,065Â Total Derivatives Liabilities$8,941Â $42,024Â For additional discussion of fair value measurements, see Note 1 â€“ Business Overview and Significant Accounting Policies to the Companyâ€™s Consolidated Financial Statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023.The following tables summarize the impact of gains and losses from the Company's derivatives on its Condensed Consolidated Statements of Comprehensive Income for the periods presented.Three Months EndedSix Months Ended June 30,20242023Derivatives Designated as Cash Flow Hedging InstrumentsCash Flow Hedging Gains (Losses) Reclassified into EarningsCash Flow Hedging Gains (Losses) Reclassified into EarningsCash Flow Hedging Gains (Losses) Reclassified into EarningsCash Flow Hedging Gains (Losses) Reclassified into EarningsNet product revenues$3,371Â $677Â $2,252Â $4,147Â Operating expenses(190)(26)$314Â $(482)Derivatives Not Designated as Hedging InstrumentsGains (Losses) Recognized in EarningsGains (Losses) Recognized in EarningsGains (Losses) Recognized in EarningsGains (Losses) Recognized in EarningsOperating expenses$13,812Â $769Â $21,541Â $(3,394)As of JuneÂ 30, 2024, the Company expects to reclassify unrealized gains of $21.2 million from Accumulated Other Comprehensive Income (Loss) (AOCI) to earnings as the forecasted revenues and operating expense transactions occur over the next twelve months. For additional discussion of balances in AOCI see Note 7 â€“ Accumulated Other Comprehensive Income.12Table of ContentsBIOMARIN PHARMACEUTICAL INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)(6) DEBTConvertible NotesAs of JuneÂ 30, 2024, the Company had outstanding fixed-rate notes with varying maturities for an undiscounted aggregate principal amount of $1.1 billion (collectively, the Notes). The Notes are senior subordinated convertible obligations, and interest is payable in arrears, semi-annually. The following table summarizes information regarding the Companyâ€™s convertible debt:June 30,2024December 31,20230.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)$495,000Â $495,000Â Unamortized discount net of deferred offering costs(163)(1,123)2024 Notes, net (1)494,837Â 493,877Â 1.25% senior subordinated convertible notes due in May 2027 (the 2027 Notes)600,000Â 600,000Â Unamortized discount net of deferred offering costs(5,884)(6,905)2027 Notes, net594,116Â 593,095Â Total convertible debt, net$1,088,953Â $1,086,972Â Fair value of fixed-rate convertible debt (2):2024 Notes$492,447Â $488,288Â 2027 Notes576,102Â 619,260Â Total fair value of fixed-rate convertible debt$1,068,549Â $1,107,548Â (1)Â Â Â Â The Companyâ€™s convertible notes due in 2024 matured on August 1, 2024, subsequent to quarter-end. Substantially all holders of the 2024 Notes were repaid with cash, totaling approximately $495.0Â million. No gain or loss was incurred upon the extinguishment.(2)Â Â Â Â The fair value of the Companyâ€™s fixed-rate convertible debt is based on open-market trades and is classified as Level 1 in the fair value hierarchy. For additional discussion of fair value measurements, see Note 1 â€“ Business Overview and Significant Accounting Policies to the Companyâ€™s Consolidated Financial Statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023.Interest expense on the Companyâ€™s convertible debt consisted of the following:Â Three Months EndedJune 30,Six Months EndedJune 30,20242023Coupon interest expense$2,617Â $2,617Â $5,233Â $5,233Â Accretion of discount on convertible notes843Â 834Â 1,684Â 1,673Â Amortization of debt issuance costs148Â 149Â 297Â 297Â Total interest expense on convertible debt$3,608Â $3,600Â $7,214Â $7,203Â See Note 10 - Debt to the Companyâ€™s Consolidated Financial Statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023 for additional information related to the Companyâ€™s convertible debt.(7) ACCUMULATED OTHER COMPREHENSIVE INCOMEThe following tables summarize changes in the accumulated balances for each component of AOCI, including current-period other comprehensive income and reclassifications out of AOCI, for the periods presented.13Table of ContentsBIOMARIN PHARMACEUTICAL INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)Three Months Ended June 30, 2024Unrealized Gains(Losses) on CashFlow HedgesUnrealized Gains(Losses) onAvailable-for-SaleDebt SecuritiesTotalAOCI balance as of MarchÂ 31, 2024(183)(863)$(1,046)Other comprehensive income (loss) beforeÂ Â Â Â reclassifications31,551Â (684)30,867Â Less: gain (loss) reclassified from AOCI3,181Â â€“Â 3,181Â Tax effectâ€“Â 159Â 159Â Net current-period other comprehensive income (loss)28,370Â (525)27,845Â AOCI balance as of JuneÂ 30, 2024$28,187Â $(1,388)$26,799Â Three Months Ended June 30, 2023Unrealized Gains(Losses) on CashFlow HedgesUnrealized Gains(Losses) onAvailable-for-SaleDebt SecuritiesTotalAOCI balance as of MarchÂ 31, 2023$(2,647)$(8,075)$(10,722)Other comprehensive income (loss) beforeÂ Â Â Â reclassifications(6,737)(661)(7,398)Less: gain (loss) reclassified from AOCI651Â â€“Â 651Â Tax effectâ€“Â 154Â 154Â Net current-period other comprehensive income (loss)(7,388)(507)(7,895)AOCI balance as of JuneÂ 30, 2023$(10,035)$(8,582)$(18,617)Six Months Ended June 30, 2024Unrealized Gains(Losses) on CashFlow HedgesUnrealized Gains(Losses) onAvailable-for-SaleDebt SecuritiesTotalAOCI balance as of DecemberÂ 31, 2023$(29,658)$870Â $(28,788)Other comprehensive income (loss) beforeÂ Â Â Â reclassifications60,411Â (2,926)57,485Â Less: gain (loss) reclassified from AOCI2,566Â â€“Â 2,566Â Tax effectâ€“Â 668Â 668Â Net current-period other comprehensive income (loss)57,845Â (2,258)55,587Â AOCI balance as of JuneÂ 30, 2024$28,187Â $(1,388)$26,799Â Six Months Ended June 30, 2023Unrealized Gains(Losses) on CashFlow HedgesUnrealized Gains(Losses) onAvailable-for-SaleDebt SecuritiesTotalAOCI balance as of DecemberÂ 31, 2022$8,226Â $(12,093)$(3,867)Other comprehensive income (loss) beforeÂ Â Â Â reclassifications(14,596)4,586Â (10,010)Less: gain (loss) reclassified from AOCI3,665Â â€“Â 3,665Â Tax effectâ€“Â (1,075)(1,075)Net current-period other comprehensive income (loss)(18,261)3,511Â (14,750)AOCI balance as of JuneÂ 30, 2023$(10,035)$(8,582)$(18,617)For additional discussion of reclassifications from AOCI see Note 5 â€“ Derivative Instruments and Hedging Strategies.14Table of ContentsBIOMARIN PHARMACEUTICAL INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)(8) REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATIONThe Company operates in one business segment, which focuses on the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions.The following table presents Total Revenues and disaggregates Net Product Revenues by product.Three Months EndedJune 30,Six Months EndedJune 30,20242023VOXZOGO$183,923Â $113,337Â $336,812Â $201,173Â VIMIZIM178,016Â 177,392Â 370,536Â 366,584Â NAGLAZYME132,049Â 90,103Â 237,678Â 213,124Â PALYNZIQ88 net product revenues702,129Â 584,698Â 1,339,944Â 1,171,124Â Royalty and other revenues9,900Â 10,577Â 20,918Â 20,566Â Total revenues$712,029Â $595,275Â $1,360,862Â $1,191,690Â The Company considers there to be revenue concentration risks for regions where Net Product Revenues exceed 10% of consolidated Net Product Revenues. The concentration of the Companyâ€™s Net Product Revenues within the regions below may have a material adverse effect on the Companyâ€™s revenues and results of operations if sales in the respective regions experience difficulties. The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for the Company's commercial products sold directly by the Company, except for ALDURAZYME, which is marketed and sold exclusively by Sanofi worldwide.Three Months EndedJune 30,Six Months EndedJune 30,20242023202342023United States$227,449Â $191,655Â $420,448Â $358,439Â Europe220,990Â 183,434Â 416,738Â 344,126Â Latin America84,418Â 75,444Â 163,012Â 143,192Â Middle East49,701Â 25,630Â 106,776Â 117,272Â Rest of world81,013Â 68,217Â 159,150Â 133,374Â Total net product revenues marketed by the Company$663,571Â $544,380Â $1,266,124Â $1,096,403Â ALDURAZYME net product revenues marketed by Sanofi38,558Â 40,318Â 73,820Â 74,721Â Total net product revenues$702,129Â $584,698Â $1,339,944Â $1,171,124Â The following table illustrates the percentage of the Companyâ€™s total Net Product Revenues attributed to the Companyâ€™s largest customers for the periods presented.Three Months EndedJune 30,Six Months EndedJune 30,20242023202342023Customer A14Â %15Â %14Â %15Â %Customer B11Â %12Â %11Â %11Â %Customer C10Â %10Â %9Â %9Â %Total35Â %37Â %34Â %35Â %15Table of ContentsBIOMARIN PHARMACEUTICAL INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)On a consolidated basis, three customers accounted for 15%, 12%, and 10% of the Companyâ€™s JuneÂ 30, 2024 accounts receivable balance, respectively, compared to DecemberÂ 31, 2023, when two customers accounted for 15% and 12% of the accounts receivable balance, respectively. As of JuneÂ 30, 2024, and DecemberÂ 31, 2023, the accounts receivable balance for Sanofi included $67.1 million and $63.4 million, respectively, of unbilled accounts receivable, which becomes payable to the Company when the product is sold through by Sanofi. The Company does not require collateral from its customers, but does perform periodic credit evaluations of its customersâ€™ financial condition and requires prepayments in certain circumstances.The Company is mindful that conditions in the current macroeconomic environment, such as inflation, changes in interest and foreign currency exchange rates, natural disasters, geopolitical instability, and supply chain disruptions, could affect the Companyâ€™s ability to achieve its goals. In addition, the Company sells its products in countries that face economic volatility and weakness. Although the Company has historically collected receivables from customers in certain countries, sustained weakness or further deterioration of the local economies and currencies may cause customers in those countries to delay payment or be unable to pay for the Companyâ€™s products. The Company believes that the allowances for doubtful accounts related to these countries, if any, are adequate based on its analysis of the specific business circumstances and expectations of collection for each of the underlying accounts in these countries. The Company will continue to monitor these conditions and will attempt to adjust its business processes, as appropriate, to mitigate macroeconomic risks to its business.(9) STOCK-BASED COMPENSATIONThe Company has stockholder-approved equity incentive plans that provide for the granting of restricted stock units (RSUs) and stock options as well as other forms of equity compensation to its employees, officers and non-employee directors. The Company also has an Employee Stock Purchase Plan (ESPP). Compensation expense included in the Companyâ€™s Condensed Consolidated Statements of Comprehensive Income for all stock-based compensation arrangements was as follows:Â Three Months EndedJune 30,Six Months EndedJune 30,20242023202342023Cost of sales$3,774Â $4,721Â $7,018Â $9,052Â Research and development12,935Â 15,055Â 33,612Â 34,883Â Selling, general and administrative31,205Â 30,386Â 65,533Â 59,922Â Total stock-based compensation expense$47,914Â $50,162Â $106,163Â $103,857Â (10) RESTRUCTURINGDuring the first half of 2024, the Company completed a strategic portfolio assessment of its research and development programs to determine which have the most transformative potential for patients and value creation for shareholders. With the combined focus on patient impact and commercial opportunity, certain programs that met the highest bar for advancement have been prioritized. As a result of the assessment, certain programs have been discontinued.During the second quarter of 2024, in connection with the discontinuation of certain research and development programs, the Company committed to a plan to reduce its global workforce by approximately 170 employees (representing approximately 5% of the Companyâ€™s global workforce). Workforce reductions are expected to be substantially completed by end of 2024.The restructuring plan includes severance and employee-related costs, asset impairments, and other costs. The asset impairment charges were for abandoned assets-in-progress and a Right-of-Use asset (ROU Asset) related to leased office space the Company decided to exit and sub-lease. The Company utilized the discounted cash flow approach to determine the fair value of the ROU Asset. The ROU Asset impairment is the difference between the existing lease terms and rates and the expected sub-lease terms and rates available in the market. The Other category includes restructuring-related costs, which are expensed as incurred, as well as other obligations related to the leased office space that will be satisfied over the remainder of the lease term.16Table of ContentsBIOMARIN PHARMACEUTICAL INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)The restructuring charges and adjustments were included in Selling, General, and Administrative in the Condensed Consolidated Statements of Comprehensive Income. Restructuring expenses consisted of the following: Three Months EndedJune 30,Six Months EndedJune 30,20242024Severance and one-time employee benefits$23,837Â $25,275Â Asset Impairments9,6719,671Other5,5197,519$39,027Â $42,465Â The following unpaid balance as of JuneÂ 30, 2024 was recorded to Accounts Payable and Accrued Liabilities on the Condensed Consolidated Balance Sheet:Severance and related costsOtherTotalBalance as of DecemberÂ 31, 2023$â€”Â $â€”Â $â€”Â Charges and Adjustments25,275Â 7,519Â $32,793Â Payments(4,321)(2,000)$(6,321)Balance as of JuneÂ 30, 2024$20,954Â $5,519Â $26,472Â (11) EARNINGS PER COMMON SHAREPotentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards, common stock issuable under the ESPP, unvested RSUs and contingent issuances of common stock related to the Companyâ€™s

convertible debt.The following table sets forth the computation of basic and diluted earnings per common share (common shares in thousands):Three Months EndedJune 30,Six Months EndedJune 30,20242023202420232Numerator:Net Income, basic$107,174Â $56,040Â $195,836Â $106,892Â Add: Interest expense, net of tax, on the Company's convertible debt2,769Â 937Â 5,538Â 1,873Â Net Income, diluted$109,943Â $56,977Â $201,374Â $108,765Â Denominator:Weighted-average common shares outstanding, basic190,114Â 187,948Â 189,490Â 187,311Â Effect of dilutive securities:Common stock issuable under the Company's equity incentive plans2,056Â 3,080Â 2,312Â 3,475Â Common stock issuable under the Companyâ€™s convertible debt(1)8,335Â 3,970Â 8,335Â 3,970Â Weighted-average common shares outstanding, diluted200,505Â 194,998Â 200,137Â 194,756Â Earnings per common share, basic$0.56Â $0.30Â $1.03Â $0.57Â Earnings per common share, diluted$0.55Â $0.29Â $1.01Â $0.56Â 17Table of ContentsBIOMARIN PHARMACEUTICAL INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (continued)(In thousands of U.S. Dollars, except per share amounts or as otherwise disclosed)In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of diluted earnings per common share as they were anti-dilutive (in thousands):Three Months EndedJune 30,Six Months EndedJune 30,20242023202420232Common stock issuable under the Company's equity incentive plans10,362Â 8,716Â 10,106Â 8,321Â Common stock issuable under the Companyâ€™s convertible debt (1)â€”Â 4,365Â â€”Â 4,365Â Total number of potentially issuable shares10,362Â 13,081Â 10,106Â 12,686Â (1)Â Â Â Â If converted, the Company would issue 4.0Â million shares under the 2024 Notes and 4.4Â million shares under the 2027 Notes. For additional discussion of the Companyâ€™s convertible debt, see Note 6 - Debt. (12) COMMITMENTS AND CONTINGENCIESContingenciesFrom time to time the Company is involved in legal actions arising in the normal course of its business. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters could adversely affect the Company, its results of operations, financial condition or cash flows. The Companyâ€™s general practice is to expense legal fees as services are rendered in connection with legal matters, and to accrue for liabilities when losses are probable and reasonably estimable based on existing information. The Company accrues for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then the minimum amount in the range is accrued. Liabilities are evaluated and refined each reporting period as additional information is known. Any receivables for insurance recoveries for these liability claims are recorded as assets when it is probable that a recovery will be realized.As previously disclosed, the Company received a subpoena from the U.S. Department of Justice (DOJ) requesting that the Company produce certain documents regarding sponsored testing programs relating to VIMIZIM and NAGLAZYME. The Company has produced the requested documents in response to the subpoena and is cooperating fully. The Company is unable to make any assurances regarding the outcome of the investigation by the DOJ, or the impact, if any, that such investigation may have on the Companyâ€™s business, Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Comprehensive Income or Condensed Consolidated Statements of Cash Flows.Contingent PaymentsAs of JuneÂ 30, 2024, the Company was subject to contingent payments, primarily comprised of development, regulatory and commercial milestones. Those considered reasonably possible totaled $495.6 million, of this amount the Company may pay up to $10.9 million over the next 12 months if certain contingencies are met.Other CommitmentsThe Company uses experts and laboratories at universities and other institutions to perform certain R&D activities. These amounts are recorded as R&D expense as services are provided. In the normal course of business, the Company enters into various firm purchase commitments primarily to procure active pharmaceutical ingredients, certain inventory-related items and certain third-party R&D services, production services and facility construction services. The Company also has commitments related to enterprise resource planning (ERP) system implementation costs for which the Company is committed. As of JuneÂ 30, 2024, such commitments were estimated at $473.0 million, of which $291.1 million is expected to be paid in 2024 as underlying goods and services are received. The Company has also licensed technology from third parties, for which it is required to pay royalties upon future sales, subject to certain annual minimums.18Table of ContentsItemÂ 2.Â Â Â Â Managementâ€™s Discussion and Analysis of Financial Condition and Results of OperationsThe following discussion of our financial condition and results of operations should be read in conjunction with our Condensed Consolidated Financial Statements and the related Notes thereto included in this Quarterly Report on Form 10-Q. This discussion contains forward-looking statements that involve risks and uncertainties. When reviewing the discussion below, you should keep in mind the substantial risks and uncertainties that could impact our business. In particular, we encourage you to review the risks and uncertainties described in â€œRisk Factorsâ€ in Part II, ItemÂ 1A of this Quarterly Report on Form 10-Q. These risks and uncertainties could cause actual results to differ significantly from those projected in forward-looking statements contained in this report or implied by past results and trends. Forward-looking statements are statements that attempt to forecast or anticipate future developments in our business, financial condition or results of operations. See the section titled â€œForward-Looking Statementsâ€ that appears at the beginning of this Quarterly Report on Form 10-Q. These statements, like all statements in this report, speak only as of the date of this Quarterly Report on Form 10-Q (unless another date is indicated), and, except as required by law, we undertake no obligation to update or revise these statements in light of future developments. Our Condensed Consolidated Financial Statements have been prepared in accordance with United States (U.S.) generally accepted accounting principles (U.S. GAAP) and are presented in U.S. Dollars (USD).19Table of ContentsManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations (continued)(In millions, except as otherwise disclosed)OverviewFounded in 1997, we are a global biotechnology company dedicated to transforming lives through genetic discovery. We develop and commercialize targeted therapies that address the root cause of genetic conditions. Our robust research and development capabilities have resulted in multiple innovative commercial therapies for patients with rare genetic disorders. Our distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. A summary of our commercial products, as of JuneÂ 30, 2024, is provided below:Commercial ProductsIndicationVOXZOGO (vosoritide)AchondroplasiaVIMIZIM (elosulfase alpha)Mucopolysaccharidosis (MPS) IVANAGLAZYME (galsulfase)MPSÂ VIPALYNZIQ (pegvaliase-pqpz)Phenylketonuria (PKU)BRINEURA (cerliponase alfa)Neuronal ceroid lipofuscinosis type 2 (CLN2)ALDURAZYME (laronidase)MPSÂ IKUVAN (sapropterin dihydrochloride)PKUROCTAVIAN (valoctocogene roxaparvovec)Severe Hemophilia AFinancial HighlightsKey components of our results of operations include the following:Three Months EndedJune 30,Six Months EndedJune 30,20242023202420232Total revenues$712.0Â $595.3Â $1,360.9Â $1,191.7Â Cost of sales$130.5Â $130.6Â $255.6Â $266.1Â Research and development (R&D)$183.8Â $177.4Â $388.8Â $349.2Â Selling, general and administrative (SG&A)$263.0Â $206.1Â $488.9Â $417.1Â Net income$107.2Â $56.0Â $195.8Â $106.9Â See â€œResults of Operationsâ€ below for discussion of our results for the periods presented.Uncertainty Relating to Macroeconomic EnvironmentConditions in the current macroeconomic environment, such as inflation, changes in interest and foreign currency exchange rates, natural disasters, geopolitical instability, and supply chain disruptions, could impact our global revenue sources and our overall business operations. The extent and duration of such effects remain uncertain and difficult to predict. We are actively monitoring and managing our response and assessing actual and potential impacts to our operating results and financial condition, as well as developments in our business, which could further impact the developments, trends and expectations described below. See the risk factor, â€œOur business is affected by macroeconomic conditions.â€ described in â€œRisk Factorsâ€ in Part II, ItemÂ 1A of this Quarterly Report on Form 10-Q.Recent DevelopmentsWe continued to grow our commercial business and advance our product candidate pipeline during the first half of 2024. We believe that the combination of our internal research programs and partnerships will allow us to continue to develop and commercialize innovative therapies for people with serious and life-threatening rare diseases and medical conditions.In the first half of 2024, we focused on value creation through working to accelerate growth, optimize efficiencies and drive operational excellence, including progress in executing on key strategic priorities first outlined in January 2024. We also completed a strategic portfolio assessment of R&D programs to determine which have the most transformative potential for patients and value creation for shareholders and have shifted focus and resources to those R&D programs that met our highest bar for prioritized 20Table of ContentsManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations (continued)(In millions, except as otherwise disclosed)advancement. The programs, namely BMN 333, a long-acting C-type natriuretic peptide for multiple growth disorders, BMN 349, a potential best-in-class, oral therapeutic for liver disease associated with Alpha-1 Antitrypsin Deficiency, and BMN 351, our next generation oligonucleotide for Duchenne Muscular Dystrophy, all met the highest bar for advancement. Based on such strategic portfolio assessment, certain programs have also been discontinued. In addition, we initiated the execution of our financial and operational strategy that improved operating results and is expected to continue to improve our results of operations. In August 2024, we announced our ROCTAVIAN strategy, which we anticipate will enable ROCTAVIAN to contribute to our long-term profitability. See the risk factor, â€œOur success depends on our ability to manage our growth.â€ described in â€œRisk Factorsâ€ in Part II, ItemÂ 1A of this Quarterly Report on Form 10-Q.Change in PresentationOn January 1, 2024, we changed our presentation of foreign currency transaction gains and losses resulting from remeasurement and idle plant costs within our Condensed Consolidated Statements of Comprehensive Income. See Note 1 to our accompanying Condensed Consolidated Financial Statements for additional details.Results of OperationsNet Product RevenuesNet Product Revenues consisted of the following:Three Months EndedJune 30,Six Months EndedJune 30,20242023Change20242023ChangeVOXZOGO$183.9Â $113.3Â $70.6Â $336.7Â $201.2Â $135.5Â VIMIZIM178.0Â 177.4Â 0.6Â 370.5Â 366.6Â 3.9Â NAGLAZYME132.0Â 90.1Â 41.9Â 237.7Â 21 net product revenues$702.1Â $584.7Â $117.4Â $1,339.9Â $1,171.1Â $168.8Â Net Product Revenues include revenues generated from our commercial products. In the U.S., our commercial products, except for PALYNZIQ and ALDURAZYME, are generally sold to specialty pharmacies or end users, such as hospitals, which act as retailers. PALYNZIQ is distributed in the U.S. through certain certified specialty pharmacies under the PALYNZIQ Risk Evaluation and Mitigation Strategy program, and ALDURAZYME is marketed worldwide by Sanofi. Outside the U.S., our commercial products are sold to authorized distributors or directly to government purchasers or hospitals, which act as the end users.The increase in Net Product Revenues for the three months ended JuneÂ 30, 2024 as compared to the three months ended JuneÂ 30, 2023 was primarily attributed to the following:â€¢VOXZOGO: higher sales volume from new patients initiating therapy across all regions;â€¢NAGLAZYME: higher sales volume due to timing of orders in countries that place large government orders, particularly in the Middle East, Europe and Latin America; andâ€¢PALYNZIQ: higher sales volume due to new patients initiating therapy, primarily in the U.S.These increases were partially offset by the following:â€¢KUVAN: lower product revenues attributed to increasing generic competition as a result of the loss of market exclusivity.The increase in Net Product Revenues for the six months ended JuneÂ 30, 2024 as compared to the six months ended JuneÂ 30, 2023 was primarily attributed to the following:â€¢VOXZOGO: higher sales volume from new patients initiating therapy across all regions;21Table of ContentsManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations (continued)(In millions of U.S. dollars, except as otherwise disclosed)â€¢PALYNZIQ: higher sales volume from new patients initiating therapy, primarily in the U.S.; andâ€¢NAGLAZYME: higher sales volume due to timing of orders in countries that place large government orders, particularly in the Middle East and Europe.These increases were partially offset by the following:â€¢KUVAN: lower product revenues attributed to increasing generic competition as a result of the loss of market exclusivity.In certain countries, governments place large periodic orders for our products. We expect that the timing of these large government orders will continue to be inconsistent, which has created in the past and may continue to create significant period to period variation in our revenues. With respect to KUVAN, see also the risk factor â€œThe sale of generic versions of KUVAN by generic manufacturers has adversely affected and will continue to adversely affect our revenues and may cause a decline in KUVAN revenues faster than expectedâ€ in â€œRisk Factorsâ€ included in Part II, Item 1A of this Quarterly Report for additional information on risks we face. Strong demand for VOXZOGO in certain markets had outpaced our projections in recent quarters and we anticipated challenges meeting our estimated VOXZOGO demand during the first half of 2024. We have recently increased fill-finish capacity to meet this demand and continue to implement actions to manage growth and minimize patient impact. While supply constraints have eased in the second quarter of 2024 and we expect to have the ability to meet estimated demand and support ongoing clinical programs, if actual demand continues to exceed estimates, the supply constraint could be prolonged. We do not expect a material impact on our revenues if we successfully execute our manufacturing plans. See "Risk Factors" in Part II, Item 1A of this Quarterly Report for additional information on risk factors that could impact our business and operations.We face exposure to movements in foreign currency exchange rates, which we expect to continue in future periods. We use foreign currency exchange forward contracts to hedge a percentage of our foreign currency exposure, primarily the Euro. Certain currencies are not included in our hedging program, such as the Argentine Peso. With respect to the risks posed by fluctuations of both hedged and unhedged currencies against the U.S. dollar, see the risk factor â€œOur international operations pose currency risks, which may adversely affect our operating results and net incomeâ€ in â€œRisk Factorsâ€ included in Part II, Item 1A of this Quarterly Report for additional information. The following table shows our Net Product Revenues denominated in USD and foreign currencies:Three Months EndedJune 30,Six Months EndedJune 30,20242023Change20242023ChangeSales denominated in USD$330.7Â $275.1Â $55.6Â $638.6Â $572.7Â $65.9Â Sales denominated in foreign currencies371.4Â 309.6Â 61.8Â 701.3Â 598.4Â 102.9Â Total net product revenues$702.1Â $584.7Â $117.4Â $1,339.9Â $1,171.1Â $168.8Â Three Months EndedJune 30,Six Months EndedJune 30,20242023Change20242023ChangeUnfavorable impact of foreign currency exchange rates on product sales denominated in currencies other than USD(29.9)(21.8)(8.1)(52.6)(50.1)(2.5)The unfavorable impact for the three and six months ended JuneÂ 30, 2024 as compared to the three and six months ended JuneÂ 30, 2023 was primarily driven by weakening of Argentine Peso and Japanese Yen, partially offset by strengthening of the Euro.22Table of ContentsManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations (continued)(In millions of U.S. dollars, except as otherwise disclosed)Royalty and Other RevenuesRoyalty and Other Revenues include royalties earned on net sales of products sold by third parties, up-front licensing fees and milestones achieved by licensees or sublicensees.Three Months EndedJune 30,Six Months EndedJune 30,20242023Change20242023ChangeRoyalty and other revenues$9.9Â $10.6Â (0.7)20.9Â $20.6Â $0.3Â The change in Royalty and Other Revenues for the three and six months ended JuneÂ 30, 2024 as compared to the three and six months ended JuneÂ 30, 2023 was relatively flat. We expect to continue to earn royalties from third parties in the future.Cost of Sales and Gross MarginCost of Sales includes raw materials, personnel and facility and other costs associated with manufacturing our commercial products. These costs include production materials, production costs at our manufacturing facilities, third-party manufacturing costs, amortization of technology transfer intangible assets and internal and external final formulation and packaging costs. Cost of Sales also includes royalties payable to third parties based on sales of our products, idle plant costs and charges for inventory valuation reserves.The following table summarizes our Cost of Sales and gross margin:Three Months EndedJune 30,Six Months EndedJune 30,20242023Change20242023ChangeTotal revenues$712.0Â $595.3Â $116.7Â $1,360.9Â $1,191.7Â $169.2Â Cost of sales$130.5Â $130.6Â (0.1)255.6Â $266.1Â $(10.5)Gross margin81.7Â %78.1Â %3.6Â %81.2Â %77.7Â %3.5Â %Cost of Sales decreased in the three and six months ended JuneÂ 30, 2024 as compared to the three and six months ended JuneÂ 30, 2023, primarily from lower per-unit manufacturing costs partially offset by higher sales volumes. Gross margin increased in the current three and six month period due to higher sales volumes for products with higher margin, driven by VOXZOGO sales volume.We expect gross margin to increase modestly as our product mix is expected to shift, with increasing sales volumes for our higher margin commercial products.Research and DevelopmentR&D expense includes costs associated with the research and development of product candidates and post-marketing research commitments related to our commercial products. R&D expense primarily includes preclinical and clinical studies, personnel and raw materials costs associated with manufacturing clinical product, quality control and assurance, other R&D activities, R&D facilities and regulatory costs.23Table of ContentsManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations (continued)(In millions of U.S. dollars, except as otherwise disclosed)We group all of our R&D activities and related expense into three categories: (i) research and early pipeline, (ii) later-stage clinical programs and (iii) marketed products as follows:CategoryDescriptionResearch and early pipelineR&D expense incurred in activities substantially in support of early research through the completion of phase 2 clinical trials, including drug discovery, toxicology, pharmacokinetics and drug metabolism and process development.Later-stage clinical programsR&D expense incurred in or related to phase 3 clinical programs intended to result in registration of a new product or a new indication for an existing product primarily in the U.S. or the EU.Marketed productsR&D expense incurred in support of our marketed products that are authorized to be sold primarily in the U.S. or the EU. Includes clinical trials designed to gather information on product safety (certain of which may be required by regulatory authorities) and their product characteristics after regulatory approval has been obtained, as well as the costs of obtaining regulatory approval of a product in a new market after approval in either the U.S. or EU has been obtained.We manage our R&D expense by identifying the R&D activities we anticipate will be performed during a given period and then prioritizing efforts based on scientific data, probability of successful development, market potential, available human and capital resources and other similar considerations. We continually review our product pipeline and the development status of product candidates and, as necessary, reallocate resources among the research and development portfolio that we believe will best support the future growth of our business.R&D consisted of the following:Three Months EndedJune 30,Six Months EndedJune

30,20242023Change20242023ChangeResearch and early pipeline$106.1Â $90.3Â $15.8Â $226.5Â $176.5Â $50.0Â Later-stage clinical programs7.7Â â€”Â 7.7Â 7.7Â 30.7Â (23.0)Marketed Products70.0Â 87.1Â (17.1)154.6Â 142.0Â 12.6Â Total R&D$183.8Â $177.4Â $6.4Â $388.8Â $349.2Â $39.6Â The increase in R&D expense for the three months ended JuneÂ 30, 2024 as compared to the three months ended JuneÂ 30, 2023 was primarily due to the following:â€¢Research and early pipeline: higher spend related to pre-clinical activities for new VOXZOGO indications for idiopathic short stature (ISS) and multiple genetic short stature pathway conditions (PC) and our prioritized pipeline comprised of BMN 333, BMN 349 and BMN 351; andâ€¢Later-stage clinical programs: higher spend on clinical activities related to VOXZOGO for the treatment of hypochondroplasia.These increases were partially offset by the following:â€¢Marketed products: lower spend on ROCTAVIAN and VOXZOGO for achondroplasia as we shift resources to the new VOXZOGO indications and our prioritized pipeline.The increase in R&D expense for the six months ended JuneÂ 30, 2024 as compared to the six months ended JuneÂ 30, 2023 was primarily due to the following:â€¢Research and early pipeline: higher spend related to pre-clinical activities for new VOXZOGO indications for ISS and PC and our prioritized pipeline; andâ€¢Marketed products: higher spend primarily related to ROCTAVIAN, which was moved to Marketed products following Food and Drug Administration approval in the second quarter of 2023.These increases were partially offset by the following:â€¢Later-stage clinical programs: lower spend on ROCTAVIAN, which was moved to Marketed products following Food and Drug Administration approval in the second quarter of 2023, partially offset by higher spend on the new VOXZOGO indication for hypochondroplasia. 24Table of ContentsManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations (continued)(In millions of U.S. dollars, except as otherwise disclosed)We expect R&D expense to increase in future periods, primarily due to increased spending for the new VOXZOGO indications and research and early pipeline programs.Selling, General and AdministrativeSales and marketing (S&M) expense primarily consisted of employee-related expenses for our sales group, brand marketing, patient support groups and pre-commercialization expenses related to our product candidates. General and administrative (G&A) expense primarily consisted of corporate support and other administrative expenses, including employee-related expenses.SG&A consisted of the following: Three Months EndedJune 30,Six Months EndedJune 30,20242023Change20242023ChangeS&M$122.8Â $115.6Â $7.2Â $242.2Â $233.3Â $8.9Â G&A140.2Â 90.5Â 49.7Â 246.7Â 183.8Â 62.9Â Total SG&A$263.0Â $206.1Â $56.9Â $488.9Â $417.1Â $71.8Â S&M consisted of the following:Three Months EndedJune 30,Six Months EndedJune 30,20242023Change20242023ChangeEnzyme Products$56.4Â $53.7Â $2.7Â $111.6Â $112.7Â $(1.1)VOXZOGO31.7Â 26.3Â 5.4Â 62.4Â 51.0Â 11.4Â ROCTAVIAN24.1Â 23.9Â 0.2Â 48.0Â 47.4Â 0.6Â Other10.6Â 11.7Â (1.1)20.2Â 22.2Â (2.0)Tot S&M$122.8Â $115.6Â $7.2Â $242.2Â $233.3Â $8.9Â The increase in S&M expense for the three months ended JuneÂ 30, 2024 as compared to the three months ended JuneÂ 30, 2023 was primarily attributed to continued global expansion of VOXZOGO for achondroplasia and higher partner distribution fees. The increase in S&M expense for the six months ended JuneÂ 30, 2024 as compared to the six months ended JuneÂ 30, 2023 was primarily a result of the continued global expansion of VOXZOGO for achondroplasia. The increase in G&A expense for the three and six months ended JuneÂ 30, 2024 as compared to the three and six months ended JuneÂ 30, 2023 was primarily due to severance and restructuring costs associated with our portfolio strategy review and the associated organizational redesign efforts announced in the second quarter of 2024. The increase in G&A expense for the six months ended JuneÂ 30, 2024 as compared to the six months ended JuneÂ 30, 2023 also included incremental administrative costs, including consulting and legal fees.We expect SG&A expense to increase in future periods as a result of ongoing corporate initiatives and the continued market expansion of our commercial products.25Table of ContentsManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations (continued)(In millions of U.S. dollars, except as otherwise disclosed)Intangible Asset Amortization and Gain on Sale of Nonfinancial AssetsIntangible Asset Amortization and Gain on Sale of Nonfinancial Assets were as follows:Three Months EndedJune 30,Six Months EndedJune 30,20242023Change20242023ChangeAmortization of intangible assets$14.3Â $15.6Â (1.3)28.6Â $31.3Â $(2.7)Gain on sale of nonfinancial assets$â€”Â $â€”Â $â€”Â $10.0Â $â€”Â $10.0Â Amortization of intangible assets â€” the decrease in expense for the three and six months ended JuneÂ 30, 2024 as compared to the three and six months ended JuneÂ 30, 2023 was due to an intangible asset becoming fully amortized during the fourth quarter of 2023.Gain on Sale of Nonfinancial Assets â€” in the first quarter of 2024, we recognized a gain of $10.0 million due to a third partyâ€™s achievement of a regulatory approval milestone related to previously sold intangible assets.Interest IncomeWe invest our cash equivalents and investments in U.S. government securities and other high credit quality debt securities in order to limit default and market risk.Three Months EndedJune 30,Six Months EndedJune 30,20242023Change20242023ChangeInterest income$19.8Â $12.6Â $7.2Â $39.2Â $24.6Â $14.6Â The increase in Interest Income for the three and six months ended JuneÂ 30, 2024 compared to the three and six months ended JuneÂ 30, 2023 was primarily due to higher balances and higher yields on our cash equivalents and investment portfolio. We expect Interest Income to increase moderately over the next 12 months due to anticipated higher overall returns on our cash equivalents and investments. Interest ExpenseWe incur interest expense primarily on our convertible debt. Interest Expense for the periods presented was as follows:Three Months EndedJune 30,Six Months EndedJune 30,20242023Change20242023ChangeInterest expense$3.6Â $3.8Â (0.2)7.1Â $7.5Â $(0.4)Interest Expense for the three and six months ended JuneÂ 30, 2024 as compared to the three and six months ended JuneÂ 30, 2023 was relatively flat. We expect Interest Expense to decrease over the next 12 months due to the settlement of our convertible debt that matured on August 1, 2024. See Note 6 to our accompanying Condensed Consolidated Financial Statements for additional information regarding our debt. Other Expense, NetOther Expense, Net for the periods presented was as follows:Three Months EndedJune 30,Six Months EndedJune 30,20242023Change20242023ChangeOther expense, net$4.5Â $3.6Â $0.9Â $3.3Â $17.5Â $(14.2)26Table of ContentsManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations (continued)(In millions of U.S. dollars, except as otherwise disclosed)The increase in Other Expense, Net for the three months ended JuneÂ 30, 2024 compared to the three months ended JuneÂ 30, 2023 was primarily due to a loss on non-marketable securities partially offset by lower foreign currency transaction losses in the comparable period in 2023. The decrease in Other Expense, Net for the six months ended JuneÂ 30, 2024 compared to the six months ended JuneÂ 30, 2023 was primarily due to the decrease in loss on non-marketable securities partially offset by lower foreign currency transaction losses.Provision for Income TaxesThe Provision for Income Taxes for the periods presented was as follows:Three Months EndedJune 30,Six Months EndedJune 30,20242023Change20242023ChangeProvision for income taxes$25.0Â $14.8Â $10.2Â $41.8Â $20.7Â $21.1Â The increase in Provision for Income Taxes for the three and six months ended JuneÂ 30, 2024 as compared to the three and six months ended JuneÂ 30, 2023 was primarily due to higher pre-tax income and a lower tax benefit related to stock option exercises.There was no material impact resulting from the adoption of Pillar Two of the Organisation for Economic Co-operation and Development (OECD) Base Erosion and Profit Shifting Project on our financial statements.Financial Condition, Liquidity and Capital Resources Our cash, cash equivalents, and investments as of JuneÂ 30, 2024 and DecemberÂ 31, 2023 were as follows:June 30, 2024December 31, 2023ChangeCash and cash equivalents$972.1Â $755.1Â $217.0Â Short-term investments252.2Â 318.7Â (66.5)Long-term investments557.1Â 611.1Â (54.0)Cash, cash equivalents and investments$1,781.4Â $1,684.9Â $96.5Â We believe cash generated from sales of our commercial products, in addition to our cash, cash equivalents and short-term investments will be sufficient to satisfy our liquidity requirements for at least the next 12 months. We believe we will meet longer-term expected future cash requirements and obligations through a combination of cash flows from operating activities and available cash and long-term investment balances. We will need to raise additional funds by issuing equity, debt or convertible securities, taking loans or entering into collaborative or other agreements if we are unable to satisfy our liquidity requirements. For example, we may require additional financing to fund the repayment of our convertible debt due in 2027, future milestone payments and our future operations, including the commercialization of our products and product candidates currently under development, preclinical studies and clinical trials, and potential licenses and acquisitions. The timing and mix of our funding alternatives could change depending on many factors, including how much we elect to spend on our development programs, potential licenses and acquisitions of complementary technologies, products and companies or if we settle our convertible debt in cash. We are mindful that conditions in the current macroeconomic environment, such as inflation, changes in interest and foreign currency exchange rates, natural disasters, geopolitical instability, and supply chain disruptions could affect our ability to achieve our goals. In addition, we sell our products in certain countries that face economic volatility and weakness. Although we have historically collected receivables from customers in such countries, sustained weakness or further deterioration of the local economies and currencies may cause customers in those countries to be unable to pay for our products. We will continue to 27Table of ContentsManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations (continued)(In millions of U.S. dollars, except as otherwise disclosed)monitor these conditions and will attempt to adjust our business processes, as appropriate, to mitigate macroeconomic risks to our business.Our cash flows are summarized as follows:Six Months Ended June 30,20242023ChangeNet cash provided by (used in) operating activities$165.7Â (3.9)169.6Â Net cash provided by (used in) investing activities$76.2Â (0.5)76.7Â Net cash used in financing activities(30.2)(28.8)$(1.4)The increase in net cash provided by operating activities in the six months ended JuneÂ 30, 2024 compared to JuneÂ 30, 2023 was primarily attributed to the improved operating performance and timing of cash receipts from our customers, partially offset by the timing of payments to vendors and payments of income taxes.The increase in net cash provided by investing activities in the six months ended JuneÂ 30, 2024 compared to JuneÂ 30, 2023 was primarily attributable to lower purchases of available-for-sale debt securities net of maturities and a $10.0Â million milestone received in connection with the sale of previously sold intangible assets, partially offset by an increase in purchases of intangible assets.The increase in net cash used in financing activities in the six months ended JuneÂ 30, 2024 compared to JuneÂ 30, 2023 was primarily due to lower proceeds from stock option exercises, partially offset by the absence of milestone payments to third parties. FinancingOur $1.1 billion (undiscounted) of total convertible debt as of JuneÂ 30, 2024 will impact our liquidity due to the semi-annual cash interest payments as well as the repayment of the principal amount, if not converted. As of JuneÂ 30, 2024, our indebtedness consisted of our 0.599% senior subordinated convertible notes due in 2024 and our 1.25% senior subordinated convertible notes due in 2027, which, if not converted, will be required to be repaid in cash at maturity in August 2024 and May 2027, respectively. As of JuneÂ 30, 2024, the outstanding principal of our convertible notes due in 2024 (2024 Notes) was classified as a current liability.Our 2024 Notes matured on August 1, 2024, subsequent to quarter-end. Substantially all holders of the 2024 Notes were repaid with cash, totaling approximately $495.0Â million in cash. No gain or loss was incurred upon the extinguishment.For additional information related to our convertible debt, see Note 6 to our accompanying Condensed Consolidated Financial Statements and Note 10 - Debt to the Consolidated Financial Statements accompanying our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023. Material Cash RequirementsPurchase ObligationsAs of JuneÂ 30, 2024, we had obligations of approximately $473.0Â million, of which $291.1Â million is expected to be paid in 2024. Our purchase obligations are primarily related to firm purchase commitments entered into in the normal course of business to procure active pharmaceutical ingredients, certain inventory-related items, certain third-party R&D services, production services and facility construction services. The amount also includes hosting fees and other enterprise resource planning (ERP) system implementation costs for which we are committed.Other ObligationsAs of JuneÂ 30, 2024, we were subject to contingent payments considered reasonably possible of $495.6 million, of this amount we may pay up to $10.9 million over the next 12 months if certain contingencies are met. See Note 12 to our accompanying Condensed Consolidated Financial Statements for additional discussion on our contingent obligations.Our lease and unrecognized tax benefits as of JuneÂ 30, 2024 have not materially changed from those discussed in â€œFinancial Condition, Liquidity and Capital Resourcesâ€ in Part II, Item 7 of our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023.28Table of ContentsManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations (continued)(In millions of U.S. dollars, except as otherwise disclosed)See Note 12 to our accompanying Condensed Consolidated Financial Statements for additional information on our commitments.Critical Accounting EstimatesIn preparing our Condensed Consolidated Financial Statements in accordance with U.S. GAAP and pursuant to the rules and regulations promulgated by the Securities and Exchange Commission (the SEC), we make assumptions, judgments and estimates that can have a significant impact on our net income/loss and affect the reported amounts of certain assets, liabilities, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our estimates and discuss our critical accounting policies and estimates with the Audit Committee of our Board of Directors. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ materially from these estimates under different assumptions or conditions. Historically, our assumptions, judgments and estimates relative to our critical accounting estimates have not differed materially from actual results. There have been no significant changes to our critical accounting estimates during the six months ended JuneÂ 30, 2024, compared to those disclosed in â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ included in our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, filed with the SEC on FebruaryÂ 26, 2024.Recent Accounting PronouncementsSee Note 1 to our accompanying Condensed Consolidated Financial Statements for a description of recent accounting pronouncements, if any, and our expectation of their impact on our results of operations and financial condition.29Table of ContentsItemÂ 3.Â Â Â Â Quantitative and Qualitative Disclosures About Market RiskOur market risks during the six months ended JuneÂ 30, 2024 have not materially changed from those discussed in Part II, ItemÂ 7A of our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023.ItemÂ 4.Â Â Â Â Controls and Procedures(a) Controls and ProceduresAn evaluation was carried out, under the supervision of and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)), as of the end of the period covered by this report.Based on the evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective, at the reasonable assurance level, as of JuneÂ 30, 2024.In designing and evaluating our disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management must apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure controls system are met.(b) Changes in Internal Control over Financial ReportingThere were no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during our most recently completed quarter that have materially affected or are reasonably likely to materially affect our internal control over financial reporting. We continue to utilize the Committee of Sponsoring Organizations of the Treadway Commission (COSO) 2013 Framework on internal control. We rely extensively on information systems and technology to manage our business, including integrated supply chain operations, and global consolidated financial results. We are currently implementing a new global enterprise resource planning (ERP) system, which will replace existing operating and financial systems. The ERP system is designed to accurately maintain our financial records, support integrated supply chain and other operational functionality, and provide timely information to our management team related to the operation of the business. We are implementing the ERP system in phases through 2025, with post-implementation activities following thereafter. As the implementation and post-implementation activities take place, we will have changes to certain of our processes and procedures, and we will evaluate quarterly whether the changes materially affect our internal control over financial reporting.30Table of ContentsPART II. OTHER INFORMATIONItemÂ 1.Â Â Â Â Legal Proceedings On January 19, 2023 and May 30, 2023, certain of our officers and directors were named as defendants in two shareholder derivative actions filed in the Delaware Court of Chancery. The complaints assert, inter alia, breach of fiduciary duty claims arising from the facts underlying a securities class action related to ROCTAVIAN that was previously settled in the United States District Court for the Northern District of California. The derivative complaints seek unspecified monetary damages, internal governance reforms by the Company, attorneysâ€™ fees and costs, and any other relief the court may deem just and proper. The parties in the derivative lawsuits have entered into a stipulation of settlement, that, subject to final approval by the Court of Chancery, will resolve the derivative lawsuits. The Court of Chancery held a final approval hearing on July 23, 2024 and did not approve the settlement. Instead, it instructed the plaintiffs to voluntarily dismiss the case or brief a motion to dismiss.On April 4, 2024, a purported stockholder class action was filed against us and our Board of Directors in the Delaware Court of Chancery. The complaint also named as defendants Elliott Investment Management L.P., Elliott Associates, L.P., and Elliott International, L.P., which are parties to the Cooperation Agreement with the Company. The complaint asserted a claim for declaratory judgment, seeking an order that certain provisions of the Cooperation Agreement are invalid, and, on April 4, 2024, the plaintiff moved for expedited proceedings as to the claim for declaratory judgment. In addition, the complaint asserted a claim for breach of fiduciary duty against certain directors in connection with approval of the Cooperation Agreement, as well as a claim against the Elliott parties for aiding and abetting the directorsâ€™ alleged breaches of fiduciary duty. On April 11, 2024, the Elliott parties executed a waiver of the challenged provisions in the Cooperation Agreement. In light of that waiver, on April 16, 2024, the plaintiff filed a stipulation and proposed order to dismiss the action as moot, with the court to retain jurisdiction to determine plaintiffâ€™s counselâ€™s application for an award of attorneysâ€™ fees and expenses. Also on April 16, 2024, the Court granted the order, dismissing all claims with prejudice, as to the named plaintiff only. The

Company subsequently agreed to pay the attorneysâ€™ fees and expenses of the plaintiff in full satisfaction of any and all claims by plaintiff and all of his counsel for fees and expenses in the action. On August 1, 2024, the Court entered an order closing the action, subject to the Company filing and affidavit with the Court regarding issuance of notice. ItemÂ 1A. Â Â Â Â Risk FactorsAn investment in our securities involves a high degree of risk. We operate in a dynamic and rapidly changing industry that involves numerous risks and uncertainties. The risks and uncertainties described below are not the only ones we face. Other risks and uncertainties, including those that we do not currently consider material, may impair our business. If any of the risks discussed below actually occur, our business, financial condition, operating results or cash flows could be materially adversely affected. This could cause the value of our securities to decline, and you may lose all or part of your investment.We have marked with an asterisk (*) those risk factors below that include a substantive change from or update to the risk factors included in our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, which was filed with the SEC on FebruaryÂ 26, 2024. Business and Operational RisksIf we fail to obtain and maintain an adequate level of coverage and reimbursement for our products by third-party payers, the sales of our products would be adversely affected or there may be no commercially viable markets for our products.The course of treatment for patients using our products is expensive. For all our products except ROCTAVIAN, we expect patients to need treatment for extended periods, and for some products throughout the lifetimes of the patients. We expect that most families of patients will not be capable of paying for this treatment themselves. There will be no commercially viable market for our products without coverage and reimbursement from third-party payers. Additionally, even if there is a commercially viable market, if the level of reimbursement is below our expectations, our revenues and gross margin will be adversely affected.Third-party payers, such as government or private healthcare insurers, carefully review and increasingly challenge the prices charged for drugs. Reimbursement rates from private companies vary depending on the third-party payer, the insurance plan and other factors. Obtaining coverage and adequate reimbursement for our products may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. Reimbursement systems in international markets vary significantly by country and by region, and reimbursement approvals must be obtained on a country-by-country basis.Government authorities and other third-party payers are developing increasingly sophisticated methods of controlling healthcare costs, such as by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party 31Table of Contentspayers are requiring that drug companies provide them with predetermined discounts from list prices as a condition of coverage, are using restrictive formularies and preferred drug lists to leverage greater discounts in competitive classes, and are challenging the prices charged for medical products. Further, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payers in the U.S. Therefore, coverage and reimbursement for drug products can differ significantly from payer to payer. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payer separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.We cannot be sure that coverage and reimbursement will be available for any product that we commercialize or will continue to be available for any product that we have commercialized and, if reimbursement is available, what the level of reimbursement will be. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future based on new legislation, the availability of alternative therapies and their pricing, coverage and reimbursement decisions by third-party payers, or other factors. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval or continue to market any product that has already been commercialized.Reimbursement in the European Union (EU) and many other territories must be negotiated on a country-by-country basis and in many countries the product cannot be commercially launched until pricing and/or reimbursement is approved. The timing to complete the negotiation process in each country is highly uncertain, and in some countries, we expect that it will exceed 12 months. Even after a price is negotiated, countries frequently request or require reductions to the price and other concessions over time.For our future products, we will not know what the reimbursement rates will be until we are ready to market the product and we actually negotiate the rates. If we are unable to obtain sufficiently high reimbursement rates for our products, they may not be commercially viable or our future revenues and gross margin may be adversely affected.As compared to our other, more traditional products, gene therapy products may present additional challenges with respect to the pricing, coverage, reimbursement, and acceptance of the product.In addition to the risks set forth in this Risk Factors section associated with commercializing more traditional pharmaceutical drugs, there are additional, unique commercial risks associated with gene therapy products like ROCTAVIAN. Due to the relative novelty of gene therapy and the potential to provide extended duration therapeutic treatment with a one-time administration, we face uncertainty with respect to the pricing, coverage and reimbursement of these products. In order to recover our research and development costs and commercialize one-time treatments on a profitable basis, the cost of a single administration of ROCTAVIAN is substantial, and it is likely other gene therapy products would also require relatively high prices. Therefore, coverage and reimbursement by governments and other third-party payers is essential for the vast majority of patients to be able to afford ROCTAVIAN or other gene therapy products that we may commercialize in the future. Accordingly, sales of our gene therapy products will depend substantially on the extent to which its cost will be paid by third-party payers. Even if coverage is provided, the reimbursement amounts approved by third-party payers may not be high enough to allow us to realize sufficient revenues from our investment in the development of our gene therapy products. With respect to ROCTAVIAN specifically, we have entered into, and plan to enter into additional, outcomes-based agreements for the product with third-party payers to assist with realizing the value and sharing the risk of a one-time treatment, which make us subject to potential repayments if a patient does not respond to therapy or the therapeutic effect of the drug falls below specified thresholds. Although we will record reserves for potential refunds under the outcomes-based agreements for ROCTAVIAN in the same period as sales, our revenues and financial results could be adversely affected if our assumptions underlying our refund reserves differ from actual experience or otherwise underestimate refund obligations. Additionally, the novelty and increased complexity of reimbursement with outcomes-based arrangements heightens the risk that our price reporting may be inaccurate or delayed, which may result in fines and liability.We also face uncertainty as to whether gene therapy will gain the acceptance of the public or the medical community. The commercial success of ROCTAVIAN or any other gene therapy product candidate that may be approved in the future will depend, in part, on the acceptance of physicians, patients and third-party payers of gene therapy products in general, and our product in particular, as medically necessary, cost-effective and safe. In particular, our success will depend upon physicians prescribing our product in lieu of existing treatments they are already familiar with and for which greater clinical data may be available. Moreover, physicians and patients may delay acceptance of one of our gene therapy treatments until the product has been on the market for a certain amount of time. Although administration of a gene therapy product like ROCTAVIAN is intended to correct an inborn genetic defect for at least several years, there is a risk that the therapeutic effect will not be durable and production of the desired protein or ribonucleic acid will decrease more quickly or cease entirely earlier than expected. If the therapeutic effect decreases significantly or ceases entirely, it is uncertain whether redosing is possible or would be effective. Furthermore, because gene therapy treatment is irreversible, there may be challenges in managing side effects, particularly those caused by potential 32Table of Contentsoverproduction of the desired protein. Adverse effects would not be able to be reversed or relieved by stopping dosing, and we may have to develop additional clinical safety procedures. Additionally, because the new gene copies are designed to reside permanently in a patient, there is a risk that they will disrupt other normal biological molecules and processes, including other healthy genes, and we may not learn the nature and magnitude of these side effects until long after clinical trials have been completed. Negative public opinion or more restrictive government regulations could have a negative effect on our business and financial condition and may delay or impair the successful commercialization of, and demand for, ROCTAVIAN or future gene therapy products. *Because the target patient populations for our products are relatively small, we must achieve significant market share and maintain high per-patient prices for our products to achieve and maintain profitability.All of our products target diseases with relatively small patient populations. As a result, our per-patient prices must be relatively high in order to recover our development and manufacturing costs and achieve and maintain profitability. For BRINEURA, NAGLAZYME and VIMIZIM in particular, we must market worldwide to achieve significant market penetration of the product. In addition, because the number of potential patients in each disease population is small, it is not only important to find patients who begin therapy to achieve significant market penetration of the product, but we also need to be able to maintain these patients on therapy for an extended period of time. Due to the expected costs of treatment for our products, we may be unable to maintain or obtain sufficient market share at a price high enough to justify our product development efforts and manufacturing expenses.If we fail to compete successfully with respect to product sales, we may be unable to generate sufficient sales to recover our expenses related to the development of a product program or to justify continued marketing of a product and our revenues could be adversely affected.Our competitors may develop, manufacture and market products that are more effective or less expensive than ours. They may also obtain regulatory approvals for their products faster than we can obtain them (including those products with orphan drug designation, which may prevent us from marketing our product entirely for seven years, along with other regulatory exclusivities that could block approval) or commercialize their products before we do. With respect to ROCTAVIAN, we face a highly developed and competitive market for hemophilia A treatments. As we commercialize ROCTAVIAN, we may face intense competition from large pharmaceutical companies with extensive resources and established relationships in the hemophilia A community. If we do not compete successfully, our revenues would be adversely affected, and we may be unable to generate sufficient sales to recover our expenses related to the development of a product program or to justify continued marketing of a product.Changes in methods of treatment of disease could reduce demand for our products and adversely affect revenues.Even if our product candidates are approved, if doctors elect a course of treatment which does not include our products, this decision would reduce demand for our products and adversely affect revenues. For example, if gene therapy becomes widely used as a treatment of genetic diseases, the use of enzyme replacement therapy, such as ALDURAZYME, NAGLAZYME, and VIMIZIM in MPS diseases, could be greatly reduced. Changes in treatment method can be caused by the introduction of other companiesâ€™ products or the development of new technologies or surgical procedures which may not directly compete with ours, but which have the effect of changing how doctors decide to treat a disease.If we fail to develop new products and product candidates or compete successfully with respect to acquisitions, joint ventures, licenses or other collaboration opportunities, our ability to continue to expand our product pipeline and our growth and development would be impaired.Our future growth and development depend in part on our ability to successfully develop new products from our development activities. The development of biopharmaceutical products is very expensive and time intensive and involves a great degree of risk. The outcomes of research and development programs, especially for innovative biopharmaceuticals like gene therapy products, are inherently uncertain and may not result in the commercialization of any products.Our competitors compete with us to attract organizations for acquisitions, joint ventures, licensing arrangements or other collaborations. To date, several of our former and current product programs have been acquired through acquisitions and several of our former and current product programs have been developed through licensing or collaborative arrangements, such as ALDURAZYME, KUVAN and NAGLAZYME. These collaborations include licensing proprietary technology from, and other relationships with, academic research institutions. Our future success will depend, in part, on our ability to identify additional opportunities and to successfully enter into partnering or acquisition agreements for those opportunities. If our competitors successfully enter into partnering arrangements or license agreements with academic research institutions, we will then be precluded from pursuing those specific opportunities. Because each of these opportunities is unique, we may not be able to find a substitute. Several pharmaceutical and biotechnology companies have already established themselves in the field of genetic diseases. These companies have already begun many drug development programs, some of which target diseases that we are also targeting or may target in the future, and have already entered into partnering and licensing arrangements with academic research institutions, reducing the pool of available opportunities.33Table of ContentsUniversities and public and private research institutions also compete with us. While these organizations primarily have educational or basic research objectives, they may develop proprietary technology and acquire patents that we may need for the development of our product candidates. We will attempt to license this proprietary technology, if available. These licenses may not be available to us on acceptable terms, if at all. If we are unable to compete successfully with respect to acquisitions, joint venture and other collaboration opportunities, we may be limited in our ability to develop new products and to continue to expand our product pipeline.The sale of generic versions of KUVAN by generic manufacturers has adversely affected and will continue to adversely affect our revenues and may cause a decline in KUVAN revenues faster than expected.Generic versions of KUVAN are available in several countries around the world, including multiple generic versions in the U.S. and the EU. This generic competition has adversely affected and will continue to adversely affect our revenues from KUVAN, and we cannot accurately predict the rate of decline of KUVAN revenues in these countries. We are also aware that manufacturers are challenging our patent portfolio related to KUVAN in several jurisdictions, and several generic versions of KUVAN have been approved either centrally by the European Commission (EC) or on a country-by-country basis throughout the EU. If these patent challenges are successful, or if a manufacturer chooses to offer a generic version of KUVAN, notwithstanding our existing patents, our revenues from KUVAN may decline faster than expected.If we do not achieve our projected development goals in the timeframes we announce or fail to achieve such goals, the commercialization of our product candidates may be delayed or never occur and the credibility of our management may be adversely affected and, as a result, our stock price may decline.For planning purposes, we estimate the timing of the accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials and the submission of regulatory filings. From time to time, we publicly announce the expected timing of some of these milestones. All of these milestones are based on a variety of assumptions. The actual timing of these milestones can vary dramatically compared to our estimates or the milestones may never be achieved, in many cases for reasons beyond our control. For example, in 2021 and early 2022, we announced that we planned to resubmit our Biologics License Application (BLA) for ROCTAVIAN to the Food and Drug Administration (FDA) in the first half of 2022; however, we did not file the BLA until the third quarter of 2022 due to the additional time we needed to include supplemental information and analyses of data requested by the FDA. If we do not meet development milestones as publicly announced, the commercialization of our products may be delayed or never occur and the credibility of our management may be adversely affected and, as a result, our stock price may decline.We have in the past entered and may in the future enter into licensing arrangements, and we may not realize the benefits of such licensing arrangements. We have in the past entered and may in the future enter into licensing arrangements with third parties. It is possible that we may not achieve financial or strategic benefits that justify a specific license, or we may otherwise not realize the benefits of such licensing arrangement. Further, licensing arrangements impose various diligence, milestone and royalty payment and other obligations on us. If we fail to comply with our obligations under any current or future licenses, our licensors may have the right to terminate these license agreements, which could harm our business prospects, financial condition and results of operations. Additionally, counterparties to our license agreements have in the past alleged and may in the future allege that we have breached a license agreement, which can result in litigation or other disputes that can divert managementâ€™s attention away from our business and require us to expend resources, as well as potentially having to negotiate new or reinstated licenses with less favorable terms. Any such situation could adversely affect our business, financial condition, and results of operations.Activist investor actions threatened or commenced against us have and could in the future cause us to incur substantial costs, divert management's attention and resources, cause uncertainty about the strategic direction of our business and adversely affect our business, financial position and results of operations.We have been, and may in the future be, subject to activities initiated by activist investors. In December 2023, we entered into a Cooperation Agreement with Elliott Investment Management L.P., Elliott Associates, L.P. and Elliott International, L.P. (collectively, Elliott). We may not be successful in engaging constructively with one or more investors in the future despite our efforts to maintain constructive and ongoing communications with all investors, including Elliott. Resulting actions taken by activist investors from time to time have and could in the future conflict with our strategic direction, divert the attention of our Board of Directors, management, and employees, be costly and time-consuming, and disrupt the momentum in our business and operations, as well as our ability to execute our strategic plan. These types of actions may also create perceived uncertainties as to the future direction of our business or strategy, which may be exploited by our competitors and may make it more difficult to attract and retain qualified personnel, and may impact our relationships with investors, vendors, customers and other third parties. These types of actions could also impact the market price and the volatility of our common stock. In addition, we may choose to initiate, or may become subject to, litigation as a result of activist investor actions, which would serve as a further distraction to our Board of Directors, senior management and employees and could require us to incur significant additional costs.34Table of ContentsRegulatory RisksIf we fail to obtain regulatory approval to commercially market and sell our product candidates, or if approval of our product candidates is delayed, we will be unable to generate revenues from the sale of these product candidates, our potential for generating positive cash flow

will be diminished, and the capital necessary to fund our operations will increase.We must obtain regulatory approval to market and sell our product candidates. For example, in the U.S., we must obtain FDA approval for each product candidate that we intend to commercialize, and in the EU, we must obtain approval from the EC, based on the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The FDA and EC approval processes are typically lengthy and expensive, and approval is never certain. To obtain regulatory approval, we must first show that our product candidates are safe and effective for target indications through preclinical studies and clinical trials. Preclinical studies and clinical development are long, expensive and uncertain processes. Completion of clinical trials may take several years, and failure may occur at any stage of development. The length of time required varies substantially according to the type, complexity, novelty and intended use of a product candidate. Interim results of a preclinical test or clinical trial do not necessarily predict final results, and acceptable results in early clinical trials may not be repeated in later clinical trials. Accordingly, there are no assurances that we will obtain regulatory approval for any of our product candidates. Furthermore, there can be no assurance that approval of one of our product candidates by one regulatory authority will mean that other authorities will also approve the same product candidate. Similarly, in the EU, a positive CHMP opinion for approval of a product candidate does not guarantee that the EC will approve the product candidate. Moreover, regulatory authorities may approve a product candidate for fewer or more limited indications than requested. In addition, regulatory authorities may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates.We have had fewer interactions with regulatory authorities outside the U.S. and the EU as compared to our interactions with the FDA, the EC and the EMA. The approval procedures vary among countries and can involve additional clinical testing, and the time required to obtain approval may differ from that required to obtain FDA or EC approval. Moreover, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Approval by the FDA or EC does not ensure approval by regulatory authorities in other countries, and approval by one or more non-U.S. regulatory authorities does not ensure approval by regulatory authorities in other non-U.S. countries or by the FDA or EC. However, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. The non-U.S. regulatory approval process may include all of the risks associated with obtaining FDA or EC approval. We may not obtain non-U.S. regulatory approvals on a timely basis, if at all. We may not be able to file for regulatory approvals and even if we file, we may not receive necessary approvals to commercialize our product candidates in any market.We also rely on independent third-party Contract Research Organizations (CROs) to file some of our non-U.S. marketing applications, and while we keep a close oversight on the activities we delegate to CROs, important aspects of the services performed for us by the CROs are out of our direct control. If we fail to adequately manage our CROs, if the CRO elects to prioritize work on our projects below other projects or if there is any dispute or disruption in our relationship with our CROs, the filing of our applications may be delayed.Although the FDA, the EC and the EMA have programs to facilitate expedited development and accelerated approval processes, the timelines agreed under legislative goals or mandated by regulations are subject to the possibility of substantial delays. Accordingly, even if any of our applications receives a designation to facilitate expedited development and accelerated approval processes, these designations may not result in faster review or approval for our product candidates compared to product candidates considered for approval under conventional procedures and, in any event, do not assure ultimate approval of our product candidates by regulatory authorities. In addition, the FDA, the EC, the EMA and other comparable international regulatory authorities have substantial discretion over the approval process for pharmaceutical products. These regulatory authorities may not agree that we have demonstrated the requisite level of product safety and efficacy to warrant approval and may require, and in the past have required, additional data. If we fail to obtain regulatory approval for our product candidates, we will be unable to market and sell those product candidates, which would have a negative effect on our business and financial condition.Regulatory authorities and the new requirements and guidelines they promulgate may lengthen the regulatory review process, require us to perform additional or larger studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval studies, limitations or restrictions. For example, on August 18, 2020, the FDA issued a Complete Response Letter (CRL) to our BLA for ROCTAVIAN for the treatment of adults with severe hemophilia A. In the CRL, the FDA introduced a new request for two-year follow-up safety and efficacy data on all study participants from our ongoing Phase 3 study of ROCTAVIAN. In January 2022, we announced results from the requested two-year data analysis from our Phase 3 study. In the third quarter of 2022, we resubmitted our BLA, and the FDA subsequently accepted our submission with an original Prescription Drug User Fee Act (PDUFA) target action date of March 31, 2023. In early 2023, we supplemented our BLA by submitting our three-year analysis of the global Phase 3 study of ROCTAVIAN, which the FDA deemed to be a Major Amendment to our BLA due to the substantial amount of additional data, and extended the PDUFA target action date by three months. The FDA approved ROCTAVIAN for the treatment of adults with severe hemophilia A on June 29, 2023. Further, on April 26, 2023, the EC adopted a proposal for a new Directive and Regulation to 35Table of Contentsrevise the existing pharmaceutical legislation. If adopted in the form proposed, the recent EC proposals to revise the existing EU laws governing authorization of medicinal products may result in a decrease in data and market exclusivity for our product candidates in the EU.In addition, some of our product candidates are intended to be used in combination with a medical device, such as an injector or other delivery system. Some of these products intended to be used with a medical device may be regulated as â€œcombination productsâ€ in the U.S. and the EU, which are generally defined as products consisting of components from two or more regulatory categories (e.g., drug/device, device/biologic, drug/biologic). In the U.S., each component of a combination product is subject to the requirements established by the FDA for that type of component, whether a new drug, biologic or device. In order to facilitate pre-market review of combination products, the FDA designates one of its centers to have primary jurisdiction for the pre-market review and regulation of the overall product based upon a determination by the FDA of the primary mode of action of the combination product. The determination whether a product is a combination product or two separately regulated products is made by the FDA on a case-by-case basis. In the EU, medical devices and medicinal products are regulated separately, through different legislative instruments. The related applicable requirements will vary depending on the type of drug-device combination product. If, for example, a device intended to administer a medicinal product is sold together with such medicinal product in such a way that they form a single integral product which is intended exclusively for use in the given combination and which is not reusable, that single integral product is regulated as a medicinal product. In addition, the relevant general safety and performance requirements (GSPRs) established for medical devices by EU medical devices legislation apply to the device component of such combination products. In addition, some of our products require use with an in vitro companion diagnostic. For example, ROCTAVIAN is approved with a companion diagnostic test intended to detect pre-existing anti-AAV5 antibodies, which may render the gene therapy less effective or ineffective. Our other products and product candidates may also require use with an in vitro companion diagnostic if the FDA determines that the companion diagnostic is essential for safe and effective use of the product candidate. The FDA generally will require approval or clearance of the diagnostic, known as a companion diagnostic, at the same time that the FDA approves the therapeutic product. Most companion diagnostics require approval of a premarket approval application. In the EU, companion diagnostics are deemed to be in vitro diagnostic medical devices and must conform with the applicable GSPRs. To demonstrate compliance with the GSPRs, companion diagnostics must undergo a conformity assessment by a Notified Body. If the related medicinal product has been, or is in the process of being, authorized through the centralized procedure for the authorization of medicinal products, the Notified Body will, before it can issue a CE Certificate of Conformity, be required to seek a scientific opinion from the EMA on the suitability of the companion diagnostic for use in relation to the medicinal product concerned. For medicinal products that have been or are in the process of authorization through any other route provided in EU legislation, the Notified Body must seek the opinion of the national competent authority of an EU Member State. Our product candidates intended for use with separately regulated devices, such as companion diagnostics, or expanded indications that we may seek for our products used with such devices, may not be approved or may be substantially delayed in receiving approval if the devices do not gain and/or maintain their own regulatory approvals, clearances, or certifications. Where approval of the drug or biologic product and device is sought under a single application, such as a drug with an injector or delivery system, the increased complexity of the review process may delay approval. The FDA and EU review processes and related criteria are complex, which could also lead to delays in the approval process. In addition, because these devices are provided by unaffiliated third-party companies, we are dependent on the sustained cooperation and effort of those third-party companies both to obtain regulatory approval and to maintain their own regulatory compliance. Failure of third-party companies to assist in the approval process or to maintain their own regulatory compliance could delay or prevent approval of our product candidates, or limit our ability to sell a product once it is approved.Furthermore, despite our recent success obtaining regulatory approval for ROCTAVIAN in the U.S. and conditional approval in the EU, we may experience regulatory challenges for other gene therapy product candidates that cause significant delays or unanticipated costs, or that cannot be solved. Although numerous companies are currently advancing gene therapy product candidates through clinical trials, the FDA and EC have only approved a relatively small number of vector-based gene therapy products thus far. As a result, it is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our future gene therapy product candidates in any jurisdiction. Regulatory requirements governing gene and cell therapy products are still evolving and may continue to change in the future. Further, the FDA continues to develop and publish new guidance and policies, generally, by releasing one or more gene therapy-specific guidance documents each year. These guidance documents and other recent policy statements demonstrate that regulatory requirements for gene therapies are likely to continue to evolve based upon factors such as the intended disease or class of diseases, product type or mechanism of action, broader considerations such as the kinds of evidence that will be required for gene therapy products to take advantage of expedited development programs, and the experiences obtained by FDA when applying their legal and regulatory authorities to an evolving field, like gene therapy products. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring our gene therapy product candidates to market could have a negative effect on our business and financial condition.From time to time during the development and regulatory approval process for our products and product candidates, we engage in discussions with the FDA, the EC, the EMA and other comparable international regulatory authorities regarding our development programs, including discussions about the regulatory requirements for approval. As part of these discussions, we sometimes seek advice in the design of our clinical programs from various regulatory authorities globally, but we do not always follow such guidance. This increases the chance of adverse regulatory actions, but we try to always provide appropriate scientific evidence to support approval. Moreover, sometimes different regulatory authorities provide different or conflicting advice. While we 36Table of Contentsattempt to harmonize the advice we receive from multiple regulatory authorities, it is not always practical to do so. Also, we may choose not to harmonize conflicting advice when harmonization would significantly delay clinical trial data or is otherwise inappropriate. If we are unable to effectively and efficiently resolve and comply with the inquiries and requests of the FDA, the EC, the EMA and other comparable international regulatory authorities, the approval of our product candidates may be delayed and their value may be reduced.Any product for which we have obtained regulatory approval, or for which we obtain approval in the future, is subject to, or will be subject to, extensive ongoing regulatory requirements by the FDA, the EC, the EMA and other comparable international regulatory authorities, and if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, we may be subject to penalties, we will be unable to generate revenues from the sale of such products, our potential for generating positive cash flow will be diminished, and the capital necessary to fund our operations will be increased.Our products have received regulatory approval to be commercially marketed and sold in the U.S., the EU, and certain other countries except ROCTAVIAN, which has received regulatory approval to be commercially marketed in the U.S. and conditional approval to be commercially marketed in the EU. Any product for which we have obtained regulatory approval, or for which we obtain regulatory approval in the future, along with the manufacturing processes and practices, post-approval clinical research, product labeling, advertising and promotional activities for such product, are subject to continual requirements of, and review by, the FDA, the EC, the EMA and/or other comparable international and national regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, current Good Manufacturing Practices (cGMP) requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, import and export requirements and record keeping.An example of the ongoing regulatory requirements our products are subject to is the PALYNZIQ Risk Evaluation and Mitigation Strategy (REMS) program. In the U.S., PALYNZIQ is only available through the REMS program, which is required by the FDA to mitigate the risk of anaphylaxis while using the product. Notable requirements of our REMS program include the following:â€¢prescribers must be certified by enrolling in the REMS program and completing training;â€¢prescribers must prescribe auto-injectable epinephrine with PALYNZIQ;â€¢pharmacies must be certified with the REMS program and must dispense PALYNZIQ only to patients who are authorized to receive it;â€¢patients must enroll in the REMS program and be educated about the risk of anaphylaxis by a certified prescriber to ensure they understand the risks and benefits of treatment with PALYNZIQ; andâ€¢patients must have auto-injectable epinephrine available at all times while taking PALYNZIQ.Failure of prescribers, pharmacies or patients to enroll in our REMS program or to successfully complete and comply with its requirements may result in regulatory action from the FDA or decreased sales of PALYNZIQ. The restrictions and requirements under our REMS program, as well as potential changes to these restrictions and requirements in the future, subject us to increased risks and uncertainties, any of which could harm our business. The requirement for a REMS program can materially affect the potential market for and profitability of a drug. We cannot predict whether the FDA will request, seek to require or ultimately require modifications to, or impose additional requirements on, the PALYNZIQ REMS program, or whether the FDA will permit modifications to the PALYNZIQ REMS program that we consider warranted. Any modifications required or rejected by the FDA could make it more difficult or expensive for us to distribute PALYNZIQ in the U.S., impair the safety profile of PALYNZIQ, disrupt continuity of care for PALYNZIQ patients and/or negatively affect sales of PALYNZIQ.In addition, in the EU, the marketing authorization for BRINEURA was granted under â€œexceptional circumstancesâ€. As a result, the risk-benefit balance of BRINEURA is reviewed annually and the marketing authorization may be withdrawn if the risk-benefit ratio is no longer favorable. The conditional marketing authorization for ROCTAVIAN is, moreover, valid for one year and must be reviewed annually until all related conditions have been fulfilled to permit transfer to a full authorization. Failure to continue to show favorable risk-benefit balance for BRINEURA or satisfy the conditions related to ROCTAVIANâ€™s conditional marketing authorization could result in the withdrawal of the marketing approvals for these products.Moreover, promotional communications with respect to prescription drugs, including biologics, are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the productâ€™s approved labeling and Summary of Product Characteristics. In particular, a product may not be promoted for uses that are not approved by the FDA or the EC as reflected in the productâ€™s approved labeling. Although the FDA and other comparable international and national regulatory authorities do not regulate a physicianâ€™s choice of drug treatment made in the physicianâ€™s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. The FDA and other national competent authorities or international regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant civil, criminal and administrative penalties. Thus, we are not able 37Table of Contentsto promote any products we develop for indications or uses for which they are not approved. Additionally, in the EU, it is prohibited to promote prescription drugs to the general public and we are therefore limited to promote our products exclusively to healthcare professionals. Public prosecutors, industry associations, healthcare professionals and other members of the public closely scrutinize advertising and promotion of any product in the EU.Moreover, if original FDA approval for one of our product candidates is granted via the accelerated approval pathway, we will be required to conduct a post-marketing confirmatory trial to verify and describe the clinical benefit in support of full approval. An unsuccessful post-marketing study or failure to complete such a study with due diligence could result in the withdrawal of the FDAâ€™s marketing approval for a product candidate. For example, VOXZOGO is approved in the U.S. under accelerated approval based on an improvement in annualized growth velocity. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory studies. To fulfill this post-marketing requirement, we intend to use our ongoing open-label extension studies compared to available natural history. In addition, the FDA and the EC often require post-marketing testing and surveillance to monitor the effects of products. The FDA, the EC and other comparable international regulatory authorities may condition approval of our product candidates on the completion of such post-marketing clinical studies. These post-marketing studies may suggest that a product causes undesirable side effects or may present a risk to the patient.Discovery after approval of previously unknown problems with any of our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in actions such as:â€¢the issuance of safety alerts, press releases or other communications containing warnings about related products; â€¢modifications to promotional materials or corrective information to healthcare professionals; â€¢restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;â€¢suspensions or restrictions on our operations, including product manufacturing processes;â€¢restrictions on the marketing of a product;â€¢restrictions on product distribution;â€¢requirements to conduct post-marketing clinical

trials;â€¢untitled or warning letters or other adverse publicity;â€¢withdrawal of the products from the market;â€¢suspended or withdrawn regulatory approvals;â€¢refusal or delays to approve pending applications or supplements to approved applications that we submit;â€¢recall of products;â€¢refusal to permit the import or export of our products;â€¢product seizure;â€¢fines, restitution or disgorgement of profits or revenue;â€¢injunctions; orâ€¢imposition of civil or criminal penalties.If such regulatory actions are taken, our value and our operating results will be adversely affected. Additionally, if the FDA, the EC or any other comparable international regulatory authorities withdraws its approval of a product, we will be unable to generate revenues from the sale of that product in the relevant jurisdiction, our potential for generating positive cash flow will be diminished and the capital necessary to fund our operations will be increased. Accordingly, we continue to expend significant time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance, post-marketing studies and quality control.To obtain regulatory approval to market our products, preclinical studies and costly and lengthy clinical trials are required and the results of the studies and trials are highly uncertain. Likewise, preliminary, initial or interim data from clinical trials should be considered carefully and with caution because the final data may be materially different from the preliminary, initial or interim data, particularly as more patient data become available.As part of the drug development process, we must conduct, at our own expense, preclinical studies in the laboratory, including studies in animals, and clinical trials on humans for each product candidate. The number of preclinical studies and clinical trials that regulatory authorities require varies depending on the product candidate, the disease or condition the drug is being developed to address and regulations applicable to the particular drug. Generally, new drugs for diseases or conditions that affect larger patient populations, are less severe, or are treatable by alternative strategies must be validated through additional preclinical and clinical trials and/or clinical trials with higher enrollments. With respect to our early-stage product candidates, we may need to 38Table of Contentsperform multiple preclinical studies using various doses and formulations before we can begin clinical trials, which could result in delays to our development timeline. Furthermore, even if we obtain favorable results in preclinical studies, the results in humans may be significantly different. After we have conducted preclinical studies, we must demonstrate that our product candidates are safe and efficacious for the intended indication and for use in the targeted human patients in order to receive regulatory approval for commercial sale. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials, and favorable data from interim analyses do not ensure the final results of a trial will be favorable. From time to time, we have published and may in the future publish or report preliminary, initial or interim data from our clinical trials. Preliminary, initial or interim data from our clinical trials may not be indicative of the final results of the trial and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. In this regard, such data may show initial evidence of clinical benefit, but as patients continue to be followed and more patient data become available, there is a risk that any therapeutic effects will not be durable in patients and/or will decrease over time or cease entirely. Preliminary, initial or interim data also remain subject to audit and verification procedures that may result in the final data being materially different from such preliminary, initial or interim data. As a result, preliminary, initial or interim data should be considered carefully and with caution until the final data are available.Product candidates may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials, or despite having favorable data in connection with an interim analysis. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Also, as noted above, we do not always follow the advice of regulatory authorities or comply with all of their requests regarding the design of our clinical programs. In those cases, we may choose a development program that is inconsistent with the advice of regulatory authorities, which may limit the jurisdictions where we conduct clinical trials and/or adversely affect our ability to obtain approval in those jurisdictions where we do not follow the regulatory advice.Adverse or inconclusive clinical results could stop us from obtaining regulatory approval of our product candidates. Additional factors that can cause delay or termination of our clinical trials include:â€¢slow or insufficient patient enrollment;â€¢slow recruitment of, and completion of necessary institutional approvals at, clinical sites;â€¢budgetary constraints or prohibitively high clinical trial costs;â€¢longer treatment time required to demonstrate efficacy;â€¢lack of sufficient supplies of the product candidate;â€¢adverse medical events or side effects in treated patients, including immune reactions;â€¢lack of effectiveness of the product candidate being tested;â€¢availability of competitive therapies to treat the same indication as our product candidates;â€¢regulatory requests for additional clinical trials or preclinical studies;â€¢deviations in standards for Good Clinical Practice (GCP); andâ€¢disputes with or disruptions in our relationships with clinical trial partners, including CROs, clinical laboratories, clinical sites, and principal investigators.Government price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our current and future products, which would adversely affect our revenues and results of operations.We expect that coverage and reimbursement may be increasingly restricted in all the markets in which we sell our products. The escalating cost of healthcare has led to increased pressure on the healthcare industry to reduce costs. In particular, drug pricing by pharmaceutical companies has been under scrutiny for many years and continues to be subject to intense political and public debate in the U.S. and abroad. Governmental and private third-party payers have proposed healthcare reforms and cost reductions. A number of federal and state proposals to control the cost of healthcare, including the cost of drug treatments, have been made in the U.S. Specifically, there have been several recent U.S. congressional inquiries and proposed bills and enacted legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. Further, Congress and the executive branch have each indicated that they will continue to seek new legislative and/or administrative measures to control drug costs. In some international markets, the government controls the pricing, which can affect the profitability of drugs. Current government regulations and possible future legislation regarding healthcare may affect coverage and reimbursement for medical treatment by third-party payers, which may render our products not commercially viable or may adversely affect our future revenues and gross margins.39Table of ContentsInternational operations are also generally subject to extensive price and market regulations, and there are many proposals for additional cost-containment measures, including proposals that would directly or indirectly impose additional price controls or mandatory price cuts or reduce the value of our intellectual property portfolio. As part of these cost containment measures, some countries have imposed and continue to propose revenue caps limiting the annual volume of sales of our products. Some of these caps are significantly below the actual demand in certain countries, and if the trend regarding revenue caps continues, our future revenues and gross margins may be adversely affected. For example, in the EU, governments influence the price of medicinal products through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to consumers. EU Member States are free to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed to by the government. An EU Member State may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market, including volume-based arrangements, caps and reference pricing mechanisms. Other EU Member States allow companies to fix their own prices for medicines but monitor and control company profits. The downward pressure on healthcare costs in general, particularly prescription medicines, has become very intense. Pharmaceutical products may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products and may also compete with imported foreign products. Furthermore, there is no assurance that a product will be considered medically reasonable and necessary for a specific indication or cost-effective by third-party payers. There is also no assurance that an adequate level of reimbursement will be established even if coverage is available or that the third-party payersâ€™ reimbursement policies will not adversely affect our business.We cannot predict the extent to which our business may be affected by these or other potential future legislative or regulatory developments. However, future price controls or other changes in pricing regulation or negative publicity related to our product pricing or the pricing of pharmaceutical drugs generally could restrict the amount that we are able to charge for our current and future products or our sales volume, which would adversely affect our revenues and results of operations.Government healthcare reform could increase our costs and adversely affect our revenues and results of operations.Our industry is highly regulated and changes in law may adversely impact our business, operations or financial results. In the U.S., there have been and continue to be a number of legislative initiatives to contain healthcare costs. In the U.S., there have been several recent congressional inquiries, proposed and enacted federal and state legislation and executive action designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies for drug products. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payers. Recently, several healthcare reform initiatives culminated in the enactment of the Inflation Reduction Act (IRA) in August 2022, which allows, among other things, U.S. Department of Health and Human Services (HHS) to negotiate the selling price of a statutorily specified number of drugs and biologics each year that the CMS reimburses under Medicare Part B and Part D. Only high-expenditure single-source drugs that have been approved for at least 7 years (11 years for biologics) can be selected by CMS for negotiation. The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs are implemented. Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties. The IRA's provisions are taking effect progressively starting in 2023, although they may be subject to legal challenges. Thus, while it is unclear how the IRA will be implemented, it will likely have a significant impact on the pharmaceutical industry.Prior to the IRA, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the PPACA) is a sweeping measure intended to, among other things, expand healthcare coverage within the U.S., primarily through the imposition of health insurance mandates on employers and individuals and expansion of the Medicaid program. Several provisions of the law have affected us and increased certain of our costs. Since its enactment, there have been executive, judicial and congressional challenges to certain aspects of the PPACA. Although the PPACA has generally been upheld thus far, it is unclear how continued challenges to the law may impact the PPACA and our business. In addition, other legislative changes have been adopted since the PPACA was enacted. Some of these changes have resulted in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our customers and, accordingly, our financial operations.In addition, individual states in the U.S. have also increasingly enacted laws and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, price disclosure and reporting requirements, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Moreover, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. 40Table of ContentsLikewise, in many EU Member States, legislators and other policymakers continue to propose and implement healthcare cost-containing measures in response to the increased attention being paid to healthcare costs in the EU. Certain of these changes could impose limitations on the prices we will be able to charge for our commercial products and any product candidates or the amounts of reimbursement available for these products from governmental and private third-party payers, may increase the tax obligations on pharmaceutical companies or may facilitate the introduction of generic competition with respect to our products. Further, an increasing number of EU Member States and other non-U.S. countries use prices for medicinal products established in other countries as â€œreference pricesâ€ to help determine the price of the product in their own territory. If the price of one of our products decreases substantially in a reference price country, it could impact the price for that product in other countries. Consequently, a downward trend in prices of our products in some countries could contribute to similar downward trends elsewhere, which would have a material adverse effect on our revenues and results of operations. Moreover, some EU Member States require the completion of additional studies that compare the cost-effectiveness of a particular medicinal product candidate to currently available therapies. This Health Technology Assessment (HTA) process, which is currently governed by the national laws of the individual EU Member States, is the procedure according to which the assessment of the public health impact, therapeutic impact and the economic and societal impact of use of a given medicinal product in the national healthcare systems of the individual country is conducted. The outcome of HTA regarding specific medicinal products will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU Member States. In 2022, the EC adopted the HTA regulation, which is intended to boost cooperation among EU Member States in evaluating new medicinal products. The HTA regulation will apply starting in 2025 and may result in increased downward pricing pressure in the EU.We anticipate that the IRA, PPACA and other healthcare reform measures that may be adopted in the future in the U.S. or abroad, may result in more rigorous coverage criteria and an additional downward pressure on the reimbursement our customers may receive for our products. Legally mandated price controls on payment amounts by governmental and private third-party payers or other restrictions could harm our business, results of operations, financial condition and prospects. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.If we fail to obtain or maintain orphan drug exclusivity for some of our products, our competitors may obtain approval to sell the same drugs to treat the same conditions and our revenues will be reduced.As part of our business strategy, we have developed and may in the future develop some drugs that may be eligible for FDA and EU orphan drug designation. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is intended to treat a rare disease or condition, defined as a patient population of fewer than 200,000 in the U.S. or as a condition that affects more than 200,000 individuals in the U.S. and for which there is no reasonable expectation that the costs of development of said drug will be recovered from sales in the U.S. In the EU, pursuant to the Regulation (EC) No. 141/2000 (the Orphan Regulation), as implemented by Regulation (EC) No. 847/2000, orphan drug designation is available if a sponsor can establish that: (1) the medicine is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting no more than five in 10,000 people in the EU at the time the application is made, or, (2) that it is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the EU and that without incentives derived from the orphan status, it is unlikely that the marketing of the medicine in the EU would generate sufficient return to justify the necessary investment. In both cases, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the medicine will be of significant benefit to those affected by that condition.In the U.S., the company that first obtains FDA approval for a designated orphan drug for a given rare disease receives marketing exclusivity for use of that drug for the designated condition for a period of seven years. Orphan drug exclusive marketing rights may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug. In addition, the FDA may approve another drug during a period of orphan drug exclusivity if the second drug is found to be clinically superior to the first drug. In the EU, a ten-year period of market exclusivity for the approved therapeutic indication (extendable to twelve years for orphan drugs that have complied with an agreed Pediatric Investigation Plan (PIP) pursuant to Regulation 1901/2006), during which the EMA cannot accept another marketing authorization application or accept an application to extend existing authorizations for similar medicinal products for the same indication and no related marketing authorization (MA) can be granted. MAs may also be granted to a similar medicinal product with the same orphan indication if: (i) the applicant can establish that the second medicinal product, although similar to the orphan medicinal product already authorized is safer, more effective or otherwise clinically superior to the orphan medicinal product already authorized; (ii) the MA holder for the first orphan medicinal product grants its consent; or (iii) if the MA holder of the orphan medicinal product is unable to supply sufficient quantities. MAs may also be granted for the same therapeutic indication in relation to products that are not similar. The period of market exclusivity may, in addition, be reduced to six years if, at the end of the fifth year, it can be demonstrated on the basis of available evidence that the criteria for its designation as an orphan medicine are no longer satisfied, for example if the original orphan medicinal product has become sufficiently profitable not to justify maintenance of market exclusivity. Because the extent and scope of patent protection for some of our products is limited, orphan drug designation and resulting regulatory exclusivity is especially important for our products that are eligible for orphan drug designation. For eligible products, we plan to rely on the exclusivity period under the Orphan Drug Act and/or the Orphan Regulation, as applicable, to maintain a competitive position. If we do not obtain orphan drug designation and related regulatory exclusivity for our products that 41Table of Contentsdo not have broad patent protection or if a competing product is determined to be "clinically superior" to any of our products that has secured orphan drug exclusivity, our competitors may then sell the same drug to treat the same condition and our revenues will be reduced.Even though we have obtained orphan drug designation for certain of our product candidates and even if we obtain orphan drug designation for our future product candidates, due to the

uncertainties associated with developing biopharmaceutical products, we may not be the first to obtain marketing approval for any particular orphan indication, which means that we may not obtain orphan drug regulatory exclusivity and could also potentially be blocked from approval of certain product candidates until the competitor productâ€™s orphan drug exclusivity period expires. Moreover, with respect to certain biologics and gene therapies, there may be some uncertainty regarding how similarity between product candidates designed to treat the same rare disease or condition may affect such product candidatesâ€™ orphan drug regulatory exclusivities. For biologics and gene therapies, the FDAâ€™s determination of whether a drug is the same drug or a different drug will be based on the principal molecular structural features of the products. For gene therapy products, the FDA has stated in guidance that it generally intends to consider certain key features such as transgenes and vectors used in gene therapy products to be principal molecular structural features. The FDA has not yet proffered additional information on orphan drug sameness for gene therapy or similar products. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition and the same drug can be approved for different conditions and potentially used off-label in the orphan indication. Even after an orphan drug is approved and granted orphan drug exclusivity, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is safer or more effective or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug, nor gives the drug any advantage in the regulatory review or approval process.We may face competition from biosimilars approved through an abbreviated regulatory pathway.Our ALDURAZYME, BRINEURA, NAGLAZYME, PALYNZIQ, ROCTAVIAN and VIMIZIM products are regulated by the FDA as biologics under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act (the PHS Act). Biologics require the submission of a BLA and licensure by the FDA prior to being marketed in the U.S. The Biologics Price Competition and Innovation Act of 2009 (BPCIA) created a regulatory pathway under the PHS Act for the abbreviated licensure of biological products that are demonstrated to be â€œbiosimilarâ€ to or â€œinterchangeableâ€ with an FDA-licensed biological product. A similar abridged MA process is available to biosimilar products in the EU. In particular, applicants for MAs of biosimilars are required to demonstrate through comprehensive comparability studies with the reference biological medicine that: a) their biological medicine is highly similar to the reference medicine, notwithstanding natural variability inherent to all biological medicines; and b) there are no clinically meaningful differences between the biosimilar and the reference medicine in terms of safety, quality and efficacy.In the U.S., in order to meet the standard of interchangeability, a sponsor must demonstrate that the biosimilar product can be expected to produce the same clinical result as the reference product in any given patient, and for a product that is administered more than once, that the risk of switching in terms of safety or diminished efficacy of alternating or switching between the reference product and biosimilar product is not greater than the risk of maintaining the patient on the reference product. The BPCIA establishes a period of 12 years of data exclusivity for reference products but such data exclusivity only blocks licensure of biosimilars relying on the product as a reference product; it will not prevent the licensure of the same product for the same or different indications that does not seek to rely on reference product data. In the EU, a medicinal product containing a new active substance benefits from eight years of data exclusivity, during which biosimilar applications referring to the data of that product may not be accepted by the regulatory authorities, and a further two years of market exclusivity, during which biosimilar applications may be submitted and the reference product's data may be referenced but biosimilar products may not be placed on the market. The two-year period may be extended to three years if during the first eight years a new therapeutic indication with significant clinical benefit over existing therapies is approved. Our products approved under BLAs in the U.S. or as a result of Marketing Authorization Applications (MAAs) in the EU, as well as our product candidates that may be approved in the future, could be reference products for biosimilar marketing applications.Changes in funding for the FDA, the EMA, other comparable regulatory authorities and other government agencies or government shutdowns could hinder the ability of such authorities and agencies to hire and retain key leadership and other personnel or otherwise prevent those authorities and agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.Changes in funding levels of regulatory authorities and government agencies can affect their ability to hire and retain key personnel and carry out their normal functions that support our business. For example, the ability of the FDA or the EMA to timely review and approve INDs or MAAs for our product candidates may be hindered by a lack of resources and qualified personnel. In addition, funding of other regulatory authorities and government agencies on which our operations rely, including those that fund research and development activities, is subject to the political budget process, which is inherently fluid and unpredictable.Government shutdowns could also impact the ability of regulatory authorities and government agencies to function normally and support our operations. For example, the U.S. federal government has shut down repeatedly since 1980, including for a period of 35 days beginning on December 22, 2018. During a shutdown, certain regulatory authorities and agencies, such as the 42Table of ContentsFDA, have had to furlough key personnel and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.Financial and Financing RisksIf we incur operating losses or are unable to sustain positive cash flows for a period longer than anticipated, we may be unable to continue our operations at planned levels and may be forced to reduce our operations.Since we began operations in March 1997, we have been engaged in substantial research and development and capital investments, and we have operated at a net loss for most years since our inception and there is no guarantee that we will achieve or maintain profitability in the future. Our future profitability and cash flows depend on our marketing and selling of our products, the receipt of regulatory approval of our product candidates, our ability to successfully manufacture and market any products, either by ourselves or jointly with others, our spending on our development programs, the impact of any possible future business development transactions and other risks set forth in this Risk Factors section. The extent of our future losses and the timing of profitability and positive cash flows are highly uncertain. If we are unable to sustain profitability and positive cash flows on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations.*If we fail to obtain the capital necessary to fund our operations, our financial results and financial condition will be adversely affected and we will have to delay or terminate some or all of our product development programs.As of JuneÂ 30, 2024, we had cash, cash equivalents and investments totaling $1.8 billion and debt obligations of $1.1 billion (undiscounted), which consisted of our 0.599% senior subordinated convertible notes due in 2024 (the 2024 Notes) and our 1.25% senior subordinated convertible notes due in 2027 (the 2027 Notes). The 2024 Notes matured on August 1, 2024 and substantially all holders of the 2024 Notes were repaid with cash, and the 2027 Notes, if not converted, will be required to be repaid in cash at maturity in May 2027. We will need cash not only to pay the ongoing interest due on the 2027 Notes during their term, but also to repay the principal amount of the 2027 Notes if not converted.We may require additional financing to fund the repayment of the 2027 Notes, future milestone payments and our future operations, including the commercialization of our products and product candidates currently under development, preclinical studies and clinical trials, and potential licenses and acquisitions. We may be unable to raise additional financing due to a variety of factors, including our financial condition, the status of our product programs, and the general condition of the financial markets. If we fail to raise any necessary additional financing we may have to delay or terminate some or all of our product development programs and our financial condition and operating results will be adversely affected.We expect to continue to spend substantial amounts of capital for our operations for the foreseeable future. The amount of capital we will need depends on many factors, including:â€¢our ability to successfully market and sell our products;â€¢the time and cost necessary to develop commercial manufacturing processes, including quality systems, and to build or acquire manufacturing capabilities the progress and success of our preclinical studies and clinical trials (including studies and the manufacture of materials);â€¢the timing, number, size and scope of our preclinical studies and clinical trials;â€¢the time and cost necessary to obtain regulatory approvals and the costs of post-marketing studies which may be required by regulatory authorities;â€¢the progress of research programs carried out by us;â€¢any changes made to, or new developments in, our existing collaborative, licensing and other commercial relationships or any new collaborative, licensing and other commercial relationships that we may establish;â€¢Sanofiâ€™s ability to continue to successfully commercialize ALDURAZYME; andâ€¢whether our convertible debt is converted to common stock in the future.Moreover, our fixed expenses such as rent, license payments, interest expense and other contractual commitments are substantial and may increase in the future. These fixed expenses may increase because we may enter into:â€¢additional licenses and collaborative agreements;â€¢additional contracts for product manufacturing; andâ€¢additional financing facilities or arrangements.43Table of ContentsWe will need to raise additional funds from equity or debt securities, loans or collaborative agreements if we are unable to satisfy our liquidity requirements. The sale of additional equity and/or equity-linked securities will result in additional dilution to our stockholders. Furthermore, additional financing may not be available in amounts or on terms satisfactory to us or at all. This could result in the delay, reduction or termination of our research, which could harm our business.*We have incurred substantial indebtedness that may decrease our business flexibility, access to capital, and/or increase our borrowing costs, which may adversely affect our operations and financial results. As of JuneÂ 30, 2024, we had $1.1 billion (undiscounted) principal amount of indebtedness, including $495.0 million (undiscounted) principal amount of indebtedness under the 2024 Notes and $600.0 million (undiscounted) principal amount of indebtedness under the 2027 Notes. The 2024 Notes matured on August 1, 2024 and substantially all holders of the 2024 Notes were repaid with cash. Our indebtedness may:â€¢limit our ability to borrow additional funds for working capital, capital expenditures, acquisitions or other general business purposes;â€¢limit our ability to use our cash flow or obtain additional financing for future working capital, capital expenditures, acquisitions or other general business purposes;â€¢require us to use a substantial portion of our cash flow from operations to make debt service payments;â€¢limit our flexibility to plan for, or react to, changes in our business and industry;â€¢place us at a competitive disadvantage compared to our less leveraged competitors; andâ€¢increase our vulnerability to the impact of adverse economic and industry conditions.If we default under the 2027 Notes, the 2027 Notes could become immediately due and payable.*In addition, our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time.Our outstanding indebtedness consists primarily of the 2027 Notes, which, if not converted, will be required to be repaid in cash at maturity in May 2027. While we could seek to obtain additional third-party financing to pay for any amounts due in cash upon maturity of the 2027 Notes, we cannot be sure that such third-party financing will be available on commercially reasonable terms, if at all.Manufacturing RisksIf we fail to comply with manufacturing regulations, our financial results and financial condition will be adversely affected.Prior to commercialization of our products, regulatory authorities must approve marketing applications that identify authorized manufacturing facilities operated by us or our contract manufacturers that are in compliance with cGMP requirements. In addition, our pharmaceutical manufacturing facilities are continuously subject to scheduled and unannounced regulatory inspections by the FDA, and other comparable EU and other national and international regulatory authorities, before and after product approval, to monitor and ensure compliance with cGMP and other regulations. Our manufacturing facilities in the U.S. are licensed for the manufacture of PALYNZIQ, ROCTAVIAN, ALDURAZYME, BRINEURA, NAGLAZYME, VIMIZIM, and VOXZOGO. Our manufacturing facility in Shanbally, Cork, Ireland is licensed for the manufacture of VIMIZIM and BRINEURA and packaging operations for VOXZOGO and PALYNZIQ. In addition, our third-party manufacturersâ€™ facilities involved with the manufacture of our products have also been inspected and approved by various regulatory authorities. Although we are not involved in the day-to-day operations of our contract manufacturers, we are ultimately responsible for ensuring that our products are manufactured in accordance with cGMP regulations.Due to the complexity of the processes used to manufacture our products and product candidates, we may be unable to continue to pass or initially pass federal, national or international regulatory inspections in a cost-effective manner. For the same reason, any potential third-party manufacturer of our products or our product candidates may be unable to comply with cGMP regulations in a cost-effective manner and may be unable to initially or continue to pass a federal, national or international regulatory inspection.If we, or third-party manufacturers with whom we contract, are unable to comply with manufacturing regulations, we may be subject to delay of approval of our product candidates, warning or untitled letters, fines, unanticipated compliance expenses, recall or seizure of our products, total or partial suspension of production and/or enforcement actions, including injunctions, and criminal or civil prosecution. These possible sanctions would adversely affect our financial results and financial condition. 44Table of Contents*If we are unable to successfully develop and maintain manufacturing processes for our product candidates to produce sufficient quantities at acceptable costs, we may be unable to support a clinical trial or be forced to terminate a program, or if we are unable to produce sufficient quantities of our products at acceptable costs, we may be unable to meet commercial demand, lose potential revenue, have reduced margins or be forced to terminate a program.Due to the complexity of manufacturing our product candidates and products, we may not be able to manufacture sufficient quantities. Our inability to produce enough of our product candidate at acceptable costs may result in the delay or termination of development programs. With respect to our commercial portfolio, we may not be able to manufacture our products successfully with a commercially viable process or at a scale large enough to support their respective commercial markets or at acceptable margins. For example, demand for VOXZOGO in certain markets outpaced our projections in recent quarters, and we have faced, and may in the future face, challenges meeting demand, requiring us to postpone planned entry into additional markets until VOXZOGO inventory levels increase or delay certain VOXZOGO development activities. As a result of such inventory constraints, we have lost, and may in the future lose, potential VOXZOGO revenues that may never be recouped and our VOXZOGO development program could be adversely impacted.The development of commercially viable manufacturing processes typically is very difficult to achieve and is often very expensive and may require extended periods of time. Changes in manufacturing processes (including manufacturing cell lines), equipment or facilities (including moving manufacturing from one of our facilities to another one of our facilities or a third-party facility, or from a third-party facility to one of our facilities) may require us to complete clinical trials to receive regulatory approval of any manufacturing modifications.Our gene therapy product and product candidates are based on relatively novel technology, which presents additional manufacturing risks in relation to our other, more traditional drug development programs. Gene therapy products are complex and have only in limited cases been manufactured at scales sufficient for pivotal trials and commercialization. Few pharmaceutical contract manufacturers specialize in gene therapy products and those that do are still developing appropriate processes and facilities for large-scale production. We invested a considerable amount of capital building our own commercial gene therapy manufacturing facility, which may be subject to significant impairment if our gene therapy programs are unsuccessful. As we develop, seek to optimize and operate the gene therapy manufacturing process, we will likely face technical and scientific challenges, considerable capital costs, and potential difficulty in recruiting and hiring experienced, qualified personnel. There may also be unexpected technical or operational issues during clinical or commercial manufacturing campaigns. As a result, we could experience manufacturing delays that prevent us from completing our gene therapy clinical studies in a timely manner, if at all, or commercializing our gene therapy products on a profitable basis, if at all.Also, we may be required to demonstrate product comparability between a biological product made after a manufacturing change and the product made before implementation of the change through additional types of analytical and functional testing or may have to complete additional clinical studies. If we contract for manufacturing services with an unproven process, our contractor is subject to the same uncertainties, high standards and regulatory controls, and may therefore experience difficulty if further process development is necessary.Even a developed manufacturing process can encounter difficulties. Problems may arise during manufacturing for a variety of reasons, including human error, mechanical breakdowns, problems with raw materials and cell banks, malfunctions of internal information technology systems, and other events that cannot always be prevented or anticipated. Many of the processes include biological systems, which add significant complexity, as compared to chemical synthesis. We expect that, from time to time, consistent with biotechnology industry expectations, certain production lots will fail to produce product that meets our quality control release acceptance criteria. To date, our historical failure rates for all of our product programs have been within our expectations, which are based on industry norms. If the failure rate increased substantially, we could experience increased costs, lost revenue, damage to customer relations, time and expense investigating the cause and, depending upon the cause, similar losses with respect to other lots or products. If problems are not discovered before the product is released to the market, recall and product liability costs may also be incurred.In order to produce product within our time and cost parameters, we must continue to produce product within our expected success rate and yield expectations. Because of the complexity of our manufacturing processes, it may be difficult or impossible for us to determine the cause of any particular lot failure and we must effectively take corrective action in response to any failure in a timely manner.We currently rely on third parties for portions of the manufacture of each of our products. If those manufacturers are unwilling or unable to fulfill their contractual obligations or satisfy demand outside of or in excess of the contractual obligations, we may be unable to meet demand for these products or sell these products at all and we may lose potential revenue. Further, the availability of suitable contract manufacturing capacity at scheduled or optimum times is not certain.In addition, our manufacturing processes subject us to a variety of federal, state, supranational, national, and local laws and regulations governing the use, generation, manufacture, storage, handling and disposal of hazardous materials and wastes resulting from their use. We incur significant costs in complying with these laws and regulations.45Table of ContentsSupply interruptions may disrupt our inventory levels and the availability of our products and product candidates and cause delays in obtaining regulatory approval for our product candidates, or harm our business by reducing our revenues.We depend on single-source

suppliers for critical raw materials and a limited number of manufacturing facilities to manufacture our finished products and product candidates. Numerous factors could cause interruptions in the supply or manufacture of our products and product candidates, including:â€¢timing, scheduling and prioritization of production by our contract manufacturers or a breach of our agreements by our contract manufacturers;â€¢labor interruptions;â€¢changes in our sources for manufacturing;â€¢the timing and delivery of shipments;â€¢our failure to locate and obtain replacement suppliers and manufacturers as needed on a timely basis; andâ€¢conditions affecting the cost and availability of raw materials, including inflation.If one of our suppliers or manufacturers fails or refuses to supply us with necessary raw materials or finished products or product candidates on a timely basis or at all, it would take a significant amount of time and expense to qualify a new supplier or manufacturer. We may not be able to obtain active ingredients or finished products from new suppliers or manufacturers on acceptable terms and at reasonable prices, or at all.Any interruption in the supply of finished products could hinder our ability to distribute finished products to meet commercial demand and adversely affect our financial results and financial condition.With respect to our product candidates, production of product is necessary to perform clinical trials and successful registration batches are necessary to file for approval to commercially market and sell product candidates. Delays in obtaining clinical material or registration batches could adversely impact our clinical trials and delay regulatory approval for our product candidates.If our Manufacturing, Marketing and Sales Agreement with Sanofi were terminated, we could be prevented from continuing to commercialize ALDURAZYME or our ability to successfully commercialize ALDURAZYME would be delayed or diminished.Either party may terminate the Manufacturing, Marketing and Sales Agreement (the MMS Agreement) between Sanofi and us related to ALDURAZYME for specified reasons, including if the other party is in material breach of the MMS Agreement, has experienced a change of control, as such term is defined in the MMS Agreement, or has declared bankruptcy and also is in breach of the MMS Agreement. Although we are not currently in breach of the MMS Agreement, there is a risk that either party could breach the MMS Agreement in the future. Either party may also terminate the MMS Agreement upon one-year prior written notice for any reason.If the MMS Agreement is terminated for breach, the breaching party will transfer its interest in the BioMarin/Genzyme LLC to the non-breaching party, and the non-breaching party will pay a specified buyout amount for the breaching partyâ€™s interest in ALDURAZYME and in the BioMarin/Genzyme LLC. If we are the breaching party, we would lose our rights to ALDURAZYME and the related intellectual property and regulatory approvals. If the MMS Agreement is terminated without cause, the non-terminating party would have the option, exercisable for one year, to buy out the terminating partyâ€™s interest in ALDURAZYME and in the BioMarin/Genzyme LLC at a specified buyout amount. If such option is not exercised, all rights to ALDURAZYME will be sold and the BioMarin/Genzyme LLC will be dissolved. In the event of termination of the buyout option without exercise by the non-terminating party as described above, all right and title to ALDURAZYME is to be sold to the highest bidder, with the proceeds to be split between Sanofi and us in accordance with our percentage interest in the BioMarin/Genzyme LLC.If the MMS Agreement is terminated by either party because the other party declared bankruptcy, the terminating party would be obligated to buy out the other party and would obtain all rights to ALDURAZYME exclusively. If the MMS Agreement is terminated by a party because the other party experienced a change of control, the terminating party shall notify the other party, the offeree, of its intent to buy out the offereeâ€™s interest in ALDURAZYME and the BioMarin/Genzyme LLC for a stated amount set by the terminating party at its discretion. The offeree must then either accept this offer or agree to buy the terminating partyâ€™s interest in ALDURAZYME and the BioMarin/Genzyme LLC on those same terms. The party who buys out the other party would then have exclusive worldwide rights to ALDURAZYME. The Amended and Restated Collaboration Agreement between us and Sanofi will automatically terminate upon the effective date of the termination of the MMS Agreement and may not be terminated independently from the MMS Agreement.46Table of ContentsIf we were obligated or given the option to buy out Sanofiâ€™s interest in ALDURAZYME and the BioMarin/Genzyme LLC, and thereby gain exclusive rights to ALDURAZYME, we may not have sufficient funds to do so and we may not be able to obtain the financing to do so. If we fail to buy out Sanofiâ€™s interest, we may be held in breach of the agreement and may lose any claim to the rights to ALDURAZYME and the related intellectual property and regulatory approvals. We would then effectively be prohibited from developing and commercializing ALDURAZYME. If this happened, not only would our product revenues decrease, but our share price would also decline.Risks Related to International Operations*We conduct a significant amount of our operations and generate a significant percentage of our sales outside of the U.S., which subjects us to additional business risks that could adversely affect our revenues and results of operations.A significant portion of the sales of our products are generated from countries other than the U.S., and we expect international markets will continue to be important for the sales of any products approved in the future. We have operations in Canada and in several European, Middle Eastern, Asian, and Latin American countries. We expect that we will continue to expand our international operations in the future. International operations inherently subject us to a number of risks and uncertainties, including:â€¢the increased complexity and costs inherent in managing international operations;â€¢diverse regulatory and compliance requirements, and changes in those requirements that could restrict our ability to manufacture, market and sell our products;â€¢geopolitical and economic instability, such as the instability caused by Russiaâ€™s invasion of Ukraine;â€¢diminished protection of intellectual property in some countries outside of the U.S.;â€¢trade protection measures and import or export licensing requirements;â€¢difficulty in staffing and managing international operations;â€¢differing labor regulations and business practices;â€¢potentially negative consequences from changes in or interpretations of tax laws;â€¢changes in international medical reimbursement policies and programs;â€¢financial risks such as longer payment cycles, difficulty collecting accounts receivable, exposure to fluctuations in foreign currency exchange rates and potential currency controls imposed by non-U.S. governments;â€¢regulatory and compliance risks that relate to maintaining accurate information and control over sales and distributorsâ€™ and service providersâ€™ activities that may fall within the purview of the Foreign Corrupt Practices Act (the FCPA); andâ€¢rapidly evolving global laws and regulations relating to data protection and the privacy and security of commercial and personal information.Any of these factors may, individually or as a group, have a material adverse effect on our business and results of operations. For example, Russiaâ€™s invasion of Ukraine and the related impacts to Ukraineâ€™s infrastructure and healthcare system has significantly impacted our ability to provide our therapies to patients in Ukraine. Sanctions issued by the U.S. and other countries against Russia and Belarus in response to the attack on Ukraine and related counter-sanctions issued by Russia have made it very difficult for us to operate in Russia and may have a material adverse impact on our ability to sell our products and/or collect receivables from customers in Russia and Belarus. As we continue to expand our existing international operations, we may encounter new risks. For example, as we focus on building our international sales and distribution networks in new geographic regions, we must continue to develop relationships with qualified local distributors and trading companies. If we are not successful in developing and maintaining these relationships, we may not be able to grow sales in these geographic regions. These or other similar risks could adversely affect our revenues and profitability.A significant portion of our international sales are made based on special access programs, and changes to these programs could adversely affect our product sales and revenues in these countries.We make a significant portion of our initial international sales of newly launched products through early access, special access or â€œnamed patient salesâ€ programs in markets where we are not required to obtain regulatory approval before establishing these programs. For example, a significant portion of our international sales of VOXZOGO since the productâ€™s launch have been made through such programs. The specifics of the programs vary from country to country. Generally, special approval must be obtained to initiate such programs, and in some cases, special approval must be obtained for each patient. The approval normally 47Table of Contentsrequires an application to national competent authorities in which the product is intended to be supplied or a lawsuit accompanied by evidence of medical need.These programs are not well defined in some countries and are subject to changes in requirements, funding levels, unmet medical need and classification of the disease treated by our product. Any change to these programs could adversely affect our ability to sell our products in those countries and delay sales. If the programs are not funded by the respective government, there could be insufficient funds to pay for all patients. Further, governments have and may continue to undertake unofficial measures to limit purchases of our products, including initially denying coverage for purchasers, delaying orders, requiring additional in-country testing and denying or taking excessively long to approve customs clearance. Any such actions could materially delay or reduce our revenues from such countries.Without the special access programs, we would need to seek full product approval or official reimbursement to commercially market and sell our products in certain jurisdictions. This can be an expensive and time-consuming process and may subject our products to additional price controls. Because the number of patients is so small in some countries, it may not be economically feasible to seek, obtain and maintain a full product approval or official reimbursement, and therefore the sales in such country would be permanently reduced or eliminated. For all of these reasons, if the special access programs that we are currently using are eliminated or restricted, our revenues could be adversely affected.Our international operations pose currency risks, which may adversely affect our operating results and net income.A significant and growing portion of our revenues and earnings, as well as our substantial international assets and liabilities, are exposed to changes in foreign exchange rates. As we operate in multiple foreign currencies, including the Euro, the Brazilian Real, the Russian Ruble, the Colombian Peso, the Argentine Peso and several other currencies, changes in those currencies relative to the U.S. Dollar (USD) will impact our revenues and expenses. If the USD were to weaken against another currency, assuming all other variables remained constant, our revenues would increase, having a positive impact on earnings, and our overall expenses would increase, having a negative impact on earnings. Conversely, if the USD were to strengthen against another currency (as was the case for many currencies in 2022), assuming all other variables remained constant, our revenues would decrease, having a negative impact on earnings, and our overall expenses would decrease, having a positive impact on earnings. In addition, because our financial statements are reported in USD, changes in currency exchange rates between the USD and other currencies have had, and will continue to have, an impact on our results of operations. Therefore, significant changes in foreign exchange rates can impact our results and our financial guidance.We implement currency hedges intended to reduce our exposure to changes in certain foreign currency exchange rates. However, our hedging strategies may not be successful, and any of our unhedged foreign exchange exposures will continue to be subject to market fluctuations. These risks could cause a material adverse effect on our business, financial position and results of operations and could cause the market value of our common stock to decline.U.S. export control and economic sanctions may adversely affect our business, financial condition and operating results. Moreover, compliance with such regulatory requirements may increase our costs and negatively impact our ability to sell our products and collect cash from customers.Our products are subject to U.S. export control laws and regulations, including the U.S. Export Administration Regulations and various economic and trade sanctions regulations administered by the U.S. Treasury Departmentâ€™s Office of Foreign Assets Control (OFAC). Exports of our products and solutions must be made in compliance with these laws and regulations. Changes to these laws and regulations, or to the countries, governments, persons or activities targeted by such laws, could result in decreased use of our products, or hinder our ability to export or sell our products to existing or potential customers, which would likely adversely affect our results of operations, financial condition or strategic objectives. For example, sanctions issued by the U.S. and other jurisdictions against Russia and Belarus in response to the invasion of Ukraine have made it very difficult for us to operate in Russia and may have a material adverse impact on our ability to sell our products and/or collect receivables from customers in Russia and Belarus. Moreover, if we fail to comply with these laws and regulations, we could be subject to substantial civil or criminal penalties, including the possible loss of export or import privileges and fines.We rely on a general license from OFAC to sell our medicines for eventual use by hospital and clinic end-users in Iran. The use of this OFAC general license requires us to observe strict conditions with respect to products sold, end-user limitations and payment requirements. Although we believe we have maintained compliance with the general license requirements, there can be no assurance that the general license will not be revoked, the general license will be renewed in the future or we will remain in compliance with the general license. A violation of the OFAC general license could result in substantial fines, sanctions, civil or criminal penalties, competitive or reputational harm, litigation or regulatory action and other consequences that might adversely affect our results of operations, financial condition or strategic objectives.48Table of ContentsMoreover, U.S. export control and economic sanctions may make operating in certain countries more difficult and expensive. For example, we may be unable to find distributors or financial institutions willing to facilitate the sale of our products and collection of cash from such sales in a cost-effective manner, if at all.Failure to comply with applicable anti-corruption legislation could result in fines, criminal penalties and materially adversely affect our business, financial condition and results of operations.We are required to comply with anti-corruption and anti-bribery laws in the jurisdictions in which we operate, including the FCPA in the U.S. and other similar laws in other countries in which we do business. We operate in a number of countries that are recognized to have a reputation for corruption and pose an increased risk of corrupt practices. We also regularly interact with government regulators in many countries, including those that are considered higher risk for corruption, in order to secure regulatory approval to manufacture and distribute our products. The anti-corruption and anti-bribery laws to which we are subject generally prohibit companies and their intermediaries from making improper payments to non-U.S. government officials or other persons for the purposes of influencing official decisions or obtaining or retaining business and/or other benefits. These laws also require us to make and keep books and records that accurately and fairly reflect our transactions and to devise and maintain an adequate system of internal accounting controls. As part of our business, we deal with state-owned business enterprises, the employees and representatives of which may be considered non-U.S. government officials for purposes of applicable anti-corruption laws.Although we have adopted policies and procedures designed to ensure that we, our employees and third-party agents will comply with such laws, there can be no assurance that such policies or procedures will work effectively at all times or protect us against liability under these or other laws for actions taken by our employees, partners and other third parties with respect to our business. If we are not in compliance with anti-corruption laws and other laws governing the conduct of business with government entities and/or officials (including local laws), we may be subject to criminal and civil penalties and other remedial measures, which could harm our business, financial condition, results of operations, cash flows and prospects. Investigations of any actual or alleged violations of such laws or policies related to us could harm our business, financial condition, results of operations, cash flows and prospects.Moreover, there has been enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party independent charities that provide such assistance. There has also been enhanced scrutiny by governments on reimbursement support offerings, clinical education programs and promotional speaker programs. If we, our third-party agents or donation recipients are deemed to have failed to comply with laws, regulations or government guidance in any of these areas, we could be subject to criminal or civil sanctions. Any similar violations by our competitors could also negatively impact our industry reputation and increase scrutiny over our business and our products. We face credit risks from government-owned or sponsored customers outside of the U.S. that may adversely affect our results of operations.Our product sales to government-owned or supported customers in various countries outside of the U.S. are subject to significant payment delays due to government funding and reimbursement practices. This has resulted and may continue to result in an increase in days sales outstanding due to the average length of time that we have accounts receivable outstanding. If significant changes were to occur in the reimbursement practices of these governments or if government funding becomes unavailable, we may not be able to collect on amounts due to us from these customers and our results of operations would be adversely affected.Intellectual Property Risks*If we are unable to protect our intellectual property, we may not be able to compete effectively or preserve our market shares.Where appropriate, we seek patent protection for certain aspects of our technology. Patent protection may not be available for some of the products we are developing. If we must spend significant time and money protecting or enforcing our patents, designing around patents held by others or licensing, potentially for large fees, patents or other proprietary rights held by others, our business and financial prospects may be harmed.The patent positions of biopharmaceutical products are complex and uncertain. The scope and extent of patent protection for some of our products and product candidates are particularly uncertain because key information on some of our product candidates has existed in the public domain for many years. The composition and genetic sequences of animal and/or human versions of ALDURAZYME, NAGLAZYME and many of our product candidates have been published and are believed to be in the public domain. The chemical structure of 6R-BH4 (the active ingredient in KUVAN) has also been published. Publication of this information may prevent us from obtaining or enforcing patents relating to our products and product candidates, including without limitation composition-of-matter patents, which are generally believed to offer the strongest patent protection.49Table of ContentsWe own or have licensed patents and patent applications related to our products. However, these patents and patent applications do not ensure the protection of our intellectual property for a number of reasons, including without limitation the following:â€¢With respect to pending patent applications, unless and until actually issued, the protective value of these applications is impossible to determine. We do not know whether our patent applications will result in issued patents.â€¢Patents have limited duration and expire. â€¢Enforcing patents is expensive and may absorb significant time of our management. Management would spend less time and resources on developing products, which could increase our operating expenses and delay product programs.â€¢Receipt of a patent may not provide much, if any, practical protection. For example, if we receive a patent with a narrow scope, then it will be easier for competitors to design products that do not infringe on our patent.â€¢The Leahy-Smith America Invents Act of 2011, which reformed certain patent laws in the U.S., may create additional uncertainty. Among the significant changes are switching from a â€œfirst-to-inventâ€ system to a â€œfirst-to-fileâ€ system, and the

implementation of new procedures that permit competitors to challenge our patents in the U.S. Patent and Trademark Office after grant.Our current and former employees, consultants or contractors may unintentionally or willfully disclose trade secrets to competitors. Enforcing a claim that someone else illegally obtained and is using our trade secrets, as with patent litigation, is expensive and time consuming, requires significant resources and has an unpredictable outcome. In addition, courts outside of the U.S. are sometimes less willing to protect trade secrets. Furthermore, our competitors may independently develop equivalent knowledge, methods and know-how, in which case we would not be able to enforce our trade secret rights against such competitors.In the EU, materials we submit to the EMA in connection with our clinical trials that were traditionally regarded as confidential, proprietary information, such as study protocols, information regarding manufacturing methods and controls, and intermediate data analyses, are now subject to public disclosure. Moreover, clinical trial data submitted to the EMA in our MAAs are also available to the public. We are only permitted to redact from public disclosures commercially confidential information, a standard which is construed narrowly and subject to the interpretation and final decision of the EU regulatory authorities. EU regulations have resulted and will continue to result in the EMAâ€™s public disclosure of certain of our proprietary information related to recently completed and future clinical trials and MAA submissions. The move toward public disclosure of such development information could adversely affect our business in many ways, including, for example, resulting in the disclosure of our confidential methodologies for development of our products, preventing us from obtaining intellectual property right protection for innovations, requiring us to allocate significant resources to prevent other companies from violating our intellectual property rights, adding even more complexity to processing health data from clinical trials consistent with applicable data privacy regulations, increasing scrutiny of our product candidates and products, and enabling competitors to use our clinical trial information and data to gain approvals for their own products.Competitors or other third parties may interfere with our patent process in a variety of ways. Competitors or other third parties may claim that they invented the claimed invention prior to us or that they filed their application for a patent on a claimed invention before we did. Competitors or other third parties may also claim that we are infringing on their patents and therefore we cannot practice our technology. Competitors or other third parties may also contest our patents by showing the patent examiner or a court that the invention was not original, was not novel or was obvious, for example. In litigation, any such party could claim that our issued patents are not valid or are unenforceable for a number of reasons. If a court agrees, we would not be able to enforce that patent. Moreover, follow-on manufacturers, including generic and biosimilar manufacturers, may use litigation and regulatory means to obtain approval for generic, biosimilar, or other follow-on versions of our products notwithstanding our filed patents or patent applications.If we are unable to protect our intellectual property, third parties could develop competing products, which could adversely affect our revenues and financial results generally.*Competitors and other third parties may have developed intellectual property that could limit our ability to market and commercialize our products and product candidates, if approved.Similar to us, competitors and other third parties continually seek intellectual property protection for their technology. Several of our products, such as ROCTAVIAN, and development programs, focus on therapeutic areas that have been the subject of extensive research and development by third parties for many years. Due to the amount of intellectual property in our field of technology, we cannot be certain that we do not infringe intellectual property rights of competitors or other third parties or that we will not infringe intellectual property rights of competitors or other third parties granted or created in the future. For example, if a patent holder believes our product infringes its patent, the patent holder may sue us even if we have received patent protection for 50Table of Contentsour technology. If someone else claims we infringe their intellectual property, we would face a number of issues, including the following:â€¢Defending a lawsuit takes significant executive resources and can be very expensive.â€¢If a court decides that our product infringes a competitorâ€™s intellectual property, we may have to pay substantial damages.â€¢With respect to patents, in addition to requiring us to pay substantial damages, a court may prohibit us from making, selling, offering to sell, importing or using our product unless the patent holder licenses the patent to us. The patent holder is not required to grant us a license. If a license is available, it may not be available on commercially reasonable terms. For example, we may have to pay substantial royalties or grant cross licenses to our patents and patent applications.â€¢We may need to redesign our product so it does not infringe the intellectual property rights of others. â€¢Redesigning our product so it does not infringe the intellectual property rights of others may not be possible or could require substantial funds and time.We may also support and collaborate in research conducted by government organizations, hospitals, universities or other educational institutions. These research partners may be unwilling to grant us any exclusive rights to technology or products derived from these collaborations. For example, under the Bayh-Dole Act which only applies to patents for inventions generated from federally funded research, the U.S. Department of Commerce may allow the government to use â€œmarch-inâ€ rights for prescription drug patents as a means to control prices.If we do not obtain required licenses or rights, we could encounter delays in our product development efforts while we attempt to design around other patents or may be prohibited from making, using, importing, offering to sell or selling products requiring these licenses or rights. There is also a risk that disputes may arise as to the rights to technology or products developed in collaboration with other parties. If we are not able to resolve such disputes and obtain the licenses or rights we need, we may not be able to develop or market our products.Risks Related to Ownership of Our Securities*Our stock price has been and may in the future be volatile, and an investment in our stock could suffer a decline in value.Our stock price has been and may in the future be volatile. Our valuation and stock price may have no meaningful relationship to current or historical earnings, asset values, book value or many other criteria based on conventional measures of stock value. The market price of our common stock has fluctuated, and in the future could fluctuate, due to factors including: â€¢product sales and profitability of our products;â€¢manufacturing, supply or distribution of our product candidates and products;â€¢progress of our product candidates through the regulatory process and our ability to successfully commercialize any such products that receive regulatory approval;â€¢results of clinical trials, announcements of technological innovations or new products by us or our competitors;â€¢generic competition to KUVAN tablets and powder described above in this Risk Factors section or potential generic competition from future competitors;â€¢government regulatory action affecting our product candidates, our products or our competitorsâ€™ product candidates and products in both the U.S. and non-U.S. countries;â€¢developments or disputes concerning patent or proprietary rights;â€¢general market conditions and fluctuations for the emerging growth and pharmaceutical market sectors;â€¢economic conditions in the U.S. or abroad;â€¢negative publicity about us or the pharmaceutical industry;â€¢changes in the structure of healthcare payment systems;â€¢cybersecurity incidents experienced by us or others in our industry;â€¢broad market fluctuations in the U.S., the EU or in other parts of the world;â€¢actual or anticipated fluctuations in our operating results, including due to timing of large periodic orders for our products by governments in certain countries;51Table of Contentsâ€¢changes in company assessments or financial estimates by securities analysts;â€¢certain actions by activist investors that may be threatened or commenced against us;â€¢acquisitions of products, businesses, or other assets; â€¢industry, financial analyst, or investor reaction to our public announcements; andâ€¢sales of our shares of stock by us, our significant stockholders, or members of our management or Board of Directors.Furthermore, the stock markets have recently experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. In some cases, these fluctuations have been unrelated or disproportionate to the operating performance of those companies. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. For example, in September 2020, after a substantial drop in our stock price that followed an announcement providing a regulatory update regarding ROCTAVIAN, we and certain of our officers were sued in a putative class action lawsuit alleging violations of the federal securities laws for allegedly making materially false or misleading statements. In addition, in October 2021, after a drop in our stock price that followed an announcement providing a regulatory update regarding BMN 307, we and certain of our current and former officers were sued in a putative class action lawsuit alleging violations of the federal securities laws for allegedly making materially false or misleading statements. We may be the target of additional litigation of this type in the future as well. Securities litigation against us could result in substantial costs and divert our managementâ€™s time and attention from other business concerns, which could harm our business. In addition, our stock price can be materially adversely affected by factors beyond our control, such as disruptions in global financial markets or negative trends in the biotechnology sector of the economy, even if our business is operating well.*Conversion of the 2027 Notes will dilute the ownership interest of existing stockholders, including holders who had previously converted their 2027 Notes, or may otherwise depress the price of our common stock.The conversion of some or all of the 2027 Notes will dilute the ownership interests of existing stockholders. Any sales in the public market of the common stock issuable upon such conversion could adversely affect prevailing market prices of our common stock. In addition, the existence of the 2027 Notes may encourage short selling by market participants because the conversion of the 2027 Notes could be used to satisfy short positions, or anticipated conversion of the 2027 Notes into shares of our common stock could depress the price of our common stock.*The fundamental change repurchase feature of the 2027 Notes may delay or prevent an otherwise beneficial attempt to take us over.The terms of the 2027 Notes require us to offer to repurchase the 2027 Notes in the event of a fundamental change (as defined in the indenture governing the 2027 Notes). A takeover of us would trigger options by the respective holders of the 2027 Notes to require us to repurchase such 2027 Notes. This may have the effect of delaying or preventing a takeover of us that would otherwise be beneficial to our stockholders or investors in the 2027 Notes.Anti-takeover provisions in our charter documents and under Delaware law may make an acquisition of us, which may be beneficial to our stockholders, more difficult.We are incorporated in Delaware. Certain anti-takeover provisions of Delaware law and our charter documents as currently in effect may make a change in control of us more difficult, even if a change in control would be beneficial to the stockholders. Our anti-takeover provisions include provisions in our restated certificate of incorporation and amended and restated bylaws providing that stockholdersâ€™ meetings may only be called by our Chairman, the lead independent director or the majority of our Board of Directors and that the stockholders may not take action by written consent and requiring that stockholders that desire to nominate any person for election to our Board of Directors or to make any proposal with respect to business to be conducted at a meeting of our stockholders be submitted in appropriate form to our Secretary within a specified period of time in advance of any such meeting. Additionally, our Board of Directors has the authority to issue shares of preferred stock and to determine the terms of those shares of stock without any further action by our stockholders. The rights of holders of our common stock are subject to the rights of the holders of any preferred stock that may be issued. The issuance of preferred stock could make it more difficult for a third party to acquire a majority of our outstanding voting stock. Delaware law also prohibits corporations from engaging in a business combination with any holders of 15% or more of their capital stock until the holder has held the stock for three years unless, among other possibilities, our Board of Directors approves the transaction. Our Board of Directors may use these provisions to prevent changes in the management and control of us. Also, under applicable Delaware law, our Board of Directors may adopt additional anti-takeover measures in the future.52Table of ContentsOur amended and restated bylaws designate the Court of Chancery of the State of Delaware and the federal district courts of the U.S. as the exclusive forums for the adjudication of certain disputes, which could limit our stockholdersâ€™ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:â€¢any derivative claim or cause of action brought on our behalf;â€¢any claim or cause of action for breach of a fiduciary duty owed by any current or former director, officer or other employee of BioMarin to us or our stockholders;â€¢any claim or cause of action against us or any of our current or former directors, officers or other employees arising pursuant to any provision of the General Corporation Law of the State of Delaware, our restated certificate of incorporation or our amended and restated bylaws; any claim or cause of action seeking to interpret, apply, enforce or determine the validity of our restated certificate of incorporation or our amended and restated bylaws;â€¢any claim or cause of action as to which the General Corporation Law of the State of Delaware confers jurisdiction to the Court of Chancery of the State of Delaware; andâ€¢any claim or cause of action against us or any of our current or former directors, officers or other employees that is governed by the internal affairs doctrine. This exclusive-forum provision would not apply to suits brought to enforce a duty or liability created by the Securities Act of 1933, as amended, the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction. In addition, our amended and restated bylaws provide that the federal district courts of the U.S. of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act.While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated bylaws. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.These exclusive forum provisions may limit a stockholderâ€™s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. If a court were to find either of our exclusive forum provisions to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business. Our amended and restated bylaws further provide that any person or entity that acquires any interest in shares of our capital stock will be deemed to have notice of and consented to the provisions of such provisions.General Risk FactorsWe depend upon our key personnel and our ability to attract and retain qualified employees.Our future growth and success will depend in large part on our continued ability to attract, retain, manage and motivate our employees. The loss of the services of a significant portion of our workforce or any member of our senior management or the inability to hire or retain qualified personnel could adversely affect our ability to execute our business plan and harm our operating results.Because of the specialized nature of our business, we rely heavily on our ability to attract and retain qualified scientific, technical and managerial personnel. In particular, the loss of one or more of our senior executive officers could be detrimental to us if we do not have an adequate succession plan or if we cannot recruit suitable replacements in a timely manner. While our senior executive officers are parties to employment agreements with us, these agreements do not guarantee that they will remain employed with us in the future. In addition, in many cases, these agreements do not restrict our senior executive officersâ€™ ability to compete with us after their employment is terminated. In November 2023, we announced the retirement of Jean-Jacques BienaimÃ©, our then-current President and Chief Executive Officer, and the appointment of Alexander Hardy as President and Chief Executive Officer, each effective December 1, 2023. If Mr. Hardyâ€™s succession as President and Chief Executive Officer is not managed successfully, including his ability to lead a team that can effectively implement our strategic plans, it could disrupt our business and affect our financial condition and operating results. Additionally, in March 2024, we announced that Cristin Hubbard will succeed Jeffrey Ajer, our Executive Vice President and Chief Commercial Officer, effective May 20, 2024. The recent changes in our management team could cause retention and morale concerns among current employees, as well as operational risks. The competition for qualified personnel in the pharmaceutical field is intense, and there is a limited pool of qualified potential employees to recruit. Recently, like many other employers in the U.S., we experienced increased employee turnover. Due 53Table of Contentsto the intense competition for talent, we may be unable to continue to attract and retain qualified personnel necessary for the development of our business or to recruit suitable replacement personnel. Additionally, we cannot be sure that the compensation costs of doing so will not adversely affect our operating results, and we may not be able to hire and train employees quickly enough to meet our needs. If we fail to retain employees and effectively manage our hiring needs, our efficiency, ability to meet forecasts, employee morale, productivity, and the success of our strategic plans could suffer, which may have an adverse effect on our business, financial condition, and operating results.*Our success depends on our ability to manage our growth.VOXZOGO addresses larger patient populations than most of our other products, and product candidates that we are currently developing or may license or acquire in the future may be intended for similarly larger patient populations than we have historically targeted. In order to continue development of such product candidates and marketing of products with larger markets, we will need to continue expanding our operations. To manage expansion effectively, we need to continue to develop and improve our research and development capabilities, manufacturing and quality capacities, sales and marketing capabilities, financial and administrative systems and standard processes for global operations. For example, strong demand for VOXZOGO in certain markets outpaced our projections in recent quarters, and we faced, and may in the future face, challenges meeting our estimates of VOXZOGO demand. Our staff, financial resources, systems, procedures or controls may be inadequate to support our operations and may increase our exposure to regulatory, competitive, and corruption risks and our management may be unable to manage successfully current or future market opportunities or our relationships with customers and other third parties.In addition, there is no guarantee that our research and development prioritization activities, including the acceleration or discontinuation of certain programs, will generate their expected benefits and the costs associated with such activities may be greater than anticipated. Such activities may also adversely affect our internal programs and initiatives as well as our ability to recruit and retain skilled and motivated personnel. If we are unable to realize the expected benefits of such activities, then our operating results and financial condition may be materially and adversely affected. New tax laws or regulations that are enacted or existing tax laws and regulations that are interpreted, modified or applied adversely to us or our customers may have a material adverse effect on our business and financial condition.New tax laws or regulations

could be enacted at any time, and existing tax laws or regulations could be interpreted, modified or applied in a manner that is adverse to us or our customers, which could adversely affect our business and financial condition. For example, the Tax Cuts and Jobs Act, the Coronavirus Aid, Relief, and Economic Security Act and the Inflation Reduction Act enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to such legislation may affect us, and certain aspects of such legislation could be repealed or modified in future legislation. Among other changes, the Tax Cuts and Jobs Act amended the Code to require that, for tax years beginning after December 31, 2021, certain research and experimental expenditures be capitalized and amortized over five years if incurred in the United States or fifteen years if incurred in foreign jurisdictions. Although the U.S. Congress has considered legislation that would defer, modify, or repeal the capitalization and amortization requirement, there is no assurance that such changes will be made. If the requirement is not deferred, repealed or otherwise modified, it may increase our cash tax. In addition, it is uncertain if and to what extent various states will conform to federal tax laws. Any future tax legislation could increase our U.S. tax expense and could have a material adverse impact on our business and financial condition.Moreover, changes in the tax laws of jurisdictions in which we conduct business could arise, including as a result of the base erosion and profit shifting (BEPS) project that is being led by the Organization for Economic Co-operation and Development (OECD), and other initiatives led by the OECD or the EC. For example, the OECD, which represents a coalition of member countries including the U.S. and other countries in which we have operations, is working on proposals, commonly referred to as â€œBEPS 2.0â€, which, if and to the extent implemented, would make important changes to the international tax system. These proposals are based on two â€œpillarsâ€, Pillar One focuses on the allocation of taxing rights in respect of certain profits of multinational enterprises with annual global revenue above 20 billion euros and profitability above 10% to the jurisdictions within which they carry on business (based on the thresholds, we currently expect to be outside the scope of the Pillar One proposals, but could fall within their scope in the future) and Pillar Two imposes a minimum effective tax rate of 15% on certain multinational enterprises that have consolidated revenues of at least 750 million euros in at least two out of the last four years (based on the thresholds, we currently expect that we are likely to fall within the scope of the Pillar Two proposals). A number of countries in which we conduct business have enacted with effect from January 1, 2024, or are in the process of enacting, core elements of Pillar Two rules. The OECD has issued administrative guidance providing transition and safe harbor rules around the implementation of Pillar Two. We are monitoring developments and evaluating the impacts these new rules will have on our tax rate, including eligibility to qualify for these safe harbor rules. It is not uncommon for taxing authorities in different countries to have conflicting views, for instance, with respect to, among other things, the manner in which the armâ€™s length standard is applied for transfer pricing purposes, or with respect to the valuation of intellectual property. If tax authorities successfully challenge our transfer prices as not reflecting armâ€™s length transactions, they could require us to adjust our transfer prices and thereby reallocate our income to reflect these revised transfer prices, resulting in a higher tax liability. In addition, if a country from which income is reallocated does not agree with the reallocation, both that country and the other country to which the income was allocated could tax the same income, potentially resulting in double taxation. If tax authorities were to allocate income to a higher tax jurisdiction, subject our income to double 54Table of Contentstaxation or assess interest and penalties, it would increase our consolidated tax liability, which could adversely affect our business, financial condition, results of operations and cash flows.If we are found in violation of healthcare laws or privacy and data protection laws, we may be required to pay penalties, be subjected to scrutiny by regulators or governmental entities, or be suspended from participation in government healthcare programs, which may adversely affect our business, reputation, financial condition and results of operations.We are subject to various healthcare laws and regulations in the U.S. and internationally, including anti-kickback laws, false claims laws, data privacy and security laws, and laws related to ensuring compliance. In the U.S., the federal Anti-Kickback Statute makes it illegal for any person or entity, including a pharmaceutical company, to knowingly and willfully offer, solicit, pay or receive any remuneration, directly or indirectly, in exchange for or to induce the referral of business, including the purchase, order or prescription of a particular drug, for which payment may be made under federal healthcare programs, such as Medicare and Medicaid. Under the federal Anti-Kickback Statute and related regulations, certain arrangements are deemed not to violate the federal Anti-Kickback Statute if they fit within a statutory exception or regulatory safe harbor. However, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration not intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from Anti-Kickback liability, although we seek to comply with these safe harbors. Many states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to referral of patients for healthcare services reimbursed by any source, not just governmental payers. As previously disclosed, we received a subpoena from the U.S. Department of Justice requesting that we produce certain documents regarding our sponsored testing programs relating to VIMIZIM and NAGLAZYME. We have produced documents in response to the subpoena and are cooperating fully, but there is no assurance that such sponsored testing programs, or our other operations or programs, will not be found to violate such laws.Federal and state false claims laws, including the civil False Claims Act and the Civil Monetary Penalties Law, prohibit any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid, or knowingly making, using, or causing to be made or used, a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws. Under the Health Insurance Portability and Accountability Act of 1996 (HIPAA), we also are prohibited from, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private payers, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.In addition, federal and state healthcare legislation have strengthened these laws in the U.S. For example, the PPACA, among other things, amends the intent requirement of the federal Anti-Kickback Statute and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of these statutes or specific intent to violate them in order to commit a violation. Moreover, the PPACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act.HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms, on certain types of individuals and entities, with respect to safeguarding the privacy, integrity, availability, security and transmission of individually identifiable health information. Many state and non-U.S. laws also govern the privacy and security of health information. They often differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. In the U.S., state privacy laws and regulations impose restrictive requirements regulating the use and disclosure of health information and other sensitive personal information that is not subject to HIPAA. For example, California enacted the California Consumer Privacy Act (CCPA), which took effect on January 1, 2020. The CCPA gives California consumers expanded rights to access and delete their personal information, opt out of certain personal information sales, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA was expanded substantially on January 1, 2023 when the California Privacy Rights Act of 2020 (CPRA) took effect and amended the CCPA. Following the CPRA amendments, the CCPA, among other things, gives consumers the ability to limit use of information deemed to be sensitive, increase the maximum penalties for violations concerning consumers under age 16, expands an individualâ€™s private right of action and establishes the California Privacy Protection Agency to implement and enforce the new law and impose administrative fines. Other U.S. states have recently adopted consumer data protection and privacy laws, and more U.S. states may do so in the future. This creates the potential for a patchwork of overlapping but different state laws and could mark the beginning of a trend toward more stringent privacy legislation in the U.S., which could increase our potential liability and adversely affect our business, 55Table of Contentsfinancial condition, and results of operations. Many other states are considering proposed comprehensive data privacy legislation and all 50 states have passed some form of legislation relating to privacy or cybersecurity. Aspects of the CCPA, CPRA and similar laws in other states and their interpretation and enforcement remain uncertain. The potential effects of these laws are far-reaching and may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to comply. Complying with these or other similar laws, regulations, amendments to or re-interpretations of existing laws and regulations, and contractual or other obligations relating to privacy, data protection, data transfers, data localization, or information security may require us to make changes to our services to enable us or our customers to meet new legal requirements, incur substantial operational costs, modify our data practices and policies, and restrict our business operations. Any actual or perceived failure by us to comply with these laws, regulations, or other obligations may lead to significant fines, penalties, regulatory investigations, lawsuits, significant costs for remediation, damage to our reputation, or other liabilities. The European Regulation 2016/679, known as the General Data Protection Regulation (GDPR), as well as EEA Member State legislations supplementing such regulation, apply to the processing of personal data of individuals located in the EEA, including health-related information, by companies located in the EEA, or in certain circumstances, by companies located outside of the EEA. These laws impose strict obligations on the ability to collect, record, store, disclose, use and transmit personal data, including health-related information. These include several requirements relating to (i) obtaining, in some situations, the informed consent of the individuals to whom the personal data relates, (ii) the information provided to the individuals about how their personal information is used, (iii) ensuring the security and confidentiality of the personal data, (iv) the obligation to notify regulatory authorities and affected individuals of personal data breaches, (v) extensive internal privacy governance obligations, and (vi) obligations to honor rights of individuals in relation to their personal data (for example, the right to access, correct and delete their data). Switzerland has adopted similar restrictions. The GDPR and other European data protection laws generally restrict the transfer of personal information from Europe, including the EEA and Switzerland, to the U.S. and most other countries unless the U.S. companies participate in the EU-U.S. Data Privacy Framework in accordance with the EC's adequacy decision adopted on July 10, 2023, or have implemented specific safeguards to protect the transferred personal information. U.S. companies can join the EU-U.S. Data Privacy Framework by committing to comply with a detailed set of privacy obligations and U.S. companies that do not fall under the EU-U.S. Data Privacy Framework must implement certain specific safeguards. One of the primary safeguards allowing U.S. companies to import personal information from the EEA has been the ECâ€™s Standard Contractual Clauses (SCCs). However, the Court of Justice of the EU (CJEU) issued a decision that called into question whether the SCCs can lawfully be used for transfers of personal information from Europe to the United States or most other countries. After the mentioned CJEU judgment, new sets of SCCs were published on June 4, 2021. Most importantly, the use of SCCs does not any longer automatically ensure compliance with the GDPR. Instead, companies remain required to conduct a data transfer impact assessment for each transfer, which adds a compliance burden.Potential pecuniary fines for noncompliance with the GDPR may be up to the greater of â‚¬20 million or 4% of annual global revenue. The GDPR has increased our responsibility and liability in relation to personal data that we process and has increased our compliance costs. The EU regulations that make certain materials we submit to the EMA in connection with our clinical trials subject to public disclosure have increased the risk that we may unintentionally disclose personal information protected under the GDPR and thereby incur associated penalties and suffer reputational damage.In addition to the U.S. and European countries, other countries in which we operate have also enacted data privacy laws or may do so in the future. For example, Brazilâ€™s General Data Protection Law (LGPD), which is modeled on the GDPR, took effect in 2020.Substantial new laws and regulations affecting compliance have also been adopted in the U.S. and certain non-U.S. countries, which may require us to modify our business practices with healthcare practitioners. For example, in the U.S., the PPACA, through the Physician Payments Sunshine Act, requires certain drug, biologicals and medical supply manufacturers to collect and report to CMS information on payments or transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other health care professionals (such as physicians assistants and nurse practitioners), and teaching hospitals, as well as investment and ownership interests held by such physicians and their immediate family members during the preceding calendar year. In addition, there has been a recent trend of increased state regulation of payments made to physicians. Certain states and/or local jurisdictions mandate implementation of compliance programs, compliance with the Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and the Pharmaceutical Research and Manufacturers of America (PhRMA) Code on Interactions with Healthcare Professionals, the registration of pharmaceutical sales representatives and/or the tracking and reporting of gifts, compensation and other remuneration to physicians, marketing expenditures, and drug pricing. Likewise, in many non-U.S. countries there is an increasing focus on the relationship between drug companies and healthcare practitioners. Recently enacted non-U.S. legislation creates reporting obligations on payments, gifts and benefits made to these professionals. Outside the U.S., interactions between pharmaceutical companies and health care professionals are also governed by strict laws, such as national anti-bribery laws of European countries, national sunshine rules, regulations, industry self-regulation codes of conduct and physiciansâ€™ codes of professional conduct. The shifting regulatory environment and the need to implement systems to comply with multiple jurisdictions with different compliance and/or reporting 56Table of Contentsrequirements increases the costs of maintaining compliance and the possibility that we may violate one or more of the requirements and be subject to fines or sanctions.Due to the breadth of the healthcare and privacy and data protection laws described above, the narrowness of available statutory and regulatory exceptions and safe harbors and the increased focus by law enforcement authorities in enforcing such laws, our business activities could be subject to challenge under one or more of such laws. If we are found in violation of one of these laws, we may be subject to significant criminal, civil or administrative sanctions, including damages, fines, disgorgement, imprisonment, contractual damages, reputational harm, public reprimands, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, curtailment of our operations, and debarment, suspension or exclusion from participation in government healthcare programs, any of which could adversely affect our business, financial condition and results of operations.If product liability lawsuits are successfully brought against us, we may incur substantial liabilities.We are exposed to the potential product liability risks inherent in the testing, manufacturing and marketing of human pharmaceuticals. We currently maintain insurance against product liability lawsuits for the commercial sale of our products and for the clinical trials of our product candidates. Pharmaceutical companies must balance the cost of insurance with the level of coverage based on estimates of potential liability. Historically, the potential liability associated with product liability lawsuits for pharmaceutical products has been unpredictable. Although we believe that our current insurance is a reasonable estimate of our potential liability and represents a commercially reasonable balancing of the level of coverage as compared to the cost of the insurance, we may be subject to claims in connection with our clinical trials and commercial use of our products and product candidates for which our insurance coverage may not be adequate and we may be unable to avoid significant liability if any product liability lawsuit is brought against us. If we are the subject of a successful product liability claim that exceeds the limits of any insurance coverage we obtain, we may incur substantial charges that would adversely affect our earnings and require the commitment of capital resources that might otherwise be available for the development and commercialization of our product programs.In the EU, new rules on liability of defective products were proposed on September 28, 2022. If adopted, these rules will make it easier for patients to claim damages for defective products, for example by alleviating their burden of proof.*We rely significantly on information technology systems and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively and have a material adverse effect on our business, reputation, financial condition, and results of operations.We rely significantly on our information technology systems, including enterprise resource planning (ERP), production management, and other information systems, to effectively manage and maintain our operations, inventory and internal reports, to manufacture and ship products to customers and to timely invoice them. Any failure, inadequacy or interruption of that infrastructure or security lapse (whether intentional or inadvertent) of that technology, including cybersecurity incidents or attacks, could harm our ability to operate our business effectively.We are currently implementing a new global ERP system, which will replace existing operating and financial systems. The preparation and implementation of a new ERP system has required, and will continue to require, significant investment of capital and human resources. Our results of operations could be adversely affected if we continue to experience delays or cost overruns during the implementation process, or if the ERP system or associated process changes do not give rise to the benefits that we expect. Potential failure or flaws in the new ERP system may pose risks to our ability to operate successfully and efficiently and failure to implement the appropriate internal controls with respect to the new ERP system may result in the system producing inaccurate or unreliable information. Any disruptions, delays or deficiencies in the design or implementation of the new ERP system or related internal controls, or in the performance of legacy information technology systems, could result in potentially much higher costs than we had incurred and adversely affect our ability to effectively fulfill contractual obligations, file related government reports in a timely manner, operate and manage our

business or otherwise affect our controls environment. Any of these consequences could have an adverse effect on our results of operations and financial condition.In addition, our technology systems, including our cloud technologies, continue to increase in multitude and complexity, making them potentially vulnerable to breakdown, cyberattack and other disruptions. Potential problems and interruptions associated with the implementation of new or upgraded technology systems or with maintenance or adequate support of existing systems could disrupt or reduce the efficiency of our operations and expose us to greater risk of security breaches. Cybersecurity incidents resulting in the failure of our enterprise resource planning system, production management or other systems to operate effectively or to integrate with other systems, or a breach in security or other unauthorized access or unavailability of these systems or those of any third parties in our supply chain or on whom we otherwise depend, have occurred in the past and may affect our ability in the future to manage and maintain our operations, inventory and internal reports, and result in delays in product fulfillment and reduced efficiency of our operations. 57Table of ContentsAs part of our business, we collect, store, and transmit large amounts of confidential information, proprietary data, intellectual property, and personal data. The information and data processed and stored in our technology systems, and those of our research collaborators, CROs, contract manufacturers, suppliers, distributors, or other third parties on whom we depend on to operate our business, may be vulnerable to loss, damage, denial-of-service, unauthorized access or misappropriation. Data security incidents may be the result of unauthorized or unintended activity (or lack of activity) by our employees, contractors, or others with authorized access to our network or malware, hacking, business email compromise, phishing, ransomware or other cyberattacks directed by third parties. While we have implemented measures to protect our information and data stored in our technology systems and those of the third parties with whom we work, our efforts may not be successful.We have experienced and may continue to experience cybersecurity incidents, although to our knowledge we have not experienced any material incident or interruption to date. If such a significant event were to occur, it could result in a material disruption of our development programs and commercial operations, including due to a loss, corruption or unauthorized disclosure of our trade secrets, personal data or other proprietary or sensitive information. Further, these cybersecurity incidents can lead to the public disclosure of personal information (including sensitive personal information) of our employees, clinical trial patients and others and result in demands for ransom or other forms of blackmail. Such attacks, including phishing attacks and attempts to misappropriate or compromise confidential or proprietary information or sabotage enterprise IT systems, are of ever-increasing levels of sophistication and are made by groups and individuals with a wide range of motives (including industrial espionage) and expertise, including by organized criminal groups, â€œhacktivistsâ€, nation states and others. Moreover, the costs to us to investigate and mitigate cybersecurity incidents could be significant. For example, the loss of clinical trial data could result in delays in our product development or regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Any security breach that results in the unauthorized access, use or disclosure of personal data may require us to notify individuals, governmental authorities, credit reporting agencies, or other parties pursuant to privacy and security laws and regulations or other obligations. Such a security compromise could harm our reputation, erode confidence in our information security measures, and lead to regulatory scrutiny. To the extent that any disruption or security breach resulted in a loss of, or damage to, our data or systems, or inappropriate disclosure of confidential, proprietary or personal information, we could be exposed to a risk of loss, enforcement measures, penalties, fines, indemnification claims, litigation and potential civil or criminal liability, which could materially adversely affect our business, financial condition and results of operations.Not all our contracts contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.Further, the SEC has adopted new rules that require us to provide greater disclosures around proactive security protections that we employ and reactive issues (e.g., security incidents). Any such disclosures, including those under state data breach notification laws, can be costly, and the disclosures we make to comply with, or the failure to comply with, such requirements could lead to adverse consequences.If a natural disaster, terrorist or criminal activity or other unforeseen event caused significant damage to our facilities or those of our third-party manufacturers and suppliers or significantly disrupted our operations or those of our third-party manufacturers and suppliers, we may be unable to meet demand for our products and lose potential revenue, have reduced margins, or be forced to terminate a program.The occurrence of an earthquake or other catastrophic disaster could cause damage to our facility and equipment, or that of our third-party manufacturers or single-source suppliers, which could materially impair the ability for us or our third-party manufacturers to manufacture our products and product candidates. Our Galli Drive facility, located in Novato, California, is currently our only manufacturing facility for ALDURAZYME, NAGLAZYME, VOXZOGO and PALYNZIQ and is one of two manufacturing facilities for BRINEURA and VIMIZIM. Our gene therapy manufacturing facility is also located in Novato, California, and it is currently our only manufacturing facility to support ongoing ROCTAVIAN clinical development activities and commercial demand for ROCTAVIAN. These facilities are located in the San Francisco Bay Area near known earthquake fault zones and are vulnerable to significant damage from earthquakes. We, the third-party manufacturers with whom we contract and our single-source suppliers of raw materials, which include many of our critical raw materials, are also vulnerable to damage from other types of disasters, including fires, explosions, floods, and similar events. If any disaster were to occur, or any terrorist or criminal activity caused significant damage to our facilities or the facilities of our third-party manufacturers and suppliers, our ability to manufacture our products, or to have our products manufactured, could be seriously, or potentially completely, impaired, and our commercialization efforts and revenues could be seriously impaired. Moreover, other unforeseen events, such as power outages, could significantly disrupt our operations or those of our third-party manufacturers and suppliers, which could result in damage to our facilities and significant delays in the manufacture of our products and adversely impact our commercial operations and revenues. The insurance that we carry, the inventory that we maintain and our risk mitigation plans may not be adequate to cover our losses resulting from disasters or other business interruptions.58Table of ContentsOur business is affected by macroeconomic conditions.Various macroeconomic factors could adversely affect our business and the results of our operations and financial condition, including changes in inflation, interest rates, or foreign currency exchange rates, natural disasters, geopolitical instability resulting from war, terrorism and other violence, such as the instability caused by Russia's invasion of Ukraine, effects of potential global public health threats and overall economic conditions and uncertainties, including those resulting from the current and future conditions in the global financial markets and volatility and disruptions in the equity and debt markets. For instance, COVID-19 previously adversely affected our ability to source materials and supplies. Inflation (such as that recently observed in the U.S. and elsewhere) has increased our business costs and could become more significant in the future, and it may not be feasible to pass price increases on to our customers due to the process by which healthcare providers are reimbursed for our products by the government. Interest rates, the liquidity of the credit markets and the volatility of the capital markets could also affect the value of our investments and our ability to liquidate our investments in order to fund our operations. We purchase or enter into a variety of financial instruments and transactions, including investments in commercial paper, the extension of credit to corporations, institutions and governments and hedging contracts. If any of the issuers or counterparties to these instruments were to default on their obligations, it could materially reduce the value of the transaction and adversely affect our cash flows.We sell our products in countries that face economic volatility and weakness. Although we have historically collected receivables from customers in those countries, sustained weakness or further deterioration of the local economies and currencies may cause customers in those countries to be unable to pay for our products. Additionally, if one or more of these countries were unable to purchase our products, our revenues would be adversely affected.Interest rates and the ability to access credit markets could also adversely affect the ability of our customers/distributors to purchase, pay for and effectively distribute our products, which could limit our ability to obtain sufficient materials and supplies necessary for production of our therapies. Similarly, these macroeconomic factors could affect the ability of our contract manufacturers, sole-source or single-source suppliers to remain in business or otherwise manufacture or supply product. Failure by any of them to remain a going concern could affect our ability to manufacture products.Additionally, effects of any pandemic or other global public health threat on all aspects of our business and operations and the duration of such effects are highly uncertain and difficult to predict. For instance, a global pandemic could result in significant disruption of global financial markets, which could reduce our ability to access capital and could negatively affect our liquidity and the liquidity and stability of markets for our common stock and Notes. In addition, a recession, further market correction or depression resulting from a future global public health threat could materially adversely affect our business and the value of our common stock and Notes. To the extent macroeconomic conditions continue to adversely affect our business and financial results, they may also have the effect of heightening many of the other risks described in this Risk Factors section, such as those relating to our conducting a significant amount of our sales and operations outside of the U.S., exposure to changes in foreign exchange rates, our need to generate sufficient cash flows to service our indebtedness and finance our operations and the volatility of our stock price.ItemÂ 2.Â Â Â Â Unregistered Sales of Equity Securities and Use of ProceedsNone.ItemÂ 3.Â Â Â Â Defaults Upon Senior SecuritiesNone.ItemÂ 4.Â Â Â Â Mine Safety DisclosuresNot applicable.59Table of ContentsItemÂ 5.Â Â Â Â Other InformationRule 10b5-1 Trading PlansDuring the three months ended JuneÂ 30, 2024, none of our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any contracts, instructions or written plans for the purchase or sale of BioMarin securities. In addition, in Item 5 of Part II of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, we inadvertently omitted the disclosure regarding the termination of the Rule 10b5-1 trading arrangement (as defined in Item 408(a) of Regulation S-K under the Exchange Act) by Henry J. Fuchs, M.D., President of Worldwide Research & Development, on March 5, 2024. Such Rule 10b5-1 trading arrangement, which details were previously disclosed in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, was adopted on August 17, 2023 with an expiration date of November 15, 2024, and provided for the sale of up to 64,659 shares of our common stock.LitigationOn April 4, 2024, Plaintiff Aaron Jones (â€œPlaintiffâ€), a purported stockholder of ours, filed a putative class action complaint (â€œComplaintâ€) in the Court of Chancery of the State of Delaware (â€œCourtâ€) against the Company and the members of our Board of Directors, as well as Elliott Investment Management L.P., Elliott Associates, L.P., and Elliott International, L.P. (together, the â€œElliott Partiesâ€ and collectively, the â€œDefendantsâ€) under the caption Jones v. BioMarin Pharmaceutical, Inc., et al., C.A. No. 2024-0360-JTL (the â€œActionâ€). Plaintiff alleged that certain provisions in a Cooperation Agreement dated December 20, 2023 between the Company and the Elliott Parties, as defined and described in the Companyâ€™s prior Form 8-K, filed with the SEC on December 20, 2023, were invalid under Section 141(a) of the Delaware General Corporation Law insofar as they allegedly required the Companyâ€™s Board to (i) cap the size of the Board of Directors for a certain period of time (the â€œBoard Size Provisionâ€) and (ii) â€œrecommend that the stockholders of the Company vote to electâ€ certain directors in connection with the Companyâ€™s 2024 annual meeting (the â€œRecommendation Provisionâ€). The Defendants believe that the allegations of the Complaint were meritless, deny those allegations, and deny that any violation of applicable law has occurred. However, solely to minimize expenses and distraction and to avoid the uncertainty of any litigation, on April 11, 2024, the Elliott Parties executed a Waiver Letter, pursuant to which, among other things, the Elliott Parties irrevocably waived (i) any and all obligations of the Company pursuant to the Board Size Requirement and (ii) any and all obligations of the Company pursuant to the Recommendation Provision to the extent it is superseded by the Boardâ€™s fiduciary obligations under Delaware law.On April 16, 2024, the parties entered into a proposed Stipulation and Order Dismissing the Action as Moot and Retaining Jurisdiction to Determine Plaintiffâ€™s Counselâ€™s Application for an Award of Attorneysâ€™ Fees and Expenses (the â€œStipulation and Proposed Orderâ€), pursuant to which the Court would retain jurisdiction regarding any application Plaintiff may make for an award of attorneysâ€™ fees. The Court entered the Stipulation and Proposed Order the same day, and retained jurisdiction to approve a form of notice concerning attorneysâ€™ fees payable to Plaintiff in connection with the Waiver Letter. The Company subsequently agreed to pay $600,000 in attorneysâ€™ fees and expenses in full satisfaction of any and all claims by Plaintiff and all of his counsel for fees and expenses in the Action.On August 1, 2024, the Court entered an order closing the Action, subject to the Company filing an affidavit with the Court confirming that this notice has been issued.In entering the order, the Court was not asked to review, and did not pass judgment on, the payment of the attorneysâ€™ fees and expenses or their reasonableness. Plaintiffâ€™s counsel are Kurt M. Heyman and Aaron M. Nelson of Heyman Enerio Gattuso & Hirzel LLP, (302) 472-7300. Counsel to the Company and the Board of Directors is Blake Rohrbacher of Richards, Layton & Finger, P.A., (302) 651-7700. Counsel to the Elliott Parties is Michael A. Barlow of Quinn Emanuel Urquhart & Sullivan, LLP, (302) 302-4000.60Table of ContentsItemÂ 6.Â Â Â Â ExhibitsExhibit NumberDescription2.1Amended and Restated Termination and Transition Agreement, dated as of December 23, 2015, between BioMarin Pharmaceutical Inc. and Ares Trading S.A., previously filed with the SEC on January 7, 2016 as Exhibit 2.1 to the Companyâ€™s Current Report on Form 8-K (File No. 000-26727), which is incorporated herein by reference. Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment. Omitted portions have been filed separately with the SEC.2.2Termination and Transition Agreement, dated as of October 1, 2015, between BioMarin Pharmaceutical Inc. and Ares Trading S.A., previously filed with the SEC on January 7, 2016 as Exhibit 2.3 to the Companyâ€™s Current Report on Form 8-K (File No. 000-26727), which is incorporated herein by reference. Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment. Omitted portions have been filed separately with the SEC.2.3First Amendment, dated as of December 12, 2016, to the Amended and Restated Termination and Transition Agreement, dated as of December 23, 2015 and effective as of October 1, 2015, between BioMarin Pharmaceutical Inc. and Ares Trading S.A., previously filed with the SEC on February 27, 2017 as Exhibit 2.6 to the Companyâ€™s Annual Report on Form 10-K (File No. 000-26727), which is incorporated herein by reference. Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment. Omitted portions have been filed separately with the SEC.3.1Restated Certificate of Incorporation of BioMarin Pharmaceutical Inc., previously filed with the SEC on June 12, 2017 as Exhibit 3.2 to the Companyâ€™s Current Report on Form 8-K (File No. 000-26727), which is incorporated herein by reference.3.2Amended and Restated Bylaws of BioMarin Pharmaceutical Inc., previously filed with the SEC on December 21, 2022 as Exhibit 3.1 to the Companyâ€™s Current Report on Form 8-K (File No. 000-26727), which is incorporated herein by reference.10.1*Amendment, dated as of June 8, 2024, to the Consulting Agreement by and between BioMarin Pharmaceutical Inc. and Jean-Jacques BienaimÃ©, dated October 30, 2023.10.2*BioMarin Pharmaceutical Inc. Summary of Independent Director Compensation.31.1*Certification of Chief Executive Officer pursuant to Rules 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.31.2*Certification of Chief Financial Officer pursuant to Rules 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.32.1*+Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. This Certification accompanies this report and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed for purposes of Â§18 of the Securities Exchange Act of 1934, as amended.101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.101.SCH*Inline XBRL Taxonomy Extension Schema Document101.CAL*Inline XBRL Taxonomy Extension Calculation Document101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase101.LAB*Inline XBRL Taxonomy Extension Labels Linkbase Document101.PRE*Inline XBRL Taxonomy Extension Presentation Link Document104XBRL tags for the cover page from the Companyâ€™s Quarterly Report on Form 10-Q for the quarter ended JuneÂ 30, 2024, are embedded within the Inline XBRL document.*Â Â Â Â Filed herewith61Table of Contents+Â Â Â Â The certifications attached as ExhibitÂ 32.1 accompany this Quarterly Report on FormÂ 10-Q pursuant to 18 U.S.C. SectionÂ 1350, as adopted pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed â€œfiledâ€ by the Registrant for purposes of SectionÂ 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any of the Registrantâ€™s filings under the Securities Act of 1933, as amended, irrespective of any general incorporation language contained in any such filing.Attached as Exhibit 101 to this report are documents formatted in XBRL (Extensible Business Reporting Language): (i)Â Condensed Consolidated Balance Sheets as of JuneÂ 30, 2024 and DecemberÂ 31, 2023, (ii)Â Condensed Consolidated Statements of Comprehensive Income for the three and six months ended JuneÂ 30, 2024 and 2023, (iii)Â Condensed Consolidated Statement of Stockholdersâ€™ Equity for the three and six months ended JuneÂ 30, 2024 and 2023, (iv)Â Condensed Consolidated Statements of Cash Flows for the six months ended JuneÂ 30, 2024 and 2023, and (v)Â Notes to Condensed Consolidated Financial Statements.62Table of ContentsSIGNATUREPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.BIOMARIN PHARMACEUTICAL INC.Dated: August 5, 2024By/S/Â BRIAN R. MUELLERBrian R. MuellerExecutiveÂ ViceÂ President, Finance & ChiefÂ FinancialÂ Officer(Principal Financial Officer)63 EX-10.1 2 bmrn-exx101xq22024.htm EX-10.1 DocumentExhibit 10.1AMENDMENT TO CONSULTING AGREEMENTThis Amendment (this â€œAmendmentâ€), entered into and effective as of June 8, 2024 (the â€œEffective Dateâ€), is made by and between BioMarin Pharmaceutical Inc. (â€œBioMarinâ€), a Delaware corporation, located at 105 Digital Drive, Novato, CA 94949 and Jean-Jacques Bienaime (â€œProviderâ€). WHEREAS, BioMarin and Provider entered into a Consulting Agreement on October 30, 2023, effective as of December 1, 2023 (the â€œConsulting Agreementâ€) WHEREAS, BioMarin and Provider desire to amend the Consulting Agreement pursuant to this Amendment;NOW,

THEREFORE, in consideration of the above recitals and mutual covenants contained herein, BioMarin and Provider agree as follows:1.The final sentence of Section 2.3.1 of the Consulting Agreement is hereby amended and restated to read as follows:â€œChange in Controlâ€ means any one or more of the following events: (i) a merger, consolidation, share exchange, business combination, issuance of securities, direct or indirect acquisition of securities, tender offer, exchange offer or other similar transaction as a result of which any one person, or more than one person acting as a group, acquires ownership of shares of BioMarinâ€™s voting stock that, together with other such stock held by such person or group, constitutes more than fifty percent (50%) of the total voting power of all outstanding classes of voting stock of BioMarin or the continuing or surviving corporation if BioMarin is not the continuing or surviving corporation in such transaction, or (ii) a sale of all or substantially all of the assets of BioMarin; provided, however, that an event will constitute a Change in Control only if it is also a change in ownership or effective control of the corporation or a change in the ownership of a substantial portion of the assets of the corporation, as defined in Treas. Reg. Â§ 1.409A-3(i)(5).2.Counterparts. This Amendment may be signed in counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.3.Ratification. All other provisions of the Consulting Agreement remain unchanged and are hereby ratified by BioMarin and Participant.[Remainder of the page intentionally left blank]1Â Â Â Â Â Â Â Â IN WITNESS WHEREOF, the parties hereto, intending to be legally bound hereby, have caused this Amendment to be executed and delivered by their proper and duly authorized officers effective as of the Effective Date.ACCEPTED AND AGREED TO:Jean-Jacques BienaimeBioMarin Pharmaceutical Inc.By: /s/ Jean-Jacques BienaimeBy: /s/ G. Eric DavisDate:June 7, 2024Name: G. Eric DavisIts: Chief Legal OfficerDate: June 8, 20242 EX-10.2 3 bmrn-exx102xq2x2024.htm EX-10.2 DocumentExhibit 10.2BioMarin Pharmaceutical Inc.Summary of Independent Director CompensationThe summary below sets forth the compensation received by independent directors serving on the Board of Directors (the â€œBoardâ€) of BioMarin Pharmaceutical Inc. (the â€œCompanyâ€). This summary is consistent with what was reported in the Companyâ€™s proxy statement previously filed with the Securities and Exchange Commission on April 9, 2024. All independent directors are entitled to receive a combination of annual cash retainers and restricted stock unit (â€œRSUâ€) grants as summarized below as compensation for their service on the Companyâ€™s Board and Board committees.Cash CompensationThe following table is a summary of the annual cash compensation payable to the independent directors. Each applicable line item is an additional element of compensation.Director PositionAnnual Cash CompensationCompensation to All Independent DirectorsAll Independent Directors$Â Â Â Â 65,000Â Â Â Â Elements of Compensation in Addition to Director Membership RetainerIndependent Chair of the Board (if applicable)$Â Â Â Â 80,000Â Â Â Â Lead Independent Director (if applicable)$Â Â Â Â 65,000Â Â Â Â Audit Committee Member$Â Â Â Â 13,500Â Â Â Â Audit Committee Chair (premium in addition to committee membership retainer)$Â Â Â Â 13,000Â Â Â Â Compensation Committee Member$Â Â Â Â 10,000Â Â Â Â Compensation Committee Chair (premium in addition to committee membership retainer)$Â Â Â Â 10,000Â Â Â Â Corporate Governance and Nominating Committee Member$Â Â Â Â 10,000Â Â Â Â Corporate Governance and Nominating Committee Chair (premium in addition to committee membershipÂ retainer)$Â Â Â Â 10,000Â Â Â Â Science and Technology Committee Member$Â Â Â Â 10,000Â Â Â Â Science and Technology Committee Chair (premium in addition to committee membership retainer)$Â Â Â Â 10,000Â Â Â Â Strategic and Operating Review Committee Member$Â Â Â Â 13,500Â Â Â Â Strategic and Operating Review Committee Chair (premium in addition to committee membership retainer)$Â Â Â Â 13,500Â Â Â Â Equity CompensationAnnual AwardOn the date of our annual meeting of stockholders for a given year, each re-elected independent director receives a RSU grant valued at $400,000, based on the Black-Scholes model valuation using a 30-day trailing average closing price of the Companyâ€™s common stock. The shares of common stock subject to the RSUs vest in full on the date immediately prior to the date of the Companyâ€™s next regular annual meeting of stockholders (approximately on the one-year anniversary of the grant date), subject to each respective director providing services to the Company through the vesting date.New Independent DirectorsUpon election or appointment, a new independent director will receive an RSU grant on the same terms as the annual award, pro-rated for amount and vesting to the nearest quarter for the time such new director will serve prior to the Companyâ€™s next annual meeting of stockholders.1 EX-31.1 4 bmrn-exx311xq22024.htm EX-31.1 DocumentExhibit 31.1CERTIFICATIONI, Alexander Hardy, certify that:1.I have reviewed this Quarterly Report on Form 10-Q of BioMarin Pharmaceutical Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c)evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd)disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andb)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.Date: August 5, 2024/S/ ALEXANDER HARDYAlexander HardyPresident & Chief Executive Officer EX-31.2 5 bmrn-exx312xq22024.htm EX-31.2 DocumentExhibit 31.2CERTIFICATIONI, Brian R. Mueller certify that:1.I have reviewed this Quarterly Report on Form 10-Q of BioMarin Pharmaceutical Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c)evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd)disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andb)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.Date: August 5, 2024/S/ BRIAN R. MUELLERBrian R. MuellerExecutive Vice President, Finance &Chief Financial Officer EX-32.1 6 bmrn-exx321xq22024.htm EX-32.1 DocumentExhibit 32.1CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002We, Alexander Hardy and Brian R. Mueller, hereby certify, pursuant to 18 U.S.C. Â§1350, as adopted pursuant to Â§906 of the Sarbanes-Oxley Act of 2002, that BioMarin Pharmaceutical Inc.â€™s Quarterly Report on Form 10-Q for the period ended JuneÂ 30, 2024, fully complies with the requirements of SectionÂ 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of BioMarin Pharmaceutical Inc./s/ ALEXANDER HARDYAlexander HardyPresident & Chief Executive OfficerDate: AugustÂ 5, 2024 /s/Â BRIAN R. MUELLERBrian R. MuellerExecutiveÂ ViceÂ President, Finance & ChiefÂ FinancialÂ OfficerDate: AugustÂ 5, 2024 This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of BioMarin Pharmaceutical Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing. EX-101.SCH 7 bmrn-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 9952156 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - FINANCIAL INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - RESTRUCTURING link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - EARNINGS PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - FINANCIAL INSTRUMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - RESTRUCTURING (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - EARNINGS PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES - Schedule of Error Corrections and Prior Period Adjustments (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - FINANCIAL INSTRUMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Schedule of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Schedule of Property, Plant and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Schedule of Intangible Assets, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Schedule of Accounts Payable and Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - FAIR VALUE MEASUREMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Schedule of Aggregate Notional Amounts for the Derivatives Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Schedule of Fair Value Carrying Amounts of Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Schedule of Impact of Gains and Losses from Derivatives Designated and Not Designated as Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - DEBT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - DEBT - Schedule of Convertible Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - DEBT - Schedule of Interest Expense on Convertible Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Disaggregation of Total Net Product Revenues by Product (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Disaggregation of Total Net Product Revenues by Geographic Region (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Total Net Product Revenue Concentrations Attributed to Largest Customers (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - STOCK-BASED COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - RESTRUCTURING - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - RESTRUCTURING - Schedule of Restructuring and Related Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - RESTRUCTURING - Schedule of Restructuring Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - EARNINGS PER COMMON SHARE - Schedule of Computation of Basic and Diluted Earnings Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - EARNINGS PER COMMON SHARE - Schedule of Anti-Dilutive

Common Stock Excluded from Computation of Diluted Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 bmrn-20240630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 bmrn-20240630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 bmrn-20240630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Lease liability Operating And Finance Lease Liability, Current Operating And Finance Lease Liability, Current Adjustments to reconcile net income to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Range Statistical Measurement [Domain] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Cover page. Cover [Abstract] NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Number of positions eliminated Restructuring and Related Cost, Expected Number of Positions Eliminated Trading Symbol Trading Symbol All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Asset Derivatives Derivative Asset, Subject to Master Netting Arrangement, before Offset Non-NEOs Non-NEOs [Member] Schedule of Computation of Basic and Diluted Earnings Per Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Derivative [Line Items] Derivative [Line Items] Schedule of Available-for-sale Securities [Line Items] Schedule Of Cash Cash Equivalents And Available For Sale Securities [Line Items] Schedule of cash, cash equivalents and available-for-sale securities. Position Position [Axis] Pay vs Performance Disclosure [Line Items] Marketed by Sanofi Sales Channel, Through Intermediary [Member] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Accounts receivable, net Increase (Decrease) in Accounts Receivable Derivative [Table] Derivative [Table] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Fair Value Carrying Amounts of Derivatives Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Restructuring and Related Activities [Abstract] Award Timing Disclosures [Line Items] Decrease in accounts payable and accrued liabilities related to intangible assets Supplemental Accounts Payable And Accrued Liabilities Increase (Decrease), Intangible Assets Supplemental Accounts Payable And Accrued Liabilities Increase (Decrease), Intangible Assets Derivatives Not Designated as Hedging Instruments Derivative, Gain (Loss) on Derivative, Net Other Performance Measure, Amount Other Performance Measure, Amount Common stock, shares outstanding (in shares) Shares of common stock, beginning balances (in shares) Shares of common stock, ending balances (in shares) Common Stock, Shares, Outstanding Company common stock held by the Nonqualified Deferred Compensation Plan Common Stock Issued, Employee Stock Trust Contract with Customer, Sales Channel Contract with Customer, Sales Channel [Axis] Deferred revenue Contract with Customer, Liability, Current United States UNITED STATES Other assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION Concentration Risk And Segment Reporting Disclosure [Text Block] Concentration risk and segment reporting disclosure. Finite-lived intangible assets Finite-Lived Intangible Assets, Gross Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Money market instruments Money Market Funds [Member] Selling, general and administrative Selling, General and Administrative Expenses [Member] Add: Interest expense, net of tax, on the Company's convertible debt Interest on Convertible Debt, Net of Tax Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Schedule of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income and Reclassifications Out of AOCI Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Equity Components Equity Components [Axis] Other current assets Other Assets, Current Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Restructuring Type [Axis] Restructuring Type [Axis] Aggregate Fair Value Debt Securities, Available-for-Sale Measurement Frequency Measurement Frequency [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Financial assets remeasured Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Revision of Prior Period, Adjustment Revision of Prior Period, Adjustment [Member] Use of Estimates Use of Estimates, Policy [Policy Text Block] Total operating expenses Total operating expenses Costs and Expenses Less: gain (loss) reclassified from AOCI Reclassification from AOCI, Current Period, before Tax, Attributable to Parent Adjustment to Compensation, Amount Adjustment to Compensation Amount Additional paid-in capital Additional Paid in Capital, Common Stock Compensation Amount Outstanding Recovery Compensation Amount SUPPLEMENTAL CASH FLOW DISCLOSURES FOR NON-CASH INVESTING AND FINANCING ACTIVITIES: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Error Corrections and Prior Period Adjustments Restatement [Line Items] Error Corrections and Prior Period Adjustments Restatement [Line Items] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Geographical Geographical [Axis] Strategic Investment Strategic Investment [Member] Strategic investment. Summary of Restructuring and Related Costs Restructuring and Related Costs [Table Text Block] Tabular List, Table Tabular List [Table Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Sanofi Customers [Member] Customers. Long term marketable securities maturity period Long Term Marketable Securities Maturity Period Long-term marketable securities maturity period. Total number of potentially issuable shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule Of Interest Expenses [Line Items] Schedule Of Interest Expenses [Line Items] Schedule of interest expenses. Payments Payments for Restructuring Beginning of period End of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Proceeds from sale of nonfinancial assets Proceeds From Sale Of Nonfinancial Assets Proceeds From Sale Of Nonfinancial Assets Accretion of discount on investments Accretion (Amortization) of Discounts and Premiums, Investments Current assets: Assets, Current [Abstract] Goodwill Goodwill Taxes paid related to net share settlement of equity awards Payment, Tax Withholding, Share-Based Payment Arrangement Restricted Investments Restricted Investments [Member] Restricted investments. Fair value of other current liabilities Other Liabilities Current Fair Value Disclosure Other liabilities current fair value disclosure. Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service Product and Service [Domain] Employee Stock Option Share-Based Payment Arrangement, Option [Member] ROCTAVIAN ROCTAVIAN [Member] ROCTAVIAN Depreciation Depreciation Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] COMPREHENSIVE INCOME Comprehensive Income (Loss), Net of Tax, Attributable to Parent Accrued income taxes Accrued Income Taxes, Current Common stock issuable under the Companyâ€™s convertible debt Common Stock Issuable Under Convertible Debt [Member] Common Stock Issuable Under Convertible Debt Security Exchange Name Security Exchange Name Award Type Award Type [Axis] Corporate debt securities Corporate Debt Securities [Member] Marketed by Company Sales Channel, Directly to Consumer [Member] Work-in-process Inventory, Work in Process, Net of Reserves Property, plant and equipment, net Total property, plant and equipment, net Property, Plant and Equipment, Net Debt repayments Repayments of Debt Total liabilities Liabilities Convertible Senior Notes Convertible Debt [Member] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Research and development Research and Development Expense Royalty and other revenues Royalty And Other [Member] Royalty and other. Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Expiration Date Trading Arrangement Expiration Date Fair Value, Nonrecurring Fair Value, Nonrecurring [Member] CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] 2024 Workforce Reduction Plan 2024 Workforce Reduction Plan [Member] 2024 Workforce Reduction Plan Tax effect Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent Total Shareholder Return Amount Total Shareholder Return Amount Common stock, shares issued (in shares) Common Stock, Shares, Issued Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Concentration risk, percentage Concentration Risk, Percentage Restructuring expenses Restructuring Costs and Asset Impairment Charges VIMIZIM VIMIZIM [Member] VIMIZIM Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Error Correction [Table] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Cash Cash Customer One Customer A Customer One [Member] Customer 1 Property, plant and equipment, gross Property, Plant and Equipment, Gross Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Research and development Research and Development Expense [Member] Europe Europe [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Weighted average common shares outstanding, diluted (in shares) Weighted-average common shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Long-term Debt, Type Long-Term Debt, Type [Axis] Total stockholdersâ€™ equity Beginning balances Ending balances Equity, Attributable to Parent BRINEURA BRINEURA [Member] BRINEURA FINANCIAL INSTRUMENTS Financial Instruments Disclosure [Text Block] Balance Sheet Location Statement of Financial Position Location, Balance [Axis] Hedging Designation Hedging Designation [Domain] Interest expense Interest Expense, Nonoperating Deferred income taxes Deferred Income Tax Expense (Benefit) Derivatives Designated as Cash Flow Hedging Instruments Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Payments of contingent consideration Payment for Contingent Consideration Liability, Financing Activities Concentration Risk Type Concentration Risk Type [Domain] Selling, general and administrative Selling, General and Administrative Expense Equity securities decline amount Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount Other comprehensive income (loss) Net current-period other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Accounts receivable, net Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Cost of sales Cost of Sales [Member] Net product revenues Product Product [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Asset Impairments Asset Impairment Charges Other long-term liabilities Increase (Decrease) in Other Operating Liabilities Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] Balance Sheet Location Statement of Financial Position Location, Balance [Domain] Schedule of Restructuring Reserve Activity Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Unrealized Gains (Losses) on Available-for-Sale Debt Securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] PALYNZIQ PALYNZIQ [Member] PALYNZIQ Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] ASSETS Assets [Abstract] Document Type Document Type Derivative Contract Derivative Contract [Domain] Commercial paper Commercial Paper [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Products excluding ALDURAZYME Products Excluding ALDURAZYME [Member] Products excluding product one. Coupon interest expense Interest Expense, Debt, Excluding Amortization Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Maximum Maximum [Member] Intangible asset amortization Amortization of Intangible Assets Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Net carrying value Finite-Lived Intangible Assets, Net Antidilutive Securities Antidilutive Securities [Axis] Accounting Policies [Abstract] Accounting Policies [Abstract] REVENUES: Revenues [Abstract] NAGLAZYME NAGLAZYME [Member] NAGLAZYME Current Fiscal Year End Date Current Fiscal Year End Date Accounts payable and accrued operating expenses Accounts Payable and Other Accrued Liabilities, Current Noncurrent assets: Assets, Noncurrent [Abstract] Range Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] INCOME BEFORE INCOME TAXES Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest All Award Types Award Type [Domain] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Name Outstanding Recovery, Individual Name Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table Text Block] Schedule of cash, cash equivalents and available-for-sale securities. Rest of world Rest Of World [Member] Rest of world. Schedule of Anti-Dilutive Common Stock Excluded from Computation of Diluted Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Revision of Prior Period [Axis] Revision of Prior Period [Axis] Deferred tax assets Deferred Income Tax Assets, Net Non-PEO NEO Non-PEO NEO [Member] Fair value of other assets Other Assets Noncurrent Fair Value Disclosure Other assets noncurrent fair value disclosure. Additional paid-in capital: Additional Paid-in Capital [Member] Award Timing Predetermined Award Timing Predetermined [Flag] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Percentage of workforce expected to be eliminated Restructuring and Related Cost, Expected Number Of Positions Eliminated, Percentage Of Workforce Restructuring and Related Cost, Expected Number Of Positions Eliminated, Percentage Of Workforce Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] DEBT Long-Term Debt [Text Block] EARNINGS PER SHARE, DILUTED (in dollars per share) Earnings per common share, diluted (in dollars per share) Earnings Per Share, Diluted $0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes) Zero Point Five Nine Nine Percent Senior Subordinated Convertible Notes Due In August Two Thousand Twenty Four [Member] Zero point five nine nine percent senior subordinated convertible notes due in August two thousand twenty four. Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Type of Restructuring [Domain] Type of Restructuring [Domain] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Number of operating business segment Number of Operating Segments Cash paid for income taxes Income Taxes Paid Customer Customer [Axis] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Unrealized foreign exchange loss (gain) Unrealized Gain (Loss), Foreign Currency Transaction, before Tax Severance and related costs Employee Severance [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Asset-backed securities Asset-Backed Securities [Member] RESTRUCTURING Restructuring and Related Activities Disclosure [Text Block] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Concentration Risk And Geographic Information [Line Items] Concentration Risk And Geographic Information [Line Items] Concentration risk and geographic information. Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones Contingent Payments Reasonably Possible Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones. Provision for income taxes Income Tax Expense (Benefit) Convertible notes stated rate Debt Instrument, Interest Rate, Stated Percentage Notional amount Derivative, Notional Amount Short-term investments Short-term marketable securities Debt Securities, Available-for-Sale, Current Issuances under equity incentive plans (in shares) Stock Issued During Period Value New Issues Net Excess Tax Benefit Tax Deficiency Shares Stock issued during period value new issues net excess tax benefit tax deficiency, shares. SUPPLEMENTAL CASH FLOW DISCLOSURES: Supplemental Cash Flow Information [Abstract] Net Income, diluted Net Income (Loss) Available to Common Stockholders, Diluted Operating expenses Operating Expense [Member] Total revenues Revenue Revenue from Contract with Customer, Excluding Assessed Tax Schedule of Impact of Gains and Losses from Derivatives Designated and Not Designated as Hedging Instruments Derivative Instruments, Gain (Loss) [Table Text Block] Purchase of intangible assets Payments to Acquire Intangible Assets Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Middle East Middle East [Member] Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities INCOME FROM OPERATIONS Operating Income (Loss) Total interest expense on convertible debt Interest Expense, Operating and Nonoperating Total liabilities and stockholdersâ€™ equity Liabilities and Equity Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Accrued compensation expense Employee-related Liabilities, Current Fair Value Hierarchy and

NAV Fair Value Hierarchy and NAV [Axis] Increase in accounts payable and accrued liabilities related to fixed assets Supplemental Accounts Payable And Accrued Liabilities Increase (Decrease), Fixed Assets Increase (decrease) in accounts payable and accrued liabilities related to purchase of property, plant and equipment during the reporting period. Hedging Designation Hedging Designation [Axis] Foreign currency exchange forward contracts Derivative Liability, Current DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES Derivative Instruments and Hedging Activities Disclosure [Text Block] Charges and Adjustments Restructuring Charges Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Interest income Investment Income, Interest Milestone payments received Milestone Payments Received Milestone Payments Received Underlying Security Market Price Change Underlying Security Market Price Change, Percent Individual: Individual [Axis] Schedule Of Interest Expenses [Table] Schedule Of Interest Expenses [Table] Schedule of interest expenses table. Accumulated other comprehensive income (loss): AOCI attributable to parent AOCI Attributable to Parent [Member] Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent Unrealized Gains (Losses) on Cash Flow Hedges Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Inventory Total inventory Inventory, Net U.S. government agency securities US Government Agencies Debt Securities [Member] Schedule of Aggregate Notional Amounts for the Derivatives Outstanding Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block] Long-term Debt, Type Long-Term Debt, Type [Domain] Product and Service Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Statement [Line Items] Statement [Line Items] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] NQDC Plan assets Nonqualified Deferred Compensation Plan Assets [Member] Nonqualified deferred compensation plan assets. Impairment of assets and other non-cash adjustments Asset Impairment Charges And Other Non-Cash Adjustments Asset Impairment Charges And Other Non-Cash Adjustments Change in Presentation Change In Presentation [Policy Text Block] Change In Presentation Schedule of Property, Plant and Equipment, Net Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments [Domain] Financial Instruments [Domain] LIABILITIES AND STOCKHOLDERSâ€™ EQUITY Liabilities and Equity [Abstract] KUVAN KUVAN [Member] KUVAN Financial liabilities remeasured Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Summary of Changes in Prior Period Presentation Schedule of Error Corrections and Prior Period Adjustments [Table Text Block] Unamortized discount net of deferred offering costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Long-term investments Long-term marketable securities Debt Securities, Available-for-Sale, Noncurrent Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Concentration Risk [Table] Concentration Risk [Table] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Derivative Instrument Derivative Instrument [Axis] Customer Two Customer B Customer Two [Member] Customer 2 Carrying value of equity component Convertible notes Long-Term Debt, Gross Exercise Price Award Exercise Price EARNINGS PER COMMON SHARE Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Subsequent Event Subsequent Event [Member] OPERATING EXPENSES: Costs and Expenses [Abstract] Schedule of Convertible Debt Convertible Debt [Table Text Block] Stockholdersâ€™ equity: Equity, Attributable to Parent [Abstract] Fair value of other current assets Other Assets Current Fair Value Disclosure Other assets current fair value disclosure. Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Restructuring Plan [Axis] Restructuring Plan [Axis] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] All Individuals All Individuals [Member] PEO PEO [Member] Credit Concentration Risk Credit Concentration Risk [Member] Name Trading Arrangement, Individual Name Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Other assets Increase (Decrease) in Other Noncurrent Assets Proceeds from exercises of awards under equity incentive plans Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Schedule of Total Net Product Revenue Concentrations Attributed to Largest Customers Schedules of Concentration of Risk, by Risk Factor [Table Text Block] 1.25% senior subordinated convertible notes due in May 2027 (the 2027 Notes) One Point Two Five Percent Senior Subordinated Convertible Notes Due in May 2027 [Member] One Point Two Five Percent Senior Subordinated Convertible Notes Due in May 2027 Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Assets: Assets, Fair Value Disclosure [Abstract] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Cash, aggregate fair value Cash and Cash Equivalents, Fair Value Disclosure Accounts payable and accrued liabilities Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Local Phone Number Local Phone Number Liability Class Liability Class [Axis] Cash and cash equivalents: Cash and Cash Equivalents, at Carrying Value [Abstract] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Other Other Restructuring [Member] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Noncurrent liabilities: Liabilities, Noncurrent [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Liability Derivatives Derivative Liability, Subject to Master Netting Arrangement, before Offset Income Statement Location Statement of Income Location, Balance [Axis] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Common stock: Common Stock [Member] Measure: Measure [Axis] Asset Class Asset Class [Domain] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Entity Emerging Growth Company Entity Emerging Growth Company Fair value of total financial liabilities Liabilities, Fair Value Disclosure Entity Central Index Key Entity Central Index Key Sell Short [Member] Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Maturity of derivatives Derivative, Remaining Maturity Other Other Restructuring Costs Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Schedule of Accounts Payable and Accrued Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Accounts payable and other short-term liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Concentration Risk And Geographic Information [Abstract] Concentration Risk And Geographic Information [Abstract] Concentration risk and geographic information. Equity Component Equity Component [Domain] Financial Instrument [Axis] Financial Instrument [Axis] Issuances under equity incentive plans, net of tax Stock Issued During Period Value New Issues Net Excess Tax Benefit Tax Deficiency Stock issued during period value new issues net excess tax benefit tax deficiency. Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Concentration Risk And Geographic Information [Table] Concentration Risk And Geographic Information [Table] Concentration risk and geographic information. Accrued rebates payable Accrued Government And Other Rebates Accrued Government And Other Rebates Title Trading Arrangement, Individual Title Company common stock held by the NQDC: Deferred Compensation, Share-Based Payments [Member] Statement [Table] Statement [Table] Fair Value, Measurement Frequency Measurement Frequency [Domain] BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Position Position [Domain] City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Concentration Risk Benchmark Concentration Risk Benchmark [Axis] Level 1: Level 1 Fair Value, Inputs, Level 1 [Member] Total current assets Assets, Current Gain on sale of nonfinancial assets Gain on sale of nonfinancial assets Gain (Loss) on Disposition of Assets Schedule of Interest Expense on Convertible Debt Interest Income and Interest Expense Disclosure [Table Text Block] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Revision of Prior Period [Domain] Revision of Prior Period [Domain] Customer A, B & C Customer One, Two And Three [Member] Customer One, Two And Three Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Potential shares issued if converted (in shares) Debt Conversion, Converted Instrument, Potential Shares Issued Debt Conversion, Converted Instrument, Potential Shares Issued Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Strategic investments fair value Equity Securities without Readily Determinable Fair Value, Amount Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Schedule of Disaggregation of Total Net Product Revenues by Product Revenue from External Customers by Products and Services [Table Text Block] Equity [Abstract] Equity [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Accumulated deficit Retained Earnings (Accumulated Deficit) Purchase Long [Member] Unrealized gains reclassified from AOCI to earnings over the next 12 months Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months Inventory Increase (Decrease) in Inventories NQDC Plan liability Nonqualified Deferred Compensation Plan Liability [Member] Nonqualified deferred compensation plan liability. OtherÂ long-termÂ liabilities Other Noncurrent Liabilities [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Depreciation and amortization Depreciation, Depletion and Amortization Other Other Accounts Payable and Accrued Liabilities Short-term convertible debt, net Convertible debt, current Convertible Debt, Current Fair Value as of Grant Date Award Grant Date Fair Value Customer Concentration Risk Customer Concentration Risk [Member] Level 2: Level 2 Fair Value, Inputs, Level 2 [Member] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Geographical Geographical [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Schedule of Disaggregation of Total Net Product Revenues by Geographic Region Disaggregation of Revenue [Table Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Schedule of Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Restructuring Cost [Table] Restructuring Cost [Table] Total convertible debt, net Convertible Debt Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type Concentration Risk Type [Axis] Common stock, $0.001 par value: 500,000,000 shares authorized; 190,355,517 and 188,598,154 shares issued and outstanding, respectively Common Stock, Value, Issued Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cash and cash equivalents Cash and Cash Equivalents Cash and Cash Equivalents, at Carrying Value VOXZOGO VOXZOGO [Member] VOXZOGO Other assets Other Noncurrent Assets [Member] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Effect of exchange rate changes on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Gain (loss) on extinguishment of debt Gain (Loss) on Extinguishment of Debt Fair Value by Liability Class Fair Value by Liability Class [Domain] CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Long-term convertible debt, net Convertible debt, noncurrent Convertible Debt, Noncurrent Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Maturities and sales of investments Proceeds from Sale, Maturity and Collection of Investments Common stock issuable under the Company's equity incentive plans Share-Based Payment Arrangement [Member] EARNINGS PER SHARE, BASIC (in dollars per share) Earnings per common share, basic (in dollars per share) Earnings Per Share, Basic Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Principal repayments of financing leases Finance Lease, Principal Payments Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Derivatives designated as hedging instruments: Designated as Hedging Instrument [Member] Net Income, basic Net Income (Loss) Available to Common Stockholders, Basic Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Total assets Assets Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Other long-term liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Accrued royalties payable Accrued Royalties, Current Termination Date Trading Arrangement Termination Date AccountsÂ payableÂ and accruedÂ liabilities Accounts Payable and Accrued Liabilities [Member] Fair value of other long-term liabilities Other Liabilities Noncurrent Fair Value Disclosure Other liabilities noncurrent fair value disclosure. Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] STOCK-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] Derivatives not designated as hedging instruments: Not Designated as Hedging Instrument [Member] Entity Address, City or Town Entity Address, City or Town Debt Instrument Debt Instrument [Axis] Change in Common stock held by the Nonqualified Deferred Compensation plan (NQDC) Adjustments To Additional Paid In Capital, Shares Held By Nonqualified Deferred Compensation Plan Adjustments To Additional Paid In Capital, Shares Held By Nonqualified Deferred Compensation Plan Total stock-based compensation expense Share-Based Payment Arrangement, Expense Total fair value of fixed-rate convertible debt Convertible Debt, Fair Value Disclosures NET INCOME Net income Net income Net Income (Loss) Attributable to Parent Other expense, net Other Operating Income (Expense), Net Trading Arrangement: Trading Arrangement [Axis] Schedule of Fair Value of Financial Assets and Liabilities Fair Value, by Balance Sheet Grouping [Table Text Block] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Accretion of discount on convertible notes Amortization of Debt Discount (Premium) ACCUMULATED OTHER COMPREHENSIVE INCOME Comprehensive Income (Loss) Note [Text Block] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Schedule of Intangible Assets, Net Schedule of Finite-Lived Intangible Assets [Table Text Block] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Contingent payments reasonably possible upon achievement of certain development and regulatory activities commercial sales and licensing milestones, to be paid next 12 months Contingent Payments Reasonably Possible Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones, To Be Paid, Due In Rolling Next 12 Months Contingent Payments Reasonably Possible Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones, To Be Paid, Due In Rolling Next 12 Months Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Liabilities: Liabilities, Fair Value Disclosure [Abstract] Document Fiscal Year Focus Document Fiscal Year Focus Revenue from External Customers by Products and Services [Table] Segment Reporting, Revenue from External Customer, Product and Service [Table] Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Other comprehensive income (loss) before Â Â Â Â reclassifications OCI, before Reclassifications, before Tax, Attributable to Parent Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Debt Instrument, Name Debt Instrument, Name [Domain] Severance and one-time employee benefits Severance Costs Restructuring Plan [Domain] Restructuring Plan [Domain] Fair value of total financial assets Assets, Fair Value Disclosure Name Forgone Recovery, Individual Name Document Period End Date Document Period End Date Finished goods Inventory, Finished Goods, Net of Reserves Other Other Noncash Income (Expense) Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Equity investment impairment amount Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount Asset Class Asset Class [Axis] Insider Trading Arrangements [Line Items] SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION Supplemental Balance Sheet Disclosures [Text Block] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount

Contract with Customer, Sales Channel Contract with Customer, Sales Channel [Domain] OtherÂ currentÂ assets Other Current Assets [Member] Other current assets Increase (Decrease) in Other Current Assets PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Effect of dilutive securities: Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Cost of sales Cost of Revenue Adjustment to Compensation: Adjustment to Compensation [Axis] Accounts Receivable Accounts Receivable [Member] Forward Foreign Exchange Contracts Foreign Exchange Contract [Member] Short term marketable securities maturity period Short Term Marketable Securities Maturity Period Short-term marketable securities maturity period. Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Purchase commitment Purchase Obligation Latin America Latin America [Member] Customer Customer [Domain] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Accumulated Deficit: Retained Earnings [Member] Amortization of debt issuance costs Amortization of Debt Issuance Costs Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table] Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table] Schedule of cash, cash equivalents and available-for-sale securities. Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Weighted average common shares outstanding, basic (in shares) Weighted-average common shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Purchase commitments expected to be paid in 2024 Purchase Obligation, to be Paid, Remainder of Fiscal Year Non-cash interest expense Amortization of Debt Issuance Costs and Discounts Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Purchases of investments Payments to Acquire Investments Name Awards Close in Time to MNPI Disclosures, Individual Name Net Product Revenue Revenue Benchmark [Member] ALDURAZYME ALDURAZYME [Member] ALDURAZYME Entity Filer Category Entity Filer Category Beginning balance Ending balance Restructuring Reserve Customer Three Customer C Customer Three [Member] Customer 3 Effect of dilutive securities (in shares) Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Income Statement Location Statement of Income Location, Balance [Domain] Company Selected Measure Name Company Selected Measure Name EX-101.PRE 11 bmrn-20240630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 13 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Cover Page - shares 6 Months Ended Jun. 30, 2024 Jul. 31, 2024 Cover [Abstract] Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Jun. 30, 2024 Â Document Transition Report false Â Entity File Number 000-26727 Â Entity Registrant Name BioMarin Pharmaceutical Inc Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 68-0397820 Â Entity Address, Address Line One 770 Lindaro Street Â Entity Address, City or Town San Rafael Â Entity Address, State or Province CA Â Entity Address, Postal Zip Code 94901 Â City Area Code 415 Â Local Phone Number 506-6700 Â Title of 12(b) Security Common Stock, par value $0.001 Â Trading Symbol BMRN Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Large Accelerated Filer Â Entity Small Business false Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 190,382,822 Amendment Flag false Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q2 Â Entity Central Index Key 0001048477 Â Current Fiscal Year End Date --12-31 Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 REVENUES: Â Â Â Â Total revenues $ 712,029 $ 595,275 $ 1,360,862 $ 1,191,690 OPERATING EXPENSES: Â Â Â Â Cost of sales 130,459 130,619 255,639 266,091 Research and development 183,787 177,363 388,774 349,209 Selling, general and administrative 263,032 206,103 488,938 417,126 Intangible asset amortization 14,299 15,624 28,597 31,294 Gain on sale of nonfinancial assets 0 0 (10,000) 0 Total operating expenses 591,577 529,709 1,151,948 1,063,720 INCOME FROM OPERATIONS 120,452 65,566 208,914 127,970 Interest income 19,785 12,612 39,150 24,555 Interest expense (3,574) (3,755) (7,121) (7,458) Other expense, net (4,527) (3,613) (3,260) (17,500) INCOME BEFORE INCOME TAXES 132,136 70,810 237,683 127,567 Provision for income taxes 24,962 14,770 41,847 20,675 NET INCOME $ 107,174 $ 56,040 $ 195,836 $ 106,892 EARNINGS PER SHARE, BASIC (in dollars per share) $ 0.56 $ 0.30 $ 1.03 $ 0.57 EARNINGS PER SHARE, DILUTED (in dollars per share) $ 0.55 $ 0.29 $ 1.01 $ 0.56 Weighted average common shares outstanding, basic (in shares) 190,114 187,948 189,490 187,311 Weighted average common shares outstanding, diluted (in shares) 200,505 194,998 200,137 194,756 COMPREHENSIVE INCOME $ 135,019 $ 48,145 $ 251,423 $ 92,142 Net product revenues Â Â Â Â REVENUES: Â Â Â Â Total revenues 702,129 584,698 1,339,944 1,171,124 Royalty and other revenues Â Â Â Â REVENUES: Â Â Â Â Total revenues $ 9,900 $ 10,577 $ 20,918 $ 20,566 X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -

URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B + Details Name: us-gaap_CostOfRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTotal costs of sales and operating expenses for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CostsAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnDispositionOfAssets1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -

SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InterestExpenseNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_InvestmentIncomeInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations. + ReferencesNo definition available. + Details Name: us-gaap_OtherOperatingIncomeExpenseNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name

Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=bmrn_RoyaltyAndOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 15 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 [1] Current assets: Â Â Cash and cash equivalents $ 972,150 $ 755,127 Short-term investments 252,201 318,683 Accounts receivable, net 691,232 633,704 Inventory 1,183,621 1,107,183 Other current assets 160,426 141,391 Total current assets 3,259,630 2,956,088 Noncurrent assets: Â Â Long-term investments 557,083 611,135 Property, plant and equipment, net 1,052,898 1,066,133 Intangible assets, net 265,533 294,701 Goodwill 196,199 196,199 Deferred tax assets 1,545,006 1,545,809 Other assets 190,772 171,538 Total assets 7,067,121 6,841,603 Current liabilities: Â Â Accounts payable and accrued liabilities 572,500 683,147 Short-term convertible debt, net 494,837 493,877 Total current liabilities 1,067,337 1,177,024 Noncurrent liabilities: Â Â Long-term convertible debt, net 594,116 593,095 Other long-term liabilities 119,369 119,935 Total liabilities 1,780,822 1,890,054 Stockholdersâ€™ equity: Â Â Common stock, $0.001 par value: 500,000,000 shares authorized; 190,355,517 and 188,598,154 shares issued and outstanding, respectively 190 189 Additional paid-in capital 5,696,701 5,611,562 Company common stock held by the Nonqualified Deferred Compensation Plan (11,673) (9,860) Accumulated other comprehensive income (loss) 26,799 (28,788) Accumulated deficit (425,718) (621,554) Total stockholdersâ€™ equity 5,286,299 4,951,549 [2] Total liabilities and stockholdersâ€™ equity $ 7,067,121 $ 6,841,603 [1] (1)DecemberÂ 31, 2023 balances were derived from the audited Consolidated Financial Statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, filed with the SEC on FebruaryÂ 26, 2024. [2] The beginning balances for the six-month periods were derived from the audited Consolidated Financial Statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023 filed with the SEC on FebruaryÂ 26, 2024. X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AssetsNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value

recognized in other comprehensive income (available-for-sale), classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionValue of common stock issued to a trust (for example, a 'rabbi trust') set up specifically to accumulate stock for the sole purpose of distribution to participating employees. This trust does not allow employees to immediately or after a holding period diversify into nonemployer securities. The deferred compensation plan for which this trust is set up must be settled by the delivery of a fixed number of shares of employer stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 710 -SubTopic 10 -Section 25 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483070/710-10-25-16 + Details Name: us-gaap_CommonStockIssuedEmployeeStockTrust Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ConvertibleDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ConvertibleDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6 + Details Name: us-gaap_DeferredIncomeTaxAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -

Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares Jun. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Â Â Common stock, par value (in dollars per share) $ 0.001 $ 0.001 Common stock, shares authorized (in shares) 500,000,000 500,000,000 Common stock, shares issued (in shares) 190,355,517 188,598,154 Common stock, shares outstanding (in shares) 190,355,517 188,598,154 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 17 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands Total Common stock: Additional paid-in capital: Company common stock held by the NQDC: Accumulated other comprehensive income (loss): Accumulated Deficit: Shares of common stock, beginning balances (in shares) at Dec. 31, 2022 [1] Â 186,251,000 Â Â Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Issuances under equity incentive plans (in shares) Â 1,901,000 Â Â Â Â Shares of common stock, ending balances (in shares) at Jun. 30, 2023 Â 188,152,000 Â Â Â Â Beginning balances at Dec. 31, 2022 [1] $ 4,603,156 $ 186 $ 5,404,895 $ (8,859) $ (3,867) $ (789,199) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Issuances under equity incentive plans, net of tax Â 2 (17,951) Â Â Â Stock-based compensation Â Â 105,478 Â Â Â Change in Common stock held by the Nonqualified Deferred Compensation plan (NQDC) Â Â 1,534 (1,534) Â Â Other comprehensive income (loss) (14,750) Â Â Â (14,750) Â Net income 106,892 Â Â Â Â 106,892 Ending balances at Jun. 30, 2023 4,782,827 $ 188 5,493,956 (10,393) (18,617) (682,307) Shares of common stock, beginning balances (in shares) at Mar. 31, 2023 [1] Â 187,601,000 Â Â Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Issuances under equity incentive plans (in shares) Â 551,000 Â Â Â Â Shares of common stock, ending balances (in shares) at Jun. 30, 2023 Â 188,152,000 Â Â Â Â Beginning balances at Mar. 31, 2023 [1] 4,659,043 $ 188 5,417,873 (9,949) (10,722) (738,347) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Issuances under equity incentive plans, net of tax Â 24,489 Â Â Â Stock-based compensation Â Â 51,150 Â Â Â Change

in Common stock held by the Nonqualified Deferred Compensation plan (NQDC) Â Â 444 (444) Â Â Other comprehensive income (loss) (7,895) Â Â Â (7,895) Â Net income 56,040 Â Â Â Â 56,040 Ending balances at Jun. 30, 2023 $ 4,782,827 $ 188 5,493,956 (10,393) (18,617) (682,307) Shares of common stock, beginning balances (in shares) at Dec. 31, 2023 188,598,154 188,598,000 [1] Â Â Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Issuances under equity incentive plans (in shares) Â 1,758,000 Â Â Â Â Shares of common stock, ending balances (in shares) at Jun. 30, 2024 190,355,517 190,356,000 Â Â Â Â Beginning balances at Dec. 31, 2023 [1] $ 4,951,549 [2] $ 189 5,611,562 (9,860) (28,788) (621,554) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Issuances under equity incentive plans, net of tax Â 1 (30,343) Â Â Â Stock-based compensation Â Â 113,669 Â Â Â Change in Common stock held by the Nonqualified Deferred Compensation plan (NQDC) Â Â 1,813 (1,813) Â Â Other comprehensive income (loss) 55,587 Â Â Â 55,587 Â Net income 195,836 Â Â Â Â 195,836 Ending balances at Jun. 30, 2024 $ 5,286,299 $ 190 5,696,701 (11,673) 26,799 (425,718) Shares of common stock, beginning balances (in shares) at Mar. 31, 2024 [1] Â 189,777,000 Â Â Â Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Issuances under equity incentive plans (in shares) Â 579,000 Â Â Â Â Shares of common stock, ending balances (in shares) at Jun. 30, 2024 190,355,517 190,356,000 Â Â Â Â Beginning balances at Mar. 31, 2024 [1] $ 5,073,816 $ 190 5,619,264 (11,700) (1,046) (532,892) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Issuances under equity incentive plans, net of tax Â Â 25,326 Â Â Â Stock-based compensation Â Â 52,138 Â Â Â Change in Common stock held by the Nonqualified Deferred Compensation plan (NQDC) Â Â (27) 27 Â Â Other comprehensive income (loss) 27,845 Â Â Â 27,845 Â Net income 107,174 Â Â Â Â 107,174 Ending balances at Jun. 30, 2024 $ 5,286,299 $ 190 $ 5,696,701 $ (11,673) $ 26,799 $ (425,718) [1] The beginning balances for the six-month periods were derived from the audited Consolidated Financial Statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023 filed with the SEC on FebruaryÂ 26, 2024. [2] (1)DecemberÂ 31, 2023 balances were derived from the audited Consolidated Financial Statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, filed with the SEC on FebruaryÂ 26, 2024. X - DefinitionAdjustments To Additional Paid In Capital, Shares Held By Nonqualified Deferred Compensation Plan + ReferencesNo definition available. + Details Name: bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan Namespace Prefix: bmrn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionStock issued during period value new issues net excess tax benefit tax deficiency. + ReferencesNo definition available. + Details Name: bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency Namespace Prefix: bmrn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock issued during period value new issues net excess tax benefit tax deficiency, shares. + ReferencesNo definition available. + Details Name: bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares Namespace Prefix: bmrn_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-

gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 18 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 CASH FLOWS FROM OPERATING ACTIVITIES: Â Â Net income $ 195,836 $ 106,892 Adjustments to reconcile net income to net cash used in operating activities: Â Â Depreciation and amortization 53,813 51,840 Non-cash interest expense 1,981 2,058 Accretion of discount on investments (4,678) (4,533) Stock-based compensation 106,163 103,857 Gain on sale of nonfinancial assets (10,000) 0 Impairment of assets and other non-cash adjustments 14,204 12,650 Deferred income taxes 1,537 (5,108) Unrealized foreign exchange loss (gain) (19,958) 7,455 Other (858) 361 Changes in operating assets and liabilities: Â Â Accounts receivable, net (56,081) (145,831) Inventory (47,409) (56,476) Other current assets 1,615 (53,430) Other assets (22,880) (5,616) Accounts payable and other short-term liabilities (54,261) (25,093) Other long-term liabilities 6,709 7,104 Net cash provided by (used in) operating activities 165,733 (3,870) CASH FLOWS FROM INVESTING ACTIVITIES: Â Â Purchases of property, plant and equipment (47,431) (46,039) Maturities and sales of investments 317,649 491,063 Purchases of investments (195,462) (444,049) Proceeds from sale of nonfinancial assets 10,000 0 Purchase of intangible assets (8,512) (1,457) Net cash provided by (used in) investing activities 76,244 (482) CASH FLOWS FROM FINANCING ACTIVITIES: Â Â Proceeds from exercises of awards under equity incentive plans 36,618 50,193 Taxes paid related to net share settlement of equity awards (66,739) (67,862) Payments of contingent consideration 0 (9,475) Principal repayments of financing leases (60) (1,635) Net cash used in financing activities (30,181) (28,779) Effect of exchange rate changes on cash 5,227 2,981 NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 217,023 (30,150) Cash and cash equivalents: Â Â Beginning of period 755,127 724,531 End of period 972,150 694,381 SUPPLEMENTAL CASH FLOW DISCLOSURES: Â Â Cash paid for interest 5,126 5,175 Cash paid for income taxes 22,884 28,183 SUPPLEMENTAL CASH FLOW DISCLOSURES FOR NON-CASH INVESTING AND FINANCING ACTIVITIES: Â Â Increase in accounts payable and accrued liabilities related to fixed assets 11,941 8,669 Decrease in accounts payable and accrued liabilities related to intangible assets $ 8,290 $ 2,344 X - DefinitionAsset Impairment Charges And Other Non-Cash Adjustments + ReferencesNo definition available. + Details Name: bmrn_AssetImpairmentChargesAndOtherNonCashAdjustments Namespace Prefix: bmrn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds From Sale Of Nonfinancial Assets + ReferencesNo definition available. + Details Name: bmrn_ProceedsFromSaleOfNonfinancialAssets Namespace Prefix: bmrn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease (decrease) in accounts payable and accrued liabilities related to purchase of property, plant and equipment during the reporting period. + ReferencesNo definition available. + Details Name: bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets Namespace Prefix: bmrn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionSupplemental Accounts Payable And Accrued Liabilities Increase (Decrease), Intangible Assets + ReferencesNo definition available. + Details Name: bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets Namespace Prefix: bmrn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of amortization expense attributable to debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -SubTopic 10 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9 + Details Name: us-gaap_DeferredIncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for principal payment on finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5 + Details Name: us-gaap_FinanceLeasePrincipalPayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before tax, of unrealized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossUnrealized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnDispositionOfAssets1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_IncomeTaxesPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherCurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherNoncurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in operating liabilities classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OtherNoncashIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (f) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the purchase of all investments (debt, security, other) during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 19 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIESNature of OperationsFounded in 1997, BioMarin Pharmaceutical Inc. (the Company or BioMarin) is a global biotechnology company dedicated to transforming lives through genetic discovery. The Company develops and commercializes targeted therapies that address the root cause of genetic conditions. The Company's robust research and development (R&D) capabilities have resulted in multiple innovative commercial therapies for patients with rare genetic disorders. The Company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. Basis of PresentationThese Condensed Consolidated Financial Statements have been prepared pursuant to U.S. generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the SEC for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. GAAP for complete financial statements, although management believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial

Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended DecemberÂ 31, 2023 included in the Companyâ€™s Annual Report on Form 10-K. The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions have been eliminated. The results of operations for the three and six months ended JuneÂ 30, 2024 are not necessarily indicative of the results that may be expected for the fiscal year ending DecemberÂ 31, 2024 or any other period.Change in Presentation Effective January 1, 2024, the Company changed its presentation for foreign currency transaction gains and losses resulting from remeasurement and idle plant costs within its Condensed Consolidated Statements of Comprehensive Income. Effective with this change in presentation, foreign currency transaction gains and losses resulting from remeasurement are presented in Other Expense, Net and idle plant costs are presented in Cost of Sales. Prior to this change in presentation, both foreign currency transaction gains and losses resulting from remeasurement and idle plant costs were presented in Selling, General and Administrative (SG&A) expense. The Company believes that this change in presentation is preferable because the revised presentation is more consistent with how management measures the Companyâ€™s operating performance.Prior period amounts were revised to conform to current period presentation. The following table reflects the impacts of the change in presentation for the prior periods presented. The change in presentation had no impact to Net Income, Total Stockholdersâ€™ Equity or earnings per share for the three and six months ended JuneÂ 30, 2023.Three Months ended JuneÂ 30, 2023Six Months ended JuneÂ 30, 2023Cost of sales$2,537Â $11,460Â SG&A$(9,233)$(21,213)Total operating expenses$(6,696)$(9,753)Other expense, net$6,696Â $9,753Â Use of EstimatesU.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on managementâ€™s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods.Management performed an evaluation of the Companyâ€™s activities through the date of filing of this Quarterly Report on Form 10-Q to determine if there were any subsequent events that occurred subsequent to the balance sheet date and prior to filing this Quarterly Report on Form 10-Q, that would require recognition or disclosure in the Condensed Consolidated Financial Statements. Further to this evaluation, the Company has included a subsequent event noted relating to the maturity and settlement of the Companyâ€™s convertible notes due in August 2024 that is discussed in Note 6 - Debt.Significant Accounting PoliciesThere have been no material changes to the Companyâ€™s significant accounting policies during the six months ended JuneÂ 30, 2024, as compared to the significant accounting policies disclosed in Note 1 â€“ Business Overview and Significant Accounting Policies to the Companyâ€™s Consolidated Financial Statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023.Recent Accounting PronouncementsThere have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board (FASB) during the six months ended JuneÂ 30, 2024, as compared to the recent accounting pronouncements described in Note 1 to the Companyâ€™s Consolidated Financial Statements of the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, that the Company believes are of significance or potential significance to the Company. The following paragraphs discuss new accounting pronouncements issued by the FASB, but not yet adopted by the Company.In November 2023, the FASB issued Accounting Standards Update (ASU) 2023-07, Segment Reporting Topic 280, Improvements to Reportable Segment Disclosures, to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. ASU 2023-07 expands public entitiesâ€™ segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items and interim disclosures of a reportable segmentâ€™s profit or loss and assets. The effective date for the update is for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024 and should be applied on a retrospective basis to all periods presented. The Company is currently evaluating the effect of adopting the update on its related disclosures.In December 2023, the FASB issued ASU 2023-09, Income Taxes Topic 740, Improvements to Income Tax Disclosures. The guidance requires disclosure of disaggregated information about the Companyâ€™s effective tax rate reconciliation as well as information on income taxes paid. The disclosure requirements will be applied on a prospective basis, with the option to apply it retrospectively. The effective date for the update is for fiscal years beginning after December 15, 2024. The Company is currently evaluating the effect of the update on its related disclosures. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 FINANCIAL INSTRUMENTS 6 Months Ended Jun. 30, 2024 Investments, Debt and Equity Securities [Abstract] Â FINANCIAL INSTRUMENTS FINANCIAL INSTRUMENTSAll marketable securities were classified as available-for-sale as of JuneÂ 30, 2024 and DecemberÂ 31, 2023.The following tables show the Companyâ€™s cash, cash equivalents and available-for-sale securities by significant investment category for each period presented:June 30, 2024Amortized CostGrossUnrealizedGainsGrossUnrealizedLossesAggregate Fair ValueCash and Cash EquivalentsShort-termMarketableSecurities (1)Long-termMarketableSecurities (2)Level 1:Cash$285,666Â $â€”Â $â€”Â $285,666Â $285,666Â $â€”Â $â€”Â Level 2:Money market instruments676,505Â â€”Â â€”Â 676,505Â 676,505Â â€”Â â€”Â Corporate debt securities537,626Â 670Â (1,460)536,836Â â€”Â 162,959Â 373,877Â U.S. government agency securities184,487Â 39Â (966)183,560Â 9,979Â 88,310Â 85,271Â Asset-backed securities98,958Â 105Â (196)98,867Â 932Â 97,935Â Subtotal1,497,576Â 814Â (2,622)1,495,768Â 686,484Â 252,201Â 557,083Â Total$1,783,242Â $814Â $(2,622)$1,781,434Â $972,150Â $252,2(31, 2023Amortized CostGrossUnrealizedGainsGrossUnrealizedLossesAggregate Fair ValueCash and Cash EquivalentsShort-termMarketableSecurities (1)Long-termMarketableSecurities (2)Level 1:Cash$229,676Â $â€”Â $â€”Â $229,676Â $229,676Â $â€”Â $â€”Â Level 2:Money market instruments499,483Â â€”Â â€”Â 499,483Â 499,483Â â€”Â â€”Â Corporate debt securities587,896Â 3,476Â (1,996)589,376Â â€”Â 193,251Â 396,125Â U.S. government agency securities251,952Â 556Â (1,140)251,368Â 19,976Â 111,343Â 120,049Â Commercial paper20,076Â 5Â â€”Â 20,081Â 5,992Â 14,089Â â€”Â Asset-backed securities94,744Â 351Â (134)94,961Â â€”Â â€”Â 94,961Â Subtotal1,454,151Â 4,388Â (3,270)1,455,269Â 525,451Â 318,683Â 611,135Â Total$1,683,827Â $4,388Â $(3,270)$1,684,945Â $755,127 Companyâ€™s short-term marketable securities mature in one year or less.(2)Â Â Â Â The Companyâ€™s long-term marketable securities mature between one and five years.As of JuneÂ 30, 2024, the Company had the ability and intent to hold all investments that were in an unrealized loss position until maturity. The Company considered its intent and ability to hold the securities until recovery of amortized cost basis, the extent to which fair value is less than amortized cost basis, conditions specifically related to the securityâ€™s industry and geography, payment structure and history and changes to the ratings (if any) in determining that the decline in fair value compared to carrying value is not related to a credit loss.The Company has certain investments in non-marketable equity securities, measured using unobservable valuation inputs and remeasured on a nonrecurring basis, which are collectively considered strategic investments. As of JuneÂ 30, 2024 and DecemberÂ 31, 2023, the fair value of the Companyâ€™s strategic investments was $6.7 million and $11.3 million, respectively. These investments were recorded to Other Assets in the Companyâ€™s Condensed Consolidated Balance Sheets. In the second quarter of 2024, based on new developments, the Company became aware of factors that indicated a $4.5Â million decline in the fair value of one of its strategic investments. In the first quarter of 2023, the Company concluded that factors existed indicating it would no longer realize a $12.6Â million equity investment in its non-marketable securities. The losses on the Companyâ€™s non-marketable equity investments were recorded to Other Expense, Net on the Companyâ€™s Condensed Consolidated Statements of Comprehensive Income for the respective periods. See Note 1 - Business Overview and Significant Accounting Policies included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023 for additional information related to the Companyâ€™s non-marketable securities policy. X - DefinitionThe entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures. + ReferencesNo definition available. + Details Name: us-gaap_FinancialInstrumentsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 21 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION 6 Months Ended Jun. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATIONSupplemental Balance Sheet InformationInventory consisted of the following:June 30,2024December 31,2023Raw materials$154,153Â $155,704Â Work-in-process605,770Â 571,107Â Finished goods423,698Â 380,372Â Total inventory$1,183,621Â $1,107,183Â Property, Plant and Equipment, Net consisted of the following:June 30,2024December 31,2023Property, plant and equipment, gross$1,962,948Â $1,933,222Â Accumulated depreciation(910,050)(867,089)Total property, plant and equipment, net$1,052,898Â $1,066,133Â Depreciation expense, net of amounts capitalized into inventory, for the three and six months ended JuneÂ 30, 2024 was $11.5 million and $24.1 million, respectively. Depreciation expense, net of amounts capitalized into inventory, for the three and six months ended JuneÂ 30, 2023 was $9.4 million and $19.7 million, respectively. Intangible Assets, Net consisted of the following:June 30,2024December 31,2023Finite-lived intangible assets$710,533Â $710,011Â Accumulated amortization(445,000)(415,310)Net carrying value$265,533Â $294,701Â In the first quarter of 2024, the Company received $10.0Â million due to the achievement of a regulatory approval milestone by a third party related to previously sold intangible assets, which the Company recorded as a Gain on Sale of Nonfinancial Assets in the Condensed Consolidated Statements of Comprehensive Income.Accounts Payable and Accrued Liabilities consisted of the following:June 30,2024December 31,2023Accounts payable and accrued operating expenses$257,412Â $315,509Â Accrued compensation expense147,737Â 201,067Â Accrued rebates payable113,432Â 96,179Â Accrued income taxes 18,864Â 2,651Â Lease liability10,689Â 8,779Â Foreign currency exchange forward contracts7,684Â 33,853Â Accrued royalties payable7,667Â 14,299Â Deferred revenue1,912Â 4,620Â Other7,103Â 6,190Â Total accounts payable and accrued liabilities$572,500Â $683,147Â X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details Name: us-gaap_SupplementalBalanceSheetDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 FAIR VALUE MEASUREMENTS 6 Months Ended Jun. 30, 2024 Fair Value Disclosures [Abstract] Â FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTSThe Company measures certain financial assets and liabilities at fair value in accordance with the policy described in Note 1 â€“ Business Overview and Significant Accounting Policies to the Companyâ€™s Consolidated Financial Statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023.Other than the Companyâ€™s fixed-rate convertible debt disclosed in Note 6 â€“ Debt, there were no financial assets or liabilities that were remeasured using quoted prices in active markets for identical assets (Level 1) as of JuneÂ 30, 2024 or DecemberÂ 31, 2023. The Company had no financial assets or liabilities that are remeasured on a recurring basis using unobservable inputs that reflect estimates and assumptions (Level 3) as of JuneÂ 30, 2024 or DecemberÂ 31, 2023.Level 2 assets and liabilities that are remeasured using significant observable inputs consisted of the following:Â June 30, 2024December 31, 2023Assets:Other current assets:NQDC Plan assets$2,649Â $2,026Â Other assets:NQDC Plan assets33,112Â 28,119Â Restricted investments (1)2,419Â 2,393Â Total other assets35,531Â 30,512Â Total assets$38,180Â $32,538Â Liabilities:Current liabilities:NQDC Plan liability$2,649Â $2,026Â Other long-term liabilities:NQDC Plan liability33,112Â 28,119Â Total liabilities$35,761Â $30,145Â (1)Â Â Â Â The restricted investments as of JuneÂ 30, 2024 and DecemberÂ 31, 2023 secure the Company's irrevocable standby letters of credit obtained in connection with certain commercial agreements.There were no transfers between levels during the three and six months ended JuneÂ 30, 2024. X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1 DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES 6 Months Ended Jun. 30, 2024 Derivative Instruments and Hedging Activities Disclosure [Abstract] Â DERIVATIVE

INSTRUMENTS AND HEDGING STRATEGIES DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIESThe Company uses foreign currency exchange forward contracts (forward contracts) to protect against the impact of changes in the value of forecasted foreign currency cash flows resulting from revenues and operating expenses denominated in currencies other than the U.S. Dollar (USD), primarily the Euro. Certain of these forward contracts are designated as cash flow hedges and have maturities of up to 24 months. The Company also enters into forward contracts to manage foreign exchange risk related to asset or liability positions denominated in currencies other than USD. Such forward contracts are considered to be economic hedges, are not designated as hedging instruments and have maturities of up to three months. The Company does not use derivative instruments for speculative trading purposes. The Company is exposed to counterparty credit risk on its derivatives. The Company has established and maintains strict counterparty credit guidelines and enters into hedging agreements with financial institutions that are investment grade or better to minimize the Companyâ€™s exposure to potential defaults. The Company is not required to pledge collateral under these agreements.The following table summarizes the aggregate notional amounts for the Companyâ€™s derivatives outstanding as of the periods presented.Forward ContractsJune 30,2024December 31,2023Derivatives designated as hedging instruments:Sell$1,086,980Â $1,249,662Â Purchase$192,162Â $198,408Â Derivatives not designated as hedging instruments:Sell$281,438Â $350,269Â Purchase$28,824Â $90,102Â The fair value carrying amounts of the Companyâ€™s derivatives, which are classified as Level 2 within the fair value hierarchy, were as follows:Balance Sheet LocationJune 30,2024December 31,2023Derivatives designated as hedging instruments:Asset DerivativesOtherÂ currentÂ assets$27,599Â $6,663Â Other assets8,236Â 1,855Â Subtotal$35,835Â $8,518Â Liability DerivativesAccountsÂ payableÂ and accruedÂ liabilities$6,407Â $30,005Â OtherÂ long-termÂ liabilities1,257Â 8,171Â Subtotal$7,664Â $38,176Â Derivatives not designated as hedging instruments:Asset DerivativesOtherÂ currentÂ assets$2,352Â $547Â Liability DerivativesAccountsÂ payableÂ and accruedÂ liabilities$1,277Â $3,848Â Total Derivatives Assets$38,187Â $9,065Â Total Derivatives Liabilities$8,941Â $42,024Â For additional discussion of fair value measurements, see Note 1 â€“ Business Overview and Significant Accounting Policies to the Companyâ€™s Consolidated Financial Statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023.The following tables summarize the impact of gains and losses from the Company's derivatives on its Condensed Consolidated Statements of Comprehensive Income for the periods presented.Three Months EndedSix Months Ended June 30,20242023202420230Derivatives Designated as Cash Flow Hedging InstrumentsCash Flow Hedging Gains (Losses) Reclassified into EarningsCash Flow Hedging Gains (Losses) Reclassified into EarningsCash Flow Hedging Gains (Losses) Reclassified into EarningsCash Flow Hedging Gains (Losses) Reclassified into EarningsNet product revenues$3,371Â $677Â $2,252Â $4,147Â Operating expenses(190)(26)$314Â $(482)Derivatives Not Designated as Hedging InstrumentsGains (Losses) Recognized in EarningsGains (Losses) Recognized in EarningsGains (Losses) Recognized in EarningsGains (Losses) Recognized in EarningsOperating expenses$13,812Â $769Â $21,541Â $(3,394)As of JuneÂ 30, 2024, the Company expects to reclassify unrealized gains of $21.2 million from Accumulated Other Comprehensive Income (Loss) (AOCI) to earnings as the forecasted revenues and operating expense transactions occur over the next twelve months. For additional discussion of balances in AOCI see Note 7 â€“ Accumulated Other Comprehensive Income. X - ReferencesNo definition available. + Details Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5CReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/815/tableOfContent + Details Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 DEBT 6 Months Ended Jun. 30, 2024 Debt Disclosure [Abstract] Â DEBT DEBTConvertible NotesAs of JuneÂ 30, 2024, the Company had outstanding fixed-rate notes with varying maturities for an undiscounted aggregate principal amount of $1.1 billion (collectively, the Notes). The Notes are senior subordinated convertible obligations, and interest is payable in arrears, semi-annually. The following table summarizes information regarding the Companyâ€™s convertible debt:June 30,2024December 31,20230.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)$495,000Â $495,000Â Unamortized discount net of deferred offering costs(163)(1,123)2024 Notes, net (1)494,837Â 493,877Â 1.25% senior subordinated convertible notes due in May 2027 (the 2027 Notes)600,000Â 600,000Â Unamortized discount net of deferred offering costs(5,884)(6,905)2027 Notes, net594,116Â 593,095Â Total convertible debt, net$1,088,953Â $1,086,972Â Fair value of fixed-rate convertible debt (2):2024 Notes$492,447Â $488,288Â 2027 Notes576,102Â 619,260Â Total fair value of fixed-rate convertible debt$1,068,549Â $1,107,548Â (1)Â Â Â Â The Companyâ€™s convertible notes due in 2024 matured on August 1, 2024, subsequent to quarter-end. Substantially all holders of the 2024 Notes were repaid with cash, totaling approximately $495.0Â million. No gain or loss was incurred upon the extinguishment.(2) Â Â Â Â The fair value of the Companyâ€™s fixed-rate convertible debt is based on open-market trades and is classified as Level 1 in the fair value hierarchy. For additional discussion of fair value measurements, see Note 1 â€“ Business Overview and Significant Accounting Policies to the Companyâ€™s Consolidated Financial Statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023.Interest expense on the Companyâ€™s convertible debt consisted of the following:Â Three Months EndedJune 30,Six Months EndedJune 30,20242023202420230Coupon interest expense$2,617Â $2,617Â $5,233Â $5,233Â Accretion of discount on convertible notes843Â 834Â 1,684Â 1,673Â Amortization of debt issuance costs148Â 149Â 297Â 297Â Total interest expense on convertible debt$3,608Â $3,600Â $7,214Â $7,203Â See Note 10 - Debt to the Companyâ€™s Consolidated Financial Statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023 for additional information related to the Companyâ€™s convertible debt. X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContent + Details Name: us-gaap_LongTermDebtTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 ACCUMULATED OTHER COMPREHENSIVE INCOME 6 Months Ended Jun. 30, 2024 Equity [Abstract] Â ACCUMULATED OTHER COMPREHENSIVE INCOME ACCUMULATED OTHER COMPREHENSIVE INCOMEThe following tables summarize changes in the accumulated balances for each component of AOCI, including current-period other comprehensive income and reclassifications out of AOCI, for the periods presented.Three Months Ended June 30, 2024Unrealized Gains(Losses) on CashFlow HedgesUnrealized Gains(Losses) onAvailable-for-SaleDebt SecuritiesTotalAOCI balance as of MarchÂ 31, 2024(183)(863)$(1,046)Other comprehensive income (loss) beforeÂ Â Â Â reclassifications31,551Â (684)30,867Â Less: gain (loss) reclassified from AOCI3,181Â â€”Â 3,181Â Tax effectâ€”Â 159Â 159Â Net current-period other comprehensive income (loss)28,370Â (525)27,845Â AOCI balance as of JuneÂ 30, 2024$28,187Â $(1,388)$26,799Â Three Months Ended June 30, 2023Unrealized Gains(Losses) on CashFlow HedgesUnrealized Gains(Losses) onAvailable-for-SaleDebt SecuritiesTotalAOCI balance as of MarchÂ 31, 2023$(2,647)$(8,075)$(10,722)Other comprehensive income (loss) beforeÂ Â Â Â reclassifications(6,737)(661)(7,398)Less: gain (loss) reclassified from AOCI651Â â€”Â 651Â Tax effectâ€”Â 154Â 154Â Net current-period other comprehensive income (loss)(7,388)(507)(7,895)AOCI balance as of JuneÂ 30, 2023$(10,035)$(8,582)$(18,617)Six Months Ended June 30, 2024Unrealized Gains(Losses) on CashFlow HedgesUnrealized Gains(Losses) onAvailable-for-SaleDebt SecuritiesTotalAOCI balance as of DecemberÂ 31, 2023$(29,658)$870Â $(28,788)Other comprehensive income (loss) beforeÂ Â Â Â reclassifications60,411Â (2,926)57,485Â Less: gain (loss) reclassified from AOCI2,566Â â€”Â 2,566Â Tax effectâ€”Â 668Â 668Â Net current-period other comprehensive income (loss)57,845Â (2,258)55,587Â AOCI balance as of JuneÂ 30, 2024$28,187Â $(1,388)$26,799Â Six Months Ended June 30, 2023Unrealized Gains(Losses) on CashFlow HedgesUnrealized Gains(Losses) onAvailable-for-SaleDebt SecuritiesTotalAOCI balance as of DecemberÂ 31, 2022$8,226Â $(12,093)$(3,867)Other comprehensive income (loss) beforeÂ Â Â Â reclassifications(14,596)4,586Â (10,010)Less: gain (loss) reclassified from AOCI3,665Â â€”Â 3,665Â Tax effectâ€”Â (1,075)(1,075)Net current-period other comprehensive income (loss)(18,261)3,511Â (14,750)AOCI balance as of JuneÂ 30, 2023$(10,035)$(8,582)$(18,617)For additional discussion of reclassifications from AOCI see Note 5 â€“ Derivative Instruments and Hedging Strategies. X - DefinitionThe entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/220/tableOfContent + Details Name: us-gaap_ComprehensiveIncomeNoteTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 26 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1 REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION 6 Months Ended Jun. 30, 2024 Concentration Risk And Geographic Information [Abstract] Â REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATIONThe Company operates in one business segment, which focuses on the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions.The following table presents Total Revenues and disaggregates Net Product Revenues by product.Three Months EndedJune 30,Six Months EndedJune 30,20242023202420230VOXZOGO$183,923Â $113,337Â $336,812Â $201,173Â VIMIZIM178,016Â 177,392Â 370,536Â 366,584Â NAGLAZYME132,049Â 90,103Â 237,678Â 213,124Â PALYNZIQ88 net product revenues702,129Â 584,698Â 1,339,944Â 1,171,124Â Royalty and other revenues9,900Â 10,577Â 20,918Â 20,566Â Total revenues$712,029Â $595,275Â $1,360,862Â $1,191,690Â The Company considers there to be revenue concentration risks for regions where Net Product Revenues exceed 10% of consolidated Net Product Revenues. The concentration of the Companyâ€™s Net Product Revenues within the regions below may have a material adverse effect on the Companyâ€™s revenues and results of operations if sales in the respective regions experience difficulties. The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for the Company's commercial products sold directly by the Company, except for ALDURAZYME, which is marketed and sold exclusively by Sanofi worldwide.Three Months EndedJune 30,Six Months EndedJune 30,20242023202420230United States$227,449Â $191,655Â $420,448Â $358,439Â Europe220,990Â 183,434Â 416,738Â 344,126Â Latin America84,418Â 75,444Â 163,012Â 143,192Â Middle East49,701Â 25,630Â 106,776Â 117,272Â Rest of world81,013Â 68,217Â 159,150Â 133,374Â Total net product revenues marketed by the Company$663,571Â $544,380Â $1,266,124Â $1,096,403Â ALDURAZYME net product revenues marketed by Sanofi38,558Â 40,318Â 73,820Â 74,721Â Total net product revenues$702,129Â $584,698Â $1,339,944Â $1,171,124Â The following table illustrates the percentage of the Companyâ€™s total Net Product Revenues attributed to the Companyâ€™s largest customers for the periods presented.Three Months EndedJune 30,Six Months EndedJune 30,20242023202420230Customer A14Â %15Â %14Â %15Â %Customer B11Â %12Â %11Â %11Â %Customer C10Â %10Â %9Â %9Â %Total35Â %37Â %34Â %35Â %On a consolidated basis, three customers accounted for 15%, 12%, and 10% of the Companyâ€™s JuneÂ 30, 2024 accounts receivable balance, respectively, compared to DecemberÂ 31, 2023, when two customers accounted for 15% and 12% of the accounts receivable balance, respectively. As of JuneÂ 30, 2024, and DecemberÂ 31, 2023, the accounts receivable balance for Sanofi included $67.1 million and $63.4 million, respectively, of unbilled accounts receivable, which becomes payable to the Company when the product is sold through by Sanofi. The Company does not require collateral from its customers, but does perform periodic credit evaluations of its customersâ€™ financial condition and requires prepayments in certain circumstances.The Company is mindful that conditions in the current macroeconomic environment, such as inflation, changes in interest and foreign currency exchange rates, natural disasters, geopolitical instability, and supply chain disruptions, could affect the Companyâ€™s ability to achieve its goals. In addition, the Company sells its products in countries that face economic volatility and weakness. Although the Company has historically collected receivables from customers in certain countries, sustained weakness or further deterioration of the local economies and currencies may cause customers in those countries to delay payment or be unable to pay for the Companyâ€™s products. The Company believes that the allowances for doubtful accounts related to these countries, if any, are adequate based on its analysis of the specific business circumstances and expectations of collection for each of the underlying accounts in these countries. The Company will continue to monitor these conditions and will attempt to adjust its business processes, as appropriate, to mitigate macroeconomic risks to its business. X - DefinitionConcentration risk and geographic information. + ReferencesNo definition available. + Details Name: bmrn_ConcentrationRiskAndGeographicInformationAbstract Namespace Prefix: bmrn_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionConcentration risk and segment reporting disclosure. + ReferencesNo definition available. + Details Name: bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock Namespace Prefix: bmrn_ Data Type: dtr-types1:textBlockItemType Balance Type: na Period Type: duration XML 27 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 STOCK-BASED COMPENSATION 6 Months Ended Jun. 30, 2024 Share-Based Payment Arrangement [Abstract] Â STOCK-BASED COMPENSATION STOCK-BASED COMPENSATIONThe Company has stockholder-approved equity incentive plans that provide for the granting of restricted stock units (RSUs) and stock options as well as other forms of equity compensation to its employees, officers and non-employee directors. The Company also has an Employee Stock Purchase Plan (ESPP). Compensation expense included in the Companyâ€™s Condensed Consolidated Statements of Comprehensive Income for all stock-based compensation arrangements was as follows:Â Three Months EndedJune 30,Six Months EndedJune 30,20242023202420230Cost of sales$3,774Â $4,721Â $7,018Â $9,052Â Research and development12,935Â 15,055Â 33,612Â 34,883Â Selling, general and administrative31,205Â 30,386Â 65,533Â 59,922Â Total stock-based compensation expense$47,914Â $50,162Â $106,163Â $103,857Â X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 28 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1 RESTRUCTURING 6 Months Ended Jun. 30, 2024 Restructuring and Related Activities [Abstract] Â RESTRUCTURING RESTRUCTURINGDuring the first half of 2024, the Company completed a strategic portfolio assessment of its research and development programs to determine which have the most transformative potential for patients and value creation for shareholders. With the combined focus on patient impact and commercial opportunity, certain programs that met the

highest bar for advancement have been prioritized. As a result of the assessment, certain programs have been discontinued.During the second quarter of 2024, in connection with the discontinuation of certain research and development programs, the Company committed to a plan to reduce its global workforce by approximately 170 employees (representing approximately 5% of the Companyâ€™s global workforce). Workforce reductions are expected to be substantially completed by end of 2024.The restructuring plan includes severance and employee-related costs, asset impairments, and other costs. The asset impairment charges were for abandoned assets-in-progress and a Right-of-Use asset (ROU Asset) related to leased office space the Company decided to exit and sub-lease. The Company utilized the discounted cash flow approach to determine the fair value of the ROU Asset. The ROU Asset impairment is the difference between the existing lease terms and rates and the expected sub-lease terms and rates available in the market. The Other category includes restructuring-related costs, which are expensed as incurred, as well as other obligations related to the leased office space that will be satisfied over the remainder of the lease term.The restructuring charges and adjustments were included in Selling, General, and Administrative in the Condensed Consolidated Statements of Comprehensive Income. Restructuring expenses consisted of the following: Three Months EndedJune 30,Six Months EndedJune 30,20242024Severance and one-time employee benefits$23,837Â $25,275Â Asset Impairments9,6719,671Other5,5197,519$39,027Â $42,465Â The following unpaid balance as of JuneÂ 30, 2024 was recorded to Accounts Payable and Accrued Liabilities on the Condensed Consolidated Balance Sheet:Severance and related costsOtherTotalBalance as of DecemberÂ 31, 2023$â€”Â $â€”Â $â€”Â Charges and Adjustments25,275Â 7,519Â $32,793Â Payments(4,321)(2,000)$(6,321)Balance as of JuneÂ 30, 2024$20,954Â $5,519Â $26,472Â X - ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/420/tableOfContentReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1 EARNINGS PER COMMON SHARE 6 Months Ended Jun. 30, 2024 Earnings Per Share [Abstract] Â EARNINGS PER COMMON SHARE EARNINGS PER COMMON SHAREPotentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards, common stock issuable under the ESPP, unvested RSUs and contingent issuances of common stock related to the Companyâ€™s convertible debt.The following table sets forth the computation of basic and diluted earnings per common share (common shares in thousands):Three Months EndedJune 30,Six Months EndedJune 30,202402320242023Numerator:Net Income, basic$107,174Â $56,040Â $195,836Â $106,892Â Add: Interest expense, net of tax, on the Company's convertible debt2,769Â 937Â 5,538Â 1,873Â Net Income, diluted$109,943Â $56,977Â $201,374Â $108,765Â Denominator:Weighted-average common shares outstanding, basic190,114Â 187,948Â 189,490Â 187,311Â Effect of dilutive securities:Common stock issuable under the Company's equity incentive plans2,056Â 3,080Â 2,312Â 3,475Â Common stock issuable under the Companyâ€™s convertible debt(1)8,335Â 3,970Â 8,335Â 3,970Â Weighted-average common shares outstanding, diluted200,505Â 194,998Â 200,137Â 194,756Â Earnings per common share, basic$0.56Â $0.30Â $1.03Â $0.57Â Earnings per common share, diluted$0.55Â $0.29Â $1.01Â $0.56Â In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of diluted earnings per common share as they were anti-dilutive (in thousands):Three Months EndedJune 30,Six Months EndedJune 30,20242023202420232Common stock issuable under the Company's equity incentive plans10,362Â 8,716Â 10,106Â 8,321Â Common stock issuable under the Companyâ€™s convertible debt (1)â€”Â 4,365Â â€”Â 4,365Â Total number of potentially issuable shares10,362Â 13,081Â 10,106Â 12,686Â (1)Â Â Â Â Â If converted, the Company would issue 4.0Â million shares under the 2024 Notes and 4.4Â million shares under the 2027 Notes. For additional discussion of the Companyâ€™s convertible debt, see Note 6 - Debt. X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1 COMMITMENTS AND CONTINGENCIES 6 Months Ended Jun. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIESContingenciesFrom time to time the Company is involved in legal actions arising in the normal course of its business. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters could adversely affect the Company, its results of operations, financial condition or cash flows. The Companyâ€™s general practice is to expense legal fees as services are rendered in connection with legal matters, and to accrue for liabilities when losses are probable and reasonably estimable based on existing information. The Company accrues for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then the minimum amount in the range is accrued. Liabilities are evaluated and refined each reporting period as additional information is known. Any receivables for insurance recoveries for these liability claims are recorded as assets when it is probable that a recovery will be realized.As previously disclosed, the Company received a subpoena from the U.S. Department of Justice (DOJ) requesting that the Company produce certain documents regarding sponsored testing programs relating to VIMIZIM and NAGLAZYME. The Company has produced the requested documents in response to the subpoena and is cooperating fully. The Company is unable to make any assurances regarding the outcome of the investigation by the DOJ, or the impact, if any, that such investigation may have on the Companyâ€™s business, Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Comprehensive Income or Condensed Consolidated Statements of Cash Flows.Contingent PaymentsAs of JuneÂ 30, 2024, the Company was subject to contingent payments, primarily comprised of development, regulatory and commercial milestones. Those considered reasonably possible totaled $495.6 million, of this amount the Company may pay up to $10.9 million over the next 12 months if certain contingencies are met.Other CommitmentsThe Company uses experts and laboratories at universities and other institutions to perform certain R&D activities. These amounts are recorded as R&D expense as services are provided. In the normal course of business, the Company enters into various firm purchase commitments primarily to procure active pharmaceutical ingredients, certain inventory-related items and certain third-party R&D services, production services and facility construction services. The Company also has commitments related to enterprise resource planning (ERP) system implementation costs for which the Company is committed. As of JuneÂ 30, 2024, such commitments were estimated at $473.0 million, of which $291.1 million is expected to be paid in 2024 as underlying goods and services are received. The Company has also licensed technology from third parties, for which it is required to pay royalties upon future sales, subject to certain annual minimums. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Net income $ 107,174 $ 56,040 $ 195,836 $ 106,892 X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45

-Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 32 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Insider Trading Arrangements 3 Months Ended Jun. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 33 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Policies) 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â Basis of Presentation Basis of PresentationThese Condensed Consolidated Financial Statements have been prepared pursuant to U.S. generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the SEC for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. GAAP for complete financial statements, although management believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended DecemberÂ 31, 2023 included in the Companyâ€™s Annual Report on Form 10-K. The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions have been eliminated. The results of operations for the three and six months ended JuneÂ 30, 2024 are not necessarily indicative of the results that may be expected for the fiscal year ending DecemberÂ 31, 2024 or any other period. Change in Presentation Change in Presentation Effective January 1, 2024, the Company changed its presentation for foreign currency transaction gains and losses resulting from remeasurement and idle plant costs within its Condensed Consolidated Statements of Comprehensive Income. Effective with this change in presentation, foreign currency transaction gains and losses resulting from remeasurement are presented in Other Expense, Net and idle plant costs are presented in Cost of Sales. Prior to this change in presentation, both foreign currency transaction gains and losses resulting from remeasurement and idle plant costs were presented in Selling, General and Administrative (SG&A) expense. The Company believes that this change in presentation is preferable because the revised presentation is more consistent with how management measures the Companyâ€™s operating performance. Use of Estimates Use of EstimatesU.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on managementâ€™s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods.Management performed an evaluation of the Companyâ€™s activities through the date of filing of this Quarterly Report on Form 10-Q to determine if there were any subsequent events that occurred subsequent to the balance sheet date and prior to filing this Quarterly Report on Form 10-Q, that would require recognition or disclosure in the Condensed Consolidated Financial Statements. Further to this evaluation, the Company has included a subsequent event noted relating to the maturity and settlement of the Companyâ€™s convertible notes due in August 2024 that is discussed in Note 6 - Debt. Recent Accounting Pronouncements Recent Accounting PronouncementsThere have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board (FASB) during the six months ended JuneÂ 30, 2024, as compared to the recent accounting pronouncements described in Note 1 to the Companyâ€™s Consolidated Financial Statements of the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, that the Company believes are of significance or potential significance to the Company. The following paragraphs discuss new accounting pronouncements issued by the FASB, but not yet adopted by the Company.In November 2023, the FASB issued Accounting Standards Update (ASU) 2023-07, Segment Reporting Topic 280, Improvements to Reportable Segment Disclosures, to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. ASU 2023-07 expands public entitiesâ€™ segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items and interim disclosures of a reportable segmentâ€™s profit or loss and assets. The effective date for the update is for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024 and should be applied on a retrospective basis to all periods presented. The Company is currently evaluating the effect of adopting the update on its related disclosures.In December 2023, the FASB issued ASU 2023-09, Income Taxes Topic 740, Improvements to Income Tax Disclosures. The guidance requires disclosure of disaggregated information about the Companyâ€™s effective tax rate reconciliation as well as information on income taxes paid. The disclosure requirements will be applied on a prospective basis, with the option to apply it retrospectively. The effective date for the update is for fiscal years beginning after December 15, 2024. The Company is currently evaluating the effect of the update on its related disclosures. X - DefinitionChange In Presentation + ReferencesNo definition available. + Details Name: bmrn_ChangeInPresentationPolicyTextBlock Namespace Prefix: bmrn_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Tables) 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â Summary of Changes in Prior Period Presentation The following table reflects the impacts of the change in presentation for the prior periods presented. The change in presentation had no impact to Net Income, Total Stockholdersâ€™ Equity or earnings per share for the three and six months ended JuneÂ 30, 2023.Three Months ended JuneÂ 30, 2023Six Months ended JuneÂ 30, 2023Cost of sales$2,537Â $11,460Â SG&A$(9,233)$(21,213)Total operating expenses$(6,696)$(9,753)Other expense, net$6,696Â $9,753Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9 + Details Name: us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 FINANCIAL INSTRUMENTS (Tables) 6 Months Ended Jun. 30, 2024 Investments, Debt and Equity Securities [Abstract] Â Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category The following tables show the Companyâ€™s cash, cash equivalents and available-for-sale securities by significant investment category for each period presented:June 30, 2024Amortized CostGrossUnrealizedGainsGrossUnrealizedLossesAggregate Fair ValueCash and Cash EquivalentsShort-termMarketableSecurities (1)Long-termMarketableSecurities (2)Level 1:Cash$285,666Â $â€”Â $â€”Â $285,666Â $285,666Â $â€”Â $â€”Â Level 2:Money market instruments676,505Â â€”Â Â â€”Â 676,505Â 676,505Â â€”Â Â â€”Â Corporate debt securities537,626Â 670Â (1,460)536,836Â â€”Â 162,959Â 373,877Â U.S. government agency securities184,487Â 39Â (966)183,560Â 9,979Â 88,310Â 85,271Â Asset-backed securities98,958Â 105Â (196)98,867Â 932Â 97,935Â Subtotal1,497,576Â 814Â (2,622)1,495,768Â 686,484Â 252,201Â 557,083Â Total$1,783,242Â $814Â $(2,622)$1,781,434Â $972,150Â $252,2(31, 2023Amortized CostGrossUnrealizedGainsGrossUnrealizedLossesAggregate Fair ValueCash and Cash EquivalentsShort-termMarketableSecurities (1)Long-termMarketableSecurities (2)Level 1:Cash$229,676Â $â€”Â $â€”Â $229,676Â $229,676Â $â€”Â $â€”Â Level 2:Money market instruments499,483Â â€”Â Â â€”Â 499,483Â 499,483Â â€”Â Â â€”Â Corporate debt securities587,896Â 3,476Â (1,996)589,376Â â€”Â 193,251Â 396,125Â U.S. government agency securities251,952Â 556Â (1,140)251,368Â 19,976Â 111,343Â 120,049Â Commercial paper20,076Â 5Â â€”Â 20,081Â 5,992Â 14,089Â â€”Â Asset-backed securities94,744Â 351Â (134)94,961Â â€”Â â€”Â 94,961Â Subtotal1,454,151Â 4,388Â (3,270)1,455,269Â 525,451Â 318,683Â 611,135Â Total$1,683,827Â $4,388Â $(3,270)$1,684,945Â $755,127 Companyâ€™s short-term marketable securities mature in one year or less.(2)Â Â Â Â The Companyâ€™s long-term marketable securities mature between one and five years. X - DefinitionSchedule of cash, cash equivalents and available-for-sale securities. + ReferencesNo definition available. + Details Name: bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock Namespace Prefix: bmrn_ Data Type: dtr-types1:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 36 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION (Tables) 6 Months Ended Jun. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Schedule of Inventory Inventory consisted of the following:June 30,2024December 31,2023Raw materials$154,153Â $155,704Â Work-in-process605,770Â 571,107Â Finished goods423,698Â 380,372Â Total inventory$1,183,621Â $1,107,183Â Schedule of Property, Plant and Equipment, Net Property, Plant and Equipment, Net consisted of the following:June 30,2024December 31,2023Property, plant and equipment, gross$1,962,948Â $1,933,222Â Accumulated depreciation(910,050)(867,089)Total property, plant and equipment, net$1,052,898Â $1,066,133Â Schedule of Intangible Assets, Net Intangible Assets, Net consisted of the following:June 30,2024December 31,2023Finite-lived intangible assets$710,533Â $710,011Â Accumulated amortization(445,000)(415,310)Net carrying value$265,533Â $294,701Â Schedule of Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities consisted of the following:June 30,2024December 31,2023Accounts payable and accrued operating expenses$257,412Â $315,509Â Accrued compensation expense147,737Â 201,067Â Accrued rebates payable113,432Â 96,179Â Accrued income taxes 18,864Â 2,651Â Lease liability10,689Â 8,779Â Foreign currency exchange forward contracts7,684Â 33,853Â Accrued royalties payable7,667Â 14,299Â Deferred revenue1,912Â 4,620Â Other7,103Â 6,190Â Total accounts payable and accrued liabilities$572,500Â $683,147Â X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3:

http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1 + Details Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1 FAIR VALUE MEASUREMENTS (Tables) 6 Months Ended Jun. 30, 2024 Fair Value Disclosures [Abstract] Â Schedule of Fair Value of Financial Assets and Liabilities Level 2 assets and liabilities that are remeasured using significant observable inputs consisted of the following:Â June 30, 2024December 31, 2023Assets:Other current assets:NQDC Plan assets$2,649Â $2,026Â Other assets:NQDC Plan assets33,112Â 28,119Â Restricted investments (1)2,419Â 2,393Â Total other assets35,531Â 30,512Â Total assets$38,180Â $32,538Â Liabilities:Current liabilities:NQDC Plan liability$2,649Â $2,026Â Other long-term liabilities:NQDC Plan liability33,112Â 28,119Â Total liabilities$35,761Â $30,145Â (1)Â Â Â Â Â The restricted investments as of JuneÂ 30, 2024 and DecemberÂ 31, 2023 secure the Company's irrevocable standby letters of credit obtained in connection with certain commercial agreements. X - DefinitionTabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11 + Details Name: us-gaap_FairValueByBalanceSheetGroupingTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 38 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1 DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables) 6 Months Ended Jun. 30, 2024 Derivative Instruments and Hedging Activities Disclosure [Abstract] Â Schedule of Aggregate Notional Amounts for the Derivatives Outstanding The following table summarizes the aggregate notional amounts for the Companyâ€™s derivatives outstanding as of the periods presented.Forward ContractsJune 30,2024December 31,2023Derivatives designated as hedging instruments:Sell$1,086,980Â $1,249,662Â Purchase$192,162Â $198,408Â Derivatives not designated as hedging instruments:Sell$281,438Â $350,269Â Purchase$28,824Â $90,102Â Schedule of Fair Value Carrying Amounts of Derivatives The fair value carrying amounts of the Companyâ€™s derivatives, which are classified as Level 2 within the fair value hierarchy, were as follows:Balance Sheet LocationJune 30,2024December 31,2023Derivatives designated as hedging instruments:Asset DerivativesOtherÂ currentÂ assets$27,599Â $6,663Â Other assets8,236Â 1,855Â Subtotal$35,835Â $8,518Â Liability DerivativesAccountsÂ payableÂ and accruedÂ liabilities$6,407Â $30,005Â OtherÂ long-termÂ liabilities1,257Â 8,171Â Subtotal$7,664Â $38,176Â Derivatives not designated as hedging instruments:Asset DerivativesOtherÂ currentÂ assets$2,352Â $547Â Liability DerivativesAccountsÂ payableÂ and accruedÂ liabilities$1,277Â $3,848Â Total Derivatives Assets$38,187Â $9,065Â Total Derivatives Liabilities$8,941Â $42,024Â Schedule of Impact of Gains and Losses from Derivatives Designated and Not Designated as Hedging Instruments The following tables summarize the impact of gains and losses from the Company's derivatives on its Condensed Consolidated Statements of Comprehensive Income for the periods presented.Three Months EndedSix Months Ended June 30,20242023202420230Derivatives Designated as Cash Flow Hedging InstrumentsCash Flow Hedging Gains (Losses) Reclassified into EarningsCash Flow Hedging Gains (Losses) Reclassified into EarningsCash Flow Hedging Gains (Losses) Reclassified into EarningsCash Flow Hedging Gains (Losses) Reclassified into EarningsNet product revenues$3,371Â $677Â $2,252Â $4,147Â Operating expenses(190)(26)$314Â $(482)Derivatives Not Designated as Hedging InstrumentsGains (Losses) Recognized in EarningsGains (Losses) Recognized in EarningsGains (Losses) Recognized in EarningsGains (Losses) Recognized in EarningsOperating expenses$13,812Â $769Â $21,541Â $(3,394) X - ReferencesNo definition available. + Details Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4E -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4EReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4C -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B + Details Name: us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B + Details Name: us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1 DEBT (Tables) 6 Months Ended Jun. 30, 2024 Debt Disclosure [Abstract] Â Schedule of Convertible Debt The following table summarizes information regarding the Companyâ€™s convertible debt:June 30,2024December 31,20230.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)$495,000Â $495,000Â Unamortized discount net of deferred offering costs(163)(1,123)2024 Notes, net (1)494,837Â 493,877Â 1.25% senior subordinated convertible notes due in May 2027 (the 2027 Notes)600,000Â 600,000Â Unamortized discount net of deferred offering costs(5,884)(6,905)2027 Notes, net594,116Â 593,095Â Total convertible debt, net$1,088,953Â $1,086,972Â Fair value of fixed-rate convertible debt (2):2024 Notes$492,447Â $488,288Â 2027 Notes576,102Â 619,260Â Total fair value of fixed-rate convertible debt$1,068,549Â $1,107,548Â (1)Â Â Â Â The Companyâ€™s convertible notes due in 2024 matured on August 1, 2024, subsequent to quarter-end. Substantially all holders of the 2024 Notes were repaid with cash, totaling approximately $495.0Â million. No gain or loss was incurred upon the extinguishment.(2)Â Â Â Â The fair value of the Companyâ€™s fixed-rate convertible debt is based on open-market trades and is classified as Level 1 in the fair value hierarchy. For additional discussion of fair value measurements, see Note 1 â€“ Business Overview and Significant Accounting Policies to the Companyâ€™s Consolidated Financial Statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023. Schedule of Interest Expense on Convertible Debt Interest expense on the Companyâ€™s convertible debt consisted of the following:Â Three Months EndedJune 30,Six Months EndedJune 30,20242023202420232Coupon interest expense$2,617Â $2,617Â $5,233Â $5,233Â Accretion of discount on convertible notes843Â 834Â 1,684Â 1,673Â Amortization of debt issuance costs148Â 149Â 297Â 297Â Total interest expense on convertible debt$3,608Â $3,600Â $7,214Â $7,203Â X - DefinitionTabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount. + ReferencesNo definition available. + Details Name: us-gaap_ConvertibleDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities. + ReferencesNo definition available. + Details Name: us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1 ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables) 6 Months Ended Jun. 30, 2024 Equity [Abstract] Â Schedule of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income and Reclassifications Out of AOCI The following tables summarize changes in the accumulated balances for each component of AOCI, including current-period other comprehensive income and reclassifications out of AOCI, for the periods presented.Three Months Ended June 30, 2024Unrealized Gains(Losses) on CashFlow HedgesUnrealized Gains(Losses) onAvailable-for-SaleDebt SecuritiesTotalAOCI balance as of MarchÂ 31, 2024(183)(863)$(1,046)Other comprehensive income (loss) beforeÂ Â Â Â reclassifications31,551Â (684)30,867Â Less: gain (loss) reclassified from AOCI3,181Â â€“Â 3,181Â Tax effectâ€“Â 159Â 159Â Net current-period other comprehensive income (loss)28,370Â (525)27,845Â AOCI balance as of JuneÂ 30, 2024$28,187Â $(1,388)$26,799Â Three Months Ended June 30, 2023Unrealized Gains(Losses) on CashFlow HedgesUnrealized Gains(Losses) onAvailable-for-SaleDebt SecuritiesTotalAOCI balance as of MarchÂ 31, 2023$(2,647)$(8,075)$(10,722)Other comprehensive income (loss) beforeÂ Â Â Â reclassifications(6,737)(661)(7,398)Less: gain (loss) reclassified from AOCI651Â â€“Â 651Â Tax effectâ€“Â 154Â 154Â Net current-period other comprehensive income (loss)(7,388)(507)(7,895)AOCI balance as of JuneÂ 30, 2023$(10,035)$(8,582)$(18,617)Six Months Ended June 30, 2024Unrealized Gains(Losses) on CashFlow HedgesUnrealized Gains(Losses) onAvailable-for-SaleDebt SecuritiesTotalAOCI balance as of DecemberÂ 31, 2023$(29,658)$870Â $(28,788)Other comprehensive income (loss) beforeÂ Â Â Â reclassifications60,411Â (2,926)57,485Â Less: gain (loss) reclassified from AOCI2,566Â â€“Â 2,566Â Tax effectâ€“Â 668Â 668Â Net current-period other comprehensive income (loss)57,845Â (2,258)55,587Â AOCI balance as of JuneÂ 30, 2024$28,187Â $(1,388)$26,799Â Six Months Ended June 30, 2023Unrealized Gains(Losses) on CashFlow HedgesUnrealized Gains(Losses) onAvailable-for-SaleDebt SecuritiesTotalAOCI balance as of DecemberÂ 31, 2022$8,226Â $(12,093)$(3,867)Other comprehensive income (loss) beforeÂ Â Â Â reclassifications(14,596)4,586Â (10,010)Less: gain (loss) reclassified from AOCI3,665Â â€“Â 3,665Â Tax effectâ€“Â (1,075)(1,075)Net current-period other comprehensive income (loss)(18,261)3,511Â (14,750)AOCI balance as of JuneÂ 30, 2023$(10,035)$(8,582)$(18,617) X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accumulated other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20 + Details Name: us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 41 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1 REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables) 6 Months Ended Jun. 30, 2024 Concentration Risk And Geographic Information [Abstract] Â Schedule of Disaggregation of Total Net Product Revenues by Product The following table presents Total Revenues and disaggregates Net Product Revenues by product.Three Months EndedJune 30,Six Months EndedJune 30,20242023202420232VOXZOGO$183,923Â $113,337Â $336,812Â $201,173Â VIMIZIM178,016Â 177,392Â 370,536Â 366,584Â NAGLAZYME132,049Â 90,103Â 237,678Â 213,124Â PALYNZIQ88 net product revenues702,129Â 584,698Â 1,339,944Â 1,171,124Â Royalty and other revenues9,900Â 10,577Â 20,918Â 20,566Â Total revenues$712,029Â $595,275Â $1,360,862Â $1,191,690Â Schedule of Disaggregation of Total Net Product Revenues by Geographic Region The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for the Company's commercial products sold directly by the Company, except for ALDURAZYME, which is marketed and sold exclusively by Sanofi worldwide.Three Months EndedJune 30,Six Months EndedJune 30,20242023202420232United States$227,449Â $191,655Â $420,448Â $358,439Â Europe220,990Â 183,434Â 416,738Â 344,126Â Latin America84,418Â 75,444Â 163,012Â 143,192Â Middle East49,701Â 25,630Â 106,776Â 117,272Â Rest of world81,013Â 68,217Â 159,150Â 133,374Â Total net product revenues marketed by the Company$663,571Â $544,380Â $1,266,124Â $1,096,403Â ALDURAZYME net product revenues marketed by Sanofi38,558Â 40,318Â 73,820Â 74,721Â Total net product revenues$702,129Â $584,698Â $1,339,944Â $1,171,124Â Schedule of Total Net Product Revenue Concentrations Attributed to Largest Customers The following table illustrates the percentage of the Companyâ€™s total Net Product Revenues attributed to the Companyâ€™s largest customers for the periods presented.Three Months EndedJune 30,Six Months EndedJune 30,20242023202420232Customer A14Â %15Â %14Â %15Â %Customer B11Â %12Â %11Â %11Â %Customer C10Â %10Â %9Â %9Â %Total35Â %37Â %34Â %35Â % X - DefinitionConcentration risk and geographic information. + ReferencesNo definition available. + Details Name: bmrn_ConcentrationRiskAndGeographicInformationAbstract Namespace Prefix: bmrn_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details Name: us-gaap_DisaggregationOfRevenueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 + Details Name: us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-21 + Details Name: us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 42 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1 STOCK-BASED COMPENSATION (Tables) 6 Months Ended Jun. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Schedule of Stock-Based Compensation Expense Compensation expense included in the Companyâ€™s Condensed Consolidated Statements of Comprehensive Income for all stock-based compensation arrangements was as follows:Â Three Months EndedJune 30,Six Months EndedJune 30,20242023202420232Cost of sales$3,774Â $4,721Â $7,018Â $9,052Â Research and development12,935Â 15,055Â 33,612Â 34,883Â Selling, general and administrative31,205Â 30,386Â 65,533Â 59,922Â Total stock-based compensation expense$47,914Â $50,162Â $106,163Â $103,857Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)

(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 43 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 RESTRUCTURING (Tables) 6 Months Ended Jun. 30, 2024 Restructuring and Related Activities [Abstract] Â Summary of Restructuring and Related Costs Restructuring expenses consisted of the following: Three Months EndedJune 30,Six Months EndedJune 30,20242024Severance and one-time employee benefits$23,837Â $25,275Â Asset Impairments9,6719,671Other5,5197,519$39,027Â $42,465Â Schedule of Restructuring Reserve Activity Severance and related costsOtherTotalBalance as of DecemberÂ 31, 2023$â€”Â $â€”Â $â€”Â Charges and Adjustments25,275Â 7,519Â $32,793Â Payments(4,321)(2,000)$(6,321)Balance as of JuneÂ 30, 2024$20,954Â $5,519Â $26,472Â X - ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 44 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 EARNINGS PER COMMON SHARE (Tables) 6 Months Ended Jun. 30, 2024 Earnings Per Share [Abstract] Â Schedule of Computation of Basic and Diluted Earnings Per Common Share The following table sets forth the computation of basic and diluted earnings per common share (common shares in thousands):Three Months EndedJune 30,Six Months EndedJune 30,20242023202420232023Numerator:Net Income, basic$107,174Â $56,040Â $195,836Â $106,892Â Add: Interest expense, net of tax, on the Company's convertible debt2,769Â 937Â 5,538Â 1,873Â Net Income, diluted$109,943Â $56,977Â $201,374Â $108,765Â Denominator:Weighted-average common shares outstanding, basic190,114Â 187,948Â 189,490Â 187,311Â Effect of dilutive securities:Common stock issuable under the Company's equity incentive plans2,056Â 3,080Â 2,312Â 3,475Â Common stock issuable under the Companyâ€™s convertible debt(1)8,335Â 3,970Â 8,335Â 3,970Â Weighted-average common shares outstanding, diluted200,505Â 194,998Â 200,137Â 194,756Â Earnings per common share, basic$0.56Â $0.30Â $1.03Â $0.57Â Earnings per common share, diluted$0.55Â $0.29Â $1.01Â $0.56Â Schedule of Anti-Dilutive Common Stock Excluded from Computation of Diluted Earnings Per Share In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of diluted earnings per common share as they were anti-dilutive (in thousands):Three Months EndedJune 30,Six Months EndedJune 30,20242023202420232023Common stock issuable under the Company's equity incentive plans10,362Â 8,716Â 10,106Â 8,321Â Common stock issuable under the Companyâ€™s convertible debt (1)â€”Â 4,365Â â€”Â 4,365Â Total number of potentially issuable shares10,362Â 13,081Â 10,106Â 12,686Â (1)Â Â Â Â If converted, the Company would issue 4.0Â million shares under the 2024 Notes and 4.4Â million shares under the 2027 Notes. For additional discussion of the Companyâ€™s convertible debt, see Note 6 - Debt. X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 45 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES - Schedule of Error Corrections and Prior Period Adjustments (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Error Corrections and Prior Period Adjustments Restatement [Line Items] Â Â Â Â Cost of sales $ 130,459 $ 130,619 $ 255,639 $ 266,091 Selling, general and administrative 263,032 206,103 488,938 417,126 Total operating expenses 591,577 529,709 1,151,948 1,063,720 Other expense, net $ (4,527) (3,613) $ (3,260) (17,500) Revision of Prior Period, Adjustment Â Â Â Â Error Corrections and Prior Period Adjustments Restatement [Line Items] Â Â Â Â Cost of sales Â 2,537 Â 11,460 Selling, general and administrative Â (9,233) Â (21,213) Total operating expenses Â (6,696) Â (9,753) Other expense, net Â $ 6,696 Â $ 9,753 X - DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B + Details Name: us-gaap_CostOfRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTotal costs of sales and operating expenses for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-12Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7 + Details Name: us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations. + ReferencesNo definition available. + Details Name: us-gaap_OtherOperatingIncomeExpenseNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_RestatementAxis=srt_RestatementAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Details) - USD ($) $ in Thousands 6 Months Ended 12 Months Ended Jun. 30, 2024 Dec. 31, 2023 Schedule of Available-for-sale Securities [Line Items] Â Â Amortized Cost $ 1,783,242 $ 1,683,827 Gross Unrealized Gains 814 4,388 Gross Unrealized Losses (2,622) (3,270) Aggregate Fair Value 1,781,434 1,684,945 Cash and Cash Equivalents 972,150 755,127 [1] Short-term marketable securities 252,201 318,683 [1] Long-term marketable securities $ 557,083 $ 611,135 [1] Maximum Â Â Schedule of Available-for-sale Securities [Line Items] Â Â Short term marketable securities maturity period 1 year 1 year Long term marketable securities maturity period 5 years 5 years Minimum Â Â Schedule of Available-for-sale Securities [Line Items] Â Â Long term marketable securities maturity period 1 year 1 year Level 1: Â Â Schedule of Available-for-sale Securities [Line Items] Â Â Cash $ 285,666 $ 229,676 Cash, aggregate fair value 285,666 229,676 Level 2: Â Â Schedule of Available-for-sale Securities [Line Items] Â Â Amortized Cost 1,497,576 1,454,151 Gross Unrealized Gains 814 4,388 Gross Unrealized Losses (2,622) (3,270) Aggregate Fair Value 1,495,768 1,455,269 Cash and Cash Equivalents 686,484 525,451 Short-term marketable securities 252,201 318,683 Long-term marketable securities 557,083 611,135 Level 2: | Money market instruments Â Â Schedule of Available-for-sale Securities [Line Items] Â Â Amortized Cost 676,505 499,483 Gross Unrealized Gains 0 0 Gross Unrealized Losses 0 0 Aggregate Fair Value 676,505 499,483 Cash and Cash Equivalents 676,505 499,483 Short-term marketable securities 0 0 Long-term marketable securities 0 0 Level 2: | Corporate debt securities Â Â Schedule of Available-for-sale Securities [Line Items] Â Â Amortized Cost 537,626 587,896 Gross Unrealized Gains 670 3,476 Gross Unrealized Losses (1,460) (1,996) Aggregate Fair Value 536,836 589,376 Cash and Cash Equivalents 0 0 Short-term marketable securities 162,959 193,251 Long-term marketable securities 373,877 396,125 Level 2: | U.S. government agency securities Â Â Schedule of Available-for-sale Securities [Line Items] Â Â Amortized Cost 184,487 251,952 Gross Unrealized Gains 39 556 Gross Unrealized Losses (966) (1,140) Aggregate Fair Value 183,560 251,368 Cash and Cash Equivalents 9,979 19,976 Short-term marketable securities 88,310 111,343 Long-term marketable securities 85,271 120,049 Level 2: | Commercial paper Â Â Schedule of Available-for-sale Securities [Line Items] Â Â Amortized Cost Â 20,076 Gross Unrealized Gains Â 5 Gross Unrealized Losses Â 0 Aggregate Fair Value Â 20,081 Cash and Cash Equivalents Â 5,992 Short-term marketable securities Â 14,089 Long-term marketable securities Â 0 Level 2: | Asset-backed securities Â Â Schedule of Available-for-sale Securities [Line Items] Â Â Amortized Cost 98,958 94,744 Gross Unrealized Gains 105 351 Gross Unrealized Losses (196) (134) Aggregate Fair Value 98,867 94,961 Cash and Cash Equivalents 0 Short-term marketable securities 932 0 Long-term marketable securities $ 97,935 $ 94,961 [1] (1)DecemberÂ 31, 2023 balances were derived from the audited Consolidated Financial Statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, filed with the SEC on FebruaryÂ 26, 2024. X - DefinitionLong-term marketable securities maturity period. + ReferencesNo definition available. + Details Name: bmrn_LongTermMarketableSecuritiesMaturityPeriod Namespace Prefix: bmrn_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionSchedule of cash, cash equivalents and available-for-sale securities. + ReferencesNo definition available. + Details Name: bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems Namespace Prefix: bmrn_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionShort-term marketable securities maturity period. + ReferencesNo definition available. + Details Name: bmrn_ShortTermMarketableSecuritiesMaturityPeriod Namespace Prefix: bmrn_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 210 -Topic 946 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20 + Details Name: us-gaap_Cash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 FINANCIAL INSTRUMENTS - Narrative (Details) - USD ($) $ in Millions 3 Months Ended Jun. 30, 2024 Mar. 31, 2023 Dec. 31, 2023 Schedule of Available-for-sale Securities [Line Items] Â Â Â Equity investment impairment amount Â $ 12.6 Â Strategic Investment | Fair Value, Measurements, Recurring Â Â Â Schedule of Available-for-sale Securities [Line Items] Â Â Â Strategic investments fair value $ 6.7 Â $ 11.3 Strategic Investment | Fair Value, Nonrecurring Â Â Â Schedule of Available-for-sale Securities [Line Items] Â Â Â Equity securities decline amount $ 4.5 Â Â X - DefinitionSchedule of cash, cash equivalents and available-for-sale securities. + ReferencesNo definition available. + Details Name: bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems Namespace Prefix: bmrn_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in equity security without readily determinable fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3 + Details Name: us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of loss from downward price adjustment on investment in equity security without readily determinable fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3 + Details Name: us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of impairment loss on investment in equity security without readily determinable fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3 + Details Name: us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_FairValueByAssetClassAxis=bmrn_StrategicInvestmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Schedule of Inventory (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Â Raw materials $ 154,153 $ 155,704 Work-in-process 605,770 571,107 Finished goods 423,698 380,372 Total inventory $ 1,183,621 $ 1,107,183 [1] [1] (1)DecemberÂ 31, 2023 balances were derived from the audited Consolidated Financial Statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, filed with the SEC on FebruaryÂ 26, 2024. X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoodsNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryRawMaterialsNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryWorkInProcessNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 49 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Schedule of Property, Plant and Equipment, Net (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Â Property, plant and equipment, gross $ 1,962,948 $ 1,933,222 Accumulated depreciation (910,050) (867,089) Total property, plant and equipment, net $ 1,052,898 $ 1,066,133 [1] [1] (1)DecemberÂ 31, 2023 balances were derived from the audited Consolidated Financial Statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, filed with the SEC on FebruaryÂ 26, 2024. X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -

Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 50 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Narrative (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Â Â Â Â Depreciation $ 11.5 Â $ 9.4 $ 24.1 $ 19.7 Milestone payments received Â $ 10.0 Â Â Â X - DefinitionMilestone Payments Received + ReferencesNo definition available. + Details Name: bmrn_MilestonePaymentsReceived Namespace Prefix: bmrn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 51 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Schedule of Intangible Assets, Net (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Â Finite-lived intangible assets $ 710,533 $ 710,011 Accumulated amortization (445,000) (415,310) Net carrying value $ 265,533 $ 294,701 X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 52 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Â Accounts payable and accrued operating expenses $ 257,412 $ 315,509 Accrued compensation expense 147,737 201,067 Accrued rebates payable 113,432 96,179 Accrued income taxes 18,864 2,651 Lease liability 10,689 8,779 Foreign currency exchange forward contracts 7,684 33,853 Accrued royalties payable 7,667 14,299 Deferred revenue 1,912 4,620 Other 7,103 6,190 Accounts payable and accrued liabilities $ 572,500 $ 683,147 [1] [1] (1)DecemberÂ 31, 2023 balances were derived from the audited Consolidated Financial Statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, filed with the SEC on FebruaryÂ 26, 2024. X - DefinitionAccrued Government And Other Rebates + ReferencesNo definition available. + Details Name: bmrn_AccruedGovernmentAndOtherRebates Namespace Prefix: bmrn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionOperating And Finance Lease Liability, Current + ReferencesNo definition available. + Details Name: bmrn_OperatingAndFinanceLeaseLiabilityCurrent Namespace Prefix: bmrn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_AccruedIncomeTaxesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8 + Details Name: us-gaap_AccruedRoyaltiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3 + Details Name: us-gaap_DerivativeLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_OtherAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 53 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1 FAIR VALUE MEASUREMENTS (Details) - USD ($) Jun. 30, 2024 Dec. 31, 2023 Level 1 Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Financial assets remeasured $ 0 $ 0 Financial liabilities remeasured 0 0 Level 3 Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Financial assets remeasured 0 0 Financial liabilities remeasured 0 0 Level 2 | Fair Value, Measurements, Recurring Â Â Assets: Â Â Fair value of other assets 35,531,000 30,512,000 Fair value of total financial assets 38,180,000 32,538,000 Liabilities: Â Â Fair value of total financial liabilities 35,761,000 30,145,000 Level 2 | Fair Value, Measurements, Recurring | NQDC Plan liability Â Â Liabilities: Â Â Fair value of other current liabilities 2,649,000 2,026,000 Fair value of other long-term liabilities 33,112,000 28,119,000 Level 2 | Fair Value, Measurements, Recurring | NQDC Plan assets Â Â Assets: Â Â Fair value of other current assets 2,649,000 2,026,000 Fair value of other assets 33,112,000 28,119,000 Level 2 | Fair Value, Measurements, Recurring | Restricted Investments Â Â Assets: Â Â Fair value of other assets $ 2,419,000 $ 2,393,000 X - DefinitionOther assets current fair value disclosure. + ReferencesNo definition available. + Details Name: bmrn_OtherAssetsCurrentFairValueDisclosure Namespace Prefix: bmrn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionOther assets noncurrent fair value disclosure. + ReferencesNo definition available. + Details Name: bmrn_OtherAssetsNoncurrentFairValueDisclosure Namespace Prefix: bmrn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionOther liabilities current fair value disclosure. + ReferencesNo definition available. + Details Name: bmrn_OtherLiabilitiesCurrentFairValueDisclosure Namespace Prefix: bmrn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionOther liabilities noncurrent fair value disclosure. + ReferencesNo definition available. + Details Name: bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure Namespace Prefix: bmrn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsFairValueDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 101 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value of financial and nonfinancial obligations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_LiabilitiesFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesFairValueDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByLiabilityClassAxis=bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=bmrn_NonqualifiedDeferredCompensationPlanAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=bmrn_RestrictedInvestmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R42.htm IDEA: XBRL DOCUMENT v3.24.2.u1 DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Narrative (Details) $ in Millions 6 Months Ended Jun. 30, 2024 USD ($) Derivative [Line Items] Â Unrealized gains reclassified from AOCI to earnings over the next 12 months $ 21.2 Derivatives designated as hedging instruments: Â Derivative [Line Items] Â Maturity of derivatives 24 months Derivatives not designated as hedging instruments: Â Derivative [Line Items] Â Maturity of derivatives 3 months X - DefinitionThe estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480870/815-30-50-1 + Details Name: us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5 + Details Name: us-gaap_DerivativeLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_DerivativeRemainingMaturity1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1 DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Schedule of Aggregate Notional Amounts for the Derivatives Outstanding (Details) - Forward Foreign Exchange Contracts - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Derivatives designated as hedging instruments: | Sell Â Â Derivative [Line Items] Â Â Notional amount $ 1,086,980 $ 1,249,662 Derivatives designated as hedging instruments: | Purchase Â Â Derivative [Line Items] Â Â Notional amount 192,162 198,408 Derivatives not designated as hedging instruments: | Sell Â Â Derivative [Line Items] Â Â Notional amount 281,438 350,269 Derivatives not designated as hedging instruments: | Purchase Â Â Derivative [Line Items] Â Â Notional amount $ 28,824 $ 90,102 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5 + Details Name: us-gaap_DerivativeLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNominal or face amount used to calculate payment on derivative. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1BReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A + Details Name: us-gaap_DerivativeNotionalAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PositionAxis=us-gaap_ShortMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PositionAxis=us-gaap_LongMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1 DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Schedule of Fair Value Carrying Amounts of Derivatives (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Derivative [Line Items] Â Â Asset Derivatives $ 38,187 $ 9,065 Liability Derivatives 8,941 42,024 Level 2: | Derivatives designated as hedging instruments: Â Â Derivative [Line Items] Â Â Asset Derivatives 35,835 8,518 Liability Derivatives 7,664 38,176 Level 2: | Derivatives designated as hedging instruments: | OtherÂ currentÂ assets Â Â Derivative [Line Items] Â Â Asset Derivatives 27,599 6,663 Level 2: | Derivatives designated as hedging instruments: | Other assets Â Â Derivative [Line Items] Â Â Asset Derivatives 8,236 1,855 Level 2: | Derivatives designated as hedging instruments: | AccountsÂ payableÂ and accruedÂ liabilities Â Â Derivative [Line Items] Â Â Liability Derivatives 6,407 30,005 Level 2: | Derivatives designated as hedging instruments: | OtherÂ long-termÂ liabilities Â Â Derivative [Line Items] Â Â Liability Derivatives 1,257 8,171 Level 2: | Derivatives not designated as hedging instruments: | OtherÂ currentÂ assets Â Â Derivative [Line Items] Â Â Asset Derivatives 2,352 547 Level 2: | Derivatives not designated as hedging instruments: | AccountsÂ payableÂ and accruedÂ liabilities Â Â Derivative [Line Items] Â Â Liability Derivatives $ 1,277 $ 3,848 X - DefinitionFair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 4D -Subparagraph (c)(2) -SubTopic 20 -Topic 860 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D + Details Name: us-gaap_DerivativeFairValueOfDerivativeAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 4D -Subparagraph (c)(2) -SubTopic 20 -Topic 860 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D + Details Name: us-gaap_DerivativeFairValueOfDerivativeLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5 + Details Name: us-gaap_DerivativeLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1 DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Schedule of Impact of Gains and Losses from Derivatives Designated and Not Designated as Hedging Instruments (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Derivatives designated as hedging instruments: | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent | Operating expenses Â Â Â Â Derivative Instruments, Gain (Loss) [Line Items] Â Â Â Â Derivatives Designated as Cash Flow Hedging Instruments $ (190) $ (26) $ 314 $ (482) Derivatives designated as hedging instruments: | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent | Net product revenues Â Â Â Â Derivative Instruments, Gain (Loss) [Line Items] Â Â Â Â Derivatives Designated as Cash Flow Hedging Instruments 3,371 677 2,252 4,147 Derivatives not designated as hedging instruments: Â Â Â Â Derivative Instruments, Gain (Loss) [Line Items] Â Â Â Â Derivatives Not Designated as Hedging Instruments $ 13,812 $ 769 $ 21,541 $ (3,394) X - DefinitionAmount of increase (decrease) in the fair value of derivatives recognized in the income statement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_DerivativeGainLossOnDerivativeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4E -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E + Details Name: us-gaap_DerivativeInstrumentsGainLossLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 4C -Subparagraph (c) -SubTopic 10 -Topic 815 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C + Details Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R46.htm IDEA: XBRL DOCUMENT v3.24.2.u1 DEBT -

Narrative (Details) $ in Billions Jun. 30, 2024 USD ($) Debt Disclosure [Abstract] Â Carrying value of equity component $ 1.1 X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 59 R47.htm IDEA: XBRL DOCUMENT v3.24.2.u1 DEBT - Schedule of Convertible Debt (Details) - USD ($) Aug. 01, 2024 Jun. 30, 2024 Dec. 31, 2023 Debt Instrument [Line Items] Â Â Â Convertible notes Â $ 1,100,000,000 Â Convertible debt, current Â 494,837,000 $ 493,877,000 [1] Convertible debt, noncurrent Â 594,116,000 593,095,000 [1] Total convertible debt, net Â 1,088,953,000 1,086,972,000 Total fair value of fixed-rate convertible debt Â $ 1,068,549,000 $ 1,107,548,000 $0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes) Â Â Â Debt Instrument [Line Items] Â Â Â Convertible notes stated rate Â 0.599% 0.599% Convertible notes Â $ 495,000,000 $ 495,000,000 Unamortized discount net of deferred offering costs Â (163,000) (1,123,000) Convertible debt, current Â 494,837,000 493,877,000 Total fair value of fixed-rate convertible debt Â $ 492,447,000 $ 488,288,000 $0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes) | Subsequent Event Â Â Â Debt Instrument [Line Items] Â Â Â Debt repayments $ 495,000,000 Â Â Gain (loss) on extinguishment of debt $ 0 Â Â 1.25% senior subordinated convertible notes due in May 2027 (the 2027 Notes) Â Â Â Debt Instrument [Line Items] Â Â Â Convertible notes stated rate Â 1.25% 1.25% Convertible notes Â $ 600,000,000 $ 600,000,000 Unamortized discount net of deferred offering costs Â (5,884,000) (6,905,000) Convertible debt, noncurrent Â 594,116,000 593,095,000 Total fair value of fixed-rate convertible debt Â $ 576,102,000 $ 619,260,000 [1] (1)DecemberÂ 31, 2023 balances were derived from the audited Consolidated Financial Statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, filed with the SEC on FebruaryÂ 26, 2024. X - DefinitionIncluding the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_ConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ConvertibleDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ConvertibleDebtFairValueDisclosures Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ConvertibleDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of unamortized debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A + Details Name: us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=bmrn_OnePointTwoFivePercentSeniorSubordinatedConvertibleNotesDueInMay2027Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1 DEBT - Schedule of Interest Expense on Convertible Debt (Details) - Convertible Senior Notes - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Schedule Of Interest Expenses [Line Items] Â Â Â Â Coupon interest expense $ 2,617 $ 2,617 $ 5,233 $ 5,233 Accretion of discount on convertible notes 843 834 1,684 1,673 Amortization of debt issuance costs 148 149 297 297 Total interest expense on convertible debt $ 3,608 $ 3,600 $ 7,214 $ 7,203 X - DefinitionSchedule of interest expenses. + ReferencesNo definition available. + Details Name: bmrn_ScheduleOfInterestExpensesLineItems Namespace Prefix: bmrn_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the

related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfDebtDiscountPremium Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of amortization expense attributable to debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F + Details Name: us-gaap_InterestExpenseDebtExcludingAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R49.htm IDEA: XBRL DOCUMENT v3.24.2.u1 ACCUMULATED OTHER COMPREHENSIVE INCOME (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 AOCI Attributable to Parent, Net of Tax [Roll Forward] Â Â Â Â Beginning balances [1] $ 5,073,816 $ 4,659,043 $ 4,951,549 [2] $ 4,603,156 Other comprehensive income (loss) before Â Â Â Â reclassifications 30,867 (7,398) 57,485 (10,010) Less: gain (loss) reclassified from AOCI 3,181 651 2,566 3,665 Tax effect 159 154 668 (1,075) Net current-period other comprehensive income (loss) 27,845 (7,895) 55,587 (14,750) Ending balances 5,286,299 4,782,827 5,286,299 4,782,827 AOCI attributable to parent Â Â Â Â AOCI Attributable to Parent, Net of Tax [Roll Forward] Â Â Â Â Beginning balances [1] (1,046) (10,722) (28,788) (3,867) Net current-period other comprehensive income (loss) 27,845 (7,895) 55,587 (14,750) Ending balances 26,799 (18,617) 26,799 (18,617) Unrealized Gains (Losses) on Cash Flow Hedges Â Â Â Â AOCI Attributable to Parent, Net of Tax [Roll Forward] Â Â Â Â Beginning balances (183) (2,647) (29,658) 8,226 Other comprehensive income (loss) before Â Â Â Â reclassifications 31,551 (6,737) 60,411 (14,596) Less: gain (loss) reclassified from AOCI 3,181 651 2,566 3,665 Tax effect 0 0 0 0 Net current-period other comprehensive income (loss) 28,370 (7,388) 57,845 (18,261) Ending balances 28,187 (10,035) 28,187 (10,035) Unrealized Gains (Losses) on Available-for-Sale Debt Securities Â Â Â Â AOCI Attributable to Parent, Net of Tax [Roll Forward] Â Â Â Â Beginning balances (863) (8,075) 870 (12,093) Other comprehensive income (loss) before Â Â Â Â reclassifications (684) (661) (2,926) 4,586 Less: gain (loss) reclassified from AOCI 0 0 0 0 Tax effect 159 154 668 (1,075) Net current-period other comprehensive income (loss) (525) (507) (2,258) 3,511 Ending balances $ (1,388) $ (8,582) $ (1,388) $ (8,582) [1] The beginning balances for the six-month periods were derived from the audited Consolidated Financial Statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023 filed with the SEC on FebruaryÂ 26, 2024. [2] (1)DecemberÂ 31, 2023 balances were derived from the audited Consolidated Financial Statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, filed with the SEC on FebruaryÂ 26, 2024. X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_AOCIAttributableToParentNetOfTaxRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A + Details Name: us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A + Details Name: us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R50.htm IDEA: XBRL DOCUMENT v3.24.2.u1 REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Narrative (Details) $ in Thousands 6 Months Ended 12 Months Ended Jun. 30, 2024 USD ($) segment Dec. 31, 2023 USD ($) Concentration Risk And Geographic Information [Line Items] Â Â Number of operating business segment | segment 1 Â Accounts receivable, net $ 691,232 $ 633,704 [1] Sanofi Â Â Concentration Risk And Geographic Information [Line Items] Â Â Accounts receivable, net $ 67,100 $ 63,400 Credit Concentration Risk | Accounts Receivable | Customer One Â Â Concentration Risk And Geographic Information [Line Items] Â Â Concentration risk, percentage 15.00% 15.00% Credit Concentration Risk | Accounts Receivable | Customer Two Â Â Concentration Risk And Geographic Information [Line Items] Â Â Concentration risk, percentage 12.00% 12.00% Credit Concentration Risk | Accounts Receivable | Customer Three Â Â Concentration Risk And Geographic Information [Line Items] Â Â Concentration risk, percentage 10.00% Â [1] (1)DecemberÂ 31, 2023 balances were derived from the audited Consolidated Financial Statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, filed with the SEC on FebruaryÂ 26, 2024. X - DefinitionConcentration risk and geographic information. + ReferencesNo definition available. + Details Name: bmrn_ConcentrationRiskAndGeographicInformationLineItems Namespace Prefix: bmrn_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.

+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - Details Name: srt_MajorCustomersAxis=bmrn_CustomersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=bmrn_CustomerOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=bmrn_CustomerTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=bmrn_CustomerThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R51.htm IDEA: XBRL DOCUMENT v3.24.2.u1 REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Disaggregation of Total Net Product Revenues by Product (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Revenue from External Customer [Line Items] Â Â Â Â Revenue $ 712,029 $ 595,275 $ 1,360,862 $ 1,191,690 Product Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Revenue 702,129 584,698 1,339,944 1,171,124 VOXZOGO Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Revenue 183,923 113,337 336,812 201,173 VIMIZIM Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Revenue 178,016 177,392 370,536 366,584 NAGLAZYME Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Revenue 132,049 90,103 237,678 213,124 PALYNZIQ Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Revenue 88,291 74,868 164,000 137,220 BRINEURA Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Revenue 45,309 38,058 84,356 77,202 ALDURAZYME Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Revenue 38,558 40,318 73,820 74,721 KUVAN Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Revenue 28,551 50,622 64,461 101,100 ROCTAVIAN Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Revenue 7,432 0 8,281 0 Royalty and other revenues Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Revenue $ 9,900 $ 10,577 $ 20,918 $ 20,566 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=bmrn_VIMIZIMMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=bmrn_VOXZOGOMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=bmrn_NAGLAZYMEMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=bmrn_PALYNZIQMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=bmrn_BRINEURAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=bmrn_ALDURAZYMEMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=bmrn_KUVANMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=bmrn_ROCTAVIANMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=bmrn_RoyaltyAndOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R52.htm IDEA: XBRL DOCUMENT v3.24.2.u1 REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Disaggregation of Total Net Product Revenues by Geographic Region (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Disaggregation of Revenue [Line Items] Â Â Â Â Revenue $ 712,029 $ 595,275 $ 1,360,862 $ 1,191,690 ALDURAZYME Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Revenue 38,558 40,318 73,820 74,721 Product Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Revenue 702,129 584,698 1,339,944 1,171,124 Marketed by Company | Products excluding ALDURAZYME Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Revenue 663,571 544,380 1,266,124 1,096,403 Marketed by Company | Products excluding ALDURAZYME | United States Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Revenue 227,449 191,655 420,448 358,439 Marketed by Company | Products excluding ALDURAZYME | Europe Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Revenue 220,990 183,434 416,738 344,126 Marketed by Company | Products excluding ALDURAZYME | Latin America Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Revenue 84,418 75,444 163,012 143,192 Marketed by Company | Products excluding ALDURAZYME | Middle East Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Revenue 49,701 25,630 106,776 117,272 Marketed by Company | Products excluding ALDURAZYME | Rest of world Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Revenue 81,013 68,217 159,150 133,374 Marketed by Sanofi | ALDURAZYME Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Revenue $ 38,558 $ 40,318 $ 73,820 $ 74,721 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=bmrn_ALDURAZYMEMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=bmrn_ProductsExcludingALDURAZYMEMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=srt_EuropeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=srt_LatinAmericaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=us-gaap_MiddleEastMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=bmrn_RestOfWorldMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelThroughIntermediaryMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R53.htm IDEA: XBRL DOCUMENT v3.24.2.u1 REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Total Net Product Revenue Concentrations Attributed to Largest Customers (Details) - Customer Concentration Risk - Net Product Revenue 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Customer A, B & C Â Â Â Â Concentration Risk [Line Items] Â Â Â Â Concentration risk, percentage 35.00% 37.00% 34.00% 35.00% Customer A Â Â Â Â Concentration Risk [Line Items] Â Â Â Â Concentration risk, percentage 14.00% 15.00% 14.00% 15.00% Customer B Â Â Â Â Concentration Risk [Line Items] Â Â Â Â Concentration risk, percentage 11.00% 12.00% 11.00% 11.00% Customer C Â Â Â Â Concentration Risk [Line Items] Â Â Â Â Concentration risk, percentage 10.00% 10.00% 9.00% 9.00% X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 310 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2 + Details Name: us-gaap_ConcentrationRiskLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=bmrn_CustomerOneTwoAndThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=bmrn_CustomerOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=bmrn_CustomerTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name:

srt_MajorCustomersAxis=bmrn_CustomerThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R54.htm IDEA: XBRL DOCUMENT v3.24.2.u1 STOCK-BASED COMPENSATION (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Total stock-based compensation expense $ 47,914 $ 50,162 $ 106,163 $ 103,857 Cost of sales Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Total stock-based compensation expense 3,774 4,721 7,018 9,052 Research and development Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Total stock-based compensation expense 12,935 15,055 33,612 34,883 Selling, general and administrative Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Total stock-based compensation expense $ 31,205 $ 30,386 $ 65,533 $ 59,922 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R55.htm IDEA: XBRL DOCUMENT v3.24.2.u1 RESTRUCTURING - Narrative (Details) - 2024 Workforce Reduction Plan 6 Months Ended Jun. 30, 2024 employee Restructuring Cost and Reserve [Line Items] Â Number of positions eliminated 170 Percentage of workforce expected to be eliminated 5.00% X - DefinitionRestructuring and Related Cost, Expected Number Of Positions Eliminated, Percentage Of Workforce + ReferencesNo definition available. + Details Name: bmrn_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce Namespace Prefix: bmrn_ Data Type: dtr-types1:percentItemType Balance Type: na Period Type: instant X - DefinitionThe expected number of positions to be eliminated as a result of restructuring activities. + ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringCostAndReserveLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RestructuringPlanAxis=bmrn_A2024WorkforceReductionPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R56.htm IDEA: XBRL DOCUMENT v3.24.2.u1 RESTRUCTURING - Schedule of Restructuring and Related Costs (Details) - 2024 Workforce Reduction Plan - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2024 Restructuring Cost and Reserve [Line Items] Â Â Severance and one-time employee benefits $ 23,837 $ 25,275 Asset Impairments 9,671 9,671 Other 5,519 7,519 Restructuring expenses $ 39,027 $ 42,465 X - DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_AssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OtherRestructuringCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringCostAndReserveLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_RestructuringCostsAndAssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_SeveranceCosts1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_RestructuringPlanAxis=bmrn_A2024WorkforceReductionPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 R57.htm IDEA: XBRL DOCUMENT v3.24.2.u1 RESTRUCTURING - Schedule of Restructuring Activity (Details) - 2024 Workforce Reduction Plan $ in Thousands 6 Months Ended Jun. 30, 2024 USD ($) Restructuring Reserve [Roll Forward] Â Beginning balance $ 0 Charges and Adjustments 32,793 Payments (6,321) Ending balance 26,472 Severance and related costs Â Restructuring Reserve [Roll Forward] Â Beginning balance 0 Charges and Adjustments 25,275 Payments (4,321) Ending balance 20,954 Other Â Restructuring Reserve [Roll Forward] Â Beginning balance 0 Charges and Adjustments 7,519 Payments (2,000) Ending balance $ 5,519 X - DefinitionAmount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17 + Details Name: us-gaap_PaymentsForRestructuring Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCarrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB

-URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringReserve Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_RestructuringReserveRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RestructuringPlanAxis=bmrn_A2024WorkforceReductionPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R58.htm IDEA: XBRL DOCUMENT v3.24.2.u1 EARNINGS PER COMMON SHARE - Schedule of Computation of Basic and Diluted Earnings Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Numerator: Â Â Â Â Net Income, basic $ 107,174 $ 56,040 $ 195,836 $ 106,892 Add: Interest expense, net of tax, on the Company's convertible debt 2,769 937 5,538 1,873 Net Income, diluted $ 109,943 $ 56,977 $ 201,374 $ 108,765 Denominator: Â Â Â Â Weighted-average common shares outstanding, basic (in shares) 190,114 187,948 189,490 187,311 Effect of dilutive securities: Â Â Â Â Weighted-average common shares outstanding, diluted (in shares) 200,505 194,998 200,137 194,756 Earnings per common share, basic (in dollars per share) $ 0.56 $ 0.30 $ 1.03 $ 0.57 Earnings per common share, diluted (in dollars per share) $ 0.55 $ 0.29 $ 1.01 $ 0.56 Common stock issuable under the Company's equity incentive plans Â Â Â Â Effect of dilutive securities: Â Â Â Â Effect of dilutive securities (in shares) 2,056 3,080 2,312 3,475 Common stock issuable under the Companyâ€™s convertible debt Â Â Â Â Effect of dilutive securities: Â Â Â Â Effect of dilutive securities (in shares) 8,335 3,970 8,335 3,970 X - ReferencesNo definition available. + Details Name: us-gaap_DilutiveSecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-42Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_InterestOnConvertibleDebtNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting

period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bmrn_CommonStockIssuableUnderConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R59.htm IDEA: XBRL DOCUMENT v3.24.2.u1 EARNINGS PER COMMON SHARE - Schedule of Anti-Dilutive Common Stock Excluded from Computation of Diluted Earnings Per Share (Details) - shares shares in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Â Â Total number of potentially issuable shares (in shares) 10,362 13,081 10,106 12,686 $0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes) | Convertible Senior Notes Â Â Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Â Â Potential shares issued if converted (in shares) Â Â 4,000 Â 1.25% senior subordinated convertible notes due in May 2027 (the 2027 Notes) | Convertible Senior Notes Â Â Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Â Â Potential shares issued if converted (in shares) Â Â 4,400 Â Common stock issuable under the Company's equity incentive plans Â Â Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Â Â Total number of potentially issuable shares (in shares) 10,362 8,716 10,106 8,321 Common stock issuable under the Companyâ€™s convertible debt Â Â Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Â Â Total number of potentially issuable shares (in shares) 0 4,365 0 4,365 X - DefinitionDebt Conversion, Converted Instrument, Potential Shares Issued + ReferencesNo definition available. + Details Name: bmrn_DebtConversionConvertedInstrumentPotentialSharesIssued Namespace Prefix: bmrn_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThese line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=bmrn_OnePointTwoFivePercentSeniorSubordinatedConvertibleNotesDueInMay2027Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bmrn_CommonStockIssuableUnderConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R60.htm IDEA: XBRL DOCUMENT v3.24.2.u1 COMMITMENTS AND CONTINGENCIES (Details) $ in Millions 6 Months Ended Jun. 30, 2024 USD ($) Commitments and Contingencies Disclosure [Abstract] Â Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones $ 495.6 Contingent payments reasonably possible upon achievement of certain development and regulatory activities commercial sales and licensing milestones, to be paid in rolling Next 12 months 10.9 Purchase commitment 473.0 Purchase commitments expected to be paid in 2024 $ 291.1 X - DefinitionContingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones. + ReferencesNo definition available. + Details Name: bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones Namespace Prefix: bmrn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionContingent Payments Reasonably Possible Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones, To Be Paid, Due In Rolling Next 12 Months + ReferencesNo definition available. + Details Name: bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestonesToBePaidDueInRollingNext12Months Namespace Prefix: bmrn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionMinimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. + ReferencesNo definition available. + Details Name: us-gaap_PurchaseObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of purchase arrangement to be paid in remainder of current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. + ReferencesNo definition available. + Details Name: us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant EXCEL 73 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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Ä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~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Ä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|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Ä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

M=8;X9,0\M:"0^!&)YVSO&BE3'J3\J3Y,%F<=1R$2L0ASI8+#GR6 1NGLA=4OGY>_3%I^V4/7,LE7&1HG"[$X7-\#*W:FD#=3SHE5 MX9_;Y#NBSC=$',(,>$8?
7TXM<.C.L[301]L\JYUV>3N[1K.;\>WP;C+]'0U' M=Y,?D[O)>'YB2=F!I[R=ISSK)EX(4!I&O"RZR0+QM4SSZ) BALGR4IV[MMV$N#3"M;:M!"@?,,>^JO\/JVP-.)MUBNZ(D%^"*'(D7X+O,&']^ P'N!
[@& MLRE$'#]>@"8Q&C@^F:@V-%\ MYEBA_LY5FB8HXY#-X.!$)LLHX9#=/$8\RX39N976 []A!_[58!OD6H(6[U$P MMD*>K#<\2M6^*\ EQB+59+X2J;*@C&JNBY;1!-
QT*2,.JUM@$"->VV8%T5:0 M=PK%4J1I42;+\LE?A!DG:0)PJ5^'V93JNM4IR3VL61E;*6]PGT"W&T?_ %!H M@J'+2QZ!(A"N>/ H4RRQ#7QXA@KX:@5-#C3[;CT%#7(^<]T6Y)I-L9U.9RH:
MC+A8$U?01-64HAYN :5Y%-N)=%1X+JMQHP[A../(4=S.D_BH1'DL;8?.T%2) M[5P)E5W5\DSU$R)ZX@^Q^*9Z"*/A30;LNI[38""3'&;0*+5MG29+;&?+"=!-
MDLOTU0BOR7Q=YC.G7X=GD',]YGLMZ#1)8CM+%M$.$Q"4%*B+EL+=)#SL8;<. MTT"++F6TK>II8L1V9BQA6N U>:Y+2! T>,4@YP)MFO$138?$3H>[D-SP5Q6/ M>[R2K:"1ZT*CM-
[/4I,1Q$".+B->/59-P,67HYELGCQ_ V M*<[S&Z%KD/+Q'ET>8M4\2.P\.'V;&3:I?(I@M$4/K^A+-4!\-4X01AL,+.FY M/JWW40:Y+@W\EL FFB?)Y\;7R?3'>/Z1\94<=7X]EK9#+VC.)7;.O=FFT!MD
M0'#0F<&&PN;EK]_0)N;J*$$JB;^WT4:U9$97&(@9BBAMY(U)SG-HOV43-3L3 M*^$-KGF^38L0*\"JGKBPY)U)H])ZT"I@WV.-#&K*L3YT^VWYKHF4V(GTP.WO M@3419-]E'JFC-0@RQAS6YF;-
I,3.I#>I#(589&B9R05G)P]B&$0-@X=!K"W' M-<<2.\>^N;GT<@Z=7%101#M6 XT&+FYXVB &/4O+;$?45[I4/NX;3B_)B_-_[R8_AE7H29C3"<$", _>(!T]$9AC$9-JKMU(UJ
M"J>!G4V*@'T'H[8KX467E"=H/"'PSA5C[@4J3R)&T'9JNNP%][P;.Q6.4)"1) M5&\NTD@NC#8;V-Z%GJ41:08YPMRVV<,4_W!@$:DPS3N4E%Q\ MDK9#G^E>@-E[@4D2IJI+46T -QW>P.,E0@+U]-
V=W=O=4T+-[EJ=T_QR>C\MTDK:9\5>]:IT!D&32G2U#I?/?! MZ6GY]E'Y(9>;X@6>!YGG&PO=V]R:W-H965T&ULM5I;4QLY%OXK*L_6+%09@PV!9))090C),KLA3 PS#UO[(?+;6VZI1Y)
M#6%__7[G2-UN R:7F7G!?9'._?(=-:IN? !OBDOETH%\;DJC7\]6(90_[2[Z.E MJJ0?V5H9O%E85\F 0U?L^MHIF?.FJMR=[.T=[E92F\'Q*WYVZ8Y?V2:4VJA+ MJ)WQ35=+=G:C2WKX>C ?M@X^Z6
9ZL'O\JI:%FJEP75\ZW.UV5')=*>.U-<*I MQ>O!=/S3R0&MYP6 :G7K>]>"-)E;^XENSO/7@ST22)4J"T1!XN=&G:JR)$(0 MX_=$<]"QI(W]ZY;Z6]8=NLRE5Z>V_$WG8?
EZ\'P@"D>K08TN6%7>#>&T(:?,@L-;C7WA^.1Z=GYQ-IN)#[^>??SU_.PW,;UX M(V;G[R[.WYZ?3B^NQ/3T],/UQ=7YQ3MQ^>%?YZ?G9[-7NP&LBOL;Z$VSS#8F:%.(2UOJ3"LO_CV=^^ 0-_]Y3.%
((^!Q>I1+/_E-9NKU ,GB ME;M1@^,??Q@?[KU\0M@3MJ#IZC_>5[[]B(QD:IX1=B ^UZ$==WB;:&] MD*(H[1Q+Y]H&E2X-+6UQ)[*T"%Q *(!7L ,+N,YY*%SFV1/Y[$9;.-L52%,HH
ML!2Y]IF]4>YN)*YZ7'-U@XI5@YW)B7:E7*9EJ?l')*0K%'-80L%:,U49A,QS M^)INE'#6!I^)QK,E6F:9-;EFBZQQ^[O'^CFR75"L2)2:EY/_)[$L(JH\1[$/8I. M6
HGX;:>6:S+E7L@*%X@3;B8"EG7SDI("U/GKBE6QH1@7N!EWF202^(%GL(6 MM:X5A1D992764&1X2/X?LN)(F9WV"?2%S7)X])Z5I?"Z,'J!1;!/8RJTL(J=
M7PJC5#Z,QKE%Q=^AX',HIC:GJ*%X:1G9&YU#$2-L75L7&J#':DS5V*AL64G MV!VTJT\@#H/9Q4(YXMR@-(MF70.BRTT7D-#H3ZS>0I$GI*!/6?KY/ 3Z1&^ M4/R2O&P"IP99UY-]
(:'QL!6N/"I0SB\5AMIV$S+%<5.XO5FBMER$XUG 8] M6N<;,@,DOQ[-1NQ&)\OR#GTO4S71DJL25R.7,HH2+[9X^;OI]'*;+<*QV] ; MNG.J:,J4PA"<7L[.3CEV?FFD"\]!PT=%EL,"(ZA3BO'>SB\Q?
JTPR +P*ALR M((;,U9BF>+@*:U'\4 ZJ-\;39K-[T0G(?.E/"^1??!/:QO?V09> M+<.2\[N2!JB"/3!'R*F;-GZ(?Y\5,D(A<2CX90ZVH$5FA#>HC'5;^B+7T8&4 M<9Y5K+OO
8E@VS9=OMZ='O*6L98HL"#7"L)7E,VH%_]M3 0PG*.Q,'Z)))GT MPL:, 55H0Y:CO0LHCK5W*#+0D"KR&Y6I:H[0W1]S-JU(<4"] KQCS\\GXR/ M7GHQ-:8!C>CVOM?_^>W*M[%!?%*
=I'6EF+21E.16EH*:'MK0(TR4.<:74$A MM-8(+0V'N+8+<.&768S<5<(@$- *2)PH:JR<;^!0$-SB(LO6^ MAPZH$G%O).*R*TM]#E=2E-0G*[7ES.4K%BM?Y;P&TISHC)<,W+&NZ.AZ_Y^
M$HS"$K46@-0Y9;(U\XH"T#^&'#+*<^Z2GB3YPMD*MY62E$N M9=:G]@.YB?>&X.F%#*Q)0CNUI-D >@RVJ->IJF5$%R9IU1^DH-_U2-X/Q> M03#B [OE#)Z%'D-QH39H_6#C*1Z3>C-94E!?
PJ^.49:IT2 M;'[EKLAGP]ZEI.Z;&)' %*XQHX;BR@8NUS;[A-I+$"J91YRA/0?& MYBA4!M)[XHM>1D']Z?5SGP2DE>\WKA S$'CB=9LYGC)'_$U,AL_VC_['@\/ M#O=$&X=XLO5B.-G?
WZ:KR7@X&>,R:KGR=XI5HK-U.#Q\<;@=]QT]P^*8W*I- M;H!EO.15^.4UXCIB C, P8IAZPX)%CC^U$(FU?R$UI!MYXL)KUOJH@<$^SE MZM:%G,/NVV_27]]TF7Z66B5IW(-
#U$L3@@J,3'MB$3:1Q)QLU*@RY@YEHI/ MQMZ6*B\BPD_!CR1?\>WIU&] U! 9I@12!*4 ,PG3I%69#43!]WH'9(R"6UK%$&8 M"-M65AIVX.".\T.*A=1N/1>QH=4PI9!7$=;HJDWKD7B_"IU4F0C<
]O M)'B&6.\YG\UD,PZ)O/^>&QQ%5DD55L2S2)8I3FBI"2;IOBS:,+*Z952=$HZ\ M9C$L1NNX7L! 1_Z,O-0&<1EH>_/*].N@BH;@#DW+!T;AL8=D+&/A29:H**ZH
MNG+E5"&4T=L;O(IF@\DS:&H>AD%_WK!:TZ:@(P5&C&P2S=-[UG@?ZP:-"_)0 M[!ASD40(U39U4#]V(G8%3MY!:<-E2X*3QK3N;_X5HG[4O9G]?XDVI+.&Q?= MJ[X ME$,?
#SL<>F,A[=\@7KT=T_ML6#1QB_%2>,1P]Z+#S#C#!TDD]V_9(H- M:G[UQ/,=TU775Y^:WD;8F:E[0CMK<)TE"1[QHB&M^^<#:QMD;OD$;/XO8.Y
MI _=I+#5M4U>J+!,":7#G#EQ.)';+V=SDZV_V TN&B!S8+ERF=.S]?"X;L= MNB$M_Z ?AP\[9 >793Q>704JRB8!/TM(EP]$^F_6%;L/.F$X63A9+[O:\&U. MA;LP@S1W)!\-B^N:6\'6=':]S?
MV]HZ&F#X* M+HG1NK3C"ETW$Y/GB(OSB#[UDKC0/BYB<-WN>],[_QG2&AWW)%C%:WU:V^L5 MJ9LDRJF%*K,D.^=KATIR;F&3?EEJR;7H$D!K=MUJ1$^A,4!T,T>!$>1'ZM,M
MW'XHBR<#1WG6$=QZ9#SDV^&5=+A'730=@W8)E"VU6O00<:XRS9_A"*BZ."*V M92S-[HJ.@3M0FB8KEB7Q!P\^)74\A=+Q:*RZ:B;,K)NT0N=!%!66Z^["2>> M=K3D--
+/)TDB0.K;AA';0UJVR;DN3 NX54B@474G"1Q\;XV,19UA&>]DQK" MOH4V- 224XFH.-2LG=/D[FL/'@AE',>A9PTG?R M:TCZ+@E>#-/<*:[D9P(;G-%'IX]D]&K=6B9C8H&U9H*7S=LK2<'[F11((AE
M')]Z)]&]GK\T"$9*Y)DG"AL8*5JJ9/A-Y65 M6UV6# .Q:W_?J<'4<'+\OL)NQ!9X,ZV%0WOU507WP/2'T=9'SV$?2W=YG[DJY M@C_F4YU $8E?O+NGW?\+3.-G\M7R^,\&[Z4KZ%"L5
MLW1L=/1L(%$.@QYM@ M:_YH/K+^?:+;IAAAT_T5J_4Z\O+@ $ @ 9(0%69<> M^C3N!P B1, !@ !X;"]W;W)K!DVMGL3C-%W?-IXVW2HY356C:F4@UI^7 OFD'-Q/ M=Q/^.J.3.#Z)-5DH]85?
[LJKT90%DK4L+",(_#W*6UG7# 0QOG:8HWY+7CA\ M/]"_<[I#EX4P\E;5_ZQ*N[H:92,JY8/8UO:CVOU-=OK$C%>HVKA?VK5S8^Q8 M(;U5ZVXQWM=5T_Z+;YT=!@NRZ8D%0;<@<'*W&SDI?
Q%67%]JM2/-LX'&#TY5 MMQK"50T[96XUOE989Z_?W=W/[F_O9K_1W?W\T\?/[]_>?YI?3BR@><*DZ&!N M6IC@!$Q"[U5C5X;>-J4LGZ^?0*1>KN @UTWP(N#?M\V8PJE'P32(7L +>SU#
MAQ>>P+MK'J6Q8),U'OTB%Y9$4]+;K]O*[FDNBZVN;"4- 6NV,%:#* \^9H1V MC^CX'AP_%V8C"GDU0H 8J1_EZ/KGG_QD^N8%#:)>@^@E]!_WU/\ 0[.Z!JOT
M%VG%HI9DG@RNDIU240MCJH=*EB0,B4=1U3SO'$GAW @LP*AZ(#A-]DYS!OY% M%G*]D)I"WXV&8_JTDO2@:F2#JEF2V\^06<$8%E]NU7HCFOW//V6!GQX0 BS
M\MPO23CK$9O!A0[[B!@#N1=[,M6R@=":%."Q5O?\!9N52Z3VDT"1%L:*-U)4J MR3FML;*\^),FL[72MOH/M+]5QM*O6AG3_^: I-]4L7YP38(Y\E#7Y%^T69Q1DL9OKXTK\4,+CB6Y;[C RR'@-
BZR*$D3;QX&O*,U6 M*CGT!FZ*P]1+@<@0KI#=BY+I:XPE7A8F_6H_";P\SBE,0R]+4_H\GH]I]Z1ZE M;IQ#43:R3C]$];/(B[*4PIQ>Y4GR&@.A%R=3BXT\S2G+O-"?$DP1I#[-C)'V M?"&*+W#P
"3/L&M&/O1YY><' P4"6I)2' >6IEX,'4ISA.O6D6TB>W^@PS4T@81 &>&>&LQVB_ M 2GDT3P-/#^>LB,[I+,>Z[M8^[_(@;9![8,TIWO9?7YKWU[R-\ASF#[_CY6\ MU/<7>)NE7I8G%'H1I)SF
Z8F\.IL0\>)IX?Q#_7,P&ZP(XU:'Z M$>*!QT*0R&?V)N3[>(U"\H.I-XUR3IEKJ8L*1-H(I#+B<R$ Z"!F0 M'^$E[[^=9'_DI5%$(:1_Y8?1:Q[($_\[$W7#PTB((W#4I\@+LXQ>P0+IU,5" MC'A+0!\?P?
04"QCULB#%,%X#[=%R:L: IMH+X4FU D4*3-V##X&6O?,?Q%(S>U. MRA9X]GW%](85D%:B=.]B4=7ZD2%0L== @3; ;/;TA7<3I+#]BS= M0,D65,N"^;UG[42??PK./^B>*],J*;\=%-
FM*E3@!TY"CRX)5<89FY5I3B! MQ-(I G=N9.%J?%WOL7>-6"T9=B#;DYNJID1'K5M;+J5::K%9[3V$S=Z%(R>, MPGF*)ZPJ=- _=Y +*+%CAXR4@.8%&:V"DLW^-=N[E$R JG%=#3N")Y:RX :,
MOP]4+-C4NA6T$%KO>4VO?:/L4!-!!:96UKGPN:M6:+L*J2W.7L]X@-=&->>< M+LJVT7WRED=K* MWGFF]:,@EA$MGG1'KOH9I[B[1O]5%4.)Q\?"X7@#V?)G8$PL.]8X'MV'=K#8 M63).
<92J:W]&12M9([>QOY'(,#C&FNN]9#OV- M2SP_MC MXMR"LCC*NE+<&%57I?/OC:A%4Z!*\@$.9KAK#LS%?/Z7GJ1JD8A7;_#G3V?] M!L?=DLN>VG1GFF'J6,A"K$'B'3L"BQ]PGE&ZRP\
(@JIPFPLZB\9Q;XH!5[\W M,:/A#<=)+WS%\T.=S4%CSYTAX"H$VECB]$-CJN-N.A]$/L.'M MMPV[VZ-[M"(GP$]P8F[QUX+#?+Q(RQ5?@SQ*&!FY0[J3B\M#/56[,PR4FDM)
M]PHMBT_G=,/!S=GT=^3D1[XD8<+/!P>C65$HSMRP]@>(4' FKP[^.4'F6=-L M4:H_2C1'3CN^($&C?/Z/7C)7-R5?!ASI2WF2*-L4+KB$M9=+[3W/LQ3^%_X8 M5)\-"
[\?'SMH3P;7(^B4ENX2")F3]6YO2OK1_IYIUEZO/$UO+ZG0V"[16*)" M/6#I=)S&()+MQ4_[8M7&7;8LE+5][1Y74B#U\01\?U!P3???&_2W;]? !5!+ M P04 " !DA 593H2VAGP% "## &
'AL+W=OC#A=/PS[0$NT3502 M59*.X_[Z/:1LQ1G28.V ?4E(ZNZYYUYX/)]LI/JL5YP;>JS*6I_V5L8TQX.! MSE>\8KHO&U[CRT*JBAELU7*@&\59X92JT%O?W
GEBMC#P9G)PU;\ADW'YNIPF[0H12BXK46LB;% M%Z>]<7!\'EMY)_"'X!M]L";KR5S*SW8S*4Y[OB7$2YX;B\#P[X%?\+*T0*#Q M98?9ZTQ:QWT]N;TX&!B:MXB#?
P9^W\.$WX(=T+6NSTO2A+GCQ7'\ JAW?<,_W M/'P5\V=UW:?()RCTP_@5O*CS/W)XT3?P;M62U>(KLR7BT86LM2Q%P=J*]0N: M*]YY;=H#N:!+4;,Z%ZRD&0XYRM-H^G,\UT:AP/YZ*4(M@?AE
O;2'>N&Y?RT MUUA;ZH'WSG[^*1CZO[SB7MRY%[^& M_3^RK\R^2_RR;-UDU3NC@BIN>L1'0Y MS5P_FM1MT[&AG]0/$)%)2SER)+3AA4V'67%:R!*M1=3+8T)U<%<=[WG,JSE7 M% 4>W;$-
KHSA"FG3=$1!$GM!$KE5XJ5^3) 0.=Z)^EVC9,ZUIJ&/\]2G) V\ MP$]MU@7N6$%+*0M-<1AYPVQ$TVG)BXXB@+U@!)DP:-=^:O3>&G<07VX]DP]+)XU*ZCR O# MD,9YOJ[6);,&"XX_YB?
^6WHR&J>>/LK<[-YO7[=5PPEKPD] ; M9:TU?SCT@B@"[P,+_!$/B^:M!IQEE5S;RY2S1L". I* O%\BJN'8"@7%+-2 MG#O+6CQ2U;88;EO,4Y!L@Z -@^]!T$_0.\MR?ZF/PK@?[$\\O"VZX>YU*+?]
M_YUDU)+,^O%SCD'63[_%<8+;4B_%O.0TUIH; :/%8PO;\'U3F4)&\ M%&601-%NYO?!LY)!.)39=4]Z$\>)Y_NV9.(@\;(*\>**;4%!WI@Y9H#*1PF M.\PPBW'_ OC3TA5*&_JR9@J7U?
I@<^BY3Q>R:EB]11QR[L@>!7[?[R)6 !A9 ML)(L7PG^X#J*RQA4EI:NO9BL0?6"AM7C>%L1DCE.H2=400WL6@NM;X!#(3P(MN=;EEO LO! @CS8KD:_^R5_JFV1DE=&OF(L(!&
<,2J!S(^M%]X2TN0/L#@"U M@6(K#IXA; [>&>A;*XJO[%3TP!&W7%:\;W/2UN64;9FCAPK"H5H#X$JPN2B% M$5S_0(5TT,T!--M!VTZ Y".WNXMB2R9,4B\.0JPBE$'B9QT3D+52SZX6!7'J MI5&*7-
M&D7;"BL_A^)/=((B\. HI0R]GS"%*P$9]@C98.2-AC&%WC)Z(IC M6J-RY_V64+_#448C=/;,,-)A8*LQ8BG%ZWP+.OD*R;4141NF+-G:O>F:4NC% MA(XYPJ/1T9-;5KJ8[@E"#/2#V NS##%<<"!;-]
84)WHN8A)C=#'IUM$7D$^ M\"-YF_:ZWLM5B7!VD\PLL4(K0^5D,\-(@AO30M# X&PXJKI1M_;!7 2LC M=J?=A#UN!\LG\78\OV9]*6I-5] U>^G28]4. *V&R,,:V;.I<'0ZI8K_$K@
MR@K@^T)*L]]8]WOCK_ 5!+ P04 " !DA 59<7N@_JT$ 5"P &0 M 'AL+W=O#A\X A,.M ML5_=&M'#3:6T.TK6WM?3X= 5:ZR$VS,U:OIG:6PE/"WM:NAJBZ(,3I4:9J/1 M9%@]J9/98=B[M+-
#TW@E-5Y:<$U5"7M[C,ILCY(TN=NXDJNUYXWA[+ 6*[Q& M_[F^M+0:=BBEK% [:3187!XE\W1Z/&;[8/!%XM;UWH&5+(SYRHMWY5$R8D*H ML/",(.BQP1-4BH&(QK<6,^F.9,?
^^QWZ>=!.6A;"X8E1?\C2KX^2@P1*7(I& M^2NS_05;/?N,5QCEPBLHVT^3]!HG#=5ZTP,*JGC4]RT<>@Y'(P><Q+PUT;O03X:0#;*QD_@Y9W2/.#ECRD5TL/7H1J$4^D*95QCT<&?\X7SEI+C
MKUV:(^1X-R07S-35HL"CA"K"H=U@,GOQ+)V,WCY!>-P1'C^%_B-7\[^ X-,: MX<14M="W4*&(\2C0>JIE6$HM=*&% N$<>@="EZ"D6$@EO21#X6')(=V$D$HN M,+8DIR0==Q*N
M/6U0*R$94A>]*2.370ASK1ORN,+:6 _4-[CX(1V]^@VH!0:76Q06D-,<3K' M:H$6\C0D:KX'\F$[<1N_*6\P?*5)3Y0&$V2O5PHI @M/)0Q+WMAFG1A.F6# M 4-
:BB_::/PDHAA_XZ(A8_&%ML;+H'CO8)OC>$8U586Z.+U<7^DWF*_,A*+ ME26%C.Z@@W_Y'C>H(/V9-L L@6H4NQKEPW?$HY]E:U'^9]KB/FONX+0N&FN9
M/G5BZ5HIC38++C[!@92Z;GP+00V>NS^@\Y(:.,8DIC.;JN9O0B$.50?U2%CYDZ886 ML:Y>4E)D@S$99(\30Z?C*?[-3UDR/<'^WG*.O8)+AITC')"/QCQ2T96[_#^ M>TBG<-(J4OW-[SSOMF\?
4::,7KWR2'7\KP#WM4:._=M]SBI>3U)^&0W2\7X0 MSCEN=\=E5UYQRCR\1,?)C?VF\1,5)@G?F"(DBO/DN+@%A9[$!-R"LDMR-G'/ MCGV#\DBW(T]HPW<-O3!5A396WA/'L-A;Z$VBT9?
(%^BTBAX6QW4#:A M[)B<7Y-WT.#D#53QJQ_;X3V9>[N^@]5)T5F$@X^2G!A^GEFZWF_GF<=3Y M;AX'Q@MA5Y)D6.&27$=[K_<3L'$(BPMOZC#X+(RG,2]\KFEN1U!P VQ. !D !X;"]W;W)K
M&ULQ5AK<]NV$OTKIVC.L1%(O*K$](S^2N-=Q M/):3?NCT T1"(B8DH0*@9???W[, +5.V[&;:SKU?)!*/?9S=/5CP8*WT-Y,+ M8=E=653FL)-;NWK;ZYDT%R4W72%6862I?V:E!
<_=AX%HNF;DR5RI;_1RGAUV0C)(M%"*U)('C[U:=I,,R ML>!U8:_5^J-H_!F2O%05QOVRM5\[PN*T-E:5S6984,K*__[!H?6AB1\84/< M;(B=W5Z1L_*46WYTH-6::5H-:?
3@7'6[89RL*=QSJ$<KL<\>G9Y=GW^=WIQ_M/6/GE(.;ZR^?SBYO9FQZ>D=??^-]W M\OHO^2^TO.64&>R\,E;72#AK&*\R]E%D2UDMV9021UH1##N5)BV4J;5@OTWG
M6(ZD^GT7*E[I8+=2*K2W9L53<=A!)1FA;T7GZ,&$4O_(+3=AA MW7/-&"QYQ7VL'(*;X&EIO@&LPIF$==P8G"A*LT+RN2RDO6"!HRZ M;%:G^0L0X,W(3&BO;RZ8P C$I@T(@5M5*?
L$K+PI:_FDW%_$R^9:B)V090KK M2 ,R&UHV3-(6#>.968FT+OP*ZX!7PI/ MI?5 XSB3UK14/A&3PT]A+)\7$D=#YORC$YI2RS 8)U$KNZ0O:T!*%>\Q::?# M VY\'3B\;VMI$1T$$L'CA7-
;VMK'&#&T+@*R@GF&K E?!>4%'-A+<59T9$F M2_FG<'70F/_C#TD<(=>:4<#O0C M>GD4_I<)_T/>P-RP*PF043)+0/<>#23 :Q>RJUBAC8(+!21Q$&*^G)!B$ MR9:B[ZJFC;(XB8)!/\%3?
Q@&\6C25A0G00(F>L,F81"%L0\!E[HA(}1K?>_ M:D!N$'L%XX"M D GM,'G M CPYY@626["9:Y O5,I=+_FOA&3J*+*]Z;-C/T^'UE.H(:C&P7 RP<,(T>HW MJYK9)
(C[(X0R&0Y!EG.K+"\MY%A"*R=!.!KN6'FQ M)3<)H,(_X,X0"=+9<]XELF&6C(TFK5Q-Q]J71Z3M12<&-%!$C"#@^D2Q,@B MYBHB>L>.:T/T#7!NT5?
2M8A\FP%7]ANAG%@/^")!56M29/\=W29A658T=UV*EM*5SB^Y2+ I__L^&-N\%6B)! M]X/M:1FY_T?JXA= ZC2W?=)O5P+;M^>L+*_AR%FQFU<]FVPRTW M(9LD:)'3?=1=%E)5BHT/.XC\QK4-
[>L/HG"W/;#A$;K-.(=;3^W<.=TJCQ/J M]]Y3O_=P1VG?79[/?G"P[%TX3/;_%PLN4:EHT[,ZM8\M-!51?TQ)/W(E%8,I M]$X'081*_?R\N7[#[]))N$__\8C^^A%1R-X@B?>WX$$-/(%H%S!/;+Q&PXBJ
M^-,G[QG7%3;\U;M]#P"X42SGAU!'P=#QQ1XPG SVP3N4E%L)%+0SW_F/B'&^(\CM=[.ZZD?=:'UQ*H9?NLY+Q';7]K(9W7RYFOH/ M-H_+ 6>O3UPO*0Z%6&!KV!'/.C:W>D>2,'F>][1?
P%02P,$% @ 9(0%6&ULS5?;PKGF:#"P^4)6PO9U(VN\F6E3"8=',Q_8QDA1>*&]',1A.!Y4 M0M6]TV. _=F5.CW7K2E7+*T.VK2IA[LJE9\WX_Z7B$# MDJ7,'6L0&&[EA2Q+5@087U8Z>YLC67!
[OM9^Z6V'+5-AY84N_U"%6YSTLAX5 MFSTD@SOAC:>>%.]-,"IFH-R[0S>*LBYT[?OSF^.!PZ: M^'F0KZ3..ZGX&:DQ?=*U6UAZ5Q>RV)4? ,$&1KR&<1Z_J/"GMNY3$@84A_'P
M!7W)QJS$ZTN>,TM.';U5-B^U;8VD/\"FUAFDP%)/&=OI&CZMB\OBR#8BER<] MY+V5YE;V3E^_BL;AFQ>0#C=(AR]I?S8 WY>B*UW?2N/4M)3TJW;2TIDE/2,X M4VZ<&9!;2&RM&E'?TT(4A-
*T3M2%JNR.#3"2:J]AJ5R"[I%>?);)'UK ME%-81_F3J*F%F,UU6SM9D)C/9RS;&-4G:M&E"0J?LDH])^1%-5EEQ\^\A3 M7XBWLKSO('G$!WVZ6<]9)(%!6UDHS:4RU 4+!Y^1;=NIIJ7 D=-H @
I2@(*H M.%*6&G$O>)-"M1M0E,$>*RMU*.JZ%65YWYTV Q:]9 .=W]X1DOH*'"KN>*ZC MG+DPWDM;'GS]*HNC](W= 54@VXX>W/Y6YK*:2D-)%%#8'TTF/WS7KL[[1>O!
MG[5S5+X/'^WSX7[6.8SV:#@9!6$8;LT^U? [-'V%UG6 J]8^#] H"6<@[C-, MV)Q<6V=I/QHG! @/HACCPPF!%]R/#]!&&1)BC$)LC2EJ!^/_J4E'\0]TTXW M9J1K\,9AZ*&OQ_IDPBC(LB&,&
>3<'2PI;\S8@0#HFB,,0G"R8ANM$.*/HY< MMW>/HB#,LF R2E9S*$UCNA3*H'!*V ,D6_7R6 WMQP=TM.5('YXK& Y3GD%U MG&5;$&F4CH,HC&D<38)X'*[0S?[Q>1[E. M&PXF?
1V&*>>9#=_.=C-T)DH?L M:YU=O$F_:$T@^+657UJ)@#A-7UIA4'*'LB[Z=(U7X!*GN+H(?[3092&-YZ'= MS*4EZA1%U0A5=#23"[L %[#9'%/1-$;?*0 !1] >Q?MPM@H:01)E^ C2Z958M"
M,=\@]ISWK?7]#L?^0:22@]\QMLE36L>8T.[A1V_HO+6X(>'6WX#\EILA!G6M MYC4 Y0@0G>6^I-C15[I4.9,ZHOF4*W"O6&PI?&E?HL3!{4!W[;#@(;#CRQ8W M_]JZQQK./-_21]F@I-EKW$%1%!
[^["\2%KD'/9/D]F&7+Y$P29_>KUE=WL'? M5I)^^J!O0H4%JZSS7-$Y?DWV1T@$ \]M=R[PT-WN@[7QK UN] ^O]1C3'L4 M!^,HW1!09PDFQ$N-]*MHKGA-
#Q^6XG9,*$L&:+FQIG_3R'>\:'8:.A2T;:(MAUPQ8(1ZCU# \23UOXY#OD'ZZ,P5?23!.,Q6(]\F:1!'PVX,$[K>9%E(A^0; MJO]KOG3=R4,=[=[BIW"Z\=WZ5#OT_GZZP,>6-+P![V<: M,5D]\ &;S[?
3OP%02P,$% @ 9(0%6:Y@KJ2%! Q@P !D !X;"]W M;W)K&ULM5?;;MLX$/TS0BT*!]#&$B5*Z79TN1,GUKER*"E9F4I7=%W9+G ME3/LV[ES->S+VA1Y)ZP_Z2S\6E,-?+ MP_U"5HRE?
(;#HZS@>.A0J(0 M]4$$#LV&(NB0"!0XWN+Z6R.1,'[_37Z9VLV$+E6HQE\6>>F<7 21R2B1FO M"W,A5T>BM87QU\GY/@4QI-^U\!9*-%-6]R#!I<^@AN1$UF9A2:3 M*A/9O_DNZ+A1E*X5/:!/
OY15[LD\%Q"/1H^@1=L# \L7O (WN1[G9L?Y*_1 M5!L%=^/O;38V$.%V"(R7/;WDJ1@X$!!:J!OA##]]\"-O_PD%PXV"X5/H;V#F M/7#)U4*0F2P@:/-J3@R?%D*WH9O_(TBZX-4<9O**&-
C)T[0NZX(;D4&0%+Q* M80U2!A$\79!4EDM9B>)*&E[8D]9&$]Q\!.NP,S ;Y$^DHZ?!#O8 M)E'3^JX71COD["K.H74>H=,!=@@$(LQGW2B)-Q!%9,H)E^ $UGMD#]JL-]J M
W2<*5DVR@6NG_CDTX>$^G2 '5WQ6R)F,TB&FP6?]>QW"KG_^2RT1]/$#6*/ M=!AE,(C=)&3;///0Q1]1S$_BQB-!DJ!O:.3&O=ZO^ G>C9\ 3Z=N%,8-0ZX7 MLX8CSXTI?0%)'= \ )1.%/GP&
[M!#RQZ-DT1NR,)^ULI"NWW*HI0(71QAWFQ M'24],/07) 6M)[R M>YA"6WW_%$:('A7E%*QZP%3/C9B]* G< M-YQ(W!C->C9-D>>&OH^<]RC$((O=,&'/IXFZ+(HVC#2C+51%46*_5U'%F@ "
M%2G:RAAX/7Y;/#U)TYNBZ;\T4>3&I32R:E#7ZS4Y+\"L]9)P\D.7]8 A:)*H MN86^]X* "MPH8O?R'HZV,(7)&$-^'W;XNN" <*(9]X#\'7*![S+Q#W""\H-@G/ MLAQ?- ! EFLH VT-#* _/W]WUFM(GZ?2"-
*ZP-\!E1^P['N)<<<5U#DUE--& MVX?T2&1S?'ZA-(!7>Y[#>[V[K6KIWJLM2Z'FMH+6X)JZ,DV9N9G=%.FCIC:] MVJY4^)"%YWBQ"C$#46\W9@Y13=7<#(Q&ULM5AK<]NX%?TK&*VS_<):?
(F4$MLSLN/-JHUE M5W;2;CK])&0A 8BM 1H1_WU/1=\B$IM;V>G_2"*CXO[(@>7/'O2Y5>S$<*R M;UM5F//!QMK=V^'09!NQY>94[T2!)RM=;KG%9;D>FETI>.X6;=4P]/UDN.6R M&%R#8-
#>6,CUQM*-X<79CJ_%O;"? M=G#:?#V,B9Y)_!9BB?3.V<4R5+KKW0QR\\'/CDD ME,@L:>#X>Q170BE2!#=^;70..I.TL'_>:O_)Q8Y8EMR(*ZW^<G.[.1^,!RP7
M*UXIN!//XLFGA'IR[0R[LB>:MD1A+/*6+UM%L.#K2SJ?_ZMR4-OP=A_84'8 M+ B=W[4AY^5[;OG%6:F?6$G2T$8G+E2W&L[)@HIR;TL\E5AG+Q;7GZ_GGZX] M=K6X?C][8%>W\ZOK^<-B^C"
[G=^SZ?P]^W!]^V$QO?MY=L5F\Y]N%S?NV=G0 MPCPI&6:-JZR$1A2^[Z92'-5S8M_WVZ M-}#-[#^>2T5M*7[>$B'MK=GQ3)P/ "4CRDQ*;W>\V#-0#)(N#),%TX5@R\K CC],B#4(P!K=G?L)4&
(B"& M[%LLS\4C2&5'$HRC4)G>;D692:[DO^H:Z154%QJ1$_11#>HHH0!59#NA=TH M;G8#.Z74E7%:E%R)/]H-&,Z*0A9K5O(2MJ01G&R3R%;D,N,*!HMU?JO,KL06RYAP9W MC]270AP!B-
W+;\W$T__C+_,OL+&X^]SYOH_5J1>&/KMB8,S2R!M#"72G8<#^_.GS=,Y"D@C8R/>2,&0P%R4Q<*$O])XKNW?EUM1\A^40I>"1TS1%[KT)@L#?*$D:HYWD"4L#)!BF
M3MAH,O+"=$0E]*+$1R)#=QY, CCA'V$*O6ED+DKCVA[-K]E2M&KI:8_J2E!= M#0KT([4S\$9KGNU*\2T3:+; ?T/P(C-:R1Q=G#\K7R/CV![6V8.K+MOINQ= M0/B4-=Y;YY8T2F 3W+,-!ZPY3BT
C*SQ_!$1"R96*^SZ+4]\;Z?LXQ 0Q09N MR*>:AIP)N6*&JYJ1:M-F)]P T7DAOD%<"L0%+*]6,H,:V<9;X[]V!CIUI7W M);R0#WM-
;:>E/FG<\)%33#LX29RG=%;GDRK7"_0/ID>%;>N"3+4BVBD1A]J3 ML=X2SY5U9YVJ \QZUC&R?1549$J:4X45"D0-#G;:[GFA5Y*&,)5CAA&_G[,^ M%9(,W5N7,'!3")#&! #7Z","0
RTQ/&8.&PT!H0G[+HJ44 (TW M%=',4L M#A(OC<8LBF. ,F$?D;"39$=4#CQ2TS\,8(R0#>)0'HA"V)P%TCO1N8YRGC- MC67QQ&$O]@(4C+XD(N="::@AX#,%,:HH8000NYZZ-DX@)]()6"3(&7!:.(%
(Z(Z MT&X:O\8J79*/JX,H$[@V2@,B 002C7T' !!L3$Q#Y_XD\6(<\D?]-&4[/7 MR/05;T\Z%CSI>/"DQX0G/Z\;GN4"OUCZYV?H@6>B"3P+O 20[P"FYM*9<5
M!0:J>VZQXN6:RE1/U<2,+6X(R#HW[7XM\M_?NU>-/,"!,-T0^G.9PZ MND&[54(\F@GY6#,=5QQ,Z/6(4H%4,E)4 MUB5Y#^GM$K%%@5,4$;D(T.N3?
LW#VK>P\^V_MG[*IH[5CYRO0WW&E=]0[;QI MT"(+\![5_R1)3P.\E"GEWB\+NA.=QNV=[Y,!7ZIB6=$HO]IJN7:I4#6T: [MOG<>'=SDS-JV@8!LF%VU%I7Z\T!UJ=\'T"NH;/0!-]?
VP"]U2M&^BIU:E MWC();[HZ>)C!:;T&X"7G@8DV)@R%%1:)AZYJIKMDN;L_O*F<]A*%LB>[(_* MS:;K?'"(0YQ;-R2#EC-16D[_LLRJK;&4>G,TF0!>) V:7=UJGJMT. M6R:TP!96E=7.^4]PJ5!
(7@\OSP&QT4,]P;..!/>YO*\U5TC3#,G-ZV1X1SUC MA%+&27;# "69.K"4CGR1R!5>1UF7KD=-B7'&R.S&]5G?P :Y MW$@4GS951<&AN1"$R'L-;NH^.V"]7_#6%ZJ-H5OB8)0!>ZNJ=!-T+FC4T\>#

TIA_1/WPRQ7FO3/S MWC7T__63KB*]S?,]>'@L$1:R;I@X0,DT4#;F3Z6L"E0=UC1*/E,H\>>.FP-P MD5,0J<*@J9C08$IFP*KP H&:!QT@;"G:AHLMR U5-$6;YX8@'"[L!#<:/CUD
M/_1G8.)T+!M;OAKH_3T5KUTE82D+6FN+=&20$U/J%LQ5NY%@T;!N*GE U#XI M;GB.2CMH(47G= <%5]0CI-+=5QZS2DOG-A.P/.EFCM-JIW*Z05B1K_!IF:U6 MG[O.\$P 7ZR,-B[5C@J"!!>"
(_K'#\,X&GS1M*=R$38G2=*RX@6S(R$%^%:0JVU0&07$A:FS=GG]*@;L5W)3[)@+X496U(?U#7FJR)W+ MDH6,O[P^L(5G/\F%M)#:6$J:5:CA-TC\P:!':\\?Q!&M S^,AK2. _#"-X8%R MC%&L7- +?
*8AT+ABBV) E*00I:260I+X 2B&I.TA&?:AG_IIDD Z\D=Q#(_2L"MA.?T9XCSP1Y$EGX9^ MU()B,(^28F3$C^8#N"M\@TN^FV-:NNFBJ97=L*TK?=\>AY-?> \SJ?_ M 5!+ P04 ! !DA 597+58 ! &
/#R#0 &0 'AL+W=O?&TT(6[:.7>E^>= MCDMS6DAW;$HJ\&9F[$)Z/-IYQY669!:4%KJ3=+LGG8541>OJ(NS=V:L+4WFM M"KJSPE6+A;2K:])F>=GJM=8;]VJ>>][H7%V4!OQ0MW=9:
<"938[[RPVUVV>IR0*0I]6Q!XO9(-Z0U&T(8 MWVJ;K<8E*VZOU]9 ,#;DCEZET=&/T%Y7Y_+)UVA(9S62E_;U9_D9U/D.VEQKM MPE4LH^P PFGEO%G4RHA@H8IXET\U#EL*I]T?
*"2U0A+BCHY"E.^DEU<7UBR% M96E8XT5(-6@C.%5P42;>XJV"GK^Z?S_Y?/]P_GA_O;/#Q<=#Y\HI/6ZM=1 M/?F!^HGX: J?. &^R"C;U>\@E":>9!W/=?*BP=^KXECTNVV1=)/!"_;Z37[]
M8*__H_S(>5NEOK*JF M99.*>M/24B3'S07E%3OP]GD(*!/EG'Y+1P6"_VZ: M]4ZZ;U\(?]"$/WC)^L_+\Z+Z_N!V;(IW$1F?DY@I MZ[S(I9X),PL%:(?)&[,H9;$2*>Z:&#LI&*]/50BZ]6&!^LND<4P"4
MPZ2P(0*9/%$I,>B5ZHZX@,,VL"+UY8"E0 ME\.;Y,<_K(&K/;_YM5ITAN]_=[+(:K?> S1<*(WI*@IQ* Q)"GP*["),)"! M8WJ;\XB3@$&-Y;'XG+.E[>D2LE5%JJL,@3N 9;GV ;1D<U>V'C\IR WPN-*1
M=LHRKKS%7I"4C3+1TW,YD8+:<[A9$E((3)M"T3"K@ZP[4L51*!*8%&Q*$3ZY M1V9V].#6%@_N/SV @5@>BG5HP$$3OG2<[$PA@3!"=NJ<4:JR*$I/*C8,@#L* M>C'BM6CEE6:B;YA6%0$
Z7(QPZ$@%E6*8SO#($PD9%OW=5WH)MSHI'G1 MRUOEXV#VEQ"C:JE@@8D./3=3+ .F!AU+?([+XLAHC(3$]Q%^S<' KNQ?G%8" MA2,GZXPS!F>"H*'0%A^H0%/H2/)QAD*K\"7AT5Z#>
(/)%5/'RM'#DH6L)AZW M:!ZQ,;DPV?EP",W; FT*VNU^[&L('8\!SO4UTF;8'!;.Q"A<7XO^6;N;L(5!TAZ<#$,AFA1$5< 2QI/4,9Z SV[:M2\GL2(W-T!7,CW$:NM*).[D*!
[E2%.+#XGX0\DI6C:4_EZ)]1WA,_C%"_[O1!N'XF&.9Z\W;NZV2+=>(MT-;P-:$E[M=-;G!./K@T&[G.0.Q4'2[G:[AY X.(D[UR\@AZIUVV=#7@QKP\E)>S!*Q+[# M76?K'(ZSPSS\;3#_@'4\DC>[S0_-.)
[C-^+Q;^@CDE1H:DTSJ'-/1\.6L/$/ M(SYX4X93_=1X_".$98Z?,K(L@/&PO=V]R:W-H965T>CT825*$B("N[+HI)GUE:I>C(>R]462R9'O,:*=M9< ME$S15&S&LA;(,B-4%F//<:)QR?
+*FIZ:M;F8GO)&%7F%L*=0MW[W'SIY0XZUX()^ 9WJTBP_(M4VQZ*0@.A#Y-:'I@3#721"ZO]*4L ME*#=G.34=*9^>W-U\]L"YK-;N/QP??WA!A;OSV]GIV-%V\K0>-5!7;10WC-0 M$5SS2FTES*H,L\?
R8Z(U4<#?FVH$OF.#YWC!$3Q_L-4W>/YSMC)1 MY=5&PAP%++9,(/QYOI1*4&C\]92]+5SP-)Q.EXFLV0K/+,H'B>(.K>G+%V[D MO#E"-AC(!L?0?^QB_4S+G"2N6L*%V[E@]ARP)!:L]
(X&M8\;*DS*$@'7'V! MO%H5339L#\>;FHZH+0+>HUCE$K4DI;]4K,K(W8!E7? 'Q Z'UVTZ[IC(I/V- MC@&40D@8U-EB/K=I?H=280:WBT\2")CDB'BU(?JM5+5Z@K/ @FDIQ0W6)2]K
M5CV\?)%X;OQ&:HP[%"K7&C-/ M%W0FZ[__8'33E"B8XF("-U3%KRK2@G9'[!=PG=AVXX!&860[@:.7TM!._AL M1G:2>G">91.25$B\%-TDU7Q&)€!7AD8V*W=O0W7+GPU__Z3WP[#A*(?5C".W0
M3\"UD]A_Q*EWD5:, MM-)[8^=>1!QO>UNZMBN&X";Q*2+^"2I':2.F?NN"[/UFMX&;:#A1:\#W?6J M$;G*44ZTI4HYS&9,'LNHO=1 MYHS"R'Q\$V
CQV\7XV/"^W"@DZ'Y>&DK[O:85U0JLBPWZ=:E\>!N*MT4^Y62 M??'*VIS"+G/9DM^1FOW"4CLZ]A^Y%% Q6ZD)U0?='1Y[L\)6K/KO8& MM(3?S#YR11=1-
>62$,FA]9&WJ:/IZMQR>YZN9T=)9/1I:?ZB?%!TT8 M_@U2Q#,$% @ 9(0%6<[X5/--!P BA !D !X;"]W;W)K&ULI5AI;QLY5$OTKA"8(9@"-),O.;1N0C\PH&#M&G)G%SF(_ M4-UL-
3=LLH=D2];^^GU59.MPXF 7^\7JH\Y75:_8/ET[_R742D7QT!@;S@9U MC.W;\3@4M6ID&+E66;RIG&]DQ*U?CD/KE2Q9J'CZ63R=^.ME5(W MR@;MK/"J.AO,CMY>G) \"_RAU3KL70O*9.'<%
[J9EV>#"06DC"HB69#X6:E+ M90P90AA_99N#K4M2W+_NK;_GW)'+0@9UZO"\\N/-S?SSS?7MYWLQN[T2EQ]O M^]O?[F^O9Q?WY^.(UR0X+C(YBZ2N>D3YEZ*&V=C'<2U+55YJ#]&:-OXIGU\
M%)/O&OS0V9$Q&S%=#(]^8ZJXVV^QVSO^E\T=/HB*Z*04A;BDN$]^U2V4*K M(*YT*(P+G5?B'[-%B!Y-\\]OH9"CE MY-
UW4CC9IG#R/>O_>\G^#W,A\'GO72,BAE)$EW]K!9FFE78C=!#:KIQ9J1(7 MPJBE-#QVS@)LKP,,T0O2L3121A2N\T$)5PF-@BPZB*@01N(S1%KO"MS02X (MLZ2..8S*!]CPKEO6PNBHEY('W'GA8-
J+1DDXY&APBU*;C>ALH7P$27'5=:37 MK0M!+PPE(2.>0ZB2*^.J$TI9+G"C8)Q654@F7TLAIP/ M;(<. .PJ.G;4O?!%S+4H@)+YORSJ>< O)X>O7H7!(H &P:X M$*:%HA10!O4
@D9P">Y*H4PR"&HZR!#NE NFT:>JP*7-C+C6LHC'?B1M2H!R"NTU4XC M=QI+$58+13E2L:D)-JE9AB23!,&NNND:(1O7V?B5>@JO'(G?]@ A$-1*F@X. MRXP"RHMK)8L:-
ZWSG#7*KUU)E9%E*CE0WX."/'RQ;@U,9HC-JT+I%2&8\- 6 MI(2FH5H6#MGJ'5!4^QS21A1&ZJ:O>N%\J9)3E"SF^N7F[TN7FK^WNP&\Q@ K M*J?1_Z:$9R2M5MIU ;4M$T>J MJ9>*^0&
[C9KXQZN/'WZ"]E^=2OW!\>Q;1J1E!\E^@$M7=(G /7K7EZ046DR6 MHJ%:/V0RTEEXV)&1D,NS$'_;^9_S&R[4[>R7WV9__OWF^K +:QEZCV5J@!0: M[G:.-1U(V&=B0HAMDV9^(8[((P_/56?,YM -
)#];\'>8OB^*6Q)E2F7>SXVL MXSA5N$9E*B*:I30S\2TV:+! #D6>'0TO1>218#9B4$.'ECQ4;21EO%(TH?$; MG-,S\I 604D\PRL3U*A+;OD+:,@M[^D$\K38?<1?@XID!>O:CK:P?
71V.T5Q)S=)9!92>UFU/3<<=NJ:Z+%;_(LIVQ$AJC;::&.(#@"' M>(UV+RA6S216X;BWPC&V):$A5:A#:SG,#-4<@HWR3.N-QMQ&!^"HZ)@5EP;MG)V]>C%Z2OD%UAJGB&?HB*@[U.=-&H.!(?
>8'N'Y+VF[8CW]=]X_/IR<@% MUB4@8",1+:UI)V9NA$!:R&"OJ&.7#@*(%@:(^+;!?'HNF_;=53JBLS(/"W!+ MB7_-9[U&O_P>;SQ,\ IX@[SF3YPW=V]CRI2I@6O+:)5C7"+7M? %J
M4%SF'IM=EU!2.*[0P3%]9XBVEO!8*&1=,-4O47R=NJO/FV;14@/]S"1%"QI- MGI#K95!_7_Y,S+G99MVG.LQ,Q:.\RQ_:E2SR/@#DT3\2>;1W37!,>_NI]0'1 M 8,PX1G@0Q& 0':8>DOD]./UI[N?1-B
(!MB'<.#FLBE<"&F+;6N-:CGT5DQ MN8MYPWP]LTQ7^S&M%6W;O-Y+ZK=G)Z^.1Y.#>4FNGDW?'(V.M@.A4]L6.2-L MMU9J/@Z1*^J>CDY(9D,I+9TK$XJ/#E%IP7V]+AA
T&FKJB*VCKCEIM^_Z& M@@JHJ6([.(>IO6B?8J+YMF[C30\/QWV"U9'I*8*H(

C5 MBX'PZ&PO=V]R:W-H965TXX1V@0FUHI&QS7DT8I7,"84Y1ZG["LR?)Y"S[=ARK9WA MGJPSJ0UV-"KQ&A8@'\HY5SN[94E) 5001A&'U=BZ=8>S0/L;AY\$MF)OC70D M2\8>]>9K.K8-
WPVFUDAJXO]ZQ?S:QUBRM,"4 MY;]($K.Q-;!0"BM;;] $T]J\R4L%^:+MK5OKV>AI!*2%0U8W: @M/[C MIR8/>P#W&,!K -Y+0' $X#< _UR%H $$YRKT&H)W:YC-XF+L<31B+,MXMI;
ML>F%R;Y!JWP1JNMD(;DZ)0HGHSE^1AN!YL!-S=$$4QDC-1<4 ?T<,B1N^N MWJ,K1"CZD;%*8)J*D2V5MF:PDT9G4NMX1W1\=,>N$ 2:T132#GQU\&A^>P-LJ MYC9P;Q?
XQ#M)^*VBU\AW/B#/\8*.^TS/A_M=X?R?^NS5Z@?)\-LJ\ V?_YHJ MZ'KLFB[HIM.];2A*G,#84LU+ -^ %;U]XX;.IZY,7Y(LOB39[$)D!V\2M&\2 MG&*/OJLA06C"BLX'J+&AP>I9L(E:W>8KPD5*
(>5DG*N^ZI9\GI4U!0)2M,+ETRJSFJ6F9JNP+6#.E\Q M)G<;+=#.Z^@/4$L#!!0 (&2$!5D0PNQ 1 ((H& 9 >&PO=V]R M:W-H965T(%5@@89-H2L+GMX0X8LR"C\;MC>OV6 M-O%T?
*1_=;6;6G98P9U@ORC19>)]\!"!'#=,;\7A&W3U3"TO$TRY*SJTL=%' M#V6-TJ+JDHU!17E[QR_=.9PD&,[YA+!-")UWNY&S_(PU3F,I#DC::$.S U>] MRS9RE-N7\JBE>4I-GD[7YG@)2/0D,:&\0$LI,2
'+M6L:_-#C;.SSK:JJ6% M%V@1>A!OUPJ/>*AP$WC=\A*+@!H5!.!G@17VYD>-%%WCG MRKQ!NU>TYH3N*6DP.U=U"YV;AL&:!SLIK?C4VVT)*+6_Q]RJSL,S#%3," V[<6F@YSO@M]>(3<,?4MN
MULO-KCJU)Y#F*\(7W(:9;[G>[?YU0CGG_2'"F3ANJ!"F6BX;EM% MO]HWVF?;7 Z&MUWZ &ULM5G;TJ MV7$RFMTXGBB>>=C:!XB$1$Q@ . 5OSW>[H!4I0C*>/LSHLMDNA&7TZ?;I!G
M"^N^^$*I(+Y6I?'G@R*$^O7NKL*54F_8VME\&1F724#+MU\U]=.R9R%JG+W M8&_O9+>2V@PNSOC>K;LXLTTHM5&W3OBFJ1[N%2E79P/]@?MC4]Z7@2ZL7MQ
M5LNYFJAP5]\Z7.UV6G)=*>.U-<*IV?E@M/_Z\I36\X+?M%KXWF]!GDRM_4(7 MX_Q\L$<&J5)E@31(_+M75ZHL21',^#/I'1;DF#_=ZO]'?L.7Z;2JRM;_J[S M4)P/7@U$KF:R*
<,GN_A9)7^.25]F2\]_Q2*N/3D>B*SQP59)&!94VL3_\FN* M0T_@U=X&@8,D<,!VQXW8RK3B?CXV_6GW\;7OXO1S5L0&;^_&;\;7XUN/HO1U=7'NYO/XYOWXO;C
MO\97X^N)>'YK2YUIY5^<[0980;IVL[3C9=SQ8,..)^*#-:'PXMKD*E^5WX7U MG0L'K0N7!UL5_M*8'7&X-Q0'>P='6_0==B$Y9'V'&_2-LLPV]F%S%ZV;XM^C
MJ0\.$/K/.H>COJ/U^JBL7OM:9NI\@+KQRMVKP<6G-9/]MYLL?:HL_9HF_:+ M2^FU%W8F;DFW9F+ OL[('U C/A>X$%<6F3):Y?3+(R2Y#+AXIXTTF9:EF&*Y M0J&+PIYK\14*2/@:RT=UM6-
\XTT000K[G8F.V*NC'*R+!]0DYFJ29=R",U3%8G_OY:\LG5MA;!#8JVQR)6!.JT2;R'5,&EB)94KDVF>E]0VB M@XW_;#1Y-GT0G86\;V8K&([ELRXVOHO-$)N$PC;S @5LP'AT%[$M;]'UE#(
MP/OWMRJ44QIF.%B88UOHHC B&WB\%.F;7,<$PCPDE%RLM"]!UXCM#B7T2>GT ML+?DP(,LK:/4"N)^[AGS1^-B>2ZT*%@2[ZODD)ZGY#ZJ!7>4.1(=@;'L?9! M201^V^6(#XGY5+'>R?
OO%B9$P#'3'M .:S_ M\^G.M]B@?1) .Z2E?=D;C=N+PA*@[<) FV^F7N=:.E#'CA@!6AH)<5F2 9$8 M+[.(W&7! @=@>#(GFHH\HK7PCNC!+B&]#58HG%*%O==?114I-48-A*@Z0F3L M$ P,8ND];
(*9VN0ZD]0/6W_:S1A2E7R@1*NO-7HG%&Y($%7KXPP="":PE)RUE M5\!N;?.=+3QWW/'<\5:"NBJDF1/2OTMT/Z)'7,]FB@<$\8L$@MR7Z/X,5]*= ML71,>=V7IQ!]@>@Y"J-
Q3IEL)=%BC@$I@A^U[9E%*.(4PYFS%2XK):FJF148 M5GFI1%T29J*%C21=4'I M.S7\OWH$&/:HR8B/#)!K8 Q^#,6-VN#U-X)7N$WN361)Y74+A#DBQ:V>3(" MOS]!ZK&M$XR;T#
4[V//8[E1CCK7-$]P&IY/WC^35?UF](K#M%HJ2IB[G&' MV.@E$3ZN9]AH6A*I9+=Q*I7WO2:T/%Y>$:>#R-\ [G%D"A0F;T.E=SV:_DV
M,1/U;>6X"9E,;:OWDZ[>3[;6Z9UG;KKV0:.Q*;^NTI^FH=>K4P?W?3>!H$I^ M >MUZRE7TN.X4D?JY?A++A\AJ]@.'#>:?C_ZZ_V%]6>I*U (>YV?VD8:%@(/ M83VSJ
U+V@(Y7#K0I62*I>*+L8M2Y7,.0<1[$$#13WV&(^YOX(,+%(SD MU:P),&I(4M1=VV:1^D2N$1/>@ L%9O?M?7K?!81+CC$:I\S_P"&HHS2)5@:, ME4,L(\H:FB9W3 DRI@ZGU>Q
M@^LJ=31X]6$)G01]FF/1QN]EV72*UM4,GT1UT%Q2KLVQH(B0R$P3941AE.CC M679UE 5J?\X,2L@JJ81%?" 7 M-A%>ZI9EDW7?-VT8MUKP)D*CK)FYT;'Z+@>X'^@?G;$N\9Q$VG)?QGZU:Y=
M2+\<'.4W0>$)GVPL(Y.E2%2$*QWBC.=5"&7,]H:L@D7O436:J-?P?)LW[-:H MF0/"<3CBD,!2' Q IL-RY7/G)[V MDKK?RCX&R_=)< /*-I]ONBE]V_EI^"WA=^,%]17LZC$AZ1F.!\0"4%E;F@SX M*-
M_LNI8)/D9SD!VP9&13LZ=K(L.ZD]+*M*%F:WATH1#80-8=C#5(M+WTWY:'+W@N5>[IT.,:W-N<)C=$GB,YI()@Y> 1=C#-.T4V11 MFQ;QI-7*O>V=W(>T1D>9-
"7P6I_6]J@OD6/2G#J",@7%.5]Y'2"G%C%9YB%T MZM+D2'/#Y*]UB.["8TR%S;2$'Y1':CL)36ML\13@:,_J0+**C&_W[=IO>BU#
M38%\U_FR@+)"JUEO8LQ5IOGE+LU=+H[4+4NGLXZ26;&MT=VN(YM56G47X^61+[?3\V(!\F\NN M.%>-:>=!%=(,I+J3%X.OK=&C;SN%P\:#+C?EU2K@HN_LWU#T71'\8YA.ON*S_(H<
MQHH^/5I3T\"]=&/0.BO(6?=9+7;^WA2*3?G3T3$$R"1^!VEN]M]A1K% MCR_+Y?$3U@?IYO02H50SB.[MG!X/A(N?A>)%L#5_BIG:$&S%/PLE<=BB!7@^ MLVBVZ8(VZ+[-7?P74$L#!!0 (
&2$!5DQ=A.+ , ,0& 9 >&PO M=V]R:W-H965T[2NV-T_WZ^'\1, EXX^\[^_-G83F\CU:O.$0V\EX70 M?2\WIKKU?9WF6#)]*2L4]+*4]F2&5+7R=:609E[;6]W\<17N;$7_J!7L14F:)ZKF2+-;U R7J+0
M7 I0N.Q[P_;MJ&/MG<$+QXW>D\%FLI#RU2IQUO<"2P@+3(U%8'3\QC$6A04B M&F];3*)\:1WWY1MZ%Y<[Y;)@&L>R^,$SD_>]&P\R7+)U89[DYBMN\[FR>*DL
MM/N%36W;C3Q(U]K(J\B1P7]D])C*)73GYF,'I.XNDD2>#Q9?+T$D]^P'#Z&9+X?AI_ MB3^]A]O@]'L>3!,[G;%&@ONCYACA8)#_=QAO5\<(C\;KP M((7)-4Q$AMG__CYQ;Q((=PF,PI.
W];B$]$*@!6$0=D[@14U!(H<7'<$;IJE< M"\%*F:RX"E'#3^'"VT4-="O0PG7>)W#>':H;G7%4NQ[-#4:U6.T!FUVJ],-(+D_8V5U-Z2;\T^M,(HNK!2V6V&;Q#I+ M6L^N7;%=]K4VN&
<=UO=3]V+VN_ZBHP?*3&U,VF!H&I]!&=%[[.!0^WH[VV6 M$M7*[4\-;D3J)=/<-BMZ6&^F?^;U?G]@=L6%A@*7Y!I<7E]YH,J=62M&5FY/ M+:2AK>?$G#XSJ*P!O2^E-#O%!F@^7(._4$L#!!0 (
&2$!5DH>/7&! 4 M L, 9 >&PO=V]R:W-H965T"D[9:A#8HZ[1Z&/=#RV18JB2Y))\U^_8Z4+3MKXO5U+Q)Y MO/OXW?$[B1#I7.K\'0EDMLE#W3*VQI9:Y-HQQ-S6)H M5P;5+
0U]5!$D1PVJFH'HXM@^VA&%WKMZJK%CP;LNFF4>;$"6C]<#OA@:_A4 M+9;.&X:CBY5:X 3=Y]5'0[-ACS*K&FQMI5LP.+\+]@\.7"A_LWAA\
M)E.MO_K)S>QR$'E"6&/I/(*BUSU>8UU[(*+Q;8,YZ+?T@?OC+?]D#OE,E46 MKW7]1S5SR\M!/H 9SM6Z=I_TPV^XR2?U>*6N;7C"P\8W&D"YMDXWFV!BT%1M MJU;?-W7XF0"Q"1"!=
[=18/E&.36Z,/H!C/U_E FSM!J17%N M].[F=GQ[?3-^#S>WD[M/GS^\O;V;P/&=FM9H3RZ&CO;PGL-R@W?5X8D7\"1\ MT*U;6GC;SG#V-'Y(W']*8DOP2AP$_'W=GD$<,1"12 [@Q7W"<<"+7\"[:>_1
M.I*5LPS>X-2!:F?P]MNZAA3_'4^L,B>:OYXK0[9$\OX=OI'.[M4B5>#JA3+)I['(Q>_<)E]/I !DF?07((?32AQIRM:P0JAVMEERP\0PKWJO:)
MA93&]ZJJ_3&>4NN>3FAE/[TI)5LMVFI>E:IUL*L*@3E<://X7-J'B=TM$>:Z MICZOV@6X("&P2\K.T_&FWMYCE> M+ PN"!'>],.5QQJ20%!E1[BR1T0G9),MCV4=S*5B1 M%A!G,_1M.% Z;?
0EH_[J#Q/6))G$!=P7$AY0H:8I3*"@A59 M 7G.8AX!E4)D',;6HCN=JO(K'? >2)'3KCEPRN>8%P1"AEQF4,0"BHP5<0J3 M]=1II^@@6$*F-).0\X0.B!*B0+ +6E&4R!YF+(I2 2
43$82(A90JQ(N8572)H7+,[VE%O0 MH::<="@9%^E/*)>\276"#E<0@\H3ZP=MB$A'WZI7 .4V3&+B(6)04_I/9H"DK M$M)*T:<,O)W\=FWH#3F)CD@*X E-BG[M1?4G+$L2B(G],8^3$V\H)/^A1!OS
M?B>D"6F40\+B/(=CJD 6A5Y([=]D :E(:4Q%X3F35'1)^7!JIETOD)7E(J-Q MAW'4HW2KM&62TC@C1![\MEA'/9H7Y-TS/Q2[4W*S4^E>XG2'6QLD^0"I"1Y1 M&:#]/VD[%E0\'.@=:_\@YA3= ^(?
BY/_QP[X)&]H(UU#Z!>IUZ[]6F_M M;[KC[H*W<^^N#=2 "VH HCVGT.@L2P=@NJMG-W%Z%:Y[4^WH\AB&2[JMH_$. MM#[7VFTG?H/^_C Z!U!+ P04 " !DA 59M[A0,:\$ "X"P &0 'AL
M+W=O>;,F>%H3K9*?S=K MSBT\5:4TIZ.UM?7Q>&SR-:^8.5(UE_AFJ73%+#[JU=C4FK.B.5258Y_2>%PQ M(4>3DV9MIBG(&STOW(O5VKJ%\>2D9BL^Y_9K
M/=/X-.Y1"E%Q:822H/GR=#3UCL\2M[_9*?@6_/*!A?)0JGO[N&J.!U11XB7 M/+<.@>'?(S_G9>F D,:/#G/4NW0'7]O/Z)=-{!C+@AE^KLIOHK#KTU$Z@H(O
MV::7]VK[.^_BB1Q>KDK3_,*VVTM'D&^,555W&!E40K;_[*G3X3T'_Z W_!N M'34LOS#+)B=:;4&[W8CFC';4YC22$](E96XUOA5XSD[F7V>SZXN;B]N'Z35<
M7MU.;\^OT)H_3!^:U3EW=],'Z[N;N'@@2U*;CZ?C"WZ=@CCO/-SUOKQ MW_ 3PXV2=FW@0A:\^/G\&#GWQ/UGXF?^(. ?&WD$ 27@4$\

#'],2"\L \O'$*?S/$V M%YN2.^I7\A'9*KW;1W(09C_)'@]RE$T8RPOGQJXY+%6)UU[(U3%@PGB3L"\\ MY]6":P@\ O=LB^5LN48E#7P"+PJ)%P6-%9&$AO -;_6AD(>U5CDW!F**ZPF% M*/&(1Q.7"
('U7\!*J<) Z (P,1+<8_OM39-W#,, M:!SU&D?OUGBFL6]JNR,P*YFT30E=_-B(VA4*@5MN]XD_B+]?_/JV](&LO(#6 M/2A_
5UI99IDD2SV21:FK1T$Q/=]F.;YIMJ4S#DL.#+%6]+\L,2/V@%UG:/RAI4U"=!I:,@Z"SJ>3]EA55*VZ[7 MP4$81H12EY70BTC@H=6P8EKOD ,\LG+#$H.3!-<<1!\HN^AU@]<1I M!BFVW
QP#L(I1^)(WC+MR,KF^V<@P7,A8$M(L9OW]2. ME8VFSP1Q&]+W0N)G&6JXY(CLPL!VC46'304U";%94[A#Y37NJV@ $&U&N][! MAK0N7Z7Q$WXR?)26HA7C%P UW%O!XU?
35,7UJID9716@EW:PZE?[L73:3F,O MV]N9]H;IE9 &2K[$H_0HP0:OVSFQ?;"J;F:SA;(XZ37F&D=KKMT&?+]4RCX_ M. ?]L#[Y%U!+ P04 " !DA 5922;Y2V\# "6!P &O0 'AL+W=O]&2D M*BNXQ <-
IBI+IE]N4*C].(B#@V'!-X5UAG RVK(-+M$^;1\TK<(6)>^O>L ILL853;!Q*#DLA[9C^82X=$E96DU_.<79R:?IYP4\3^~>YG_GRZ?%O(]?^9?');Q_9"N! MYL,HM+2+\PVS!O&F!DS.
(/;A7DE;&)C+'/.W\2&Q:RDF!XHWR47 /RIY!6G4 M@21*NA?PTE9RZO'2EN MSM!L68;C@*ZG&0;W#8/+S3W$_^NT"X6Y+N'L)?;*DFYA7 D&MX8B\6W')9,9 M@*DQ: TPF<,=9RLNN.5H3BFYO-<=
[E! NP53[SB@2V8!:.1[F.)S!U<#I7A M<@.&;R1?\XQ)"VKECL 5$""YK0@G4W2-C25O8FT+A+42U \H< B47VSS"[>8 M8;E"#6GL+6DC;0A?*4[3G= ::0_66+]\NYW!@V#R0/D=))U^]]/4=)OPLZZ
MIVDGCA-(!C1G,U1$RI+U. M+XV=CA[!U0XMHY30!Y&;).0U.$[1$&:-(G%L2-5Y,+^<42:4W/QJ49?_#_!6 M:\WQ.+OOG(J/_=A-HD[<[U0XMHY30!Y&;]K)K&ULQ5=;;]LV%/XKA#MT":#%NEM.$P-.
[:0>TC2(W>QAV ,MT1)1271) M*D[VZW<.):DN>YG6Z_-^7\49 M*Z@Z$VM6PLY*R(]J^)5I7ZTEHXEA*O*^:]MAOZ"\[(TNS-J]'%V(2N>\9/>2 MJ*HHJ'RY8KG87/:9QH7^Z&)-4S9G^O/Z7L)?OY62\
(*5BHN22+:Z M[(V=\ZL0Z0W!(V<;M3S8"8CF+-4J@,#RQ]RS/41# ^-K(M[+4JD7%_OI5^,6P'6Y94L?`XR4>REQ+V.7 IT>3Z/C\
<7JWF)/QW81\F$YN9GAKT(T2^G&CYZK6XWY'3T@^BE)GBDS+A"6' `W WM)WM\OW*,"?Z[*,^+9%G%MUSBVSL=X1EYWO<03ZXW>OG%"^]T1D_S6)/^8]-$<,CBIOHE<9_!.0?[M,
(L=9D(5&HT<:Z 0B2(&2:E9G" 03,\$T83$KEDP2S[$.')(PQ=,2L"4H.VLB@N\BY9S,H;20 M'XACV5%H#2/;S%U_:(6A2^XK&6=0/7!QZ%H.+.$LLGP[.E $IO\%96[D6+X7
MP(R&$2!^,BBV2A_DF,6&23\3@C%/(VSJE2?,5K)]^R)Y83 M%ZJOSGAIY.RIRCB3%/SZ @(8\%+5Q#*R7"^$4(R"@,RKI1::YB9@ MK,@+8!)9@1.16TZ7/.?ZY4#=.(YKWZ[IBTE9K('LB-
K*'OP.B[%O2X8^D;MND; MOCI]9Y EL<;9#=S=ZDYW*P JQ+84Q0&NR9[K@0Q:R,&2:EOD7NOL2OKCZ#I: MA-KU")3O 6=MJ#$/=![^?_C-]VA)!P. 6I^ E=*9JJ_$CE/C ES#4/=\4$V M2I
LPZNGN0[$HF!M"^IH*(M,,G9PP2%S_GRXT-8#O*_@Q]N;?<_7@)>JC%R# M2[IL7PXZ\?G=]I#)%Z#E; :M]-H#.+.NW3/VCQ=]\'Y9"PVO$ M3#-X_C&)!+"_$D)O?U!!^Z <_0%02P,$% @
9(0%6>!HR3)*!0 = P M !D !X;"]W;W)K&ULG5=;;]LV%/XK!VY6()!B MZRXY30SDTJ+=UBUHTNUAV ,M'=M$)=(EJ=CIK]\A)2MVZWK9'BQ2%,_'[]SI M\Y547_0"T<"ZKH2^&"R,69Z-
1KI88,WT4"Y1T)>95#4$]*KF([U4R$HG5%>C MT/?348U"QB5WIJ#U60JY1?[\J&\ M&/B6$%98&(O :'C :ZPJ"T0TOG:8@_Y(*[@WZ"_<[J3+E.F\5I6?_+2+"X&
M^0!*G+&F,I_DZCUV^CB"A:RT>*JW1N/!U TVLBZ$R8&-1?MR-:=';8$[4&.Y0TS;'*NY J4W4UH=N)4==)$C@OKE#NCZ"LG.3.Y>7MU#\?W M;%JA/CD?
&8*T'T9%)$BV=]5BH<_$$_AHQ1FH>&M*+"SJ*@^# M[(V&8HM*253.@%R$SD4W6&]1051X($_3,;CGT'CX-(F_51:3&:PW($0TM@ M98-$ 2Z;.6X[Y02.(!XGGN_[6[//@M62D+X1:DE.E8TP(*AT
MDV$].MO!;)1)2(A2&B// M'R=P+PVKGGFNW7L$@>?GN3=.HFY.H%D([QA7\,"JQ@7@C*^Q/%6D]#,8. Y/ MX&S+D,X_H1?'F9T1=)CG6Q0AR5(O\$-(@[$7IGI';O;B\QS+-/>2>.SF@9_1
M/'>NN_^7B-UQDJ-,0=\X$_?A%[3%QK.NUOBU07*(D?"U8^A3::\J2L8A8<"<>BE0Z%')(C1FL[5H7%PT2Z)MC\.U(:B&ZP4U2#-T M/G$IOV/5??E\R-)W&<* MJK*:MI0NM=]1BHN"_MWAA8X1+
(1J2^(1+2FEK-7M3@,_ M_86*KW(BC\@4H.V.N_62 B8:'F@;2=\VDA>WC0^" A8II-^NR7L:+:.7M)*# M)^QO>_U1^'342]J'7=!<&U?DVHC9=*DSBF!%+M^^49!KU[L++M&L\;9FU](E
M!O^>TQ&$7AID6V/BA5'4CQ0K"DT7AGTQIM?G)22/(\BCF(I%FKMG1N)M(6<] M0IM#NJ%_PJYT!U2H BI"OO5_DI]V=XDG[:W]_&/3,VYT%#AC$3]8491HMH[M;OMBY-+=*Z?2T"W531?
TMP"5W4#?9Y(LU[W8 _H_&I-_ %!+ P04 " !D MA 59/?6NU7($ "/# &0 'AL+W=O057DI0=5ER^>T(M"W%W:+G6>N J7V;:#/1'PQ5?XC7JF]6E)*N_B9+F)58J%Q5(7!Q:8_?@R#?S MFPF?
<[Q3C_I@F,R%^&*,T_30<@P@+##1)@*GYA8G6!0$,'XVL6T-DL:Q\?] M=?1?&^[$9M"7XF[$^SX!"9>(@K5O.&NF^M8D-1* MB[)S)@)1E7K4MO^_R\!P'UCFP!G>
[4(/RF&L^&DIQ!]+,IFBFTU!MO E<7AE1 MKK6DKSGYZ=%X,KDYN_DTGDV/X6)V,KV"R<79Y=7T9'I^??IY"J?G9$^A-^/S M M7>L*]I4>/:3[H%CMH%V \6".%,5#I3,*U23)_Z]PGL!C%;
(SYB.P/^7E?[MX#DV,(?Y.^)YFPQX33SO!_&F7^MHC7Z\,X-G8\[/H;@/ZNZ^-K*L2T+A#$ B89KY:H(*]@G"1U61=< M8PI'O.!50N,T97PQ.873*BGJ-*^6,*FEQ$K#)<)-U2BXJ/4ZZK;$[(8^RQ 6HJ#*-
U!TLX>Z^L__1D@> MV! LJM '1O,U(SIW 'F2 6%##8Y+=FF;0L?UFU+$7#,GG",G]@*;]C M*>I'812^(V.1/7]P$QH M7K0]=22!-*=<4DT/;>+]!YZ;NSMR38.V]:U'3_'%L M(?
1#+]K1+YS?,JB0P@D^)>X$2-%0^(Z$]$\KI,.%[0I2>(69N>V Y= M"G2=W_]/972,"99S8O5$J8$=!LU&B6F_F8'8C@RM9\L4.K;OND;S ;.:#"+; MCX/GR\3L(PWBK36%JG",&Z>5TD5M
5$$)GA&@24>AM];13IC=5T[]E8D8; MF[&P@<%L9]">>9XYM5Y23JYO!P-2B)HX;'>AZ[R@H#P[@(-'YYZQMBAE#F-3 M\NOV=<5%YW6T7]T22Q1+INKL")X=:7;^^)F='/; M'K>7S(?
I[56=3L*E$;? !;DZ^U%@@6ROOZVAQ:JY&PO M=V]R:W-H965T]@D_[!?V."0BM#52GU@F,NYG_.=&9\]N^A7$BI MZ6F9Y>5I:Z'UZD.
[728+N8S+8[62.4YFJEC&&LMBWBY7A8RG%=,R:PO+\MK+ M.,U;G9-J[[KHG*BUSM)<7A=4KI?+N'@^DYEZ/&WQUG9CE,X7VFRT.R>K>"YO
MI+Y=71=8M1LITW0I\S)5.15R=MJ*^(I?"QWYF0\F2CU8!;]Z6G+ M,@;)3";:2(CQ]U5V998903#C[XW,5J/2,.[.M](_5;[#ETEG': M"EHTE;-XG>F1>OPL-_ZX1EZBLK(:Z7%#:
[4H69=:+3?,L&"9YO5__+2)P[

'%*+K^W.]2?_!I.+]JSNBG<3S) M9/GS25O##B.MG6QTGM4ZQ1LZ/;I2N5Z4U,NGW03%KN39;\CKJCR1N2[BJG!&:?E 43ZE"ZGF1;Q:I GU\QH/ MYOS/:%*"-M%_[0M%K\,-I_' . M2>_<
,+3=29)S>@\+>/YO)#SVFCLC)6.,QH ^->%FJX332/Y5>9K6=+D>;NW MSZ6#2O>[-%Y(FJD,+2#-YZ1-Y5!UFNMR8TBC/$:HIR_68N77P;W_=\H")@(.?D."[R N.] MVU%$CLML*R0;ZMV H?9KD

9NK[/71;.]9D_&A"\ R*L.9I8R.I+;UZO*!6-,F>$WXVX'QNYWL/T M:;R8/GDPGS=2;PP7,>:<&68P KV": M;#C/8G7#.Y*"GP;P"5.***P(3L!%)-KZHA$H7]-HG?H,!=)LAEEEB\(M"M91 MNH9I2AG)>"LR"F^'NPMF'<_@ 40J+$&>4X|"!SG@11"KZ,D_X M>I^P]4["-MSAE(44O#1 08._>]R_<\!?Y\4O&+!>&;BVC@+^FJ678!LML S+ M;3C/Y'1WNRF=[XON?
/7T2C'LHAUMB>>\UXZEE@D[_1'F_1&]!<<5_/CY3)+ MLEA:B2Z$,]&!YRV8(=:"B4]#^,C%4+87:L&3]3[@G]_MM@PB/PB7!"Q==WK-- MK73TL$++#KRA_!-!0XR)-$=DB;?
3S3V;'^*6)1Y5@KDHP3Q%8A7&G8-R1Z/87 M&2_^]TRF?#')^X$4X82^F<338Y*FE2"N2K!/$5@%9K:!4WMDQ_,JG!7G[&:
MA#>QM0_4D8'$>\QV=&'VC8&^+;/08&1UJC;NH8UM.E4;KP"Z5F%4:46G:(6 MG?^'2/';L"$XR/A_68*V*,V:9>KH<;^V_U6"N2K!/$5@%?='RY3794T MJ01S58)YBL J-/4*FGK_E4SM
[7+ZF)WS9L'1IUNMV:3!W:6%;;JNG4H9%C M.MUFG>H7Q>B?7(R4OW!_6:N;ZG TQM=VK4HP5R68IPBL0I1IO'V%&3<]<7O(0 MBIA2BN8J1?-4H57)*GTRFR<_5R=IR#:R91Z\F9AVSZSIPJ3!K-
OIUQ2FP<@R MVTY-K+P&LPO;[CLUE=%+TX0$D:43,EN3TX@U^/Y>Z\!E:3!)BM.*AC,LN%T2R'_7L+QC>R%G&,V8,)W(O'C] M1!CP^RN,V>N%"% ,W$;_E!+ P04 " !DA 59L B$]! " @! &0 M
'AL+W=O&FN,G=E.L_U[;">-BM3N2^.S[WW\GGUNTBK]8I M"T^5D"8EI;7UC%*3EU@Q,U(U2K=2*%TQZT*]HZ;6R+9!5 D:1]$-K1B7)$O" MW$IGB6JLX!)7&DQ354P_SU&H-B5C0-H<#
<>@)SGSTN4 @/ M>R89MO3"X_&'_CG4[FK9,(,+)7[SK2U3\I[%@O6"'NGVB_8UW/M>;D2 M)OQ"V^5.W8YY8ZR]>K&++*RZ[+WOJS^%($,=G!'$OB(/O;@)/YT-EM^FO^$M _"#:\MBQIJ=00N-
GIF8YIL2UM$&]1Y*]?C6^ MB3Z^X'0R.)V\1,\6[E"?N=S!GHD&016 CPVWSY"KJE82I3WEN&-^"$S_I/;9 M>=#1,Z/[8"#VZ M]6PY]"]@l02P,$% @ 9(0%648[-@,A!@ H2$!D !X
M;"]W;W)K&ULK9IK;]LV%(;_"N%V10HTMJB;Y30Q MD%KIUFT=BJ:=/A3]0%NT+4P278JRDV$_?H>R*ED1Q5H8\R'6Y9R7XB->7DJZ M/C#^=[ZE5*"'-,GRF]%6B-W59)*OMC0E^9CM: 9GUHRG1,
NWTSR':D0V]I^+S[@,'O4FM$L4IS?*898C3][]@22*5X#[^:5*CNDR9>+K]?7UM67FHS)+D M=.,&2O^():(&]&P0A=$V*1'QDAU]H52%/ZJU8DI?_T:&*M49H5>2"I54R7$$: M9\=?\E"!.$G
;D^"72783Q.\G@2G2G#.37"K!/=I@M.3X%4)9=4GQ[7X$(B MR:LP/B,AK4Y$9)O\P&7G$F&\]]X' VACPQ#^_>?$*7Z!X;8%0D%+$U6K!L M3[F(E[;T]5 %R$5)$[REQ#X^3Y$%\]?
7D\$%"XE]JNJH#?'@NR>@FZ+S1A9 M^!6R+=M5I" TZ;\6V1@Y5F]Z]$\/Z0K2CZ4[[?0)$*NQV34VN]1S>O6 R[LL M%[R 7B/0E]\A +T3-,V_JM@06,8R#32MVE!H7@>:-
W,Q1'>@J2(=:,^9UH>FKJX?FU]!\ MK& 1""6HH@:+,* MHW!]<8*3^ IW=59H>V: M-]X<;TWK_'-&4@8U_P=N>]3G*U9 5X(Y38[NL(:D8 HBV(:-,-O D)8+-1NC
MIKU2.YW%+K&OF.V4@=AV^L$T=AN?[!=_ ;"OU6H.K[YQM+)6A3YUEFT#CJ['> M;!J8\/4E#.:BLM&VZZJX*$*#P [Z9WSLJY/&YWST+[HOECG]5LAY[&[? MU\B,^G"C;]$IM?8M:;PY]HUZ
6S4GAM5"TVIM5$V+A_K;7Z)DM,=>90DU8-] MUT_W3%T+?6&#T1A2:Z-IO#[6F_V?"73DBX3ET&59ANB#@#FQB/-MV>;*";-G M& PZP#J@C/IR4VIM4(TSQUK+.L=CVQLX/KXGCW)(G-
:#XU2S(-(7/[CI&C7S MIM3:CUH;-V]:9A^V&C7S1M5"4VIME,YPZ'X^C1PDBO-YAE]3("MY<[V/;> M/TS ML$3A[V;ZFVT@?WCI2V$E;;R> _X* H.KI$ M(5W1=$EY_6(1+4E"LA6,J@?*)28>
[Z%/K3E+D;0 I(AB.=A">\M9$D?ER/L6 M;$2VBH'IO1R*2X<*[F&5%!&V?W4'=T)U M9OK]\X-4\3OXX7WA& B+$<)74-QUG@*-Y\?OP&PO=V]R:W-H965TIE/1Z(IQN)=$-75-
Y9]SJ,1AYHV\IXV/;+/59L-/ISNZ M@27H3[M[B2N_9RE9#5PQP8F$]+?'A90588(W?C2<7K]E<;P^/F)_7NK';6LJ(*%]'YCI=[.O&N/ ME+"F3:4_BL,/T.D9&[Y"5,K^DD.'#3Q2-$]+NC-
&#VK&VW_ZV,7AR !YW 9A M9Q .#>)G#*+.(KI#7%G$+_TAG%G8*7[K78;N(QJFDZE.!!IT,AF'TSTK37& MBW%3)TLM,92AG4ZS?/Y OB5+K+^RJ8'(-;GC&B0H3?)'K$:%>YPL!-^#U&R% MD
O6FKS-0%-6J7=H?'RX!,Z$)#\+#0J//BTS\O:-_*&,$X>MJ)1E)=JZFMT MW3C@%YV;\]:-!DW(_)!<+U5).OY#U<0N?XC8/+Q+^V/ K M$@7?D# (8X<_BY>;1RXY_^_V_#_??
A*[^"BR/)%S_#UU?/+>?4H\OM/""=W M&FKUAROS+7?LYC9]\D;M: $S#ONA KD'+_WZJU$2?,<*^VN29:])EK\2V4F" MXCY!\27V="&:';[%["DWT,;&E8V6*+%$YB.S3\-D-
)GZ^^,HOP24G8/&812= M@O)_ 9VH'?=JQQ?5WA:%!/L9PFY6,E6(AFO3Q8JC1L5-AW(%H.4>'WET'0^\ M7C@P43R0?XX9)=<#4.X"39Z1G_3RD\OR:X$:_Z)]!$R_9DHUE!> ,5#;J3LY
M=R6^'NAV8=X/=)]CPO>#TL@O8TY43WK5DXNJ'X2FU5F%#[-N8N$2/SDKPR@) MANJ=H& @_QPT"4?#M+M P3#M_M%7O0:YL>.4(K:;V][<[_83VZT=5 ;[\]'- M8N38SW#*:P>R?^C;\?
#E1O&%:E@C5<%5O-.E6Q'KG:AQ<[.%"NA<4*QCUN< M4D$:)ZO!;Y>W<)\@P LBD !D M !X;"]W:W)K&ULS5I=<]HX%/TK&MKII#.E6/(G M;<). H[3W:;-A*3[T:D
0(\ZP_6%]'97[^2<3"69$&VGLR^)-B<>Z1[K[@Z MU];9)LW~RI>$4/ SCI+\O+.D='7:Z^73)8EQ_C%=D81],T^S&%-VF2U^2HC M>%88Q5$/&8;3BW&8= 9GQ;W;;'"6KFD4)N0V
_DZCG'V=$FB='/>@9WG&W?A M8DGYC=[@;(479$SHP^HV8U>]'G M-'",G9);&KA%LK;1+5(SPA0/SK)T S*.9FS\0Y'?PIIE)$SX4AS3C'T;.,CLZ MN!@.'VX>OES<^R/P[?
[:OP/#:S>W=_ZU_W7\^;L//GlEUSXX&1&*PRA_#[K@ M83P"\V_?@[<@3,#],EWG.)GE9SW*IL-)>]-RZ.%V:-0PM ENTH0N<^ G,S)3 MV/MZ>T=CWV-AV.4"/<=BB+2$OZV3C\
T/@#[D($LQG]'QYJ;*G5\;/?C/H]>" M8>X6AEGPF4T+X]OP,[B@- LG:XHG0T!;QU./P4GN:K_"4G'=8+A;?7KN*L#DT6JR0;J21@FM*O)UL)K[\)K M:T?[1I1CC/PWDSE MQ7P+5I;+
[23LO=F;AN>X0]!E5-@Y/Y3Z9@7F6QH"7%U4,'#D&T(-""&208PL87\8@VQ$6;: 8 MS7%LM??NSGM7ZSTOBF0^9U)+Y9\KC0AM8>F/5!A+<$ &.(ZP!@(9P[+K-KCG M[=SSM.[QTC]=9WP?
Z*Y(%]8SD![Z>:@"X M\,,)%S09=QENLA#PF.^$?R!8?Y M:AY#H]*,AM;G0AM@01NL"FV@E(%:MI&0YWKBMJ|" MF?LZIAZ]JB&!6@G=VLY3#G-HZU' 5'N/ J;:?%1LFMT'5LH?ZI7P$?M/R5!S
MV'&E[4+VC3\D&<%1^ ^3D@'3F#DX<<)239C, M3!.PQ/D27$6\YK,%@WOT/*_N+BUR>;WRA:TQ5;/5-4'0,>U]B-MQ_'BE+7) MYK?*%K3%5D]9U;Q ??=RU'XTA*K6PC/%@])
(<>2ZHD*UG=L;5^1<1Y"#;T] MK/H9J&IH7JFYAW+[84);;%M'"EC7<4TI9C+,.,2P(Q9 I>QZ[WQ2TJNF!^J[G M5U]*/6K!FOL\U'5!2%]%Z1O]OC_4-P<7#$/AP)-!"
MZJY5C032JM[6I%8Y3"T_GNE*@9!A7=<4A:6O@-FR< M4;:!##FR(2J75D5YF M'R&UD*Q]D0=%-3A2P/B#-U,4E\?!1?IZAY7DAOI);=6:ET\XC#BNW]7E)49,A7)$R:%"H3X2-
8<"9ME>@^Y"E3Q'>GG^*[H+ MR?I9VH@/0OS#D$ +]3M>J72D5^D'Q):L<^77*DJ0^%Y% 9)?K"A FC1"N;9GOB0\SBVX"!;W5\NO.MW*M%I'GRV"^Z7A!5"<6\ K#("MCQ 'O[L MQOPH#-
@NFAQL'*N9,W:Q^%P4. ZO9R%E-X:L3*91.,/AXBI,&%N((S"F[$;. MUE[.5UBTGK%O69WAED.V_G#R]Z-AZ#[*0<72;)F%G=DE6:4;T%^+ Q H_OI M:E)/!&> \),Y3!5.23QAR]B$V^,I8!Y&
[/XF9%/FV+$_ +$C()%OC] D@9WL* MYB,X@>\5YKL(_.]'"THRKYT-L[U163;%$UIQAN<+7CK$)$Y MF[:QT64U(ML>$-Q>T'15G$^;)2FP[^=I2L\O^ "[8YJ#?P%0 M2P,$% @ 9(0%615NS1JY! I!0
!D !X;"]W;W)K&ULO5A1<]HX$/KK.[3326:2V+()D!28(8:DW%U(!I+>0ZTU%X]R08B"U'(9*>V4&IY M85G27Y (RU.^)$S/S+B(L-*O8F[)I2 X2$!1:#FVW: B3%FMVT[&D2WS6.5
M4D;N!,@XBK!XNB0A7W=JJ+8=&-/Y0ID!]JM>XCF9$/6PO!/ZS>/YF48=&JV\B$Q%>& NM_*^*1,#1, MVH_O&]):MJ8![C]OV:^2X'4P4RR)Q\-_:: 6G5JK!@&9X3A48[[^3#8!G1D^
MGXQP*3//E%"SU*-4]WQX,M@ M]# X 6\\Z_OP;L=>9/1 ;AW/[P=3: WZL/UX/9ZW+O(//1@.+JZ'=\D<_ 1 M1E@(:+8-COI$81K*8W@/E,'!@L<2LT"V+:5]-"M9_L:?RI0?YQE_&G##F5I(M&+" !
5XKQR/G!("2XN3*>1L%;IT2AG_BMDIN/8).+93AX=)'XI>'X,D$SP5> M+]@/0Y8>$V;^ZS\:#D-%(OFM:)/2M>K%:YFSZ$(NL4\Z-7W82")6I-;I\ XU
M[$]%@E1$EI.EGLE2+V/OCN)H2@3P&>BCTHC#YC"-I;:2&5\9UE\9Z7Q]7R?QTQ)?0;[A*[P-"0GP$AA)"E38R^2 MQCER7.<@G (SUVW:]:Q9O]ROK^A;272-++I&*N7E>ZJ8G M2$
5%&SB3\A"&&@Y_,F*ZV"\?U".7@+;!^C[C> MS>;U/E# #,Q(2Q:;.)LYM'FSH((9-B4[9*%R2U3OEGZ_NNZ/E%F"/N8"9?- MV3@46[T"E8FC]EX5 =3G@:)YH&P!\KG4?VS.ITB.&V#+Q6AZ1\4.!-;
MM/E[HP)F&89%FHK0AA%,"-YE'RJC1+]CE,;#R_[U<(M.-1["H*6])Y=Y8[8=]Q1].P'Z3/RPQF*TH5LO+@8I50F#/KT"Y3- V7C4&SU MLFP-,NYWDA%VE!%VEA%VF'$?;H]5;H^]>9Z1M4<+7;?
Y&^% @2+8M)NC"PH8 MQ6[3:W ES+2LADITMX;Z93O-\VGZ!$VC=9ANIFW+O>7$?C^?4V_L/R8' Z+8 M[Y$#OIG'K^@W_QYPYL?S99B@0-S)0^%/ME2S>#-QO]E(H_M\!/PV2F6OYV\7 MPI^).
/(S^^B*'W9R Y0_M]#[S\02P,$% @ 9(0%666FYT5 N2LR^322<<5HRKZPZP?V M'DVFS+^\1Y.;ZPF[OI^.[R]OKN_0^-I'%^SF8CJ^_70Y09?7'V^F5]4S] NZ MDZ.V7.4ER%O?
5X$49R_D\P/=SYZ^^8=>H.B%-TOQ"H/TC _'18RX_*] MA[.ZN -U=F1':=A1=B:18Y(BE(0\5\;X^WM;$#V5/;[]:O;'W.=$2_K9*/R!J MO$?$(*;B?28 'DY5Z?R_UMG!K;4TU;ZFM) DRF/&S@13/G&?/?
##Z^2=L&[^JNAR2S(*8F^*8 M.O9170I5[Z\#[2]P_(_H>>1@.22\T^'S=K_V899G$<=]P_P^#%/;<&W2QC$% M#GO8]HP-KI6GM%, ^ MD@K8D,6!)/,AR1@06:LXSJ8XS]$]L ZTMN8C=2W+[8A
'V4:%'=0?A_E4)<8 M'050H$R'8/7\=S<9NMH,Z\6)*D-MX+[C"Y+,AR1C0&2MWO\=:?)[D,6! M)/,AR1@06:LXV&C,@7'H]*C6[/1(+BW"E#@=+->TO:X$*"'84L\SS8X*[(#8 MP9B8:B' 6U8(:
[.]"K*OO.!AZ4\F(ED&Z7?T[ZM[R1' -HM7893.D7[-H&]E MWZ$)RN:#LC$HMG:]2%,OU'D4K(+0WCVV: M6@[N"D@?9YDF=8VN@/1QF-CVMB[47:(&IXMUR4[!*2Q3%COF0X0$/G\(8W*
MF+LB*+CZ&X>VU;U'*R2;#\K&H-C:]6NL(+:.)2B@1A&4S0=E8U!L[1(U9A%K M[8Y64.S>O";$,BJ2/*S\D6-T/$PJ<20S3=+MZTL=1N<2AW@XY:;P7UINO
MP^2$K3Q5'>0MKF]!RDDFP_*QJ#8VH5K+"5VCZ4CH)X3E,T'96-0;.T2-;X3 M'YV35D<\A8X8GF=T=:2/PRXUJ=G5D3[,O+9#>SK2QU'3E&L8M8Z0QL41O8L[
M3$<^R\&;HG'"LV@6J/I)W^J^8Q64S0=E8U!L[?HUOI3@(\D) :6BH&P^*!N# M8FN7J+&B1.NC=')21VY/;U=.Z^Z'4@7,D3ZG*R8*&+:I@;N[)2J<2;%'=HA)
MX^B(WM$=)B9741C&'+$@5WYIU;>Y]S@%W=$#96-0:,WJ-0Z5F,>2$E 3"LKF M@[(O*+9VB1H32O0;DCHIL?HK"<\QNE],%#!B29'H2DD?A@W;<>RNE"APV"'. M+BEIO!S1>
[G#I&3*\Z[X]4D$W!D'9&!1;NWZ-/R7.L<0$ MU(F"LOF@; R*K5VBQHD2_>ZF3DS<_KH$&YAVO:0/LUV"G:Z8]&'8\K#5W<-5 MX2BESH[-&]I(8.]W=-MBDXBF26]'?]-
$S[CT*03<10=D8%%O[F%=C0*EQ M)*&@H!X3E,T'96-0;.T2-1Z3ZO<^-4)11VZ?O%*=]%# 5$<]%##560\53''8 M8[AU\C7AV;PZ M+\H&-H?#1 .\!4$L#!!0 (&2$!5GF*_"WZ@, #\6 9 >&PO=V]R
M:W-H965T>2C5S[@.]P3^L(V&'/P M/4TR-C(VG&_O3),%&YPB=DV%1,C*T)3O$63KDVVI1A%A5..F(YE]DIPG<887%+ \31';XH3LA\9MG'H6,.K#9<=YGBX16O\B/F7[8**
MEEE3HCC%&8M!BA>C8R)?0=M3SH4%EICO&48,^R3Y.X[X9F3<&"#"*Y0G M?$GVGW 54$_R0I*PXA/L*UO+ &'..$DK9_$&:9R5W^A[M1 G#H*C=G]!^?<
MP;O@X%8.;M<9O,K!ZSI#KW(H0C?+V(N%"Q!'XR$E>T"EM:#)AV+U"V^Q7G$F M-\HCIV(T%GY\O(1?X?P+O +^$@:S)^__S'TX?UI.GF8\T%C>%V/@3_
H=FV4)QB0%7@B'"5@+G;V@I(H#SE8XAW.<@Q\DH4X MXQ3)C<' A',:/^<<1X 3\!G1-68<^$6DF#+P>X YBA/VAYC@T-MD@&7,7L2H M8K*AR<6:R,C,L(I 6L;O7(C?!?O;&8KCU[G0+GG>!5V^
R168@GEBJ=3%9VP0"<,.H(U5.G5JO3;3TA#%2I4N0): M3&6?>)U7B5+R//((R_\N[%U[?:&YNYTM=56@Z95H+;RFE:PM1D:@??KP/L= M4X,JR%;?M^X\G:!)PQJ@C4$&-0"#'3G@X%.573" ITPJ
G64.6F5N5&)X8*9^L?VK?^:;B/Y#5T;(=\27I=5[1-=QQD"'"5V(JZWH@;C^TK%:6 M#4ZV13GNF7^1DHK'#481IM) C*\(X8>&G*'N&8 _!U!+ P04 " !DA 59 M011S2 L$ @%0 &0 'AL+W=O8F1./=:
(98$& ,5Y&E1 _<*'.A$M \XC-[!] ZMOX+0@8-<&]FL],+6!\UH/;FU0AJY7 ML9>)"R&#TS'1T $FK.)AS+I37/5UJ(C;)BA+]-N1V;KFZO%W^K* 2+ MZZME]&4UN[V\ @(^AHC!-*.?P!GXN@K!QP^?P
>0%N VP7L*BYB.=<87(&CT M=>UL7CFS7G!F@RMW9>%\G_?H?WOO),-NMH)=\MDO;84$$G0FOKH8+'#.I8C"\F.> M$0*++>+RP,#=(VCCEO"QG)X=
(8G!/W]R2G#)4$[_E>V.RK\C]R\D)8+NX![- M-*YY%)$#TJ8__V1ZQB^RTJ@D"U6218K(.D5TFB(Z0^S36\O@!KALK_K$]W; MI40/XAG)BE/Q>B6O^/=RF#I^8/)]>6AG_13E&J9G=5'A*(?E-
$_P=I2<7KMCYLV-?[4G(*%;F$9)T ?M3A)\#/U+OO/:4A3O(:-])(L5$D6*2+K ME"-HRA&\LZ $*HNHDB04218I(NI4T32>NPWC!TE*3=S^R$TKL-V>],A@KN'V M8*$$9MN>V3O'1#*8,QK9JZ/IU
MYF"[!3V*8Y^T)[9I&2>*(X'Q+L;K*\XIS'-=N]\226!N$%C]PXS>NO')$=F6 M5VV4A[8O6-7O-[/-==ZLO,3JS<_-BX4IF0_%]5]YP_1,7]T=7D&R30L*,K3A MKHOSGZLCJ:
[C]@'#N_*^Z0XSAO/R,4$P1D0 ^/L-QNQI(!PTEZ+3_P!02P,$ M% @ 9(0%68*>[9)W @ ;P4 !D !X;"]W;W)K&ULA51K;],P%/TK5I 02-"DZ6.HI)'6;K A-E7=RCX@/KC);6/-CV [MR_;ON;;;4*:M?
(E?]YY[!HF/LU:I>U.\6/(INM+33J+*VGL2Q*2H0U/14#1)/ M-DH+:G&IM[&!=#2)PD>ITDRC@5E,LHSO[?0>;8:RYF$A2:F$8+JIQEPU4ZC M2K3?6+)M9=U&G&+P '@W $AC=\[S*@KZ1((YWOT+
[YW[&5- M#D^RDW5N,IPSR; M+\]O:I>K^>UJ>7G]E7PDUU1KZH0B[\[4L;-]Q-DW1([E!>O 4%D"6431!U MP;G,8HM$%Q<[(K.0M'TE:C(:?S6RIX9 M)\"41 U5T\ 1X
'G3P##SQX31XP5F.OC69R2^;*6$)EB0(8T*C1S^\83RXM M"//K)1D"^/!E<.>WB:EI =,(#>41H_SMF_XX^7R$^K"C/CR&GE\W8@V:] VI ME6'N;QD"G.$=HO:YZ(%MP!MY/&?
FA[Q_DF3QPPLD1AV)T5$2"\#[(BW:VQ%I MNQL$CS7:$DIB%5G#?WB%$OWT@%C22T;/F,4)A"@M][JAA2JD3;KH=OM7I/3 M8**_X>$INJ)ZRU N#AM,37HGR$ '>X>%5;6WU9I9-*B?
5O@8@G8!>+Y1RNX7_MKD#WQN9_ %!+ P04 " !DA 59$-\3_/8" +" &0 'AL+W=O ;RFLY,8WT9$\SZ;7Y/CH#3DB*2-W"2\EZLF^K3 &[<2.:K]7E5_W!:\>N>5.)9+< ML!CB%O[P.-_P+GI&SWNI
MGELUTW6J"R=!+(%_XQX,E*0RQ]MR:_$N^WBNJ-V6[OTJB MMW'SN1]T=NS] ;3ESF_<^0?=?54)B#9'_MYEO5[G?,?1/BC8!&TY"AI'P4%' MV\\=GG"X26A-
6K!7+N_<<7>+NH_JNEU_MZCV1K_-02S,&()(DXB535>MM=IM) M=VD:O/T;7HW)6RH6*9,D@SE2G=, \R,JT5,M%"];]W[@"F>!^4QP6H/0 #R? MNVDI@<1F49ZIO>:&;LY0[
MLTEY;R%G$U'H+.6PD$05><[D_1PRL9\ZU'FXL4PWB38WW-EDRS:P GV[74A< MN0U*G.; 52HXD;"<.I?T8D(']J#<\3&%O3[X)B:5.R&^F,6[>.IX1A%D$&D#
MP?!K!U>0908)=7RM09V&TP0>7C^@_UXFC\G<,057(ON4QCJ9.N<.B6'-BDPO MQ?Y/J!.*#%XD.E5^DGV]UW-(5"@M%CH8%>0IK[9M[H0!P&^WQ/@UP%^J;LB
M*E5>,\UF$RGV1)K=B&8NRE3+:!270V:I9EZA=M]SQ^23UAW/!\1 M8$1<5-5>9(R3%R3EY"81A6(\5A-7HV!#ZT:UN'DESN\1%Y(/@NM$D;<\AO@X MWL5$FVSJAVSGOA7P?<'/R,#
[K=)]N[HF+U^\LN .FBH.2MQ!7Q6/*H4KD#L@ MGYGCV3\3]=Z5>HPVY48\@+M6413!UT7(GIS'[JA8;>&XOF8;-Y;$.? MS6&34-[;]5=P0ZD82PK+2%C&F(2"=6=NA7LB0=QW$@=/XMYQL^@
MF7IMW_3^NWUJC.#' _J$'#9O^7PZJD8Z.5N"/@AX)?BO!?[*)ZM C%PU[743; M#DNMS? 1/JH!CK+UQL&PA[GMD]3>*/_6"&PO=V]R:W-H965T M28^2 7B5S^_5NLDP5QDZJ;*0XS$[K?:;Y>5%DZ?
6/[UY0*])PF&3^;K878 MG&@;#]BLM5DJ=J]?T3]7SH.S=X332Y:\B".O/INY.Q31%2D2< MOM#&(:O$"UG"]_HJ9'59R@LN&!HPPK2..L_B7/#1$=!<"1*QB-@C%4F.]0 M.!L%WUU^O_UZBF^
677Z[NOIVC99?SF\#!]$M(2NC[J&(K= E2S>% M(%5P87A!>]PBDD7(CY-"T @%), B[]ZC&YJ7TBD(+M9>C.$/?LUCPH\[$OVM6<$"'R?>]\:DFP.ERZ5K8.'A1.VCL M<-!$5RP3:XZ"+**11-^?
UK&7\PI@$_*?(CI&I'R%#-^:2]5SN MKV[*W/DSZ\&;K??(,-OT,RL\=9'2G B6G\@B^O.Y;IE"3WA&Q+2LQG4 M2$[S1S1;?'B';?V3C%:58+Y*L$ 16 \\S8 \RGTQ37L15^SD*7T["RX<2B+
M0PUA5Q#ESO.XP+]#'7,V"TS]MZ) M$-4U7>:H+0F+Y\W-@:MC,Q+;G#3NNP,UEZ?)HQ MV%!W%A]'9?%1">:K! L4@?5"X+8A<"=S[D=UC*/11P(/&Q+X5&KS@W-00#. MM5S
K@_'BJ8XH8/X]>ZA+&;N^,'P=(R'A4HBYCK>?/"8^3(Q;^X-"EH@13,Q MEJ>GUW+C3:9GL%K!6;JL2M73"*=IQ&E8Y+&(*9YJ'KEFX-LE8BAR$=O6':RO'P<*L)Y'B.91=-
"0@,*%JA"ZP=OVU3@N>+-"T^V*;\=&I5HOE*T0!5:/S3:!@A/=T"3H?GE M5B7I+JC M^[/J.NZD7-,L/-5MO' 5 ML$WUZJT0 "<_+ 9 >&PO=V]R:W-H965TZ> K#3:4W?
$50@(\)"GA0VLEQ)K"MGF\0AGD9W2-B&Q9 M4)9!(8ML:?,U0S#11EEJ>XX3V!G$Q!H-=-V4C08T%RDF:,H S[,.LL=+E-+- MT'*M;<4M7JZ$JK!'@S5,>35":*B0YCF\[%7Y5(;[[UOT M3WKRP82I]G
PV\0X/.,P9^;>" _UD.G-.B\UD.W--!3MXNY MZ\"%4,#!@-$-8*JW1%,O.OK:6L8+$[509H+)5BSMQ"@;W]YFY(-K2L2@XC(4378A^WV08N]+<-;O=C; MQOC2:P7\-2=GP'=^!I[C=1K&,WF!N=\TG?
_F/?IN[[5@^-6"\S6> PR>6DC) M=AW-4)P5++#DO'45-:R>OWZ3P.!*H(S_W;1&BE%TFD>AY/>"KV&,AI;45X[8 M;/)&[]^Y@?.QB2"38*%]L.@06(W*3D5EIPUI]4*F *29W/)BF1I3062[.(T M?
028\OS.I7:46_I$[NGB];2)K<)15SM2_VWW(]?Q V@W^_3T-#+=_INO5?8 MA.4Z0;U7U-#+" _J[7K6(=*N(=%LC\H-SUCT _O%P1#!5?\=SRA),H%+ F))[MO 1602$R4APD.5)2-\Z74N?
U]@0G8H6*MQO5Y13\([?"SFY6X.JVIC"VCN[8 M16\2+#0)%AD"JU$<5!0';T*_ I-4F@0+38)%AL!J5/8]*GNMNW6ZU:OJNT.* MEF00+[:,519>$*Y6#\?29!(L[#T1N([C.
DZNR31^=^5LMW%L4P910M+M)I8=IZ(I2?=1+V.G6WE80RZ>8ZZ;Z^KW.9 MI#*@Y%#M)4@>2^(?C&A4\T0OG4)^>=NGX M0?=0GUX$BEX"!}A]UUZ9(@M)6V34I2&ULK55M:]LP$/XKIX
02%.3IF]LM)&V M=L"06J9U@P^(#VYR;2P<,]A.N_U[SDX7"F052'O]I+/O[GD>G_CG=+?3(YH MX;X0TDR"W-KR+ O-FF/!3$>5*&EEK73!+$WU)C2E1J9YIT*$<10-PX)Q&21C M;
[O6R5A55G")UQI,511,/UR@4+M)T T>#3=\DUMG")-QR3:X1'M77FN:A4V4 MC!Z_ TLI85>R="4'!9?UG]WL=#ASB^ F'>.\0>]QU(H]RQBQ+ MQEKM0+O=%,T-/%7O3>"X=(>RM)I6.?
G99/IQ\K~ZG5\N;I=POIC!.]/B]FKQ M[G(OQ;I07/@4N8Q%VT,U.R M%"HM'1)N)9=QB].4*AWU#H'XN>-) ME.RAIE*5_@;D'+?H+*#6D**F MPY54PUNZFZ4W.H>-Y5@5NF^LYPZZB[E93$09UR)L
PL3<*GKH[*C=4GF2S M2F)K@=2@3SUHURJV2?ITT!F.PVT+UT'#=?#/7*DW&2792CQ J8SA*X'_@?]? M0C>&PE=_FRPUOV[O0)=NU#EMEV78R#(*LMUI=.<>I5'
M79=S6^XZR.#P2$;]]LRC)O/H7S,;P/N2FC!FA]J0\.[]ML$:_5$I\6FWT_T- M6'C0].AD-KZUNW,JI*W[7V-M7H_SNFG^W%X_/7.F-UP:$+@FUZ@S(DETW<[K
MB56E;Z$K9:DA^V%.+R!]MX'6UTK9QXE+T+RIR0]02P,$% @ 9(0%683) M@VY) P "A4 T !X;"]S='EL97,N>&ULW5C1;MHP%/V5*%VG5IH:0MI M5D#:D"I-VJ9*[*D,
M=#N=.,@)$_YH(!;Y3:XJ;UHLA!KZ_2;DV=.W=.B\':7O6;EQD=*A_W#\)?>B M4-Z0Q MX?ZV<&/D5&NUMDXQ>N*F;[$Q34>R1\Z(\)9Q/)@)61G/&5#7&LBC(4*DBUXV4D5DAB/&P9M0-
M+3NEG-_!T^%7MJ6]$#;6S"RT:)K:4-VT,K8#^IMJ5GM3[O)5NE[)'@OU=:&' M(TP?[@MZ*VG&EJ:_S!H#F'J[JY.RY*LOG.U$3NW@#TXX&I USYL7DCWI;% J
M4QV@TO<>]51LNAGY(TEY3Y=]74[+#/?9U102?BF:5W[IWF67^TX MZKV59?-4V37L]%B_\M^[R:MC,!D?@\FCJ,G^,9A,CL!D[\V>FB\Q&,Y+DT&] M%=K8:VWMMIJH![O:H?\3]L>\3>I-
%HPK)NK>G*4I%<\V75I>D8G^1V]+7U^? MTHPLN+IOP*?MG_0E"WRI+GJ%B:BOJIM?X?AA7&SI=:YF$CIDJ;CNBMG$]T M=$-GK0\@["(WYG C&,=B;@0P+ _F_-8%I;G?QI/'QV/Q3!O?2?

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
3C46M MF@N88:I+MD9"3$PU%K%]<'"#*LC"5&,1JP:'[/5-3#X6L7QP3 =B8O*QKKE4 MlGD,,3'Y6-3R03%OX (X)A^;6#X7BTI?-*F$"!"GL=,KX6Q, M0/:?F.O*#
($]];.]\I#^V!9@\#U4QL3D$TLH#.80=D()>J&\:\[B(D)R"86 M$#Y)Z^4B3$ VL8#P21K$=# !.>2S'PP3IDP'$Y!#+" <$Z9,!Q.00RP@'!.F M3 <3D$.]XG9O9MZE3HB)"<@A%E! 9OY+BH>8Z L"?
_*YSD\)-.HM##J8A1QB M"Z&8 ;^P$,LC : >&PO7W)E;',O=V]R M:V)O;VLN>&UL+G)E;'/-VDMNHT 4A>&M6"P@Y?LB22O,]">91MD @'O0DJC-"!>+RCSX0\/"<#]VT[T]EMQ_*XN-
X.)55LYNFX5=* M9:W+QZ[<]$,^G8]L^O'83>?EN$U#MW[KMCGI0_V=B MO]GLU_EWO_YSS*?I'X/3>S^^E5W.4[-XZ<9MGE9-^CA<=Y=TV7*S>'I= M->/3JS2I=I!"D-8/,@BR^D$.05X_*"
HZ@>U$-36#[J%H-OZ07<0=%<_Z!Z" M[NL'R1)E7!(DS; FT%J0;R'P6A!L(1!;D&PA,%L0;2%06Y!M(7!;$&XAD%N0 M;B&P6Q!O(=!;46\ET%M1;R706VBOJK01Z*^JM!'HK
MZJT$>BOJK01Z*^JM!'H;ZFT$>AOJ:01Z&^IM!'K;[&4)@=Z&>AN!WH9Z&X'> MAGH;@=Z&>AN!WH9Z&X'>AGH;@=Z,>CN!WHYZ.X'>CGH[@=Z.>CN!WCY[V4V@
MMZ/>3J"WH]Y.H+>CWDZ@MZ/>3J"WH]Y.H'>@WD&@=Z#>0:!WH-Y!H'>@WD&@ M=Z#>0:!WS#Y6$N@=J'<0Z!VH=Q#H':AW$.@=J'<0Z-VBWNU/ZEVFST,NUYZO M-5[_)ZF>SN?
FZ^4ORZ^=>+]H+S@G^'?G\2]02P.$% @ 9(0%6732QF+> M 0 6B. !. !:0V]N=&5N=%]4>7!E&ULS=I=3\(P% ;@OT)V:UCI M%WX$N%%OU0O_0-T.L+"M35L0_KW= !.-
$@TFOC=:MK;G/6N3YVJ3YYVC.-@V M=1NFV3)&=\-8*);4F)!;1VT:F5O?F)@>_8(Y4ZS,@I@8C<:LL&VD-@YC5R.; M3>YH:M9U'-QOT^M0V7::>:I#-KC=3^RRIIEQKJX*$]XV[3EIY3A(2%/*_IY
M85FY<)$F9.S+A&[D^X##NL<->5^5-'@R/CZ8)LUBVYJ%N*LIY*=+?-&CG<^K M@DI;K)NT)_.DRG#DB@V=;XO>G$Z.:8=IOV5GYW?ESD5F&8^>>M".C%/OX\[M'DFW>NA2(?*Q.OV)[XFI]-
G?1]UIEU3^,#MM[ZOUJ_X\ NMOY^_QQS-^K__+ M/@1('Q*D#P72AP;I8PS2QR5('U<@?5R#],%*(V@B,I12.4HIG(45#F*JAR% M58[B*D>!E:/(*E!D%2BR"A19!8]L
D56@2*K0)%5H,@J&05*+)*%%DEBJP2 M15:)(JM$D56BR"I19)4HLDH4626*K I%5H4BJT*15:'(JE!D52BR*A19%8JL M"D56A2*K1I%5H\BJ4635*+)J%%DUBJP:15:-(JM&D56CR#K^3UE?
K%W]]=\> MW3UO3-4>\UG_2\WL#5!+ 0(4 Q0 (&2$!5D'04UB@0 +$ 0 M " 0 !D:V-0&UL4$L! A0#% @ 9(0% M60&UL4$L! A0#% @ 9(0%69E&PO=V]R:W-H965T&UL4$L! A0#% @
9(0%683"ROM;!P @", !@ ("! M$@X 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M9(0%69_1377>"P PFD !@ ("!+" 'AL+W=O&PO=V]R:W-H965TSXGM0< -L3 9 " M@0Y4
!X;"]W;W)K&UL4$L! A0#% @ 9(0% M6&PO=V]R:W-H965T&UL4$L! A0#% @ 9(0%6=:U])V[P V@< M !D ("!0' 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 9(0%6<[X5/--!P BA !D M ("!H'\
'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ 9(0%64'H3%^?"0 IQL !D ("!5(P 'AL+W=O M&PO=V]R:W-H965T/7&! 4 L, 9 " @8V9 M !X;"]W;W)K&UL4$L! A0#% @ 9(0%6:>X M4#&O!
N L !D ("!R)X 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 9(0%6>!HR3)*!0 = P !D M ("!WZP 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ 9(0%6:[9][8R P KP8 !D ("! M!;T
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ 9(0%6=OZ+@M2! GO, !D ("!X<@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 9(0%6?LW0>W4 @ RP8 !D M ("!9>8
'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ 9(0%635"Y7OV @]P@ !D ("!\?(M 'AL+W=O]@ >&PO=V]R:W-H965T&UL4$L! A0#% @ M9(0%60M(E+87! ?!, !D ("!K_X
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 9(0%6>-TF;1, P M PL !D ("!G L! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 9(0%6:=^-D>(!@ S$!D M ("!YAL! 'AL+W=O&PO=V]R:W-H
M965T&UL4$L! M A0#% @ 9(0%64$4&PO=V]R:W-H965T&UL4$L! A0#% @ 9(0% M6=2?%)9S P SPP !D ("!AC&PO=V]R:W-H965TJZT@0 "_< 9 " @;Y 0!X;"]W;W)K M&UL4$L! A0#% @
9(0%64:+I98" P 7P< M !D ("!OT4! 'AL+W=O&PO&PO M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " !DA 59=-+&8MX! M !:(P $P @ &75 $ 6T-O;G1E;G1?5'EP97-=+GAM;%!+ 4!08 1 !$),2
"F5@$! end XML 74 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w)
{if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref)
{e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function()
{Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var
d,p ,if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent)
{a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}} XML 75 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 77 FilingSummary.xml IDEA: XBRL DOCUMENT
3.24.2.u1 html 283 238 1 true 73 0 false 6 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.bmrn.com/role/CoverPage Cover Page Cover 1 false false R2.htm 9952151 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Sheet
http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statements 2 false false R3.htm 9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 3 false false R4.htm 9952153 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet
http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 4 false false R5.htm 9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet
http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet
http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 9952156 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIES BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES Notes 7 false false R8.htm 9952157 - Disclosure - FINANCIAL INSTRUMENTS Sheet
http://www.bmrn.com/role/FINANCIALINSTRUMENTS FINANCIAL INSTRUMENTS Notes 8 false false R9.htm 9952158 - Disclosure - SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION Sheet http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATION SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION Notes 9 false false R10.htm 9952159 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.bmrn.com/role/FAIRVALUEMEASUREMENTS FAIR VALUE MEASUREMENTS Notes 10 false false R11.htm 9952160 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES Sheet http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIES DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES Notes 11 false false R12.htm 9952161 - Disclosure - DEBT Sheet http://www.bmrn.com/role/DEBT DEBT Notes 12 false false R13.htm 9952162 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME Sheet http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOME ACCUMULATED OTHER COMPREHENSIVE INCOME Notes 13 false false R14.htm 9952163 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION Sheet
http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATION REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION Notes 14 false false R15.htm 9952164 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.bmrn.com/role/STOCKBASEDCOMPENSATION STOCK-BASED COMPENSATION Notes 15 false false R16.htm 9952165 - Disclosure - RESTRUCTURING Sheet http://www.bmrn.com/role/RESTRUCTURING RESTRUCTURING Notes 16 false false R17.htm 9952166 - Disclosure - EARNINGS PER COMMON SHARE Sheet http://www.bmrn.com/role/EARNINGSPERCOMMONSHARE EARNINGS PER COMMON SHARE Notes 17 false false R18.htm 9952167 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 18 false false R19.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 19 false false R20.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 20 false false R21.htm 9954471 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 21 false false R22.htm 9954472 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet
http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESTables BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables
http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIES 22 false false R23.htm 9954473 - Disclosure - FINANCIAL INSTRUMENTS (Tables) Sheet
http://www.bmrn.com/role/FINANCIALINSTRUMENTSTables FINANCIAL INSTRUMENTS (Tables) Tables http://www.bmrn.com/role/FINANCIALINSTRUMENTS 23 false false R24.htm 9954474 - Disclosure - SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION (Tables) Sheet
http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONTables SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION (Tables) Tables
http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATION 24 false false R25.htm 9954475 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet
http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.bmrn.com/role/FAIRVALUEMEASUREMENTS 25 false false R26.htm 9954476 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables) Sheet
http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables) Tables
http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIES 26 false false R27.htm 9954477 - Disclosure - DEBT (Tables) Sheet http://www.bmrn.com/role/DEBTTables DEBT (Tables) Tables http://www.bmrn.com/role/DEBT 27 false false R28.htm 9954478 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables) Sheet
http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMETables ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables) Tables
http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOME 28 false false R29.htm 9954479 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables) Sheet http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables) Tables http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATION 29 false false R30.htm 9954480 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.bmrn.com/role/STOCKBASEDCOMPENSATIONTables STOCK-BASED COMPENSATION (Tables) Tables
http://www.bmrn.com/role/STOCKBASEDCOMPENSATION 30 false false R31.htm 9954481 - Disclosure - RESTRUCTURING (Tables) Sheet http://www.bmrn.com/role/RESTRUCTURINGTables RESTRUCTURING (Tables) Tables http://www.bmrn.com/role/RESTRUCTURING 31 false false R32.htm 9954482 - Disclosure - EARNINGS PER COMMON SHARE (Tables) Sheet
http://www.bmrn.com/role/EARNINGSPERCOMMONSHARETables EARNINGS PER COMMON SHARE (Tables) Tables http://www.bmrn.com/role/EARNINGSPERCOMMONSHARE 32 false false R33.htm 9954483 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES - Schedule of Error Corrections and Prior Period Adjustments (Details) Sheet
http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES - Schedule of Error Corrections and Prior Period Adjustments (Details) Details 33 false false R34.htm 9954484 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Details) Sheet
http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Details) Details 34 false false R35.htm 9954485 - Disclosure - FINANCIAL INSTRUMENTS - Narrative (Details) Sheet http://www.bmrn.com/role/FINANCIALINSTRUMENTSNarrativeDetails FINANCIAL INSTRUMENTS - Narrative (Details) Details 35 false false R36.htm 9954486 - Disclosure - SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Schedule of Inventory (Details) Sheet
http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofInventoryDetails SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Schedule of Inventory (Details) Details 36 false false R37.htm 9954487 - Disclosure - SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Schedule of Property, Plant and Equipment, Net (Details) Sheet http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofPropertyPlantandEquipmentNetDetails SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Schedule of Property, Plant and Equipment, Net (Details) Details 37 false false R38.htm 9954488 - Disclosure - SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Narrative (Details) Sheet http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONNarrativeDetails SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Narrative (Details) Details 38 false false R39.htm 9954489 - Disclosure - SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Schedule of Intangible Assets, Net (Details) Sheet http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofIntangibleAssetsNetDetails SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Schedule of Intangible Assets, Net (Details) Details 39 false false R40.htm 9954490 - Disclosure - SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Schedule of Accounts Payable and Accrued Liabilities (Details) Sheet
http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Schedule of Accounts Payable and Accrued Liabilities (Details) Details 40 false false R41.htm 9954491 - Disclosure - FAIR VALUE MEASUREMENTS (Details) Sheet
http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails FAIR VALUE MEASUREMENTS (Details) Details http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSTables 41 false false R42.htm 9954492 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Narrative (Details) Sheet
http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESNarrativeDetails DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Narrative (Details) Details 42

false false R43.htm 9954493 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Schedule of Aggregate Notional Amounts for the Derivatives Outstanding (Details) Sheet http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofAggregateNotionalAmountsfortheDerivativesOutstandingDetails DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Schedule of Aggregate Notional Amounts for the Derivatives Outstanding (Details) Details 43 false false R44.htm 9954494 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Schedule of Fair Value Carrying Amounts of Derivatives (Details) Sheet http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofFairValueCarryingAmountsofDerivativesDetails DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Schedule of Fair Value Carrying Amounts of Derivatives (Details) Details 44 false false R45.htm 9954495 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Schedule of Impact of Gains and Losses from Derivatives Designated and Not Designated as Hedging Instruments (Details) Sheet http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofImpactofGainsandLossesfromDerivativesDesignatedandNotDesignatedasHedgingInstrumentsDetai DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Schedule of Impact of Gains and Losses from Derivatives Designated and Not Designated as Hedging Instruments (Details) Details 45 false false R46.htm 9954496 - Disclosure - DEBT - Narrative (Details) Sheet http://www.bmrn.com/role/DEBTNarrativeDetails DEBT - Narrative (Details) Details 46 false false R47.htm 9954497 - Disclosure - DEBT - Schedule of Convertible Debt (Details) Sheet http://www.bmrn.com/role/DEBTScheduleofConvertibleDebtDetails DEBT - Schedule of Convertible Debt (Details) Details 47 false false R48.htm 9954498 - Disclosure - DEBT - Schedule of Interest Expense on Convertible Debt (Details) Sheet http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonConvertibleDebtDetails DEBT - Schedule of Interest Expense on Convertible Debt (Details) Details 48 false false R49.htm 9954499 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (Details) Sheet http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails ACCUMULATED OTHER COMPREHENSIVE INCOME (Details) Details http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMETables 49 false false R50.htm 9954500 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Narrative (Details) Sheet http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONNarrativeDetails REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Narrative (Details) Details http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables 50 false false R51.htm 9954501 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Disaggregation of Total Net Product Revenues by Product (Details) Sheet http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyProductDetails REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Disaggregation of Total Net Product Revenues by Product (Details) Details 51 false false R52.htm 9954502 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Disaggregation of Total Net Product Revenues by Geographic Region (Details) Sheet http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyGeographicRegionDetails REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Disaggregation of Total Net Product Revenues by Geographic Region (Details) Details 52 false false R53.htm 9954503 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Total Net Product Revenue Concentrations Attributed to Largest Customers (Details) Sheet http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Total Net Product Revenue Concentrations Attributed to Largest Customers (Details) Details 53 false false R54.htm 9954504 - Disclosure - STOCK-BASED COMPENSATION (Details) Sheet http://www.bmrn.com/role/STOCKBASEDCOMPENSATIONDetails STOCK-BASED COMPENSATION (Details) Details http://www.bmrn.com/role/STOCKBASEDCOMPENSATIONTables 54 false false R55.htm 9954505 - Disclosure - RESTRUCTURING - Narrative (Details) Sheet http://www.bmrn.com/role/RESTRUCTURINGNarrativeDetails RESTRUCTURING - Narrative (Details) Details 55 false false R56.htm 9954506 - Disclosure - RESTRUCTURING - Schedule of Restructuring and Related Costs (Details) Sheet http://www.bmrn.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails RESTRUCTURING - Schedule of Restructuring and Related Costs (Details) Details 56 false false R57.htm 9954507 - Disclosure - RESTRUCTURING - Schedule of Restructuring Activity (Details) Sheet http://www.bmrn.com/role/RESTRUCTURINGScheduleofRestructuringActivityDetails RESTRUCTURING - Schedule of Restructuring Activity (Details) Details 57 false false R58.htm 9954508 - Disclosure - EARNINGS PER COMMON SHARE - Schedule of Computation of Basic and Diluted Earnings Per Common Share (Details) Sheet http://www.bmrn.com/role/EARNINGSPERCOMMONSHARESScheduleofComputationofBasicandDilutedEarningsPerCommonShareDetails EARNINGS PER COMMON SHARE - Schedule of Computation of Basic and Diluted Earnings Per Common Share (Details) Details 58 false false R59.htm 9954509 - Disclosure - EARNINGS PER COMMON SHARE - Schedule of Anti-Dilutive Common Stock Excluded from Computation of Diluted Earnings Per Share (Details) Sheet http://www.bmrn.com/role/EARNINGSPERCOMMONSHARESScheduleofAntiDilutiveCommonStockExcludedfromComputationofDilutedEarningsPerShareDetails EARNINGS PER COMMON SHARE - Schedule of Anti-Dilutive Common Stock Excluded from Computation of Diluted Earnings Per Share (Details) Details 59 false false R60.htm 9954510 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIES 60 false false All Reports Book All Reports bmrn-20240630.htm bmrn-20240630.xsd bmrn-20240630_cal.xml bmrn-20240630_def.xml bmrn-20240630_lab.xml bmrn-20240630_pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 80 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "bmrn-20240630.htm": { "nsprefix": "bmrn", "nsuri": "http://www.bmrn.com/20240630", "dts": { "inline": { "local": ["bmrn-20240630.htm"] }, "schema": { "local": ["bmrn-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["bmrn-20240630_cal.xml"] }, "definitionLink": { "local": ["bmrn-20240630_def.xml"] }, "labelLink": { "local": ["bmrn-20240630_lab.xml"] }, "presentationLink": { "local": ["bmrn-20240630_pre.xml"] } }, "keyStandard": 215, "keyCustom": 23, "axisStandard": 25, "axisCustom": 0, "memberStandard": 49, "memberCustom": 24, "hidden": { "total": 7, "http://xbrl.sec.gov/dei/2024": 5, "http://www.bmrn.com/20240630": 2 }, "contextCount": 283, "entityCount": 1, "segmentCount": 73, "elementCount": 539, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 816, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.bmrn.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "longName": "9952151 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-11", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "unique": true } }, "R3": { "role": "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "longName": "9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:OtherAssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "unique": true } }, "R4": { "role": "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "longName": "9952153 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "longName": "9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-19", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-19", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "unique": true } }, "R7": { "role": "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIES", "longName": "9952156 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES", "shortName": "BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.bmrn.com/role/FINANCIALINSTRUMENTS", "longName": "9952157 - Disclosure - FINANCIAL INSTRUMENTS", "shortName": "FINANCIAL INSTRUMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATION", "longName": "9952158 - Disclosure - SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION", "shortName": "SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTS", "longName": "9952159 - Disclosure - FAIR VALUE MEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIES", "longName": "9952160 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.bmrn.com/role/DEBT", "longName": "9952161 - Disclosure - DEBT", "shortName": "DEBT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOME", "longName": "9952162 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME", "shortName":

"ACCUMULATED OTHER COMPREHENSIVE INCOME", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATION", "longName": "9952163 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION", "shortName": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "bmrn:ConcentrationRiskAndSegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "bmrn:ConcentrationRiskAndSegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.bmrn.com/role/STOCKBASEDCOMPENSATION", "longName": "9952164 - Disclosure - STOCK-BASED COMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.bmrn.com/role/RESTRUCTURING", "longName": "9952165 - Disclosure - RESTRUCTURING", "shortName": "RESTRUCTURING", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.bmrn.com/role/EARNINGSPERCOMMONSHARE", "longName": "9952166 - Disclosure - EARNINGS PER COMMON SHARE", "shortName": "EARNINGS PER COMMON SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIES", "longName": "9952167 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R19": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true }, "uniqueAnchor": null }, "R20": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-11", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-11", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies", "longName": "9954471 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESTables", "longName": "9954472 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.bmrn.com/role/FINANCIALINSTRUMENTSTables", "longName": "9954473 - Disclosure - FINANCIAL INSTRUMENTS (Tables)", "shortName": "FINANCIAL INSTRUMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONTables", "longName": "9954474 - Disclosure - SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION (Tables)", "shortName": "SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSTables", "longName": "9954475 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables", "longName": "9954476 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables)", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.bmrn.com/role/DEBTTables", "longName": "9954477 - Disclosure - DEBT (Tables)", "shortName": "DEBT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ConvertibleDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ConvertibleDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMETables", "longName": "9954478 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables", "longName": "9954479 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)", "shortName": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.bmrn.com/role/STOCKBASEDCOMPENSATIONTables", "longName": "9954480 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "shortName": "STOCK-BASED COMPENSATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.bmrn.com/role/RESTRUCTURINGTables", "longName": "9954481 - Disclosure - RESTRUCTURING (Tables)", "shortName": "RESTRUCTURING (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.bmrn.com/role/EARNINGSPERCOMMONSHARETables", "longName": "9954482 - Disclosure - EARNINGS PER COMMON SHARE (Tables)", "shortName": "EARNINGS PER COMMON SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails", "longName": "9954483 - Disclosure - BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES - Schedule of Error Corrections and Prior Period Adjustments (Details)", "shortName": "BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES - Schedule of Error Corrections and Prior Period Adjustments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:CostOfRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-70", "name": "us-gaap:CostOfRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "unique": true } }, "R34": { "role": "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails", "longName": "9954484 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Details)", "shortName": "FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div",

"bmrn:ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.bmrn.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "longName": "9954485 - Disclosure - FINANCIAL INSTRUMENTS - Narrative (Details)", "shortName": "FINANCIAL INSTRUMENTS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-92", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-92", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofInventoryDetails", "longName": "9954486 - Disclosure - SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Schedule of Inventory (Details)", "shortName": "SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Schedule of Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofPropertyPlantandEquipmentNetDetails", "longName": "9954487 - Disclosure - SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Schedule of Property, Plant and Equipment, Net (Details)", "shortName": "SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Schedule of Property, Plant and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONNarrativeDetails", "longName": "9954488 - Disclosure - SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Narrative (Details)", "shortName": "SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-11", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofIntangibleAssetsNetDetails", "longName": "9954489 - Disclosure - SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Schedule of Intangible Assets, Net (Details)", "shortName": "SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Schedule of Intangible Assets, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails", "longName": "9954490 - Disclosure - SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Schedule of Accounts Payable and Accrued Liabilities (Details)", "shortName": "SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Schedule of Accounts Payable and Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails", "longName": "9954491 - Disclosure - FAIR VALUE MEASUREMENTS (Details)", "shortName": "FAIR VALUE MEASUREMENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-72", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-72", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESNarrativeDetails", "longName": "9954492 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Narrative (Details)", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofAggregateNotionalAmountsfortheDerivativesOutstandingDetails", "longName": "9954493 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Schedule of Aggregate Notional Amounts for the Derivatives Outstanding (Details)", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Schedule of Aggregate Notional Amounts for the Derivatives Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-106", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-106", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofFairValueCarryingAmountsofDerivativesDetails", "longName": "9954494 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Schedule of Fair Value Carrying Amounts of Derivatives (Details)", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Schedule of Fair Value Carrying Amounts of Derivatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofImpactofGainsandLossesfromDerivativesDesignatedandNotDesignatedasHedgingInstrumentsDeta "longName": "9954495 - Disclosure - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Schedule of Impact of Gains and Losses from Derivatives Designated and Not Designated as Hedging Instruments (Details)", "shortName": "DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Schedule of Impact of Gains and Losses from Derivatives Designated and Not Designated as Hedging Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-132", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-132", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.bmrn.com/role/DEBTNarrativeDetails", "longName": "9954496 - Disclosure - DEBT - Narrative (Details)", "shortName": "DEBT - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true }, "uniqueAnchor": null }, "R47": { "role": "http://www.bmrn.com/role/DEBTScheduleofConvertibleDebtDetails", "longName": "9954497 - Disclosure - DEBT - Schedule of Convertible Debt (Details)", "shortName": "DEBT - Schedule of Convertible Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:ConvertibleDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "unique": true } }, "R48": { "role": "http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonConvertibleDebtDetails", "longName": "9954498 - Disclosure - DEBT - Schedule of Interest Expense on Convertible Debt (Details)", "shortName": "DEBT - Schedule of Interest Expense on Convertible Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-145", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-145", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails", "longName": "9954499 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (Details)", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-26", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-11", "name": "us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "unique": true } }, "R50": { "role": "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONNarrativeDetails", "longName": "9954500 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Narrative (Details)", "shortName": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyProductDetails", "longName": "9954501 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Disaggregation of Total Net Product Revenues by Product (Details)", "shortName": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Disaggregation of Total Net Product Revenues by Product (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-169", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang":

"en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "unique": true } }, "R52": { "role": "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyGeographicRegionDetails", "longName": "9954502 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Disaggregation of Total Net Product Revenues by Geographic Region (Details)", "shortName": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Disaggregation of Total Net Product Revenues by Geographic Region (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-221", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "unique": true } }, "R53": { "role": "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails", "longName": "9954503 - Disclosure - REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Total Net Product Revenue Concentrations Attributed to Largest Customers (Details)", "shortName": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Total Net Product Revenue Concentrations Attributed to Largest Customers (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-241", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-241", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.bmrn.com/role/STOCKBASEDCOMPENSATIONDetails", "longName": "9954504 - Disclosure - STOCK-BASED COMPENSATION (Details)", "shortName": "STOCK-BASED COMPENSATION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-11", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.bmrn.com/role/RESTRUCTURINGNarrativeDetails", "longName": "9954505 - Disclosure - RESTRUCTURING - Narrative (Details)", "shortName": "RESTRUCTURING - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-264", "name": "us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated", "unitRef": "employee", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-264", "name": "us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated", "unitRef": "employee", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.bmrn.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails", "longName": "9954506 - Disclosure - RESTRUCTURING - Schedule of Restructuring and Related Costs (Details)", "shortName": "RESTRUCTURING - Schedule of Restructuring and Related Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-266", "name": "us-gaap:SeveranceCosts1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-266", "name": "us-gaap:SeveranceCosts1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.bmrn.com/role/RESTRUCTURINGScheduleofRestructuringActivityDetails", "longName": "9954507 - Disclosure - RESTRUCTURING - Schedule of Restructuring Activity (Details)", "shortName": "RESTRUCTURING - Schedule of Restructuring Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-269", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-269", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.bmrn.com/role/EARNINGSPERCOMMONSHAREScheduleofComputationofBasicandDilutedEarningsPerCommonShareDetails", "longName": "9954508 - Disclosure - EARNINGS PER COMMON SHARE - Schedule of Computation of Basic and Diluted Earnings Per Common Share (Details)", "shortName": "EARNINGS PER COMMON SHARE - Schedule of Computation of Basic and Diluted Earnings Per Common Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-11", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.bmrn.com/role/EARNINGSPERCOMMONSHARESScheduleofAntiDilutiveCommonStockExcludedfromComputationofDilutedEarningsPerShareDetails", "longName": "9954509 - Disclosure - EARNINGS PER COMMON SHARE - Schedule of Anti-Dilutive Common Stock Excluded from Computation of Diluted Earnings Per Share (Details)", "shortName": "EARNINGS PER COMMON SHARE - Schedule of Anti-Dilutive Common Stock Excluded from Computation of Diluted Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-11", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESDetails", "longName": "9954510 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-1", "name": "bmrn:ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "bmrn:ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "bmrn-20240630.htm", "first": true, "unique": true } }, "tag": { "bmrn_A2024WorkforceReductionPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "A2024WorkforceReductionPlanMember", "presentation": ["http://www.bmrn.com/role/RESTRUCTURINGNarrativeDetails", "http://www.bmrn.com/role/RESTRUCTURINGScheduleofRestructuringActivityDetails", "http://www.bmrn.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "2024 Workforce Reduction Plan", "label": "2024 Workforce Reduction Plan [Member]", "documentation": "2024 Workforce Reduction Plan" } } }, "auth_ref": [] }, "bmrn_ALDURAZYMEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "ALDURAZYMEMember", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyGeographicRegionDetails", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyProductDetails"], "lang": { "en-us": { "role": { "terseLabel": "ALDURAZYME", "label": "ALDURAZYME [Member]", "documentation": "ALDURAZYME" } } }, "auth_ref": [] }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AOCIAttributableToParentNetOfTaxRollForward", "presentation": ["http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails"], "lang": { "en-us": { "role": { "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued liabilities", "totalLabel": "Accounts payable and accrued liabilities", "label": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": ["r67", "r68"] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesMember", "presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofFairValueCarryingAmountsofDerivativesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accounts\u00a0payable\u00a0and accrued\u00a0liabilities", "label": "Accounts Payable and Accrued Liabilities [Member]", "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued operating expenses", "label": "Accounts Payable and Other Accrued Liabilities, Current", "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": ["r663"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "verboseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r892"] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Accretion of discount on investments", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r98"] }, "bmrn_AccruedGovernmentAndOtherRebates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "AccruedGovernmentAndOtherRebates", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accrued rebates payable", "label": "Accrued Government And Other Rebates", "documentation": "Accrued Government And Other Rebates" } } }, "auth_ref": [] }, "us-

gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accrued income taxes", "label": "Accrued Income Taxes, Current", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": ["r68", "r122"] }, "us-gaap_AccruedRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedRoyaltiesCurrent", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accrued royalties payable", "label": "Accrued Royalties, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r68", "r681"] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofPropertyPlantandEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofPropertyPlantandEquipmentNetDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r36", "r148", "r554"] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": ["http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofImpactofGainsandLossesfromDerivativesDesignatedandNotDesignatedasHedgingInstrumentsDeta], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent", "verboseLabel": "Unrealized Gains (Losses) on Cash Flow Hedges", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": ["r163", "r171", "r172", "r413", "r686", "r866"] }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "presentation": ["http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gains (Losses) on Available-for-Sale Debt Securities", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": ["r159", "r160", "r161", "r163", "r171", "r172", "r866"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": ["http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r170", "r171", "r453", "r454", "r455", "r456", "r457", "r458"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income (loss)", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r16", "r17", "r86", "r153", "r551", "r580", "r584"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": ["http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r170", "r171", "r453", "r454", "r455", "r456", "r457", "r458"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails", "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income (loss):", "verboseLabel": "AOCI attributable to parent", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r1", "r8", "r17", "r419", "r422", "r472", "r575", "r576", "r866", "r867", "r868", "r879", "r880", "r881", "r882"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": ["r798"] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r76"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital:", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r590", "r879", "r880", "r881", "r882", "r926", "r998"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": ["r811"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": ["r811"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": ["r811"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": ["r811"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r46", "r47", "r361"] }, "bmrn_AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "AdjustmentsToAdditionalPaidInCapitalSharesHeldByNonqualifiedDeferredCompensationPlan", "crdr": "debit", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Change in Common stock held by the Nonqualified Deferred Compensation plan (NQDC)", "label": "Adjustments To Additional Paid In Capital, Shares Held By Nonqualified Deferred Compensation Plan", "documentation": "Adjustments To Additional Paid In Capital, Shares Held By Nonqualified Deferred Compensation Plan" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": ["r844"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r770", "r780", "r790", "r822"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": ["r773", "r783", "r793", "r825"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": ["r845"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": ["r811"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": ["r818"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": ["r774", "r784", "r794", "r818", "r826", "r830", "r838"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": ["r836"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.bmrn.com/role/STOCKBASEDCOMPENSATIONDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Total stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r390", "r394"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.bmrn.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonConvertibleDebtDetails": { "parentTag": "us-gaap_InterestExpense", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonConvertibleDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accretion of discount on convertible notes", "label": "Amortization of Debt Discount (Premium)", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": ["r6", "r91", "r340", "r950"] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonConvertibleDebtDetails": { "parentTag": "us-gaap_InterestExpense", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonConvertibleDebtDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Amortization of debt issuance costs", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": ["r91", "r340", "r874", "r950"] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Non-cash interest expense", "label": "Amortization of Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense

attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": ["r340", "r704", "r705", "r874", "r950"] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"], "lang": { "en-us": { "role": { "terseLabel": "Intangible asset amortization", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } } }, "auth_ref": ["r6", "r291", "r293", "r696"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.bmrn.com/role/EARNINGSPERCOMMONSHARESScheduleofAntiDilutiveCommonStockExcludedfromComputationofDilutedEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total number of potentially issuable shares (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } } }, "auth_ref": ["r219"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.bmrn.com/role/EARNINGSPERCOMMONSHARESScheduleofAntiDilutiveCommonStockExcludedfromComputationofDilutedEarningsPerShareDetails", "http://www.bmrn.com/role/EARNINGSPERCOMMONSHARESScheduleofComputationofBasicandDilutedEarningsPerCommonShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r25"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://www.bmrn.com/role/EARNINGSPERCOMMONSHARESScheduleofAntiDilutiveCommonStockExcludedfromComputationofDilutedEarningsPerShareDetails", "http://www.bmrn.com/role/EARNINGSPERCOMMONSHARESScheduleofComputationofBasicandDilutedEarningsPerCommonShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.bmrn.com/role/EARNINGSPERCOMMONSHARESScheduleofAntiDilutiveCommonStockExcludedfromComputationofDilutedEarningsPerShareDetails", "http://www.bmrn.com/role/EARNINGSPERCOMMONSHARESScheduleofComputationofBasicandDilutedEarningsPerCommonShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r25"] }, "us-gaap_AssetBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetBackedSecuritiesMember", "presentation": ["http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Asset-backed securities", "label": "Asset-Backed Securities [Member]", "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans." } } }, "auth_ref": ["r714", "r734", "r894", "r895", "r896"] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails": { "parentTag": "us-gaap_RestructuringCostsAndAssetImpairmentCharges", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bmrn.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Asset Impairments", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": ["r6", "r34"] }, "bmrn_AssetImpairmentChargesAndOtherNonCashAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "AssetImpairmentChargesAndOtherNonCashAdjustments", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Impairment of assets and other non-cash adjustments", "label": "Asset Impairment Charges And Other Non-Cash Adjustments", "documentation": "Asset Impairment Charges And Other Non-Cash Adjustments" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r120", "r130", "r152", "r184", "r223", "r225", "r234", "r235", "r274", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r411", "r414", "r452", "r548", "r619", "r691", "r692", "r733", "r761", "r916", "r917", "r952"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r143", "r156", "r184", "r274", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r411", "r414", "r452", "r733", "r916", "r917", "r952"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "totalLabel": "Fair value of total financial assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r430", "r431", "r721"] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosureAbstract", "presentation": ["http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Assets:", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent assets:", "label": "Assets, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r246"] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Gross Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r247"] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r243", "r284", "r547"] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Fair Value", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r244", "r284", "r430", "r541", "r721", "r725", "r893", "r930", "r931", "r932"] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Short-term investments", "terseLabel": "Short-term marketable securities", "label": "Debt Securities, Available-for-Sale, Current", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": ["r241", "r284"] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Long-term investments", "terseLabel": "Long-term marketable securities", "label": "Debt Securities, Available-for-Sale, Noncurrent", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": ["r146", "r241", "r284"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": ["r833"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": ["r834"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": ["r829"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": ["r829"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": ["r829"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": ["r829"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": ["r829"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": ["r829"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r364", "r365", "r366", "r367", "r368", "r369",

"r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": ["r832"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": ["r831"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": ["r830"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": ["r830"] }, "bmrn_BRINEURAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "BRINEURAMember", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyProductDetails"], "lang": { "en-us": { "role": { "terseLabel": "BRINEURA", "label": "BRINEURA [Member]", "documentation": "BRINEURA" } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofFairValueCarryingAmountsofDerivativesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r296", "r964", "r965"] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofFairValueCarryingAmountsofDerivativesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location", "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r52", "r55", "r296", "r964", "r965"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "presentation": ["http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r132", "r549", "r591", "r614", "r733", "r761", "r865"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r20", "r145", "r679"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValueAbstract", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents:", "label": "Cash and Cash Equivalents, at Carrying Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash, aggregate fair value", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r928", "r929"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning of period", "periodEndLabel": "End of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r20", "r95", "r182"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r95"] }, "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "crdr": "credit", "presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gains reclassified from AOCI to earnings over the next 12 months", "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months", "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months." } } }, "auth_ref": ["r62"] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "SUPPLEMENTAL CASH FLOW DISCLOSURES FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "bmrn_ChangeInPresentationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "ChangeInPresentationPolicyTextBlock", "presentation": ["http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Change in Presentation", "label": "Change In Presentation [Policy Text Block]", "documentation": "Change In Presentation" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": ["r809"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": ["r806"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": ["r804"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.bmrn.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": ["r810"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": ["r810"] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": ["http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": ["r109", "r315", "r756", "r757", "r758", "r759"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIES"], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r107", "r309", "r310", "r664", "r907", "r913"] }, "bmrn_CommonStockIssuableUnderConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "CommonStockIssuableUnderConvertibleDebtMember", "presentation": ["http://www.bmrn.com/role/EARNINGSPERCOMMONSHARESScheduleofAntiDilutiveCommonStockExcludedfromComputationofDilutedEarningsPerShareDetails", "http://www.bmrn.com/role/EARNINGSPERCOMMONSHARESScheduleofComputationofBasicandDilutedEarningsPerCommonShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock issuable under the Company\u2019s convertible debt", "label": "Common Stock Issuable Under Convertible Debt [Member]", "documentation": "Common Stock Issuable Under Convertible Debt" } } }, "auth_ref": [] }, "us-gaap_CommonStockIssuedEmployeeStockTrust": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockIssuedEmployeeStockTrust", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "negatedLabel": "Company common stock held by the Nonqualified Deferred Compensation Plan", "label": "Common Stock Issued, Employee Stock Trust", "documentation": "Value of common stock issued to a trust (for example, a 'rabbi trust') set up specifically to accumulate stock for the sole purpose of distribution to participating employees. This trust does not allow employees to immediately or after a holding period diversify into nonemployer securities. The deferred compensation plan for which this trust is set up must be settled by the delivery of a fixed number of shares of employer stock." } } }, "auth_ref": ["r44"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Common stock:", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r752", "r753", "r754", "r756", "r757", "r758", "r759", "r879", "r880", "r882", "r926", "r996", "r998"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r75"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r75", "r606"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r75"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",

"http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "periodStartLabel": "Shares of common stock, beginning balances (in shares)", "periodEndLabel": "Shares of common stock, ending balances (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r9", "r75", "r606", "r625", "r998", "r999"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.001 par value: 500,000,000 shares authorized; 190,355,517 and 188,598,154 shares issued and outstanding, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r75", "r550", "r733"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": ["r815"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": ["r814"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": ["r816"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": ["r813"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"], "lang": { "en-us": { "role": { "terseLabel": "COMPREHENSIVE INCOME", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r18", "r167", "r169", "r174", "r543", "r560", "r561"] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": ["http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOME"], "lang": { "en-us": { "role": { "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE INCOME", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": ["r85", "r173", "r542", "r558"] }, "bmrn_ConcentrationRiskAndGeographicInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "ConcentrationRiskAndGeographicInformationAbstract", "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk And Geographic Information [Abstract]", "label": "Concentration Risk And Geographic Information [Abstract]", "documentation": "Concentration risk and geographic information." } } }, "auth_ref": [] }, "bmrn_ConcentrationRiskAndGeographicInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "ConcentrationRiskAndGeographicInformationLineItems", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk And Geographic Information [Line Items]", "label": "Concentration Risk And Geographic Information [Line Items]", "documentation": "Concentration risk and geographic information." } } }, "auth_ref": [] }, "bmrn_ConcentrationRiskAndGeographicInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "ConcentrationRiskAndGeographicInformationTable", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk And Geographic Information [Table]", "label": "Concentration Risk And Geographic Information [Table]", "documentation": "Concentration risk and geographic information." } } }, "auth_ref": [] }, "bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "ConcentrationRiskAndSegmentReportingDisclosureTextBlock", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATION"], "lang": { "en-us": { "role": { "terseLabel": "REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION", "label": "Concentration Risk And Segment Reporting Disclosure [Text Block]", "documentation": "Concentration risk and segment reporting disclosure." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONNarrativeDetails", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": ["r27", "r28", "r64", "r65", "r239", "r663"] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONNarrativeDetails", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": ["r27", "r28", "r64", "r65", "r239", "r586", "r663"] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONNarrativeDetails", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": ["r27", "r28", "r64", "r65", "r239", "r663", "r853"] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskLineItems", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Line Items]", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r663"] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONNarrativeDetails", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk, percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": ["r27", "r28", "r64", "r65", "r239"] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTable", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Table]", "label": "Concentration Risk [Table]", "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk." } } }, "auth_ref": ["r26", "r27", "r28", "r29", "r64", "r119", "r663"] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONNarrativeDetails", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": ["r27", "r28", "r64", "r65", "r239", "r663"] }, "bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones", "crdr": "credit", "presentation": ["http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones", "label": "Contingent Payments Reasonably Possible Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones", "documentation": "Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones." } } }, "auth_ref": [] }, "bmrn_ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestonesToBePaidDueInRollingNext12Months": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestonesToBePaidDueInRollingNext12Months", "crdr": "credit", "presentation": ["http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contingent payments reasonably possible upon achievement of certain development and regulatory activities commercial sales and licensing milestones, to be paid next 12 months", "label": "Contingent Payments Reasonably Possible Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones, To Be Paid, Due In Rolling Next 12 Months", "documentation": "Contingent Payments Reasonably Possible Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones, To Be Paid, Due In Rolling Next 12 Months" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": ["r346", "r347", "r350"] }, "us-gaap_ContractWithCustomerSalesChannelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerSalesChannelAxis", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyGeographicRegionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Sales Channel", "label": "Contract with Customer, Sales Channel [Axis]", "documentation": "Information by sales channel for delivery of good or service in contract with customer." } } }, "auth_ref": ["r713", "r919"] }, "us-gaap_ContractWithCustomerSalesChannelDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerSalesChannelDomain", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyGeographicRegionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Sales Channel", "label": "Contract with Customer, Sales Channel [Domain]", "documentation": "Sales channel for delivery of good or service in contract with customer. Includes, but is not limited to, directly to consumer and through intermediary." } } }, "auth_ref": ["r713", "r919"] }, "us-gaap_ConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebt", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/DEBTScheduleofConvertibleDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bmrn.com/role/DEBTScheduleofConvertibleDebtDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total convertible debt, net", "label": "Convertible Debt", "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company." } } }, "auth_ref": ["r14", "r123", "r962"] }, "us-gaap_ConvertibleDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtCurrent", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/DEBTScheduleofConvertibleDebtDetails": { "parentTag": "us-gaap_ConvertibleDebt", "weight": 1.0, "order": 1.0 }, "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/DEBTScheduleofConvertibleDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Short-term convertible debt, net", "totalLabel": "Convertible debt, current", "label": "Convertible Debt, Current", "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": ["r67"] }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtFairValueDisclosures", "crdr": "credit", "presentation": ["http://www.bmrn.com/role/DEBTScheduleofConvertibleDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total fair value of fixed-rate convertible debt", "label": "Convertible Debt, Fair Value Disclosures", "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or

the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": ["r929", "r930", "r931", "r932", "r939"] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtMember", "presentation": ["http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonConvertibleDebtDetails", "http://www.bmrn.com/role/EARNINGSPERCOMMONSHARESScheduleofAntiDilutiveCommonStockExcludedfromComputationofDilutedEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Convertible Senior Notes", "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": ["r110", "r325", "r326", "r331", "r332", "r333", "r336", "r337", "r338", "r339", "r340", "r701", "r702", "r703", "r704", "r705"] }, "us-gaap_ConvertibleDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 }, "http://www.bmrn.com/role/DEBTScheduleofConvertibleDebtDetails": { "parentTag": "us-gaap_ConvertibleDebt", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/DEBTScheduleofConvertibleDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-term convertible debt, net", "totalLabel": "Convertible debt, noncurrent", "label": "Convertible Debt, Noncurrent", "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock." } } }, "auth_ref": ["r14"] }, "us-gaap_ConvertibleDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtTableTextBlock", "presentation": ["http://www.bmrn.com/role/DEBTTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Convertible Debt", "label": "Convertible Debt [Table Text Block]", "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount." } } }, "auth_ref": [] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": ["http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Corporate debt securities", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": ["r714", "r716", "r721", "r734", "r750", "r993"] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails", "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": ["r88", "r184", "r274", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r452", "r691", "r916"] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": ["http://www.bmrn.com/role/STOCKBASEDCOMPENSATIONDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails", "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "terseLabel": "Total operating expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": ["r92"] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesAbstract", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"], "lang": { "en-us": { "role": { "terseLabel": "OPERATING EXPENSES:", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover page.", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditConcentrationRiskMember", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Credit Concentration Risk", "label": "Credit Concentration Risk [Member]", "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement." } } }, "auth_ref": ["r119"] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.bmrn.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": ["r100", "r239"] }, "bmrn_CustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "CustomerOneMember", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONNarrativeDetails", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Customer One", "terseLabel": "Customer A", "label": "Customer One [Member]", "documentation": "Customer 1" } } }, "auth_ref": [] }, "bmrn_CustomerOneTwoAndThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "CustomerOneTwoAndThreeMember", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"], "lang": { "en-us": { "role": { "terseLabel": "Customer A, B & C", "label": "Customer One, Two And Three [Member]", "documentation": "Customer One, Two And Three" } } }, "auth_ref": [] }, "bmrn_CustomerThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "CustomerThreeMember", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONNarrativeDetails", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Customer Three", "terseLabel": "Customer C", "label": "Customer Three [Member]", "documentation": "Customer 3" } } }, "auth_ref": [] }, "bmrn_CustomerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "CustomerTwoMember", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONNarrativeDetails", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Customer Two", "terseLabel": "Customer B", "label": "Customer Two [Member]", "documentation": "Customer 2" } } }, "auth_ref": [] }, "bmrn_CustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "CustomersMember", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sanofi", "label": "Customers [Member]", "documentation": "Customers." } } }, "auth_ref": [] }, "bmrn_DebtConversionConvertedInstrumentPotentialSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "DebtConversionConvertedInstrumentPotentialSharesIssued", "presentation": ["http://www.bmrn.com/role/EARNINGSPERCOMMONSHARESScheduleofAntiDilutiveCommonStockExcludedfromComputationofDilutedEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Potential shares issued if converted (in shares)", "label": "Debt Conversion, Converted Instrument, Potential Shares Issued", "documentation": "Debt Conversion, Converted Instrument, Potential Shares Issued" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.bmrn.com/role/DEBTScheduleofConvertibleDebtDetails", "http://www.bmrn.com/role/EARNINGSPERCOMMONSHARESScheduleofAntiDilutiveCommonStockExcludedfromComputationofDilutedEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r14", "r67", "r68", "r121", "r123", "r185", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r701", "r702", "r703", "r704", "r705", "r732", "r876", "r908", "r909", "r910", "r949", "r951"] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/DEBTScheduleofConvertibleDebtDetails": { "parentTag": "us-gaap_ConvertibleDebtCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bmrn.com/role/DEBTNarrativeDetails", "http://www.bmrn.com/role/DEBTScheduleofConvertibleDebtDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Carrying value of equity component", "terseLabel": "Convertible notes", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": ["r14", "r123", "r342"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.bmrn.com/role/DEBTScheduleofConvertibleDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Convertible notes stated rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r70", "r326"] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": ["http://www.bmrn.com/role/DEBTScheduleofConvertibleDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r185", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r701", "r702", "r703", "r704", "r705", "r732", "r876", "r949", "r951"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.bmrn.com/role/DEBTScheduleofConvertibleDebtDetails", "http://www.bmrn.com/role/EARNINGSPERCOMMONSHARESScheduleofAntiDilutiveCommonStockExcludedfromComputationofDilutedEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r14", "r185", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r701", "r702", "r703", "r704", "r705", "r732", "r876", "r908", "r909", "r910", "r949", "r951"] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": ["http://www.bmrn.com/role/DEBTScheduleofConvertibleDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": ["r14", "r42", "r43", "r66", "r111", "r112", "r185", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r701", "r702", "r703", "r704", "r705", "r732", "r876", "r949", "r951"] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/DEBTScheduleofConvertibleDebtDetails": { "parentTag": "us-gaap_ConvertibleDebtCurrent", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.bmrn.com/role/DEBTScheduleofConvertibleDebtDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Unamortized discount net of deferred offering costs", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": ["r331", "r343", "r461", "r462", "r463", "r702", "r703", "r732"] }, "us-gaap_DeferredCompensationShareBasedPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationShareBasedPaymentsMember", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Company common stock held by the NQDC:", "label": "Deferred Compensation, Share-Based Payments [Member]", "documentation": "Deferred compensation arrangements (such as stock or unit options and share or unit awards) that are equity-based payments with individual employees. The arrangements are generally based on employment contracts between the entity and one or more selected officers or key employees, and contain a promise by the employer to pay certain amounts or benefits at designated future dates, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Other \"sub-members\" can be added as necessary." } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": ["r397", "r398"] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": ["r6", "r138", "r878"] }, "us-

gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": ["http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r6", "r35"] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r6", "r223", "r230", "r235", "r691", "r692"] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofAggregateNotionalAmountsfortheDerivativesOutstandingDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": ["r596", "r598", "r611", "r612", "r613", "r615", "r616", "r617", "r618", "r620", "r621", "r622", "r623", "r634", "r635", "r636", "r637", "r640", "r641", "r642", "r643", "r656", "r657", "r658", "r659", "r752", "r754", "r933", "r934", "r935", "r936", "r937", "r938", "r940", "r941"] }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeAsset", "crdr": "debit", "presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofFairValueCarryingAmountsofDerivativesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Asset Derivatives", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": ["r13", "r84", "r116", "r117", "r157", "r685"] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofFairValueCarryingAmountsofDerivativesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Liability Derivatives", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": ["r13", "r84", "r116", "r117", "r157", "r685"] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofImpactofGainsandLossesfromDerivativesDesignatedandNotDesignatedasHedgingInstrumentsDeta], "lang": { "en-us": { "role": { "terseLabel": "Derivatives Not Designated as Hedging Instruments", "label": "Derivative, Gain (Loss) on Derivative, Net", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": ["r925"] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofAggregateNotionalAmountsfortheDerivativesOutstandingDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": ["r53", "r56", "r57", "r118", "r596", "r598", "r611", "r612", "r613", "r615", "r616", "r617", "r618", "r620", "r621", "r622", "r623", "r634", "r635", "r636", "r637", "r640", "r641", "r642", "r643", "r656", "r657", "r658", "r659", "r685", "r752", "r754", "r933", "r934", "r935", "r936", "r937", "r938", "r940", "r941"] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIES"], "lang": { "en-us": { "role": { "terseLabel": "DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": ["r115", "r417", "r424"] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofImpactofGainsandLossesfromDerivativesDesignatedandNotDesignatedasHedgingInstrumentsDeta], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Table]", "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": ["r10", "r53", "r56", "r57", "r60", "r61", "r416"] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofImpactofGainsandLossesfromDerivativesDesignatedandNotDesignatedasHedgingInstrumentsDeta], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r416"] }, "us-gaap_DerivativeLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency exchange forward contracts", "label": "Derivative Liability, Current", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": ["r158"] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLineItems", "presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESNarrativeDetails", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofAggregateNotionalAmountsfortheDerivativesOutstandingDetails", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofFairValueCarryingAmountsofDerivativesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r424"] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofAggregateNotionalAmountsfortheDerivativesOutstandingDetails"], "lang": { "en-us": { "role": { "terseLabel": "Notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": ["r923", "r924"] }, "us-gaap_DerivativeRemainingMaturity1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeRemainingMaturity1", "presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maturity of derivatives", "label": "Derivative, Remaining Maturity", "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTable", "presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESNarrativeDetails", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofAggregateNotionalAmountsfortheDerivativesOutstandingDetails", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofFairValueCarryingAmountsofDerivativesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": ["r10", "r48", "r49", "r50", "r51", "r54", "r56", "r58", "r59", "r61", "r424"] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESNarrativeDetails", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofAggregateNotionalAmountsfortheDerivativesOutstandingDetails", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofFairValueCarryingAmountsofDerivativesDetails", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofImpactofGainsandLossesfromDerivativesDesignatedandNotDesignatedasHedgingInstrumentsDeta], "lang": { "en-us": { "role": { "terseLabel": "Derivatives designated as hedging instruments:", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": ["r10"] }, "us-gaap_DilutiveSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DilutiveSecuritiesAbstract", "presentation": ["http://www.bmrn.com/role/EARNINGSPERCOMMONSHARESScheduleofComputationofBasicandDilutedEarningsPerCommonShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Effect of dilutive securities:", "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyGeographicRegionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r349", "r707", "r708", "r709", "r710", "r711", "r712", "r713"] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyGeographicRegionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r349", "r707", "r708", "r709", "r710", "r711", "r712", "r713"] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disaggregation of Total Net Product Revenues by Geographic Region", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r919"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.bmrn.com/role/STOCKBASEDCOMPENSATION"], "lang": { "en-us": { "role": { "terseLabel": "STOCK-BASED COMPENSATION", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r359", "r363", "r391", "r392", "r393", "r718"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.bmrn.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.bmrn.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.bmrn.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.bmrn.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r765"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.bmrn.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label":

"Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r797"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.bmrn.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": ["r808"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.bmrn.com/role/EARNINGSPERCOMMONSHARESScheduleofComputationofBasicandDilutedEarningsPerCommonShareDetails"], "lang": { "en-us": { "role": { "verboseLabel": "EARNINGS PER SHARE, BASIC (in dollars per share)", "terseLabel": "Earnings per common share, basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r175", "r191", "r192", "r194", "r195", "r196", "r198", "r204", "r207", "r216", "r217", "r218", "r222", "r407", "r410", "r427", "r428", "r544", "r562", "r688"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.bmrn.com/role/EARNINGSPERCOMMONSHARESScheduleofComputationofBasicandDilutedEarningsPerCommonShareDetails"], "lang": { "en-us": { "role": { "verboseLabel": "EARNINGS PER SHARE, DILUTED (in dollars per share)", "terseLabel": "Earnings per common share, diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r175", "r191", "r192", "r194", "r195", "r196", "r198", "r207", "r216", "r217", "r218", "r222", "r407", "r410", "r427", "r428", "r544", "r562", "r688"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.bmrn.com/role/EARNINGSPERCOMMONSHARE"], "lang": { "en-us": { "role": { "terseLabel": "EARNINGS PER COMMON SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r203", "r219", "r220", "r221"] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r946"] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation expense", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r68"] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeSeveranceMember", "presentation": ["http://www.bmrn.com/role/RESTRUCTURINGScheduleofRestructuringActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Severance and related costs", "label": "Employee Severance [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.bmrn.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.bmrn.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.bmrn.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.bmrn.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.bmrn.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r763"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.bmrn.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.bmrn.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.bmrn.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r763"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.bmrn.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.bmrn.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r763"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.bmrn.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.bmrn.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r847"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.bmrn.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r763"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.bmrn.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r763"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.bmrn.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r763"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.bmrn.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r763"] }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyProductDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customer [Line Items]", "label": "Revenue from External Customer [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": ["r802"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": ["r843"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": ["r843"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": ["r843"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails", "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofImpactofGainsandLossesfromDerivativesDesignatedandNotDesignatedasHedgingInstrumentsDeta], "lang": { "en-us": { "role": { "terseLabel": "Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r9", "r140", "r170", "r171", "r172", "r186", "r187", "r188", "r190", "r196", "r199", "r201", "r224", "r275", "r278", "r294", "r345", "r401", "r402", "r404", "r405", "r406", "r408", "r409", "r410", "r418", "r419", "r420", "r421", "r422", "r423", "r426", "r453", "r454", "r455", "r456", "r457", "r458", "r465", "r467", "r472", "r558", "r575", "r576", "r577", "r590", "r646"] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": ["http://www.bmrn.com/role/FINANCIALINSTRUMENTSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Strategic investments fair value", "label": "Equity Securities without

Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": ["r272"] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount", "crdr": "debit", "presentation": ["http://www.bmrn.com/role/FINANCIALINSTRUMENTSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity securities decline amount", "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount", "documentation": "Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value." } } }, "auth_ref": ["r273"] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount", "crdr": "debit", "presentation": ["http://www.bmrn.com/role/FINANCIALINSTRUMENTSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity investment impairment amount", "label": "Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount", "documentation": "Amount of impairment loss on investment in equity security without readily determinable fair value." } } }, "auth_ref": ["r273"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": ["r812"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": ["r770", "r780", "r790", "r822"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": ["r767", "r777", "r787", "r819"] }, "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems", "presentation": ["http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Error Corrections and Prior Period Adjustments Restatement [Line Items]", "label": "Error Corrections and Prior Period Adjustments Restatement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r191", "r192", "r193", "r198", "r199", "r200", "r201", "r222"] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EuropeMember", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyGeographicRegionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Europe", "label": "Europe [Member]" } } }, "auth_ref": ["r1000", "r1001", "r1002", "r1003"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": ["r818"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": ["http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r430", "r431", "r444", "r721"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r430", "r431", "r444", "r721"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": ["http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Asset Class", "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": ["r435", "r436", "r437", "r438", "r439", "r440", "r445", "r723"] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": ["http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Asset Class", "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": ["r435", "r436", "r437", "r438", "r439", "r440", "r445", "r723"] }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByBalanceSheetGroupingTextBlock", "presentation": ["http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of Financial Assets and Liabilities", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": ["r63"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofFairValueCarryingAmountsofDerivativesDetails", "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r333", "r352", "r353", "r354", "r355", "r356", "r357", "r429", "r431", "r432", "r433", "r434", "r443", "r444", "r446", "r477", "r478", "r479", "r702", "r703", "r714", "r715", "r716", "r721", "r725"] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByLiabilityClassAxis", "presentation": ["http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Liability Class", "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": ["r435", "r436", "r437", "r438", "r439", "r440", "r445"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": ["http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r430", "r431", "r432", "r434", "r721", "r931", "r942"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.bmrn.com/role/FAIRVALUEMEASUREMENTS"], "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE MEASUREMENTS", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r439", "r441", "r442", "r443", "r446", "r447", "r448", "r449", "r450", "r539", "r721", "r726"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Level 1:", "verboseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r333", "r352", "r357", "r431", "r444", "r477", "r714", "r715", "r716", "r721"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofFairValueCarryingAmountsofDerivativesDetails", "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Level 2:", "verboseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r333", "r352", "r357", "r431", "r432", "r444", "r478", "r702", "r703", "r714", "r715", "r716", "r721"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r333", "r352", "r353", "r354", "r355", "r356", "r357", "r431", "r432", "r433", "r434", "r444", "r479", "r702", "r703", "r714", "r715", "r716", "r721", "r725"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": ["http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value by Liability Class", "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": ["r435", "r436", "r437", "r438", "r439", "r440", "r445"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": ["http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurement Frequency", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": ["r430", "r431", "r432", "r434", "r721", "r931", "r942"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "crdr": "debit", "presentation": ["http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Financial assets remeasured", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r435", "r445", "r723"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": ["http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities remeasured", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r435", "r445"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofFairValueCarryingAmountsofDerivativesDetails", "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r333", "r352", "r353", "r354", "r355", "r356", "r357", "r429", "r431", "r432", "r433", "r434", "r443", "r444", "r446", "r477", "r478", "r479", "r702", "r703", "r714", "r715", "r716", "r721", "r725"] }, "us-gaap_FairValueMeasurementsNonrecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsNonrecurringMember", "presentation": ["http://www.bmrn.com/role/FINANCIALINSTRUMENTSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Nonrecurring", "label": "Fair Value, Nonrecurring [Member]", "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value." } } }, "auth_ref": ["r430", "r431", "r432", "r434", "r721", "r931"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": ["http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for

impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r721", "r928", "r929", "r930", "r931", "r932", "r942"] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Principal repayments of financing leases", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": ["r468", "r469"] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": ["http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r279", "r280", "r281", "r282", "r283", "r285", "r286", "r287", "r341", "r344", "r424", "r451", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r559", "r694", "r721", "r723", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r734", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r897", "r898", "r899", "r900", "r927", "r930", "r931", "r932", "r939", "r942"] }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentsDisclosureTextBlock", "presentation": ["http://www.bmrn.com/role/FINANCIALINSTRUMENTS"], "lang": { "en-us": { "role": { "terseLabel": "FINANCIAL INSTRUMENTS", "label": "Financial Instruments Disclosure [Text Block]", "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofIntangibleAssetsNetDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofIntangibleAssetsNetDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r150", "r288", "r292", "r696"] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofIntangibleAssetsNetDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofIntangibleAssetsNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived intangible assets", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r288", "r292", "r508", "r696"] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofIntangibleAssetsNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofIntangibleAssetsNetDetails"], "lang": { "en-us": { "role": { "totalLabel": "Net carrying value", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r507", "r905"] }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossUnrealized", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized foreign exchange loss (gain)", "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": ["r98", "r627", "r760", "r944", "r945", "r997"] }, "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignExchangeContractMember", "presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofAggregateNotionalAmountsfortheDerivativesOutstandingDetails"], "lang": { "en-us": { "role": { "terseLabel": "Forward Foreign Exchange Contracts", "label": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } }, "auth_ref": ["r685", "r714", "r720", "r721"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r774", "r784", "r794", "r826"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r774", "r784", "r794", "r826"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r774", "r784", "r794", "r826"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": ["r774", "r784", "r794", "r826"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": ["r774", "r784", "r794", "r826"] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": ["r807"] }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfAssets1", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0, "order": 3.0 }, "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gain on sale of nonfinancial assets", "negatedLabel": "Gain on sale of nonfinancial assets", "label": "Gain (Loss) on Disposition of Assets", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": ["r874"] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "presentation": ["http://www.bmrn.com/role/DEBTScheduleofConvertibleDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) on extinguishment of debt", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": ["r6", "r40", "r41"] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r149", "r289", "r540", "r692", "r695", "r722", "r733", "r902", "r903"] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationAxis", "presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESNarrativeDetails", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofAggregateNotionalAmountsfortheDerivativesOutstandingDetails", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofFairValueCarryingAmountsofDerivativesDetails", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofImpactofGainsandLossesfromDerivativesDesignatedandNotDesignatedasHedgingInstrumentsDeta], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": ["r10", "r416"] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationDomain", "presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESNarrativeDetails", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofAggregateNotionalAmountsfortheDerivativesOutstandingDetails", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofFairValueCarryingAmountsofDerivativesDetails", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofImpactofGainsandLossesfromDerivativesDesignatedandNotDesignatedasHedgingInstrumentsDeta], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": ["r10"] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"], "lang": { "en-us": { "role": { "totalLabel": "INCOME BEFORE INCOME TAXES", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r87", "r125", "r129", "r545", "r556", "r690", "r691", "r885", "r887", "r888", "r889", "r890"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofImpactofGainsandLossesfromDerivativesDesignatedandNotDesignatedasHedgingInstrumentsDeta "http://www.bmrn.com/role/STOCKBASEDCOMPENSATIONDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r295", "r296", "r301", "r436", "r440", "r445", "r572", "r574", "r631", "r676", "r724", "r966"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofImpactofGainsandLossesfromDerivativesDesignatedandNotDesignatedasHedgingInstrumentsDeta "http://www.bmrn.com/role/STOCKBASEDCOMPENSATIONDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r296", "r301", "r436", "r440", "r445", "r572", "r574", "r631", "r676", "r724", "r966"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"], "lang": { "en-us": { "role": { "terseLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r131", "r139", "r200", "r201", "r223", "r231", "r235", "r399", "r400", "r403", "r563", "r719"] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for income taxes", "label": "Income Taxes Paid", "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": ["r21", "r97", "r875", "r921", "r922"] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and other short-term liabilities", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable, net",

"label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Inventory", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Other current assets", "label": "Increase (Decrease) in Other Current Assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": ["r873"] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Other assets", "label": "Increase (Decrease) in Other Noncurrent Assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": ["r873"] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "presentation": ["http://www.bmrn.com/role/EARNINGSPERCOMMONSHARESScheduleofComputationofBasicandDilutedEarningsPerCommonShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Effect of dilutive securities (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method." } } }, "auth_ref": ["r212", "r213", "r218"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": ["r774", "r784", "r794", "r818", "r826", "r830", "r838"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": ["r836"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": ["r766", "r842"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": ["r766", "r842"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": ["r766", "r842"] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r290", "r905", "r906"] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonConvertibleDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonConvertibleDebtDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total interest expense on convertible debt", "label": "Interest Expense, Operating and Nonoperating", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": ["r223", "r225", "r229", "r232", "r235", "r460", "r691", "r692"] }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebtExcludingAmortization", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonConvertibleDebtDetails": { "parentTag": "us-gaap_InterestExpense", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonConvertibleDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Coupon interest expense", "label": "Interest Expense, Debt, Excluding Amortization", "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs." } } }, "auth_ref": ["r91", "r339", "r704", "r705"] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": ["r229", "r870"] }, "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "presentation": ["http://www.bmrn.com/role/DEBTTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Interest Expense on Convertible Debt", "label": "Interest Income and Interest Expense Disclosure [Table Text Block]", "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities." } } }, "auth_ref": [] }, "us-gaap_InterestOnConvertibleDebtNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestOnConvertibleDebtNetOfTax", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/EARNINGSPERCOMMONSHARESScheduleofComputationofBasicandDilutedEarningsPerCommonShareDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bmrn.com/role/EARNINGSPERCOMMONSHARESScheduleofComputationofBasicandDilutedEarningsPerCommonShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Add: Interest expense, net of tax, on the Company's convertible debt", "label": "Interest on Convertible Debt, Net of Tax", "documentation": "Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash." } } }, "auth_ref": ["r206", "r209", "r218"] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r178", "r180", "r181"] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofInventoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": ["r102", "r682"] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofInventoryDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofInventoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "totalLabel": "Total inventory", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r154", "r680", "r733"] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofInventoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": ["r102", "r684"] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofInventoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Work-in-process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": ["r102", "r683"] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": ["r223", "r228", "r235", "r691", "r869"] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Investments, Debt and Equity Securities [Abstract]", "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "bmrn_KUVANMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "KUVANMember", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyProductDetails"], "lang": { "en-us": { "role": { "terseLabel": "KUVAN", "label": "KUVAN [Member]", "documentation": "KUVAN" } } }, "auth_ref": [] }, "srt_LatinAmericaMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LatinAmericaMember", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyGeographicRegionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Latin America", "label": "Latin America [Member]" } } }, "auth_ref": ["r1000", "r1001", "r1002", "r1003"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r14", "r67", "r68", "r69", "r71", "r72", "r73", "r74", "r184", "r274", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r412", "r414", "r415", "r452", "r605", "r689", "r761", "r916", "r952", "r953"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r80", "r124", "r553",

"r733", "r877", "r901", "r943"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r69", "r144", "r184", "r274", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r412", "r414", "r415", "r452", "r733", "r916", "r952", "r953"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "totalLabel": "Fair value of total financial liabilities", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": ["r431", "r928"] }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": ["http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": { "terseLabel": "Liabilities:", "label": "Liabilities, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent liabilities:", "label": "Liabilities, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.bmrn.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongMember", "presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofAggregateNotionalAmountsfortheDerivativesOutstandingDetails"], "lang": { "en-us": { "role": { "terseLabel": "Purchase", "label": "Long [Member]", "documentation": "Indicates an ownership position in, or purchase of, a security." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtTextBlock", "presentation": ["http://www.bmrn.com/role/DEBT"], "lang": { "en-us": { "role": { "terseLabel": "DEBT", "label": "Long-Term Debt [Text Block]", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": ["r108"] }, "bmrn_LongTermMarketableSecuritiesMaturityPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "LongTermMarketableSecuritiesMaturityPeriod", "presentation": ["http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long term marketable securities maturity period", "label": "Long Term Marketable Securities Maturity Period", "documentation": "Long-term marketable securities maturity period." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": ["http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonConvertibleDebtDetails", "http://www.bmrn.com/role/EARNINGSPERCOMMONSHAREScheduleofAntiDilutiveCommonStockExcludedfromComputationofDilutedEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": ["r14", "r908", "r909", "r910"] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": ["http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonConvertibleDebtDetails", "http://www.bmrn.com/role/EARNINGSPERCOMMONSHAREScheduleofAntiDilutiveCommonStockExcludedfromComputationofDilutedEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": ["r14", "r39", "r908", "r909", "r910"] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONNarrativeDetails", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"], "lang": { "en-us": { "role": { "terseLabel": "Customer", "label": "Customer [Axis]" } } }, "auth_ref": ["r239", "r709", "r744", "r748", "r919", "r963", "r967", "r968", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r994", "r995"] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": ["r311", "r312", "r313", "r314", "r358", "r395", "r434", "r505", "r571", "r573", "r585", "r597", "r598", "r649", "r651", "r653", "r654", "r660", "r674", "r675", "r693", "r706", "r717", "r725", "r726", "r730", "r731", "r745", "r918", "r954", "r955", "r956", "r957", "r958", "r959"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": ["r810"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": ["r810"] }, "us-gaap_MiddleEastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MiddleEastMember", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyGeographicRegionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Middle East", "label": "Middle East [Member]", "documentation": "Region of Middle East." } } }, "auth_ref": ["r1000", "r1001", "r1002", "r1003"] }, "bmrn_MilestonePaymentsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "MilestonePaymentsReceived", "crdr": "credit", "presentation": ["http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Milestone payments received", "label": "Milestone Payments Received", "documentation": "Milestone Payments Received" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": ["r311", "r312", "r313", "r314", "r358", "r395", "r434", "r505", "r571", "r573", "r585", "r597", "r598", "r649", "r651", "r653", "r654", "r660", "r674", "r675", "r693", "r706", "r717", "r725", "r726", "r730", "r745", "r918", "r954", "r955", "r956", "r957", "r958", "r959"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": ["r829"] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": ["http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Money market instruments", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": ["r920"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": ["r837"] }, "bmrn_NAGLAZYMEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "NAGLAZYMEMember", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyProductDetails"], "lang": { "en-us": { "role": { "terseLabel": "NAGLAZYME", "label": "NAGLAZYME [Member]", "documentation": "NAGLAZYME" } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONNarrativeDetails", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"], "lang": { "en-us": { "role": { "terseLabel": "Customer", "label": "Customer [Domain]" } } }, "auth_ref": ["r239", "r709", "r744", "r748", "r919", "r963", "r967", "r968", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r994", "r995"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": ["r811"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r179"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r179"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r95", "r96", "r98"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "NET INCOME", "verboseLabel": "Net income", "terseLabel": "Net income", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r89", "r98", "r126", "r142", "r165", "r168", "r172", "r184", "r189", "r191", "r192", "r194", "r195", "r196", "r200", "r201", "r214", "r274", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r407", "r410", "r428", "r452", "r557", "r628", "r644", "r645", "r760", "r916"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/EARNINGSPERCOMMONSHAREScheduleofComputationofBasicandDilutedEarningsPerCommonShareDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 2.0 } }, "presentation": [

```
"http://www.bmrn.com/role/EARNINGSPERCOMMONSHARESScheduleofComputationofBasicandDilutedEarningsPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Income, basic", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r176", "r191", "r192", "r194", "r195", "r204", "r205", "r215", "r218", "r410" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": [
"http://www.bmrn.com/role/EARNINGSPERCOMMONSHARESScheduleofComputationofBasicandDilutedEarningsPerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator:", "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "calculation": {
"http://www.bmrn.com/role/EARNINGSPERCOMMONSHARESScheduleofComputationofBasicandDilutedEarningsPerCommonShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bmrn.com/role/EARNINGSPERCOMMONSHARESScheduleofComputationofBasicandDilutedEarningsPerCommonShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net Income, diluted", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r176", "r206", "r208", "r209", "r210", "r211", "r215", "r218" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [
"http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r810" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r774", "r784", "r794", "r818", "r826" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r801" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r800" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r818" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r837" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r837" ] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NondesignatedMember", "presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESNarrativeDetails", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofAggregateNotionalAmountsfortheDerivativesOutstandingDetails",
"http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofFairValueCarryingAmountsofDerivativesDetails",
"http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofImpactofGainsandLossesfromDerivativesDesignatedandNotDesignatedasHedgingInstrumentsDeta ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives not designated as hedging instruments:", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r10" ] },
"bmrn_NonqualifiedDeferredCompensationPlanAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bmrn.com/20240630", "localname":
"NonqualifiedDeferredCompensationPlanAssetsMember", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "NQDC Plan assets", "label": "Nonqualified Deferred Compensation Plan Assets [Member]", "documentation": "Nonqualified deferred compensation plan assets." } } }, "auth_ref": [] },
"bmrn_NonqualifiedDeferredCompensationPlanLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bmrn.com/20240630", "localname":
"NonqualifiedDeferredCompensationPlanLiabilityMember", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "NQDC Plan liability", "label": "Nonqualified Deferred Compensation Plan Liability [Member]", "documentation": "Nonqualified deferred compensation plan liability." } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [
"http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Number of operating business segment", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r692", "r886" ] }, "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent", "crdr": "credit", "calculation": {
"http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss) before \u00a0\u00a0\u00a0\u00a0 reclassifications", "label": "OCI, before Reclassifications, before Tax, Attributable to Parent", "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent." } } }, "auth_ref": [ "r17" ] },
"bmrn_OnePointTwoFivePercentSeniorSubordinatedConvertibleNotesDueInMay2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bmrn.com/20240630", "localname":
"OnePointTwoFivePercentSeniorSubordinatedConvertibleNotesDueInMay2027Member", "presentation": [ "http://www.bmrn.com/role/DEBTScheduleofConvertibleDebtDetails",
"http://www.bmrn.com/role/EARNINGSPERCOMMONSHARESScheduleofAntiDilutiveCommonStockExcludedfromComputationofDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.25% senior subordinated convertible notes due in May 2027 (the 2027 Notes)", "label": "One Point Two Five Percent Senior Subordinated Convertible Notes Due in May 2027 [Member]", "documentation": "One Point Two Five Percent Senior Subordinated Convertible Notes Due in May 2027" } } }, "auth_ref": [] }, "bmrn_OperatingAndFinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "OperatingAndFinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": {
"http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 9.0 } }, "presentation": [
"http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liability", "label": "Operating And Finance Lease Liability, Current", "documentation": "Operating And Finance Lease Liability, Current" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenseMember", "presentation": [
"http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofImpactofGainsandLossesfromDerivativesDesignatedandNotDesignatedasHedgingInstrumentsDeta ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expense [Member]", "documentation": "Primary financial statement caption encompassing expenses associated with normal operations." } } }, "auth_ref": [ "r12" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "INCOME FROM OPERATIONS", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r129", "r690", "r885", "r887", "r888", "r889", "r890" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAccountsPayableAndAccruedLiabilities": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccountsPayableAndAccruedLiabilities", "crdr": "credit", "calculation": {
"http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [
"http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofAccountsPayableandAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Accounts Payable and Accrued Liabilities", "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r155", "r733" ] },
"bmrn_OtherAssetsCurrentFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "OtherAssetsCurrentFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair value of other current assets", "label": "Other Assets Current Fair Value Disclosure", "documentation": "Other assets current fair value disclosure." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": {
"terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r151" ] },
"bmrn_OtherAssetsNoncurrentFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "OtherAssetsNoncurrentFairValueDisclosure",
"crdr": "debit", "calculation": { "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } },
"presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair value of other assets", "label": "Other Assets Noncurrent Fair Value Disclosure", "documentation": "Other assets noncurrent fair value disclosure." } } }, "auth_ref": [] }, "us-
gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": [
"http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofImpactofGainsandLossesfromDerivativesDesignatedandNotDesignatedasHedgingInstrumentsDeta ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives Designated as Cash Flow Hedging Instruments", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r137", "r162", "r164" ] }, "us-
gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": {
"http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails", "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss)", "totalLabel": "Net current-period other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r4", "r8", "r114", "r166", "r169", "r196" ] }, "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherComprehensiveIncomeLossTaxPortionAttributableToParent1", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails": {
"parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 3.0 } }, "presentation": [
"http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Tax effect", "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [
"r4", "r8", "r114" ] }, "us-gaap_OtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentAssetsMember",
"presentation": [ "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofFairValueCarryingAmountsofDerivativesDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Other\u00a0current\u00a0assets", "label": "Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing other current assets." } } },
"auth_ref": [ "r52", "r60" ] }, "bmrn_OtherLiabilitiesCurrentFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bmrn.com/20240630", "localname":
"OtherLiabilitiesCurrentFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails": { "parentTag": "us-
gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": { "role": {
```

"verboseLabel": "Fair value of other current liabilities", "label": "Other Liabilities Current Fair Value Disclosure", "documentation": "Other liabilities current fair value disclosure." } } },
"auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit",
"calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent",
"documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r72"] },
"bmrn_OtherLiabilitiesNoncurrentFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bmrn.com/20240630", "localname":
"OtherLiabilitiesNoncurrentFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails": { "parentTag": "us-
gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails"], "lang": { "en-us": { "role": {
"verboseLabel": "Fair value of other long-term liabilities", "label": "Other Liabilities Noncurrent Fair Value Disclosure", "documentation": "Other liabilities noncurrent fair value disclosure." } }
}, "auth_ref": [] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr":
"credit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0, "order": 8.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel":
"Other", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } },
"auth_ref": ["r98"] }, "us-gaap_OtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentAssetsMember",
"presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofFairValueCarryingAmountsofDerivativesDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Other assets", "label": "Other Noncurrent Assets [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent assets." } } }, "auth_ref": [] },
"us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [
"http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofFairValueCarryingAmountsofDerivativesDetails"], "lang": { "en-us": { "role": { "terseLabel":
"Other\u00a0long-term\u00a0liabilities", "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } }
}, "auth_ref": [] }, "us-gaap_OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingIncomeExpenseNet",
"crdr": "credit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails",
"http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"], "lang": { "en-us": { "role": { "terseLabel": "Other expense, net", "label": "Other
Operating Income (Expense), Net", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement,
from items that are associated with the entity's normal revenue producing operations." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Other
Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": ["r810"] }, "us-gaap_OtherRestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OtherRestructuringCosts", "crdr": "debit", "calculation": {
"http://www.bmrn.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails": { "parentTag": "us-gaap_RestructuringCostsAndAssetImpairmentCharges", "weight": 1.0,
"order": 3.0 } }, "presentation": ["http://www.bmrn.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other", "label":
"Other Restructuring Costs", "documentation": "Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a
discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r6"] }, "us-gaap_OtherRestructuringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "OtherRestructuringMember", "presentation": ["http://www.bmrn.com/role/RESTRUCTURINGScheduleofRestructuringActivityDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Other", "label": "Other Restructuring [Member]", "documentation": "Restructuring and related activities classified as other." } } }, "auth_ref": ["r697", "r698", "r699", "r700"] },
"ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate
Erroneous Compensation Amount" } } }, "auth_ref": ["r772", "r782", "r792", "r824"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel":
"Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": ["r775", "r785", "r795", "r827"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": {
"role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": ["r775", "r785", "r795", "r827"] }, "bmrn_PALYNZIQMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "PALYNZIQMember", "presentation": [
"http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyProductDetails"], "lang": { "en-
us": { "role": { "terseLabel": "PALYNZIQ", "label": "PALYNZIQ [Member]", "documentation": "PALYNZIQ" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line
Items]" } } }, "auth_ref": ["r799"] }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "crdr": "credit", "calculation": {
"http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0
} }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments of contingent
consideration", "label": "Payment for Contingent Consideration Liability, Financing Activities", "documentation": "Amount of cash outflow, not made soon after acquisition date of business
combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon
after acquisition date." } } }, "auth_ref": ["r3"] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsForRestructuring", "crdr": "credit", "presentation": ["http://www.bmrn.com/role/RESTRUCTURINGScheduleofRestructuringActivityDetails"], "lang": { "en-us": { "role": {
"negatedLabel": "Payments", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated
with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r300", "r872"] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": {
"http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0
} }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Taxes paid related to net share
settlement of equity awards", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation
for award under share-based payment arrangement." } } }, "auth_ref": ["r177"] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": {
"http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 }
}, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of intangible
assets", "label": "Payments to Acquire Intangible Assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights,
excluding goodwill." } } }, "auth_ref": ["r94"] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsToAcquireInvestments", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-
gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of investments", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all
investments (debt, security, other) during the period." } } }, "auth_ref": ["r93"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": {
"http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 }
}, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property, plant and
equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the
normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r94"] },
"ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [
"r809"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt",
"presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder
Return Amount" } } }, "auth_ref": ["r809"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO
Actually Paid Compensation Amount" } } }, "auth_ref": ["r801"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember",
"presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": ["r818"] }, "ecd_PeoName": {
"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": {
"role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": ["r811"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO
Total Compensation Amount" } } }, "auth_ref": ["r800"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label":
"Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": ["r802"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label":
"Pension Adjustments Service Cost [Member]" } } }, "auth_ref": ["r846"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote",
"label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": ["r801"] }, "us-gaap_PositionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PositionAxis", "presentation": [
"http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofAggregateNotionalAmountsfortheDerivativesOutstandingDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Position", "label": "Position [Axis]", "documentation": "Information by position taken for a security." } } }, "auth_ref": [] }, "us-gaap_PositionDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PositionDomain", "presentation": [
"http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofAggregateNotionalAmountsfortheDerivativesOutstandingDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Position", "label": "Position [Domain]", "documentation": "Indicates position taken for a security." } } }, "auth_ref": [] }, "us-
gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "crdr": "debit", "calculation": {
"http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 }
}, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercises of awards
under equity incentive plans", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "documentation": "Amount of cash inflow from issuance
of shares under share-based payment arrangement. Includes, but is not limited to, option exercised." } } }, "auth_ref": ["r2", "r11"] }, "us-
gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromSaleMaturityAndCollectionsOfInvestments", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Maturities and sales of investments", "label": "Proceeds
from Sale, Maturity and Collection of Investments", "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth
during the period." } } }, "auth_ref": ["r19"] }, "bmrn_ProceedsFromSaleOfNonfinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bmrn.com/20240630", "localname":
"ProceedsFromSaleOfNonfinancialAssets", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-
gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of nonfinancial assets", "label": "Proceeds From Sale Of Nonfinancial Assets", "documentation": "Proceeds From Sale Of
Nonfinancial Assets" } } }, "auth_ref": [] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": [
"http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
"http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofImpactofGainsandLossesfromDerivativesDesignatedandNotDesignatedasHedgingInstrumentsDeta
"http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyGeographicRegionDetails",
"http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyProductDetails"], "lang": { "en-
us": { "role": { "terseLabel": "Net product revenues", "verboseLabel": "Product", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." }

```
} }, "auth_ref": [ "r707" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [
"http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
"http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofImpactofGainsandLossesfromDerivativesDesignatedandNotDesignatedasHedgingInstruments Deta
"http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyGeographicRegionDetails",
"http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyProductDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r236", "r506", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r677", "r707",
"r743", "r745", "r746", "r749", "r751", "r914", "r915", "r919", "r963", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982",
"r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r994", "r995" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [
"http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
"http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofImpactofGainsandLossesfromDerivativesDesignatedandNotDesignatedasHedgingInstruments Deta
"http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyGeographicRegionDetails",
"http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyProductDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r236", "r506", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r677",
"r707", "r743", "r745", "r746", "r749", "r751", "r914", "r915", "r919", "r963", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981",
"r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r994", "r995" ] }, "bmrn_ProductsExcludingALDURAZYMEMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.bmrn.com/20240630", "localname": "ProductsExcludingALDURAZYMEMember", "presentation": [
"http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyGeographicRegionDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Products excluding ALDURAZYME", "label": "Products Excluding ALDURAZYME [Member]", "documentation": "Products excluding product one." } }
}, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross",
"crdr": "debit", "calculation": { "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofPropertyPlantandEquipmentNetDetails": { "parentTag": "us-
gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofPropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Property, plant and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical
assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture
and fixtures." } } }, "auth_ref": [ "r103", "r147", "r555" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight":
1.0, "order": 3.0 }, "http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofPropertyPlantandEquipmentNetDetails": { "parentTag": null, "weight":
null, "order": null, "root": true } }, "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONScheduleofPropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Property, plant and equipment, net", "totalLabel": "Total property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated
depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not
limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r7", "r470", "r546", "r555", "r733" ] }, "us-
gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [
"http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property, Plant and Equipment, Net",
"label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale.
Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } },
"auth_ref": [ "r7" ] }, "us-gaap_PurchaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligation", "crdr": "credit",
"presentation": [ "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase commitment", "label": "Purchase
Obligation", "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier." } } }, "auth_ref": [] },
"us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": [ "http://www.bmrn.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Purchase commitments expected to be paid in 2024", "label": "Purchase Obligation, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of
purchase arrangement to be paid in remainder of current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-
term purchase commitment." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [
"r799" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } },
"auth_ref": [ "r799" ] }, "bmrn_ROCTAVIANMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "ROCTAVIANMember", "presentation": [
"http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyProductDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "ROCTAVIAN", "label": "ROCTAVIAN [Member]", "documentation": "ROCTAVIAN" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [
"http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Range", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r311", "r312", "r313", "r314", "r351", "r358", "r386", "r387", "r388", "r395", "r434", "r480", "r489", "r505",
"r571", "r573", "r585", "r597", "r598", "r649", "r651", "r653", "r654", "r660", "r674", "r675", "r693", "r706", "r717", "r725", "r726", "r730", "r731", "r745", "r754", "r911", "r918", "r931", "r955",
"r956", "r957", "r958", "r959" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [
"http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Range", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r311", "r312", "r313", "r314", "r351", "r358", "r386", "r387", "r388", "r395", "r434", "r480", "r489",
"r505", "r571", "r573", "r585", "r597", "r598", "r649", "r651", "r653", "r654", "r660", "r674", "r675", "r693", "r706", "r717", "r725", "r726", "r730", "r731", "r745", "r754", "r911", "r918", "r931",
"r955", "r956", "r957", "r958", "r959" ] }, "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent", "crdr": "debit", "calculation": {
"http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
"weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: gain
(loss) reclassified from AOCI", "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent", "documentation": "Amount before tax of reclassification adjustments of
other comprehensive income (loss) attributable to parent." } } }, "auth_ref": [ "r17" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line
Items]" } } }, "auth_ref": [ "r767", "r777", "r787", "r819" ] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RepaymentsOfDebt", "crdr": "credit", "presentation": [ "http://www.bmrn.com/role/DEBTScheduleofConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt repayments",
"label": "Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r871" ] }, "us-
gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit",
"calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order":
2.0 } }, "presentation": [ "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Research and
development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software
product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both.
Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r396", "r676",
"r691", "r960" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.bmrn.com/role/STOCKBASEDCOMPENSATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and
development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development
expense have been included." } } }, "auth_ref": [] }, "bmrn_RestOfWorldMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bmrn.com/20240630", "localname":
"RestOfWorldMember", "presentation": [
"http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyGeographicRegionDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Rest of world", "label": "Rest Of World [Member]", "documentation": "Rest of world." } } }, "auth_ref": [] }, "srt_RestatementAdjustmentMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementAdjustmentMember", "presentation": [
"http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Revision of Prior Period, Adjustment", "label": "Revision of Prior Period, Adjustment [Member]" } } }, "auth_ref": [ "r186", "r187", "r188", "r198", "r199", "r222", "r426", "r427",
"r466", "r848", "r849", "r850", "r851", "r854", "r855", "r856", "r891" ] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"RestatementAxis", "presentation": [
"http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Revision of Prior Period [Axis]", "label": "Revision of Prior Period [Axis]" } } }, "auth_ref": [ "r141", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r197",
"r198", "r199", "r200", "r201", "r202", "r222", "r276", "r277", "r405", "r406", "r407", "r408", "r409", "r410", "r425", "r426", "r427", "r428", "r464", "r466", "r471", "r472", "r575", "r576", "r577",
"r578", "r579", "r580", "r581", "r582", "r583", "r584", "r587", "r891" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement
Determination Date [Axis]" } } }, "auth_ref": [ "r768", "r778", "r788", "r820" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination
Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r769", "r779", "r789", "r821" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": {
"role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r776", "r786", "r796", "r828" ] },
"srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementDomain", "presentation": [
"http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Revision of Prior Period [Domain]", "label": "Revision of Prior Period [Domain]" } } }, "auth_ref": [ "r141", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194",
"r197", "r198", "r199", "r200", "r201", "r202", "r222", "r276", "r277", "r405", "r406", "r407", "r408", "r409", "r410", "r425", "r426", "r427", "r428", "r464", "r466", "r471", "r472", "r575", "r576",
"r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r587", "r891" ] }, "bmrn_RestrictedInvestmentsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.bmrn.com/20240630", "localname": "RestrictedInvestmentsMember", "presentation": [ "http://www.bmrn.com/role/FAIRVALUEMEASUREMENTSDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Restricted Investments", "label": "Restricted Investments [Member]", "documentation": "Restricted investments." } } }, "auth_ref": [] }, "us-
gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": {
"en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [
"http://www.bmrn.com/role/RESTRUCTURING" ], "lang": { "en-us": { "role": { "terseLabel": "RESTRUCTURING", "label": "Restructuring and Related Activities Disclosure [Text Block]",
"documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances
leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the
periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r297", "r298", "r300", "r303", "r308" ] }, "us-
gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated", "presentation": [ "http://www.bmrn.com/role/RESTRUCTURINGNarrativeDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Number of positions eliminated", "label": "Restructuring and Related Cost, Expected Number of Positions Eliminated", "documentation": "The expected number of positions to be
eliminated as a result of restructuring activities." } } }, "auth_ref": [] }, "bmrn_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce": { "xbrltype":
"percentItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPercentageOfWorkforce", "presentation": [
"http://www.bmrn.com/role/RESTRUCTURINGNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of workforce expected to be eliminated", "label": "Restructuring and
Related Cost, Expected Number Of Positions Eliminated, Percentage Of Workforce", "documentation": "Restructuring and Related Cost, Expected Number Of Positions Eliminated, Percentage
Of Workforce" } } }, "auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr":
"debit", "presentation": [ "http://www.bmrn.com/role/RESTRUCTURINGScheduleofRestructuringActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Charges and Adjustments", "label":
```

"Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r6", "r304", "r305", "r912"] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveAxis", "presentation": ["http://www.bmrn.com/role/RESTRUCTURINGScheduleofRestructuringActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Type [Axis]", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": ["r299", "r300", "r305", "r306"] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": ["http://www.bmrn.com/role/RESTRUCTURINGNarrativeDetails", "http://www.bmrn.com/role/RESTRUCTURINGScheduleofRestructuringActivityDetails", "http://www.bmrn.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r299", "r300", "r301", "r302", "r305", "r306", "r307"] }, "us-gaap_RestructuringCostsAndAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostsAndAssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.bmrn.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Restructuring expenses", "label": "Restructuring Costs and Asset Impairment Charges", "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r6"] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanAxis", "presentation": ["http://www.bmrn.com/role/RESTRUCTURINGNarrativeDetails", "http://www.bmrn.com/role/RESTRUCTURINGScheduleofRestructuringActivityDetails", "http://www.bmrn.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanDomain", "presentation": ["http://www.bmrn.com/role/RESTRUCTURINGNarrativeDetails", "http://www.bmrn.com/role/RESTRUCTURINGScheduleofRestructuringActivityDetails", "http://www.bmrn.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserve", "crdr": "credit", "presentation": ["http://www.bmrn.com/role/RESTRUCTURINGScheduleofRestructuringActivityDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": ["r300", "r306"] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveRollForward", "presentation": ["http://www.bmrn.com/role/RESTRUCTURINGScheduleofRestructuringActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve [Roll Forward]", "label": "Restructuring Reserve [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r77", "r113", "r552", "r579", "r584", "r589", "r607", "r733"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit:", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r140", "r186", "r187", "r188", "r190", "r196", "r199", "r201", "r275", "r278", "r294", "r401", "r402", "r404", "r405", "r406", "r408", "r409", "r410", "r418", "r420", "r421", "r423", "r426", "r465", "r467", "r575", "r577", "r590", "r998"] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyGeographicRegionDetails", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyProductDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Total revenues", "terseLabel": "Revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": ["r127", "r128", "r223", "r226", "r227", "r233", "r235", "r236", "r237", "r239", "r348", "r349", "r506"] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"], "lang": { "en-us": { "role": { "terseLabel": "REVENUES:", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "bmrn_RoyaltyAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "RoyaltyAndOtherMember", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyProductDetails"], "lang": { "en-us": { "role": { "terseLabel": "Royalty and other revenues", "label": "Royalty And Other [Member]", "documentation": "Royalty and other." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r837"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r837"] }, "us-gaap_SalesChannelDirectlyToConsumerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesChannelDirectlyToConsumerMember", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyGeographicRegionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Marketed by Company", "label": "Sales Channel, Directly to Consumer [Member]", "documentation": "Contract with customer in which good or service is transferred directly to consumer." } } }, "auth_ref": ["r713"] }, "us-gaap_SalesChannelThroughIntermediaryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesChannelThroughIntermediaryMember", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyGeographicRegionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Marketed by Sanofi", "label": "Sales Channel, Through Intermediary [Member]", "documentation": "Contract with customer in which good or service is transferred through intermediary." } } }, "auth_ref": ["r713"] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofTotalNetProductRevenueConcentrationsAttributedtoLargestCustomersDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net Product Revenue", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": ["r239", "r852"] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": ["http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMETables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income and Reclassifications Out of AOCI", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r17", "r947", "r948"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.bmrn.com/role/EARNINGSPERCOMMONSHAREScheduleofAntiDilutiveCommonStockExcludedfromComputationofDilutedEarningsPerShareDetails", "http://www.bmrn.com/role/EARNINGSPERCOMMONSHAREScheduleofComputationofBasicandDilutedEarningsPerCommonShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r25"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.bmrn.com/role/EARNINGSPERCOMMONSHARETables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Anti-Dilutive Common Stock Excluded from Computation of Diluted Earnings Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r25"] }, "bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems", "presentation": ["http://www.bmrn.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Available-for-sale Securities [Line Items]", "label": "Schedule Of Cash Cash Equivalents And Available For Sale Securities [Line Items]", "documentation": "Schedule of cash, cash equivalents and available-for-sale securities." } } }, "auth_ref": [] }, "bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable", "presentation": ["http://www.bmrn.com/role/FINANCIALINSTRUMENTSNarrativeDetails", "http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table]", "label": "Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table]", "documentation": "Schedule of cash, cash equivalents and available-for-sale securities." } } }, "auth_ref": [] }, "bmrn_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTableTextBlock", "presentation": ["http://www.bmrn.com/role/FINANCIALINSTRUMENTSTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category", "label": "Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table Text Block]", "documentation": "Schedule of cash, cash equivalents and available-for-sale securities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Impact of Gains and Losses from Derivatives Designated and Not Designated as Hedging Instruments", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": ["r53", "r56", "r416"] }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value Carrying Amounts of Derivatives", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": ["r54"] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.bmrn.com/role/EARNINGSPERCOMMONSHARETables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Computation of Basic and Diluted Earnings Per Common Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation":

"Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r883"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.bmrn.com/role/STOCKBASEDCOMPENSATIONTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-Based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r45"] }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyProductDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customers by Products and Services [Table]", "label": "Segment Reporting, Revenue from External Customer, Product and Service [Table]", "documentation": "Disclosure of information about revenue from external customer by product and service when not provided as part of reportable operating segment information." } } }, "auth_ref": ["r33"] }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disaggregation of Total Net Product Revenues by Product", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information." } } }, "auth_ref": ["r33"] }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable", "presentation": ["http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]", "label": "Error Correction [Table]", "documentation": "Disclosure of information about prior period adjustment to correct error in previously issued financial statement. Includes, but is not limited to, effect of correction on financial statement line item, affected per-share amount, cumulative effect of change on retained earnings and other appropriate component of equity or net assets in statement of financial position, and effect of prior period adjustment on net income of each prior period presented." } } }, "auth_ref": ["r191", "r192", "r193", "r198", "r199", "r200", "r201", "r222"] }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "presentation": ["http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Changes in Prior Period Presentation", "label": "Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]", "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made." } } }, "auth_ref": ["r22", "r23", "r24"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": ["http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets, Net", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": ["r696", "r904"] }, "us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Aggregate Notional Amounts for the Derivatives Outstanding", "label": "Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]", "documentation": "Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts." } } }, "auth_ref": ["r118"] }, "bmrn_ScheduleOfInterestExpensesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "ScheduleOfInterestExpensesLineItems", "presentation": ["http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonConvertibleDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Interest Expenses [Line Items]", "label": "Schedule Of Interest Expenses [Line Items]", "documentation": "Schedule of interest expenses." } } }, "auth_ref": [] }, "bmrn_ScheduleOfInterestExpensesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "ScheduleOfInterestExpensesTable", "presentation": ["http://www.bmrn.com/role/DEBTScheduleofInterestExpenseonConvertibleDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Interest Expenses [Table]", "label": "Schedule Of Interest Expenses [Table]", "documentation": "Schedule of interest expenses table." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": ["http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATIONTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventory", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": ["r15", "r81", "r82", "r83"] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": ["http://www.bmrn.com/role/RESTRUCTURINGNarrativeDetails", "http://www.bmrn.com/role/RESTRUCTURINGScheduleofRestructuringActivityDetails", "http://www.bmrn.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost [Table]", "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": ["r299", "r300", "r301", "r302", "r305", "r306", "r307"] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": ["http://www.bmrn.com/role/RESTRUCTURINGTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Restructuring and Related Costs", "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": ["r37", "r104", "r105"] }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": ["http://www.bmrn.com/role/RESTRUCTURINGTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring Reserve Activity", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": ["r38", "r106"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://www.bmrn.com/role/STOCKBASEDCOMPENSATIONDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r360", "r362", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389"] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Total Net Product Revenue Concentrations Attributed to Largest Customers", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": ["r26", "r27", "r28", "r29", "r64", "r119"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.bmrn.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r762"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.bmrn.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r764"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyGeographicRegionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Domain]" } } }, "auth_ref": ["r237", "r238", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r593", "r594", "r595", "r650", "r652", "r655", "r661", "r662", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r678", "r708", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r747", "r754", "r919", "r963", "r967", "r968", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r994", "r995"] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails", "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r90"] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": ["http://www.bmrn.com/role/STOCKBASEDCOMPENSATIONDetails"], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeveranceCosts1", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails": { "parentTag": "us-gaap_RestructuringCostsAndAssetImpairmentCharges", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bmrn.com/role/RESTRUCTURINGScheduleofRestructuringandRelatedCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Severance and one-time employee benefits", "label": "Severance Costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r6"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r5"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.bmrn.com/role/STOCKBASEDCOMPENSATIONDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r360", "r362", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Award Types", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389"] }, "us-gaap_ShortMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortMember", "presentation": ["http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofAggregateNotionalAmountsfortheDerivativesOutstandingDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sell", "label": "Short [Member]", "documentation": "Indicates the sale of a borrowed security or written option." } } }, "auth_ref": [] }, "bmrn_ShortTermMarketableSecuritiesMaturityPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "ShortTermMarketableSecuritiesMaturityPeriod", "presentation": [

"http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Short term marketable securities maturity period", "label": "Short Term Marketable Securities Maturity Period", "documentation": "Short-term marketable securities maturity period." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIES"], "lang": { "en-us": { "role": { "terseLabel": "BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r99", "r183"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails", "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.bmrn.com/role/DERIVATIVEINSTRUMENTSANDHEDGINGSTRATEGIESScheduleofImpactofGainsandLossesfromDerivativesDesignatedandNotDesignatedasHedgingInstrumentsDeta], "lang": { "en-us": { "role": { "terseLabel": "Equity Components", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r9", "r75", "r78", "r79", "r140", "r170", "r171", "r172", "r186", "r187", "r188", "r190", "r196", "r199", "r201", "r224", "r275", "r278", "r294", "r345", "r401", "r402", "r404", "r405", "r406", "r408", "r409", "r410", "r418", "r419", "r420", "r421", "r422", "r423", "r426", "r453", "r454", "r455", "r456", "r457", "r458", "r465", "r467", "r472", "r558", "r575", "r576", "r577", "r590", "r646"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyGeographicRegionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Axis]" } } }, "auth_ref": ["r237", "r238", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r593", "r594", "r595", "r650", "r652", "r655", "r661", "r662", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r678", "r708", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r747", "r754", "r919", "r963", "r967", "r968", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r994", "r995"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r186", "r187", "r188", "r224", "r467", "r506", "r588", "r592", "r599", "r600", "r601", "r602", "r603", "r604", "r606", "r609", "r610", "r611", "r612", "r613", "r615", "r616", "r617", "r618", "r620", "r621", "r622", "r623", "r624", "r626", "r629", "r630", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r646", "r755"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r186", "r187", "r188", "r224", "r240", "r467", "r506", "r588", "r592", "r599", "r600", "r601", "r602", "r603", "r604", "r606", "r609", "r610", "r611", "r612", "r613", "r615", "r616", "r617", "r618", "r620", "r621", "r622", "r623", "r624", "r626", "r629", "r630", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r646", "r755"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": ["r771", "r781", "r791", "r823"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockCompensationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockCompensationPlanMember", "presentation": ["http://www.bmrn.com/role/EARNINGSPERCOMMONSHARESScheduleofAntiDilutiveCommonStockExcludedfromComputationofDilutedEarningsPerShareDetails", "http://www.bmrn.com/role/EARNINGSPERCOMMONSHARESScheduleofComputationofBasicandDilutedEarningsPerCommonShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock issuable under the Company's equity incentive plans", "label": "Share-Based Payment Arrangement [Member]", "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares." } } }, "auth_ref": ["r884"] }, "bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiency", "crdr": "credit", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "verboseLabel": "Issuances under equity incentive plans, net of tax", "label": "Stock Issued During Period Value New Issues Net Excess Tax Benefit Tax Deficiency", "documentation": "Stock issued during period value new issues net excess tax benefit tax deficiency." } } }, "auth_ref": [] }, "bmrn_StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "StockIssuedDuringPeriodValueNewIssuesNetExcessTaxBenefitTaxDeficiencyShares", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Issuances under equity incentive plans (in shares)", "label": "Stock Issued During Period Value New Issues Net Excess Tax Benefit Tax Deficiency Shares", "documentation": "Stock issued during period value new issues net excess tax benefit tax deficiency, shares." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.bmrn.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails", "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balances", "periodEndLabel": "Ending balances", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r75", "r78", "r79", "r101", "r608", "r625", "r647", "r648", "r733", "r761", "r877", "r901", "r943", "r998"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "bmrn_StrategicInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "StrategicInvestmentMember", "presentation": ["http://www.bmrn.com/role/FINANCIALINSTRUMENTSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Strategic Investment", "label": "Strategic Investment [Member]", "documentation": "Strategic investment." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://www.bmrn.com/role/DEBTScheduleofConvertibleDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r459", "r473"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.bmrn.com/role/DEBTScheduleofConvertibleDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r459", "r473"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://www.bmrn.com/role/DEBTScheduleofConvertibleDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r459", "r473"] }, "bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets", "crdr": "credit", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Increase in accounts payable and accrued liabilities related to fixed assets", "label": "Supplemental Accounts Payable And Accrued Liabilities Increase (Decrease), Fixed Assets", "documentation": "Increase (decrease) in accounts payable and accrued liabilities related to purchase of property, plant and equipment during the reporting period." } } }, "auth_ref": [] }, "bmrn_SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets", "crdr": "credit", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Decrease in accounts payable and accrued liabilities related to intangible assets", "label": "Supplemental Accounts Payable And Accrued Liabilities Increase (Decrease), Intangible Assets", "documentation": "Supplemental Accounts Payable And Accrued Liabilities Increase (Decrease), Intangible Assets" } } }, "auth_ref": [] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": ["http://www.bmrn.com/role/SUPPLEMENTALFINANCIALSTATEMENTSINFORMATION"], "lang": { "en-us": { "role": { "terseLabel": "SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": ["r864"] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "SUPPLEMENTAL CASH FLOW DISCLOSURES:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": ["r817"] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": ["r809"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": ["r816"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": ["r836"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": ["r838"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.bmrn.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": ["http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r341", "r344", "r424", "r451", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r559", "r721", "r723", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r734", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r897", "r898", "r899", "r900", "r927", "r930", "r931", "r932", "r939", "r942"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": ["r839"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": ["r840"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": ["r840"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [

"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": ["r838"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": ["r838"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": ["r841"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": ["r839"] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRestructuringDomain", "presentation": ["http://www.bmrn.com/role/RESTRUCTURINGScheduleofRestructuringActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Type of Restructuring [Domain]", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": ["r299", "r300", "r305", "r306"] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyGeographicRegionDetails"], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": ["http://www.bmrn.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "U.S. government agency securities", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": ["r687", "r714", "r961"] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": ["r835"] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.bmrn.com/role/BUSINESSOVERVIEWANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r30", "r31", "r32", "r133", "r134", "r135", "r136"] }, "bmrn_VIMIZIMMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "VIMIZIMMember", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyProductDetails"], "lang": { "en-us": { "role": { "terseLabel": "VIMIZIM", "label": "VIMIZIM [Member]", "documentation": "VIMIZIM" } } }, "auth_ref": [] }, "bmrn_VOXZOGOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "VOXZOGOMember", "presentation": ["http://www.bmrn.com/role/REVENUECREDITCONCENTRATIONSANDGEOGRAPHICINFORMATIONScheduleofDisaggregationofTotalNetProductRevenuesbyProductDetails"], "lang": { "en-us": { "role": { "terseLabel": "VOXZOGO", "label": "VOXZOGO [Member]", "documentation": "VOXZOGO" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": ["r805"] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.bmrn.com/role/EARNINGSPERCOMMONSHAREScheduleofComputationofBasicandDilutedEarningsPerCommonShareDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average common shares outstanding, diluted (in shares)", "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r206", "r218"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://www.bmrn.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.bmrn.com/role/EARNINGSPERCOMMONSHAREScheduleofComputationofBasicandDilutedEarningsPerCommonShareDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average common shares outstanding, basic (in shares)", "terseLabel": "Weighted-average common shares outstanding, basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r204", "r218"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": ["http://www.bmrn.com/role/EARNINGSPERCOMMONSHAREScheduleofComputationofBasicandDilutedEarningsPerCommonShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Denominator:", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": ["r803"] }, "bmrn_ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bmrn.com/20240630", "localname": "ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember", "presentation": ["http://www.bmrn.com/role/DEBTScheduleofConvertibleDebtDetails", "http://www.bmrn.com/role/EARNINGSPERCOMMONSHAREScheduleofAntiDilutiveCommonStockExcludedfromComputationofDilutedEarningsPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "$0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)", "label": "Zero Point Five Nine Nine Percent Senior Subordinated Convertible Notes Due In August Two Thousand Twenty Four [Member]", "documentation": "Zero point five nine nine percent senior subordinated convertible notes due in August two thousand twenty four." } } }, "auth_ref": [] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(f)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",

"Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "710", "SubTopic": "10", "Section": "25", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483070/710-10-25-16" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-7" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/220/tableOfContent" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/815/tableOfContent" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" },

"r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards

Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-42" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r276": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/420/tableOfContent" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)

(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher":

"FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB

Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",

"Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-

S99-3" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r754": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r788": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r795": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r796": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r797": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r799": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r800": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",

"Section": "402", "Subsection": "x", "Paragraph": "2" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "y", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "y", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "y", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/210/tableOfContent" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" } } } ZIP 81 0001048477-24-000126-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001048477-24-000126-xbrl.zip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~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lV MF\U:V0E2C4Q=3CKQK_$)]3Z2VZ$G&2M+F%6F MZ8;IXVT'-)H3#'!4TYG!'"-F8=9 4QCS(=BR.TH,S[F$&KV)X\), FX0-RZR MB'2ZTU@E96)2)T+ A$0K@\'*7V.L 3)&X<$D:6T^AN9!V%Q&/L^;]L4$ _ MTX8G 2T/=)^\.'N GDN]O5'AZD@87V9[Z9I MFWE"1>#%^XGSA9<#/-QIKFF M]F,"PXS'!%ZE0$W%V6/RTP3H=2;*@+L:F;B=VV:L9))-O!DV5X<'T+6201C9 M:2V9Y06T%@@^8JHC'(;F9X7X@NDL?*D=F96RS MIJ"PF[OEWX&48&H>[HS_C MYX OA5OG!XG7G(ZQ[K0!0#"-DP.128*$\JJ,\(:*C/&]?* UA8GS0K:8@\; MFSS%-4-PXBQ)@#GX87SO1.ZP7-./I_>T0#&*"]/,$3;@FI9,T&Q/HG;A7MA .(WB)I5T%&])V=J<7H\GW.UE(0O1FI6E M21PBV4)D0&!2'5BQ.L."R(3JZ?04,]4+-L7E,^0:@WIFK'(-7RWY!M+"G$ 5Q;GC%-HL3RV:;87 ()G@:TITS.M=G,*.E"C!8+/ M9N'$/9E51Z9ZE4ZL:XIY4[^"]E(R,%E=327 4VS] M%+(O;U>"Z)QO*1QR5= O;]@P>(E:^@ZFVG1 MA3CSX!??^>VQ+9<+[CS6$2'A7%QJ0T0<28@T%26$^!WB@%<%.52-WQN\]2^1.SM+:33MI4= M4*> M9[56K85PW[1BF_O&4C$/ZB7'9>?+11()HYS O-YXQ(0/8U8+EX#)V&^#DNX MD^N26NPHQ+A.&EW"\/%TO5T<)@V$*"ZHG)7K3O&]V[H,[H"?)GFQR'#*:+[]+#;_%^H=@S 4""!B== M TH;L>_<((]#X&T8W*]P>TY#C-'T298H3F+Q3<4=Y]JU+%Q9-T79Z!)7$ XJ0\E M%);Q4@+/CY>2^$D!V/RZ ;Y*LF!A@U+=H4M+YUK>X,*N.!&35+M1QRGQ5>E" MQS67%6!/)6:(*1HK?=&QMC?=;AE7(5A5?*M%:Q2+M/BU_GA7;S2_=UN-^JW0:C=V5JNYOD"W_O6V*=Q_M$QKW[6ZSW>T4J:U\Y5(WLMHMV%#VN].F,1GJI6KLMUOPYNUT=?GMC7EWW/ M MEUVY]MU:C161?H Y8TGE[+^WWCYO?<)W6N3V9/V8E4G$]?:,/U1@0OVO*[0N M5V>-8FS]=UC#P%:[WFZTZ'SR[1YFE6[K?MIQ]HWW3Y0T=2''8-QC_Y>5O3"R MD4H?A[N!)D15B)RUK;*W",\YF#@ZJ6:N@&R!5,?NW+A&Y6!ER(6\"86Q&!>2&B*V36=HCE L*0@. FWF4N(%E-,"@8 M=& (@3<$URI(&FT*S3\BC,3S6>8\A4@KU30N1-E::,5@H_HT6BJ^3&BXK1945 MHU33BRPK)Q.3I+^RMU>3YCE9X2X\X!7Y5*M3M/U--4YQL@]$EBD;]F(KFMWAQ4:SG&^H,^&&&?D>5, 0";"HIF#TO"H6[N#(- M*T,Y'F$&P*K$]4C>;# 2/5+^F'H$ZP!I$PS4(0^X$--&M<&5!#/HW*8DEBJ# M55KLS6#=V?2T@BFW E=L5>6T8NN#EFS==W]M/NY9KL7UVO'U&@)3E;GQDS<; MRA^()).N6/.7KYBQ"<*3<[&$'EUP]Y,^&2JH>ZA]3ASO:,A5 S.8Y*HA=S9\ M^3*$3/=]/Z<"N']@AV8@Y?@\X2'O4MD]^?VQVN)PP(B>XM.G- MU>97M-U9^ON;/0U7.RNJM*/F,3HKKF'Q.;MHK>>QDDE/1S6+GHYO['[%H/! M4_86@. ^4;#TK$:MJY_2[2"XD6=\F7\[^K?-[O7[$N MZCH"\'Z1AIQ X[Y]TVQWFC?8,+)S?]NZJ7?A2Z<+ _]QA \BXE^3=PV/S5SBO M]7L3W^W^KKG+VZEYOUUWNGJ_X[P*=QY=D=S MB^ 6=H#[X^)&,+B[0=SW.=D;(?C,Z.BCU:6O,\U\VNZD,&U<2O'4L4][TK)^ M:1A&)]U 9?FR+.W7573S[YK.X*#42C:]5]FE5':M7'.;0_)R2.RL8+< M$N+8R2N+%4ZN?IDTFQ'F9P]J.N\(.[!$L(>SMM:C+10MEN?$S93X.& ^O/T] M*]Q%DR:K+K-:HC=G0"KU4.D_*VIPX+P3.%L49<^T?CSY8*;:%\FX+(N0?O_ = M[9Q/][:/S=^:[>_-SO4NR-CTEIE 9AL)WWL]'lQI!K>WB/3I_Y9%1*#_*I>* MQEB2C(I+FX33O7K27=^6)6>?%Y8$!C3#^E?]\T'O]64Y<9' "_WDO&)RX9MO M6K2S3N0ZX2-F&:+ +M'=S6'() ?K G!K$\L9FKQ8$O&[SO8$\J9SNS:0_E ML?2X>>7#):/XDE'.73+D4DTSRJ)>-;AD<,E@1S*TW"5#*=5D456K8K54!GI7$K5*A8/J7$!5S1U4 M.H;HQ:I\L ?(0<4*]&0I=U15**HT76<$55E&U!7MLL*D?=CU0G-XF$V8O/;. M2<>S$1DY=Y$Q2K6*K(A29E']?3+'>00C."#? J22.R#I8DI-5"H:!R0'9.X* MLBS1D*PNB8:N<$1R1,JY9Y;+,HV$5F51KQXS6M7CU9[=7]0_.Q MWFVU?Q&;_WS_Q3J\"HC%EA;5>X#2^@>]X&M,_B(3[C64XQ6ZP>I-Y]/YEH_M]IT\,.6L2F)9.Z.RI \/F"UNVT& 46/ Z#('S/D YHAX*9=JBJ:)NLKQ+T' 08#0^CZZ)4E1D!S,U+%OC#ZF8]VU_M;V94;+Z.<>OI?45!A[G64,6*P9/MYP.@K3'U# &$>]E6*]** 90X@,X$0"?$ M#VY/.!ABI7)PB27'#S/XV1JQSA!50!0N2HJTL'6/X,U&,P:0E%*M#"9?53VCU9@?'DA;3+[C M(Q$D%),D5458.KK_E@;S=<=%R0]-!]SW8Z&0%Z6B[[P2^^*_O/?6"(2! M[6H-15:-^,.+C<&_YZ#9=9N"I+"-SC*^.)\8$HZKNDT#BL.I!?9,^WG][']6]5@[IK)S'K M?3T<7<'UQG*& 6V86-V9D0/]\="VPT]*0]F_M]4JEC)K#R&KW(:#L]NV,IT MG; FB]5R5GV6,-R*#+<=5G$<@C?,5HB2KH#5);L.A&RM2U]O_+*W)TB\$:3P M[?'^3DC6J-^W-^]WS-L\[&]VWJ=6? M&0"N4JKI6A;M\3C>S@!O1X>;@16JAEB5LVK7S?%69+QM,3XS %P5)]2*6*T4 MJ2M2.HB4L&6Z5?R)6]3PZQF[_@Q)72V.!!900>[#R]B+O,5:.<#G=.@1RG5 MU*HH:UF99OPY^2-GBU6?%714\"7+HJ:Q,E^=P7;26^RSI%CA(RP@\]_<;ZNR MC F8)%';GCLM -D7]&70EZ*VIA7'[K5>O&Z?'>!LM<\R XZ&P*FL498<,4 MSLEPHY=]N'QWM0\?QTT1<;/5-LL,.!4$3EE;K3(Y.7#.-G!V3[?>3*PR47#) M^SHU%LP7.= T"V#4\&DEUX"T7$HXI%)]O9-C%(-7!-EM7Z4E^07$40K9MI) M0(1]TT1=7FWFPT%41!#E@2%#0@PI.E\:=!X86C'?3@(B#.]71(V%%69G$&1[MLS[S:_/;_6-32+YUZ_]LO]J&\\)6,V_UC--*DG0W+L>-@ B)K'AN\)6 <)#X MO*[Y2H+F:^B;0$?'-?U)*R2C -PB?*KOT8Y9[XQ?&W37%464U:RVIF6B%HH7 MXA\K5F!G8XB8T:D74C:SZX'<%AFW6R.AS !7 MBVM8-;T0RY'-MKZX'O/3H*X O8EM8I*B(S_"%`7[(UPD)G$)?U*7/+0]8+ MG1: 5#/;@YE'./)'SDY6\,'(]= FK)7,%@5PY,2/G), !_,ZLFB4#YZ),7"8 M 2Q==SK?,$&T2 MOGN9897VX*N(6^"R]*%E:8N9?I LR:6:IHM2^:.,$E[DH?6A1,J(D M88:QJHG&A\DP'&WD0?@#O+MF_;'=:O_2$1Z:

MCT+GU_IC4Q2^UCNMQ@%]/%0@L.U%N%O6V>]"_=^Z8,K@@?B=@>F3M]T^95DG M-$W?A5<.TLN_FH%C3<5?FHI_N523+K4C=,G;PH:<@H)<>KCTK#IZ[Y8>#:5' M/4(+)BX]7'H8EIY,A =[@EYFMJ4S%OXN/,40'C43Z;E0PRVK?.UQI>=L)&<%^")3+ MSSG+SWZ>VV;YJ:+*$?8FX;+#YC]))T!GFW1I#X[U";,&$H9A/!-YN-,+]R)%Y@>|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l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`#GUA?(LA O3>T;+ES7:FDY]#VPIC#%&XR,]>!4^Y_@#,H4U6FOQ M-?7IB^/-@O$;0B_%X3QO]:2OFE%+#SN) ^)7:E@@-@(%(? 3]MRAX]IN'[8W MT]4)"HW$SC0!V#$4"=$7OV;'>PY3$]%58 MG!#%(ZL\I.M &O#E&"]S9+VQ-UA_<]-#6XBFB&H4OZ*11YIY?)6>7G;78=V M7'G3:PU%T@1-3-:;55#>+KE"F)W/V-T9CN6UG.5K", 6>48]3*9C[XW2I^BZ M7X"08"&]:@B&DI'!298-J(6,53%11=\A6(:5.?]F#O%C>A MPYH().=\,2*P19$R/V^\AG]Z,"4W;J@=V1Y/T:)FAK^%]42*H"]%6?85,-ZO M'D%;E.A1$&2)M8:E"Y)1E*G*K=$=^M.)6HN']Bl0HMP,S>PJP46, CE=7.(# M#0<+BWI-P=1S]T_CUF=EP+/[WE\0>#"T+^A:[L ^MSG?W_VOU XH&#4AJ MK6$*!K<\CXV$+YX/O[DS :I_X;L^"/;?<:D#/_5]@<,#;CXA[4$O&238H<] M>@\C>&%]4_+[LBRMUC! KW*+]'+@\,\B+10^&'52!#-_SW5NE>[I"?7>[#'+ M=N.^T#RW^:?Y.AZ*?(,ISOPA &Z05@8Y^UWE#5FS([=/E=?(7XIQ..[F8!S(3ZN6^(%B/; MSY^VQBWBRL!HAV(_ HPT$5A7##>."@, "D=P(S]8XY[F',ZN),L-> M0K-8$HNJ'^9F<7QYZ?%%KL>YZY?,E2I%)9:45L:$FW!"Z[7':/ M7_52G.RJ8!V8BB"I165AERE6>Y!<_+[1%#PJ8<>5V-WY7@4EMP]J^"E*>]LV MZNI'DHT!X8OM^/] >JW[J'/ZS*=!@N) $[4(GK!(=-_.XJ?P:>O$!U:;K22R MC^:7'P_DVT.S\^-IWG-^<]$W&!M2NK+'ST_Y5KFZ)/3=%2:,";79:I(^H!-Y M.);.%O%]!K\5BP^8H=D"-L1T9TA+P:;BOX ,S3(JQ-&1!M3D([^&ZB&H.\[M/9: 2MI>2(FTR#XML 4- CP7X _YFRI+TB7R>!?"W(""/()LO#GW% MR1YC?.^.I@HKT@&-Y Q!.[DAB74VEI9_QVU<,?-/MR8Q44P,4[9AQ]=@G77E MRP*J* PKCML?SP81XM*>'T'1!@L?DB4X]/T36ER]PZA!)O/G[HDO(&[7]N"O(MG'T@[@PB19U!-LA<*BKF[%X,$[+3%V+H_**#&Q\)6#M47.YSPK!O0'I[D9I= MD=L=\"!@.BQU]M' #I.EAZO863FOJX[M@!>UR!T!&/AY3?]OCY+7 1/GC=[MQ M>OF9][@*Z)9[0-3)%X"Q9_EP(N$_62Q:PURU:%OM+UMMD6_1T8EJ!P,'(URQ MV\-]03.NY4YGC$_+_TTCOKKP&l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l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a&IV>9DEC[BSZ-AAR751V]FW8ZU&25+9-25 + MXV:C#@X(UGX?:/)-(J3IE%)DD;Z?LK_XX6GJJI_4QO>CZU?]I[8 M0QCAK3U^M=\"7.,:5=" `G3_LM2SZ,6I#] M89<[#+R43+ _MKL: FY=#9:EB)EWF+6$/I$ _?K<;6 ,/M3H2D]%])SZW';\VG M5IM\ ZOY]*UY] "CV[IK?B6M]MWV#,%21]Q^[#YT2/>1W#VV[Q :G8=[*GS M^+5UW^S"+U]:[6;[K@5SZ'3AA:BXXH9\6)1#?*SFO#ZT,/ ?F\$C!BQMYV"/IU2$.\1I@G/NRI&Y-K!F;RIY3,M M] [U$WD7A:#*95U7.*ID7)A+7CO1MWW]C:;?SK1GNRM85R.O(Z8^B(H&Q'03. MT(D)]U^QOHO(+&4)KE!9^;)10WT;+D!O0E0B9@=Q5O&*^7Y5G]?*W@]8]^EA MA<_V&\0")9T1I2'YZO69.N+)O3RY[UR[4/".WO(R>]NGWUCC&[*'B8.V_!JB MWD)D)AA./HEO0\==[M=@MM-W=?MMKB_K-Y^F:!G=L&I MM89L")I5:RR96SO M&IT"9[%(&=Z* QNFl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l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Ŷ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

MBK\YRD"V%;LOBG]OITJ&9HH#4Q>57D\S3$O1]/^11+BZL@II;TB0[O&GSN/7UGVS"[]\;;6;[;L6S*'3A1>^/;2['7)# M/L0]@PX^5G->'UHN"4?>#!XQ"! \/^]=.KG'>GH_$ C]U:>@Q:<4Q'MD^Y38 M$S@L0GBG3VSX-QO1_l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|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u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l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l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l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l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`)[&\)FHSA+7%*1+64=KC ,[V#O$L-P/MD0

5S_?WT6?BSD 25/%0__+:XFY7L7XHK(O")QQ3ZF/&&#:D"1B5N2PZF MU,D30+'$87[$*Q5 HIR K&:/$A #9#$1(9*3P*L5BI9R-J1;$GWAHDD"Z4P2 MG?R!#P%;
S_D&ZLZDC8@'>;RF%/OV3[OJ\:W6/.3.&A_#!(O;X)4#%HG <:A M $I -]<>N0:CQ(XLXH)\XE4;4TB.+^CO7\5IHTD)EC_-F/ HZFD/MEG5 MA^RS4#Q((*/\?
8BQF,T99V+C8"K$2;0Z1${4[0L\%$>K+!3PF0"C#OE=C@.- MCY4Q>)0K I#3 B5# $E!V!0\8# 4Q:GXR7I 8X3D,1X9@=1/(CA'M/D%3"&N M, AC$\46HU?LIM[1
M+D&QH@!KT]:/AVA"6'(X;=3%\:7#:>-FK"\!&):Y+'/9;]?//=PEV-Y*Y:MO M/<=N4K5U1= OK)>4#I=' "T6AOAPE_ED1/C[<71*+U=O7*DJ@ET0*3:*/1V;5L MS=*HI='CB-
&NI5%+H\6FT7;MX%,BKGN?Z4M+-GRJU'S)R8M<:KY]PX'EJ'TV MJ;=)\N89X8.*I1IO+4X*A!/+(Q8?%A]"NI68O4"B$7C6:UMJH/Y;,AXVRO MKM(4_2_K4O3/J
=1=V!ELT",H%E@I?.!,VK*VL2639X\6S0VG[:L64#RP;GQ@:]K<-8 MI^>"\C0P^C82V8 "Z2^T,!KH9EBJ>>_.0R[6#+=@CSS*->/2PR2V;SW3P>[M
M^1!@IUMMST\M@@QB2O1B@:&X MS&8!9)VKD#BP]YB9VI$U U1_DZX,)CP>28=%(VR41,V:0L$\N,N_O55>S<>+% M<@)..134*7/NOT[SD=- -4G/&(77V[4JZIEE&Y^A4W?3-
LH),%01JI_T<^? M/K-FLUE1_VCUZ%7Z=[O^%G^P='4(NGHRM7:.L@*?+:.F',$9@DJE#\BGV(S& M&$TG@3,"@@B#B<'U-RVS; !6"1"^1#S.H#GCNAS"
M4XE9T4UND3_'P8/ZZ*2&9>RCX%N:OH>NZ1?NV.@FK3_=+ZO+$D&@08ACHL* ML>TL& 4H#*P=8$G_&,;L*BOA%#1?>7+(H]GB:C.$Q.VB1^]"TUESRCAV4
M9@>EV4%I=E#:=]-@YQVB_#18$.NZ9[CJZ!Y5%AV9;!(OB7+4&<:G>LJK?&*F M6JK&2C(3]EX N?C#"OM%^$#H:B1H7E,^B%*XRF]&-$4\T^FM%_=$'I]>+QG# M.M.#78PG7C
5XG)NKEXV E@-!J;Q?!76#V>^@R9"+*EWONY73_@;+HH:43 M8N4?RBA(UY^;);O8'E"=O)-X24!UM$[!]8&'Y3+++94?ALB/U/3G1L$*m BM=GTOBUB[6!?
N6%*UI']2TS9:#4NLEEA+0JS-YL"|UABM<3Z+*>]JO8*2*H: MAN6+':C0]^/+ Q7.8CNWTG1M:]76*.(GD50;=L4K"QA[M3637RP4-X!BJ[>F MU;>%XD;V=<>"\1B=\BP8-
P!CI['&*"E)8_B\W3&W=57-T6A5NR?I_GG_I&VR MH>FW0]>*%^ &' (J!>3)1J>YYQ2P P"FV%ZOY8>7Q][CQ&W_&#YX7SXH=W9 M,Y!DV<&RP_FP0^MJW\"JY0?+#V?$#_6=AT59?
K#\<';\T*WOF=1X(G;8N&MH MY]35J2I+^*GBU U;T]@ZU U6>K&UC'9/Y=V3K4.U=:C/"CY;AVHKY&%W*E! M9>M0+9=9+C1:EQT[S>)HWOL' X_I6+
ONEWF\R4,GU\!IYSAFO;V4^]L1K^E MU=/0:G--*]>E54NK!:'5AB552ZKE(-5ZO6Y+^RVQEH58K62UQ%H28KVH5^NO M"T6F6P=9 P=8Q+8N/9RY[M
@I$D+:]:U+WBQ"GM>M.16'G.U55CH9;B>;<,DIBTP_MC=:N2>@%<'S/$B'-7:MD+$*>!2'K.OM8?!R[CFS7JGN+D.=!2'?73 "+D&>2
M6#O>RM@@X0](WN%,NY<0(JOO3SO6OWMF_\&;(N$D.VN9BPNGM57VMXVMPAY M5H1LWY/<(N19I56C6CNZM+*]! \PCVF:O9SS^78&R0%9-#]9SGM"Y5B)RU9 M-
G@9;+#WE"C+!I8-2L\&^\Z?LDQ@F:#T3+#_9"O+!I8-RL\&>_,LFQ@V:#T M;'""IK'':PE8;YRX)^"WD6#2=T+!(_R'B5PQ\6,B_ A; X;4(C"FKE?C@!HW M"6SXA2)*O-
AT9]SU_%6V23?'PE&@ M'L.R@@(1ISMB8IL%YG'B)@*7B02P//<=M0R@*0X3)TY"D!7PN2B.X+M1X$B. MI/LHXQ$+$B"^((P'(%S@_3B$/PVG\.J#%(^T"FXM]U80#KDO_^!
(H8!KV+^(M0+@P.0! X =\'V2= T\"K(C !!"(R_Z= (D#A0-)(6Z7T57)^1KKD7!;@' M+W%IO[^9,9 8'(N[8^E+ H=\$ IV%?VH]:/+(#_1!AY8@@O$;^6@J9_%P1F M)TZG"]5@CX,9K
P2([_!)O"9P$7RF6'_P\%"APA$!'0![PB8TE BU+JR00$ MP."[B&<%!%(@(&\L0J P#VA:->A9#4A]DA8V9IT$D41*?!,*C[Z:]6/|S]F+ M%ZUF:]DKO \:%83XRE<6.C8=$T6-]MSM3.Z_HS"
[3AJ*RSY@Z_LE'\ .WW#O MD4\CU/%YT@.ZTXMWD?3F#[SR6((!88^EB-X%B1"2 'D#5I$(\2G8"#_M!AB(MW\%_O_H/V70;O,F=6JW3[[?JW?95S;WJU)KI?
KM[U6NV._]7KX%6H/;"0+XW M\$4@CNC//_%WF_!^>UDKL",U_2+"^L1|(!]4<__U'U>->O=MQ-[+8$DB8DCD MV6L0[--(1GB\C|(?8*,"0=UB7'HF:\D ^B1.Q
.!,R(7:2L_GHE+$YZ^(M; MG\%:'NT6]OY;]:X*9K?G\1#DN_CA"+"F0<@%F$_W*$$&@D7F>$&T<*)U\OW MIZ)EWDC03=+9X)RWH,7\H40:O8XB$+G78]#.6FT3 G_A(-
WAW_=#')X]BA -'!U\/%K;>OP):-AVY!NL]&);6ML!E7=/ MMAWY$YK(MB.W!\-9QO2<$# ME9G/RF>=;]N@_$QI[Z-5;>Z9/V'Z/EE:/1:O[9C];6K6T>KP"V&:Q>I-:,K5D
MNN@87%F1:FFU'+3:K%M3U=)J.6CUHE'M%DO|KPEBF$M?/_#%:JIV3Q7G*8O0 M,WM*(]3\6!KZ!.&.!O240;L3RA$3'%GBFU8288N]=>8IO6N MW!E)\4
UL/@F5K0@$X_'00C(GTS"X & @ "N)* Y_)S'=:^/"39&")(["0* M/'>1Y38FB)/7APIL#\%N?2!]L6[31:WT_!V%RP.>@[H(\&C$Q+\3"><C#DFP2 M#^KO8_H9"(4*?H&=(5*%)\?
PI"L&'/LBX#]ZT4$HH^]K*<(6CN9_7]!"/[LGNZ?R%8Z6H.AC M__K0,P)&N:L]G[.*YLSJT$X"JG+6H1T?5,6N]K1<5FO062XK>K7G\>.;J:LM M9]UM6]MYIDG()=Z>0W-LPKREU:--
>+*%2)96RT&K^\Z?L:1J2?58-7,]2ZN6 M5LM!JXV6-0$LK9:#5NO%I-7RCE29RP78,4?G&:99Z-DH?>[A2(LH/R]E*H7G M1IC!LL'%?S;@HLJRR0?SQ\X//A@'+O8T%[73!6@ _F
,E9OF*.DZ41 #G)" M^2%Z;_@&]W T1IR$_J;;C#8?AU*0U$/*]>KU+DC#B!&F@.9)+6,$ WJ I_X M'C.Q. ^DRN:!D#*-&90Q@:]BH-4ETK9MQ, K]M!NP=[)9H/L)91M-HC-!K'W
MU/:>NO"@LMD=ELLLEY4B&\01(M?!I+#QNMLYAW/S.)8ZX N+66Y[Z +&+)O: MARRW//6SAM=G^6JS\+HEU:*2ZM:)2Y94+:F>I--GK=K8HM.G)5-+I]?)6:I;
MB6I)M1RDVK:D:DFU#*0*RK]5+.5?G@R0E;??)VC+0LTUY .F6@S@7TLS-,PV MX2-I4YDU>1GXETC$L9=V^5AVD0^/\9B->9S@&0*?72?#!#Y85R>LLGLXS9I& M*(/!8=&C*
/.&834V>-D+$(\2D@$7[:#3! [^" 7_V';+H-WN1.K=;I]UOU M;ONJYEYU:LU^O]V]ZC7;G?]K]5Z]^QS$@G7^_!- _ Q>,D "B'#N$(7Z4VSC MD:DGU)(TL M;+:-I=E2!I%O56T7-
NGTVWT[G'2SMM)$-$]_AN3:Y)=P?[GJYFW] 5N+7N% M]V'72;SZE85XSS%OQAN=N'QL@P:3+$AQJ%GOHHH\6)Z MY&XB%@* C=N' YZ6?"/2U2EB<]/ 7MI2$(T5[IYE!+B:
A%&%B1^. '"%(S4L MZ%%&@KD &R^(%DY4Z+2:^3Y03Z39J+2^W5I [=3ZB3,)[5.\@/_4DU34NDY MV00FG.D%,_ V/8,!C7&;PEN/< ;8-AS49_!H*'QGRN(0P,0=(DQ<6,UOPCVJ
M/=/2*I<(_T"3W=BWN1EV3\!GEP99.[?%FI^M]\R0*LE$LR]A\"!).B%2^$^O M;_R'B$]1XX;$MOH(+SC?I:K:Z'0+EY]4Q-PRNR>[)\QW:I[\-YOO9O/=;=';. MS<0I&]ALOIOE,LME-
M_MP-'Y6<=1ZG[6B[ZOG3=WKDWQ&^UJK8!-\3?F-CO MX>70:KUE9^-96BT)K=;L$"=+]^6@U5;=RE5+]^6@U4:MVK6T:FFU%+1:W[Z! MGQTX]D2BR0;WW"=H1+5]_ -
@DQ%OO'R:L@DMRG3V!O^X+7PQDK/I8]>]'<>!\ M9\&DBC#Q$ZJ;A+C]X 1^,)8.NPDN Y,21C!]+QZ$%TRH M6]?%W8>;]Z_9ST@O'\(@S3D#PD%0WX_D@'8!/_\+&X7L,5V#-
TM2ALY+4)= M ?,=78 MHD2Z__U]?7)?M_/JZ/DP3V:_+,G J[!?Y;\3"3\"7@W?(+)-)B4 M\#">7IEG=QVIZ?I519FZE7FA^1I!FMY@JZD0:(B4=V=9K M5^OUUK99-
NU.M=Y>_J=M,Q!PFGSK8&V VNTSW]33;8X,J3MW&BAG0_RF^%7,_"L+X$HS'<=[/7FFT-K8[\E*^ M*@JIM1M;7P8OQ^JSB;ZYSRWU#\X((\WZU=;72!8CS]HGH-.IMC?O$W @9)RM
MR_AKX \/(VN7G+C(=-1N[SPUJP!FYCEBI%/?X1K48N0Y96V[5:UMW9/%&K9/ MA.<6;Y3F+Y2V56W:R=!7.$T N!LD>"%D3O&R7,[#0Z6 C%FO=*_IU=9NANGA
M0',BL]9RA.6(18[H7+6V;B)J.<)RQ+ER1*^S=?/'0K##&O//1+'X@2]64>91,_QV-,P.0>FX2!FSB8 M)";]=+:C&12Y/)],)9 NC7BS1^EYL \6)8.!="3F+6+N)X]E-)C2FEZ:?Q?B
MFF%^M&3,/,&C>,D$4Y] :LIW*-1WQD+ &X$_1,;&G:@1J7CD!(>7JIW/? :W M'O2!?77;O7@$TF0X8AQATI<^-VF;I.H ,]T4_'1>QOO9/=;=';. MS<0I&]ALOIOE,LME-
M_MP-'Y6<=1ZG[6B[ZOG3=WKDWQ&^UJK8!-\3?F-CO MX>70:KUE9^-96BT)K=;L$"=+]^6@U5;=RE5+]^6@U4:MVK6T:FFU%+1:W[Z! MGQTX]D2BR0;WW"=H1+5]_ -
@DQ%OO'R:L@DMRG3V!O^X+7PQDK/I8]>]'<>!\ M9\&DBC#Q$ZJ;A+C]X 1^,)8.NPDN Y,21C!]+QZ$%TRH M6]?%W8>;]Z_9ST@O'\(@S3D#PD%0WX_D@'8!/_\+&X7L,5V#-
TM2ALY+4)= M ?,=78 MHD2Z__U]?7)?M_/JZ/DP3V:_+,G J[!?Y;\3"3\"7@W?(+)-)B4 M\#">7IEG=QVIZ?I519FZE7FA^1I!FMY@JZD0:(B4=V=9K M5^OUUK99-
NU.M=Y>_J=M,Q!PFGSK8&V VNTSW]33;8X,J3MW&BAG0_RF^%7,_"L+X$HS'<=[/7FFT-K8[\E*^ M*@JIM1M;7P8OQ^JSB;ZYSRWU#\X((\WZU=;72!8CS]HGH-.IMC?O$W @9)RM
MR_AKX \/(VN7G+C(=-1N[SPUJP!FYCEBI%/?X1K48N0Y96V[5:UMW9/%&K9/ MA.<6;Y3F+Y2V56W:R=!7.$T N!LD>"%D3O&R7,[#0Z6 C%FO=*_IU=9NANGA
M0',BL]9RA.6(18[H7+6V;B)J.<)RQ+ER1*^S=?/'0K##&O//1+'X@2]64>91,_QV-,P.0>FX2!FSB8 M)";]=+:C&12Y/)],)9 NC7BS1^EYL \6)8.!="3F+6+N)X]E-)C2FEZ:?Q?B
MFF%^M&3,/,&C>,D$4Y] :LIW*-1WQD+ &X$_1,;&G:@1J7CD!(>7JIW/? :W M'O2!?77;O7@$TF0X8AQATI<^-VF;I.H ,]T4_'1>QOO9O

MF6Y1O_3ZZ<+>W,]FGRSUSSY\55)"EMN>6ME*$TG:B.'SG9DNTYS/'$Y: 90, M@"ZR"[0MF)0)X[D_#4>':C]=D&.!QP]UZFO$FQA\PQ)KUR2T'!.4VQ*((! MV9,R6*7I 0<6KEL[?_93/HR$=GWI. RWUI9_PF;,=+.E*7 MT1@P2TA[+&KNX#6 N$C)QZ9T.J8.1@OEH:R:!@&'D?L!=_3C])#]6.RST"0- M[V_^E^(K#6_10<>.S*CPBVK&:UID4=]#NTRZ7=I0$LP7-WQ&JS>=:i+=R_0I 5QJ^=$5R MHHLG.7@IZ*@W AWEB9\LI7]-%E&Z,.2*GE%AI6F!:$H9D^4\CV3QW7N*M6+U M="';XlO./TC3+&>.Q*A-%Q0C)"=^KA+5R=92_N[7"+%HJ&:5*41-IZ%M4<'^- M,"]>9YA9=WL4S2I-S>8),KWSU.5)]+K?O^OZHNZ>YY*YS8F2&PC-W1_$)Y9AX M;1!&@[DI^WTU<'I$VT\\NXN_+I^4&0_%&/B,I+T/B&;0LT M<73KQBW>$P0@-U^B5>.BU#OV<-MLZVH]Q/,YL\|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|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|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l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|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l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|[/U+"ED6_9/_>&L48"1T6:^"R"X[H7>.7'H8J8YIM''L:GL&:,*V=MNF&(1&1=CDVWG3!%U_;"7=!?%<; M.*4O:1+)P(6M\.$'+S[:B]VW"HO&1,Q6" 5IG\>#*/:2&H1JFK>AOXZBV?A M=>M2)$[E:=Y["4 M87+(.+]TBWR6?C->BADX'O8OB%#3[]@U.[!.]]^@IR;K9J37UC C<8>%-,UDA_&WV#;8@C$((?]55E3'8":P0@G,=VL M:@0WH]OKH"!WQCLRWDK)]RR>3G7/>(EX%U.]7W?T4!X.+9^:).9+DZB\>(63 MA+F_"#LI@E.)=8:(@Z/,DZ/6ZF4&_:U9@0P8I"T2]K:2,66BHS(.ABA=BI'I#OEU\|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

Q"PG0WB7_S@TY?_W_[SX\P>?_/$#B@L__$B.!C:(M2U[@5&$.!@QR 4PR:C8_#%F8-%KO__+B_*^0]%43OBE70\H=MZ4OO; O/:,$

M"O.TEIOGT;MK>JK.:72L/SC_T\@9Q1AFF;FL$+'E5) M#'B2-EI-W"5F0$5WI9L2I7UP%K)0/:9#C5Y\"#1:L^PL'AT^D6&V(S1@99S#ZGOAXKCI2\9Y:HCZ#/

Q,F5XO8AQ%YB<.BEYK_*9/8Z<)#DOQ.@Z$N37_ M7DT=>Q%*4#09 1-N"L\6AIPX 4W'0Q>W?,,;S+$">*3O25+G"1]E)GL:B>*X MMN2,'Z@$K'JEL!+X5?

K'@092?,0H8"7@&LDMK<,0<<*GQS*<')I=4?4S0R@X M^@+HD9(#3B8_2$8@/3P<"XO '8A;;63:D]XG\-WU/4,#NE+'.1XB+R&6K9Z$' MGKO

***3B.9=|'7$9'NY8B@MDAGDJ1FMZI,X?G4]FYS'$)/&WR+.#@^]C'4>P MJHZ(UA&<;V8]PBW%1F41'6$^"]+ETHO<>%O*@05<13#G3I?GO]|G7"?I/N0) M?**

T:Z[^%'&KBY/W^B3_]/NF\Z"B\^.O_KG^BU;P^F)'CB4"ZQ>Y^1U4I?&20]M#W#%F_C?;>:\#;/$L/I;_&N-(8]0.$ RG)OOGIY7U<"L+[%#, M_;Q:5K.6#([@7+"YDX3]

('@$H3]6U//!T&O<'&'=R"U5S@&CV(-H%3;Z; M1,LW'(Z<"#-P(*F"%2O4.TFCB@,K35L;K$P/72^2R749A"0WO^HROB?88,G M92'$ R^;3:REIKG7>;A#7>TTU9>F,?

%)HE3G/RZ^=$VYF9>B'F#9'W9'YX M3E.)AN2NI8=MU^']'=:DG$4K'KGA.(?Q4HF6>*!.J0"9*4CF6FEC%%*+](M;$DS=.0RLY+(KI*T,ECX?7QN=,

B3C*]H7T'#OS1>_'^ZR#R%_#O0,@E6/NZ M)4(DL%SD#SMA11FA2T Z";O..#+#U3?58%5"-ARH*1__DAE2IY%J WY7V?A M]8@W*3X8OUN49_&Z*U5M5!Q

Y%;*L5H8W2AUMAEOCCEFP4C(7X3JR@=*L'H-MEDU8R,/]#FP@J018DQ-G0DP_+8G.P9 M<,P/@IT#?)*27-X%IH=:A7 "<"OKK5,-N+3Y:5N7/U76I,UY;HI"N"JUU*5C

MSC%^W'9=>Z/JMX.V\9'4] XP2PEV!LI'\XBXOJ8C,"=0)A;,"M9T(<?)U_$ M^>)+/0[3^0=4NO\E5W*&+6OBE#0@/_+W_^X(.'NJ[@#/!9P!;,9$B:/%9;=*3!I M &<5Q+|C?"EO]BF=L*[24C;

Z_$!DKQU6(RI/*3#"#-'^T)%D MZBG>^\WF\B#FVZ"HF W1GLI&*JV!A$YS_6CG6N%BAUXGN4B\ >C>1S\HSCXK MR\>S&9S6[TMU6YE92G-SIZEZT&WW"Y)8F\?

$MB.*!+04=4N[3Z3I6V* FT M=A-.U^YXFI@'F!BP?- .0@N*IW,/'E*D_A.=WHU&0S5-!F'O.W3%.%KE4PKM M@68F"3RN#S6=)''?C-I.M+'/"_]J/G$HKOPD-7]3&'%D<$_UMT"%Q5 M-2

2HTOLK]%A3K]/+YR9H=T+I*^FX9HVDU0*W/NP!DI6;YUZM5/GT5UI7*- M@!OE=U=#,UO&*MPB5LG1C6P:E\A=8>0D4_7+^X?_6W?;ZP00^=3:B!4U#V4Q 4WC2),(9Y1#?

P!&\,>AGUXHSEN=S9T+.,<(/4#:]"0Z>7XMH4VD-R3A(]?8E4Z$ MKW]IYR]@88O6(!*H4";B?{["M6I$0 [FGU-#7[Y^,\](3PZ/D0["[$/1+00K MP[*BCAZG7U^5FT-=*N$-

V94#J.3^6.S^"<[Q7RV M9X<>!^V[$""NZ$1,+EZVW?OEXA45A9L-"WG=/@_*6TU?UR$7)W']OKA$"U3;

MT"+#CB_I+&8VFCl4DRVL.A+)XKENZVL5+LD\9=)NQDP>+&M'$@*\T60W&G&Q~@ MV'/4V47*O_E=<[ZXJ*/FBZK;V;-H7:DX!O-]MJ%NJC@.FD7)VJBE%>_JX#VR

MZTVR(.2"J;09MA]WV!7#J)LNZ4O@)RG6Z[;,3"Q=W)Q/X@3Z+$K7P.Z4/SEG MS1HY6 L!:2BW!N[N-[R#VP-.9(_CI0IFD#TX_$4HM9;1\.([,W;7VW61?>N' MLZAEL*-

>_([INXPWECW%I5 B:#/CW!:9K/@[&>K\^T;?9[Q*;GE>SVP2+Q8' M2C09DI$L?O'(/8WE"I]RR:2",[:,Q_GFJMUQ=,/F8#DJW=_3'8W+U_D:TLBY

MO1/#\>>_PB#)^UNC292TTZM_9+S9B MDMOXZ1L@H*>^F0,U2;JD@'Q16D6!.FC 1V'$@Z-&XZKY44D@^7!?=|2ZP_=8 M5]<56)$)K&!L'W7Y47"+,N69#7U;

'ZWJ[^+97HWPD$ZZ,3!.L$P7J,>?;GVW"T'#?9X62@VO8V91AZ#:$68.Y5<]%Y!Z%.U"E MG'FA]/=YKZ?A <5/9O81\Y5 +E2''E9QB,&7MX)201,*2AA

MP+6+'88]2P7PR_WH0@6B>^.YI=@C_1W)+NU6;J^%=>N@@!1!ZIKDEO]2LZ\ MZ?;DI!?]A>O_U!F[!IV+4(.%&\,#)\;3F&[7IV9!S/A;Q+M.'KL0BL7J6R?+ M15I;?

Y*GE0X1=BH=@&QO[O/R:Q5^]1O8'!B)8FF%N',@*+9T9TMN;^[S!'!LJ MQW*)8M7>]H-P.,Y% ;GJ M%V$$CE [(7TIUE,2!D5)+;?!ZG0X:QP[5->E39SB44P(&DY&>)'-;6%HZ6?

M>Q[*G3!B:B N#GK]_OD2@&9YW:_ *[1 MI&XD^3@?)L!UZ"QS+H9R02J#TN2ZKZU3PP86(E&E(7W?7 M;D"X^X021G3TY71.YQBGR$4RY5>-RFHZA,+_A0-N?

=60&IAI/.P)#H[V06\3 MDP =')257BU"X+$XE]('U141*L^BE+FS\\NL8FO1F7.!UV(RU .*L0M A9A5 M#?ICI=\KS)6* [#WS@,ZNJIK1.BR7KBU;E3V"0=<>3,NB,R47>@ E=;@6>U9

MYFL2="9T)706)IF9?'^,ZDKR6; M'P8G:KS9$[>N=X#Z&OK^$(D"S3*VW6*6)&A=T 1=-JE'LHR(A/BLHU_"W>E5 M^HH%:0Y]5!*NV0^;3/F$3P:I5V$QYY2K0PLLTZ>O_I&]9DP'-

QO(@66V+I4Z M]I>"#_Z[&BG"G/L@=&Z8,JJA>2E*U<4K,C*;S(0A(LGCI0"OP[ADDE{%;@B M::7-;+$0 D#^H6G>.M#*<<\A=0^=1QLEZG2=!Z?8F0TH:+.TU]\.S3?#5*LHH3.1>4*:

(RO.H*A/M\4(E'7N1 M|C%Q+Y=KE:)OQ[2<'0^AVT_>5&Q-_4W#.'J2$GNW<@$]C27,8MSZ$A,,@[XD MB2:%L4"+31<'!)/IFO#%MYQ9%YTU%

HEFUT(,'C=%R57%)*DNA7AQW=J>L(M0KPK:<6R@_E:*%J0[R;X;%%/LI^"O.$K-,/3XNF9(M5B7.%Z_)?9T4!OE-$ZU9NR4?TV$? MI0)YEK6!)U'[JZORIUWMHS"]!

6/!_(HS!>%'F4O8&&#Y1T4%5!89._&>?!L-HQJ9%/@5_>=IQ" M#-!N=\V"8FPN_4E4I3]U&[7-G*;QNIP?FH3/HIY/76FM"OT:=C25TV/>+P5

MW/)+N>/((=B5@X(N@$]+ZM3S%S)'4WD=L3#IRL>]E 6HZ_Q\\:FPP:@SD&2# MVPDZQ[-2FJ9ES*70";R+T@A4KNW9[>$D;.G6I0HIF-`WK3+;39)"Q(M;39^(

MMZF%9]V&Z>>\)Y=:.]A/8]T$FQV)IE5P%YD7'C.Q<|+_.M9"VF(X!16:S'F70U7130IL$PAW%DO*W8KOGM$-1MR:ASXMFS%27,]IVU\TM: MF8#;(?3"(U"ZGZ1PA4J/UUOV0K?

4<%RZ>N!:N0.3@,IV[>&<$Z8,JJA>2E*U<4K,C*;S(0A(LGCI0"OP[ADDE{%;@B M::7-;+$0 D#^H6G>.M#*<<\A=0^=1QLEZG2=!Z?8F0TH:+.TU]\.S3?#5*LHH3.1>4*:(RO.H*A/M\4(E'7N1 M|C%Q+Y=KE:)OQ[2<'0^AVT_>5&Q~_4W#.'J2$GNW<@$]C27,8MSZ$A,,@[XD MB2:%L4"+31<'!)/IFO#%MYQ9%YTU%HEFUT(,'C=%R57%)*DNA7AQW=J>L(M0KPK:<6R@_E:*%J0[R;X;%%/LI^"O.$K-,/3XNF9(M5B7.%Z_)?9T4!OE-$ZU9NR4?TV$? MI0)YEK6!)U'[JZORIUWMHS"]!6/!_(HS!>%'F4O8&&#Y1T4%5!89._&>?!L-HQJ9%/@5_>=IQ" M#-!N=\V"8FPN_4E4I3]U&[7-G*;QNIP?FH3/HIY/76FM"OT:=C25TV/>+P5MW/)+N>/((=B5@X(N@$]+ZM3S%S)'4WD=L3#IRL>]E 6HZ_Q\\:FPP:@SD&2# MVPDZQ[-2FJ9ES*70";R+T@A4KNW9[>$D;.G6I0HIF-`WK3+;39)"Q(M;39^(

MMZF%9]V&Z>>\)Y=:.]A/8]T$FQV)IE5P%YD7'C.Q<|+_.M9"VF(X!16:S'F70U7130IL$PAW%DO*W8KOGM$-1MR:ASXMFS%27,]IVU\TM: MF8#;(?3"(U"ZGZ1PA4J/UUOV0K?

4<%RZ>N!:N0.3@,IV[>&<$Z8,JJA>2E*U<4K,C*;S(0A(LGCI0"OP[ADDE{%;@B M::7-;+$0 D#^H6G>.M#*<<\A=0^=1QLEZG2=!Z?8F0TH:+.TU]\.S3?#5*LHH3.1>4*:(RO.H*A/M\4(E'7N1 M|C%Q+Y=KE:)OQ[2<'0^AVT_>5&Q~_4W#.'J2$GNW<@$]C27,8MSZ$A,,@[XD MB2:%L4"+31<'!)/IFO#%MYQ9%YTU%

HEFUT(,'C=%R57%)*DNA7AQW=J>L(M0KPK:<6R@_E:*%J0[R;X;%%/LI^"O.$K-,/3XNF9(M5B7.%Z_)?9T4!OE-$ZU9NR4?TV$? MI0)YEK6!)U'[JZORIUWMHS"]!6/!_(HS!>%'F4O8&&#Y1T4%5!89._&>?!L-HQJ9%/@5_>=IQ" M#-!N=\V"8FPN_4E4I3]U&[7-G*;QNIP?FH3/HIY/76FM"OT:=C25TV/>+P5

**

\)V.X^WR41UO.5#EUM)9L867=X@6&21\ M0[J509BLR9EB3I=0"\%(5642Z_'?ZE_!20Q^+G2>,EN&)<5T:MC^6OUN&UY;&MR4@&;UP5WV2:<'*).%,YR3D8MK&_Y.(\" MPQU#9;I?.;RHYW#6C-OLRQ;[BO=CN&-HJ*IW TEUE7U8U(ZUGQLZ>N5=Y;[$ MB"KHX,[0TH#0KO1N1!7H[4XXB-4,: '?HQP4,!<:2_/E)#(,=S%E@?8_63;U M4S3.(0=) MS=ZW%XPK"0.Y@[DK%TS$5A/Z)OHB_62^S-L;S\8FU)@?F-\,XUY6M_T=-DLA M,40U$RD5H0P.I(E84UP)%$I9.#NV,_U%&1R3K98VI.)OK3XG<|RK"&'OR:?G MZ;F0S:?,GBE,0 DQ9I*98(P2"#DH9%LH>K|+<3#%*LME4[D;*95^4F>[OZ"T MQORI-GK6D-.WL(4FV6 :4_=X4Z.6VJECS#,\78[EHX>E'B9L_HLE"V^"SU M;$R;^:WC>';7.)XUCN<^N@@P[ZZQP)@X))6@TQ'XU6BV([H]JBN|ALX:L>^\ M'M$F8AK_Y]+?0>;,..GF3;5$?Y0NQRG<^2349Z39;_/,M!/7-(;6U\11\D", MW64OF@)6Y8GO#=,+)P>TD7A/P9SQ\PFW*=$B'EPPH1!2S<8Z\4D3A(=\SZ_5 M<&UN$@#MB>C-W4^0@8+WM29R(NYU&FVPWU|/6HK\#!LS U^+BA+D/(.1W_)- M:,ASI+Y*;SBY/ZVY3^\"!8E8JG_GLD*U :%^(^A.7.7RO(N\KF9'1?[.8*I9>%,GRJN[RJLO0H(GZ MHJ<<*\K7:55,0,8ME9=[_?O<\F_XS<@W>MEN=JN9$6]|4&EQ8 *_,*G$ X MEA(:N(CZJ_THE91)F+SRGEKR_1\@F1'Y&E:VZ>I[UKUX7Z-P@!F6\8E\"C MH02M]E.L6HX\FN$8__3.!KL^!W_T.8#+RW;>YP@GNM'1B?AM[N2?&HU*W.S3 M;)HUS'(UE1[,5V>/6G9!,S)M#X78U&HS';O2L1R(T%[])&V"(JME(%+2!?OGR=X>6@2+9? U;3L9+.,,KP =5/%/=0$)'[+]A#V\(-W*'9%QV8VWBD[M_: M]EO[M'=XJ)@'DT0B]2A8TS$U\@92OI*4Y()\RQ4<6%SCE5T-U_%7$(W2Z(V2 M#;OG;U(}E3"$9%0*Q*$EJMRP;I@*>3DN:NXBZZU-X< FN- H!Q<[FCA1PJ(J M3-=K;JA(? <1\GYJT*J%!_PB?#VGH81,5R81DW*B"X&TX^#+1+HF>YFY[_LVJJZ1:Y,<I\S/I!%N K0"3:SK1FW26FT,L+?%0)=E0.,V4ANS.Z!-XW\,F M1919/A VEIY)MB$D]?\2\<6//,R4T_2T?>-()\7[<+*FP+!P.0_I"LJ19&OTQ M(8]H[&Y;5-$Q4+IHD&!(7XI8XPKT(.=A#\T%KXQDN MF!@BLG&O(0,"T6/-- 88]7P:.KM"3D,7.3E-@[DOY-<"ODT1ZPE3<6J1,7; M] GL|$W+=HCLVM,Z]PJJV))&N4+*R$R)Q3S@NEIXU/+R_)R/G\-(]+9>06<<7N+UH MESWG$4 Z:NG9Y[X+Y5)'88;XSE;+U!B]|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|F()A2[)^Y$BPQ5HR M3(L4U*!H$IP-!&X'>7'!G+%5/IE/1882J?\ <7S%#MOS[*!*OH0T;C'(8Q>RN@37AN5B0FYCQW4IKH&D%4F2V)M&F\I M&'BVRFA'9T)DB,2"/=J//"Y#A;-[%TQZ MXO>V0FQ%?&RU+W8.+DL? #S=E(*F]]EITY1(U>) 12R9W. 4-WMWO.GODC M&C1W4FQ$6!T=_N.#.]K_KNL3G2-AA5P>8*+R]'=N MQT@*:,68LQXCT9;K\C!EK"'50 M-[W'C[;=:^TVD%FD?R6!(GX9F?^8?C?'FK8-H[RGD3YT6(47 6SN?;B+ZH/15GUWA+R9DS7$&W%W57+&%V7)\XM"D1G!Y=^P8.)#$:++A6)K_=DS(L +Q2EQYXFE+FTB< M&'73_1K%@/2O$%G"Q9)+L&M ++/P;S ($0GBXP7U:? RH1&P=S[PT2.'-_M2*QM%0OJWPG&%1KWC[Y=5&;,3F7HP1M$+:)3:P%AVQLA8,B8: M"8G#!],\BU3G\)0>E^ B-.A/^?0X48>@Q7!<7MZL;9W#/_D18:PJY$B!=TD M0),8NN1JB'A&[#0#O@S\(GG*57=M?ZGF-1R+\'U=SI M_JL>[D_):.*%H5\EV_I*IE?O,^]9H KHUO-,Y%I8&;X<=?P-N3*/E+E!$(@Q MN9&;<1F.N%,N[IL@7$NV:V@O-836%H%V L=V#^OF:P VK!"S)[??>?T.)6XW[@ M:/Z;#N0,A%8YXA(U HS4(H4K03OK *,YM>'!TOHPH5%|F()A2[)^Y$BPQ5HR M3(L4U*!H$IP-!&X'>7'!G+%5/IE/1882J?\ <7S%#MOS[*!*OH0T;C'(8Q>RN@37AN5B0FYCQW4IKH&D%4F2V)M&F\I M&'BVRFA'9T)DB,2"/=J//"Y#A;-[%TQZ MXO>V0FQ%?&RU+W8.+DL? #S=E(*F]]EITY1(U>) 12R9W. 4-WMWO.GODC M&C1W4FQ$6!T=_N.#.]K_KNL3G2-AA5P>8*+R]'=N MQT@*:,68LQXCT9;K\C!EK"'50 M-[W'C[;=:^TVD%FD?R6!(GX9F?^8?C?'FK8-H[RGD3YT6(47 6SN?;B+ZH/15GUWA+R9DS7$&W%W57+&%V7)\XM"D1G!Y=^P8.)#$:++A6)K_=DS(L +Q2EQYXFE+FTB< M&'73_1K%@/2O$%G"Q9)+L&M ++/P;S (

\)V.X^WR41UO.5#EUM)9L867=X@6&21\ M0[J509BLR9EB3I=0"\%(5642Z_'?ZE_!20Q^+G2>,EN&)<5T:MC^6OUN&UY;&MR4@&;UP5WV2:<'*).%,YR3D8MK&_Y.(\" MPQU#9;I?.;RHYW#6C-OLRQ;[BO=CN&-HJ*IW TEUE7U8U(ZUGQLZ>N5=Y;[$ MB"KHX,[0TH#0KO1N1!7H[4XXB-4,: '?HQP4,!<:2_/E)#(,=S%E@?8_63;U M4S3.(0=) MS=ZW%XPK"0.Y@[DK%TS$5A/Z)OHB_62^S-L;S\8FU)@?F-\,XUY6M_T=-DLA M,40U$RD5H0P.I(E84UP)%$I9.#NV,_U%&1R3K98VI.)OK3XG<|RK"&'OR:?G MZ;F0S:?,GBE,0 DQ9I*98(P2"#DH9%LH>K|+<3#%*LME4[D;*95^4F>[OZ"T MQORI-GK6D-.WL(4FV6 :4_=X4Z.6VJECS#,\78[EHX>E'B9L_HLE"V^"SU M;$R;^:WC>';7.)XUCN<^N@@P[ZZQP)@X))6@TQ'XU6BV([H]JBN|ALX:L>^\ M'M$F8AK_Y]+?0>;,..GF3;5$?Y0NQRG<^2349Z39;_/,M!/7-(;6U\11\D", MW64OF@)6Y8GO#=,+)P>TD7A/P9SQ\PFW*=$B'EPPH1!2S<8Z\4D3A(=\SZ_5 M<&UN$@#MB>C-W4^0@8+WM29R(NYU&FVPWU|/6HK\#!LS U^+BA+D/(.1W_)- M:,ASI+Y*;SBY/ZVY3^\"!8E8JG_GLD*U :%^(^A.7.7RO(N\KF9'1?[.8*I9>%,GRJN[RJLO0H(GZ MHJ<<*\K7:55,0,8ME9=[_?O<\F_XS<@W>MEN=JN9$6]|4&EQ8 *_,*G$ X MEA(:N(CZJ_THE91)F+SRGEKR_1\@F1'Y&E:VZ>I[UKUX7Z-P@!F6\8E\"C MH02M]E.L6HX\FN$8__3.!KL^!W_T.8#+RW;>YP@GNM'1B?AM[N2?&HU*W.S3 M;)HUS'(UE1[,5V>/6G9!,S)M#X78U&HS';O2L1R(T%[])&V"(JME(%+2!?OGR=X>6@2+9? U;3L9+.,,KP =5/%/=0$)'[+]A#V\(-W*'9%QV8VWBD[M_: M]EO[M'=XJ)@'DT0B]2A8TS$U\@92OI*4Y()\RQ4<6%SCE5T-U_%7$(W2Z(V2 M#;OG;U(}E3"$9%0*Q*$EJMRP;I@*>3DN:NXBZZU-X< FN- H!Q<[FCA1PJ(J M3-=K;JA(? <1\GYJT*J%!_PB?#VGH81,5R81DW*B"X&TX^#+1+HF>YFY[_LVJJZ1:Y,<I\S/I!%N K0"3:SK1FW26FT,L+?%0)=E0.,V4ANS.Z!-XW\,F M1919/A VEIY)MB$D]?\2\<6//,R4T_2T?>-()\7[<+*FP+!P.0_I"LJ19&OTQ M(8]H[&Y;5-$Q4+IHD&!(7XI8XPKT(.=A#\T%KXQDN MF!@BLG&O(0,"T6/-- 88]7P:.KM"3D,7.3E-@[DOY-<"ODT1ZPE3<6J1,7; M] GL|$W+=HCLVM,Z]PJJV))&N4+*R$R)Q3S@NEIXU/+R_)R/G\-(]+9>06<<7N+UH MESWG$4 Z:NG9Y[X+Y5)'88;XSE;+U!B]|8<"M:,^GO-JO>Y)? N[OW(,^!QH0T,C'(8Q>RN@37AN5B0FYCQW4IKH&D%4F2V)M&F\I M&'BVRFA'9T)DB,2"/=J//"Y#A;-[%TQZ MXO>V0FQ%?&RU+W8.+DL? #S=E(*F]]EITY1(U>) 12R9W. 4-WMWO.GODC M&C1W4FQ$6!T=_N.#.]K_KNL3G2-AA5P>8*+R]'=N MQT@*:,68LQXCT9;K\C!EK"'50 M-[W'C[;=:^TVD%FD?R6!(GX9F?^8?C?'FK8-H[RGD3YT6(47 6SN?;B+ZH/15GUWA+R9DS7$&W%W57+&%V7)\XM"D1G!Y=^P8.)#$:++A6)K_=DS(L +Q2EQYXFE+FTB< M&'73_1K%@/2O$%G"Q9)+L&M ++/P;S (

$@GBXP7U:? RH1&P=S[PT2.'-_M2*QM%0OJWPG&%1KWC[Y=5&;,3F7HP1M$+:)3:P%AVQLA8,B8: M"8G#!],\BU3G\)0>E^ B-.A/^?0X48>@Q7!<7MZL;9W#/_D18:PJY$B!=TD M0),8NN1JB'A&[#0#O@S\(GG*57=M?ZGF-1R+\'U=SI M_JL>[D_):.*%H5\EV_I*IE?O,^]9H KHUO-,Y%I8&;X<=?P-N3*/E+E!$(@Q MN9&;<1F.N%,N[IL@7$NV:V@O-836%H%V L=V#^OF:P VK!"S)[??>?T.)6XW[@ M:/Z;#N0,A%8YXA(U HS4(H4K03OK *,YM>'!TOHPH5%|F()A2[)^Y$BPQ5HR M3(L4U*!H$IP-!&X'>7'!G+%5/IE/1882J?\ <7S%#MOS[*!*OH0T;C'(8Q>RN@37AN5B0FYCQW4IKH&D%4F2V)M&F\I M&'BVRFA'9T)DB,2"/=J//"Y#A;-[%TQZ MXO>V0FQ%?&RU+W8.+DL? #S=E(*F]]EITY1(U>) 12R9W. 4-WMWO.GODC M&C1W4FQ$6!T=_N.#.]K_KNL3G2-AA5P>8*+R]'=N MQT@*:,68LQXCT9;K\C!EK"'50 M-[W'C[;=:^TVD%FD?R6!(GX9F?^8?C?'FK8-H[RGD3YT6(47 6SN?;B+ZH/15GUWA+R9DS7$&W%W57+&%V7)\XM"D1G!Y=^P8.)#$:++A6)K_=DS(L +Q2EQYXFE+FTB< M&'73_1K%@/2O$%G"Q9)+L&M ++/P;S (

$@GBXP7U:?

**

L%Q_F%W]K&WHX>95XY.>'LU>2&_D#Q!/XFL]-[,*6SEA;_)`M;IK1-LU'5F85)WZ,@-\LBM#3K&5#6W?H'M1N]U3E1,$\G#44>W%6%HWZZ2>N_MU0T?^X3WW*U4NC=^H0L=.[.
[M?/5Y)"GZA`7V2^M[+)[_K="S'#R\O++3>NK?/RXN%A-1@1"_/#/#M/JX?$]O=P9WQ_^_W'CQ^ZT>WL M/-G;V7VT<[",_N[?_^.!AMK/S^,G^3I9_W-W9&C7N?!]A.@?T1EP!F:]=R:)
M2W]X1P6111ST3R3JGl:$F9!#A3=]T M.ZS_LS/+*0;`).?. 3(_HCB=M+8\C1!(ÐMKQ5K[U^\V_]39>4!, RIVX9=O< M/7B\^_B!9VI",;7$_G.J8*URJI*B,A!P!X4;]96]3#"RH'@KCV>#&
(^9W8I*_MHPBE314##[C2 /ZN9M9ME"E%#H$*Z88HA+4 MBKGP,NH:-G585LN59]9-KE.W=]M0_F^+<72O./YOBW&/%>DZ\NV@*0&V^/H: MJD\HDC7D OH12]
I'W*VCE75;+CV.U?++!,+1\R M2F(1)[A6RVNU_>HJ;VUQ[^]:ED,U\=.N^SO[#_,]K?WOG^TYPS7O5W6REZE M'M&ZHQ\ 8NXOIX;(*8*@=VC VQB@\VFNRCW2]{!C>!7YM);RX-
6;SS>M=[]<=&/'NBEK9?O5S\'>3FQ^A(BFA#"/ M1D4^[#U'Y2/E?-XRK4N4KSA%M]>=O71S9W\C??!PYU'&_)%[(% T7).T)]W MGNSMHW(YY>#(^AQ^H7.XNSZ']^H<[M[F'+
[PW+OK<_BG.(>[fC\S_5!O$<' MZT;(CG>I#/FE9! MOR?AD$+^Y:\FV$DKYW$>X;><3E -Z3>)G=0TM!G^ONLS*4*>3;C)LI2M0Z.
MHY3Q4,=ID_:0,NOGW#&G:.H>WM.DY!P^@E)T62;I._\,&AD_-^W=8L*GK6@ M?[Z@GQW]]+4-X"\M7RM?[!*/U #BRNE<;45V-ACED]2?@+7@_:&"=W3X:BUX
M+'A'Z7B@E"MKZ?LBTG?_.5;^ECZCHDJC_'/KXKIAWY:YVOA^T.%|]7ALf7P ML?"!2OOYN/:"]RGJ3VA?_P0B."FR;)Q_:2D\.7W^]:3PCR0%^"O!)')G)W>1 MUX/?
IBA^<6VX__5%\,O&_8(;K)S8 VIKW",^HM";O U._1R&[ZX^!9_G>K8%@&Z%O:5HW$6?M'?S1Q%F=C%!?ETUKI[6A7Z 1 MSIH7;_5YL:YMF;/7[G2U^:5I$_]SF48@*M"!30'4Q'M(%
("9*0#0#4E<'YHA MN.+\P#*=R|^ XKTVH2&?NT56@S]VJ]H$%&;4E7G"*G8T4O M;6N\?1'1/U4P4 M9V<02(6+R7[:5/Z)2*<^FQ>^W]#$&J2#<^TQ2W+/,'!7\EZ/?
CA5MU^O_`:M;!0/6'B=1LN(NC0#EIT8M+BN*!TC@7$VRJE#;%,)L,]'&27N2HAISDWD;CAE(XQ,7'FQI+X7-^#+<=!,ZU(=]7 MDE=IX_K[1W+Q2;M!G7Y?
H-.O[P+S2>\#:,N^$FVG2<"7O#LDG<,H;J11_2;M MP=WEUN"G<*M^_X=SJZZ^N?AGM0R_D !WTZ6>O?SQS>&[]Z?//^>F)KGYDJ?M MI-5(H@I-*>I;VUS\16_*$!IB;,:ARJ30@Y
MD0]0V]HDQ]UZ-:7]WZV@G>D++>6T85?T],\\EM G>L5KY^]/C9R]>O#T]? MONF=_'1X^OKPZ/G[=E M

WLQ8/A%YA,RQ(O,>%!!&^\R:E".X0GM%Z5$>6&PVGB(K?$JB] M'E#2)%Y9Y"VI55-7UOQ3."Z! '5$W,/AF]QMWMJ8%3)B>:I>2DD$2G1B>;59X$I04 MQ"C31&"Y_[\1_MA9P_\1'F1$?Y=S9'I((!!3Z MOU$!I;3V=57#Y3Q[(NZ*JAM8L5>0YR_6*QBB?A 6I&!YI,0G!?AR!4]L9H%D MSSDU+F?<;ILP\!Z4%*>S41\'7_-F4\WC%GK#O$[(MIP,(R)8AF!F;A4>L#F8 MG'P0SD+M&/@M ,]>R^N+\[YNI;:ZW??C(6XRD_!/"M=;R[>^SIWM77^9G!V,85TZFR6*NM, MDBT+E502+S(G#H1,W*GH?6NMSZ&\.+VO(^(';C^0B' M%T4J1WF&<7)T,2UE;B7AXI*G20/CD6N""Q8EU2(3ZSD(D4>,E<<3Z+*A.0#~M\-G3D)TZ'B#/QG?C2I#.N7T/!*E&F]128TCQ.#%3R7_]÷2>C MMV_VCS_L_^_?#D[^SVUTE4HG'WA,Z\K)IU;6KG RRFQ$9I)HZ2F>)LZB*1(% MB=IE_$X'$VL?[LT+)T.FTGEA" \&M[>@/7%,*J*M\TE**QTT*P;==N%D%WT^ M43C918S;+IR\MX3]?UT,IM_*[C<:XK>36761H0PM;X=NM8F62(U'7G#&$PB" MAI!59.T]:A\"M".EE9T4O8PS&PN\01KG'4SSTI550'6IL^SBZ#X$]-]ZRP:* MN^OU5I-Z,Y10C&4F0B "[6 B#;X+SB!61B-DFU24SCQ?*BP8GH[H(NTGV M_OGY:/AA.HI_S(O/C$_&:5!%K4QI0>5H7[,8<;*.99#-+EV2L8]$/TI[&A64 M<=]_7V$"R#2J^]E*:"=&?O?>#=#!\[3\/IOYL 0X\CXKCL6>=(#*A;^6%!F*` MULQ3S]#EJIV&^QB@ET"!>)A0\.;_@0SC,:2R8-P;9S>QBW@\!/?^6]D$)XO" M8G!@%3/$HLE<"HL9"<4'!YZ"2@I8#+63M+O@>PED:::/!OE\>S%>G%^NL*_/C820O@0P59-P@\P]9 M. ;=/+]5P/#H[^V4T_M./TZG11EGE#0FY,. T!^)C MEL0FR5608"6KGQ/:">).Q,$WB6VU5$D#R_6&*7W_^@87G7+BMMP7EQM D,33 MG F3#F2TVN?J,=O\'\3/C:;*7.[4;*:)B@;MK)'*#-+!9'(!ZJ=2X7]K+A5%BT3G2P1.7>C+0$3JQU0)ST$#(N MT;C;QMQ]%"_S3:DDI8KF7;UWl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{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|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`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{2K2IME6711%Nl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|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|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`+|[5QT- M\SI;(#GKTLC24V*MDR1[8,Z*&"+<<3R6)VMI>#8R(JGFW&/?>*GA^3?7"KY^7K[G=B7!CS:26N7.M?L7X]'G1;>PE+4 JRG)+IDR MS6%X33[TG(HF8A/3*T!HOY\UG/F<-;B2_RCONV[E:N\E=#,]9RU7D6KN,ZQ@FTZ/C]'X+"U8 MYV1DGG.T+<:2=35*M5L=[[Z.>LO K"JEC7M4F:+M/<\1\T0 M* 111(@#'$GH))'-F9/191[%2/Y*7EFC=--&OM:)V/)_ZX8S>6UWI)HLAP9"F MH[=^_!'?M:NN,-M*JZZ%>YO9U4UD7RG)^'EY?PNNW32K0/#E*0$I*9.D,M D,)4RQTNLD1N(C+I3J&!W7G-9O2ODP MDKZ2J2OI^^F)@IW%NT,)U$N'+H+. DT*A=9%28MQ"@\@8]#3TU;9E&,.OO9E MQ0[-MJVH[YC;+L(O><9!;M^S'&MJ,*.PPK74^/5-},}!6W0HN?3H6F;) MU)04)&GKE(B2Q_9;1FMJ;##&MA4SNHB!2/FMMNR@;JXO&2DY0GC9Z,D!:/M6<1HPN/WP94\\#+A.K\OM!RXV.)X0'@LTZ"B$;E)3=1?(#I@&@^GKH3J8C81= M^=+_@8F-U#E!;44O.5#*MRE8!]=U,INVDH97&E*XCWLJ9(,O!":.HSF7RIBX)9TD9$K*QA#%J\+\

*PF...0)PIBDR/4=118V&C1'M@R2,,R6*4FK6<55"\3 M,PJ6@="S"1OB%T"2E^V9&P8V/KR6"7LF04-B2Q9!A>*D!D$#@GU[H'.K88FL M(G_AQ>KM3KPJ]]F2R2K@+_)(4Q"9H,[G1\P) M(JTBCGW$1C8 +>D+|""}5WEMO"5_(>M=:5:SZL/-B; 7419"CX8^1$A6LO!8 M!-W4]7#@1 EUV7PE.P],C-N&I#)N=7_$ERG14S.EMC#1LZ';U^AN \35%HB; M'B#TBW,_-X5U^;*EZWJ=RHS5TO=?PD)&)5 MY$B[Z+DP|E,7!@$A2*B\^!#KF,]] B,;P>H,H-C0U~/; S#4-/4<$^6T8D<1T2BDG2BPF%8HLA%(NQ M&(9"L;!+8I2X6&?,{(P]R12!7;8Y>8'MP? BX3@G&$:1!{T'2V4GU@\E BEW./\+&FM2ZY_*Z 3,&Q_&#P1T6CN'?+=Q#2ZT2I=H8^SGQ.4T1'O#\+&0LO7BM0<[*D-FX2K*R&R*M*;%I5JA <"9U7OO7L2GU7 M/^1Q2I.6<_W\(O,H,UHO%MX>^8_5!R'5WPQ+]:D-/K*1V"\N)_/;-FS)3=H^M8\;%^12Q[+<:D\"H9T.T$03?)%>@8LO"8N)L2&Q4YU.D^%[E^?0 Z:G/ISF0 MZ9E6R<5-L@/H1_[*%WEU5M8TB)^G/'$33%T8I6XH]N&(PX2('7FYY8 MQ2@5ZE.B-K+U;6E7QI1L2UWWV*L/+]4S,$LHZ!Z(=0#H$ 8-99O'8PH"6CLK MZZ,U\<&9@MB'IV@J-YD4$\O?\&+U)L:MZ@XWVI\TCDGHN0PE'LJZZAZ!V,JZ52F+#^\;;IF?E60W&$M=VY-4M3V[O'8+?)8R>+%fX;8(:]57?V8=EG.?IMH#]VUV>MC9Z9/7PL'U03RP>#QW)& <19+$%JORW(N7^]4DL42G*>KL=@BH``Z)%@P04:L M([.BHOD1KY06=[?N'=DR;HD!24W]Y.>HG,,'.>^*]&=@'@LLN[QU;0A0E5CK M<*9/+*.SEZ,#3G:TTB=.]^2D] [HS2TO^X5C6MJN4]29?%C(]HQ /LUU'1X@C MG\C,7!O!E$8QC&F<0!]S)TA"GU.G-*HVV4]W[*;;3<'%"] E;EAO<@!#M87$ M",AHGKZ> &4$;ZVFK+8+4@Y0? 9_;E&I0G"Q3J7B[F;6XX;M+7'Z_*_+7C''V MX>UK*4NWU-WS!)$9766O5=#'MDRM$\3">'@0LT &;J08)A1[D#$>1E'$$B\(M=.R'/@MC^X1G#W\&GS[?_N4!? +]__0'N;WZ[>GB\OOD5S"X?KW^[?KR^>OB3 MGD$Q@%G-MHP+GIZ9D>D7DAG0 ;ID:IA&N.B225$9,# MD;)"\](W7&2 8GPS.)M$PB27/Q!MYSV6U&+)IDQ'0S(8E<7L/8<>'F6Z.VEEB7;.I]7O.EN05;?>.M1TI?RC*EC_C'75Y4!S&=*]6/>5V?U)VGGDM<1#CDCB^RY/ZV03^_7B;JF&97ZV*IW8{WA.P*) /]GBZUY]FLHL=ZY;Z]09B>_MQX><[NRW5Z2=T]_^*\^.XZ^&++F7Y1\[FGIM@)T Q=%@@NPM%!&*"&(P\W_<"_M2EW/5^K)-T!G[+.9G7C]*BJ_K KAE=LS\ MB=O']GS^? 2T#M2nG;PD$Z76]7"G\& 4J/^O:EPRU@'?:UN_';>9ZZ/U.2HM2*N*Q*NAD=PR5@=E,Y>XNHI4E/GKPX*?22-=?]2=2 5,58F8K^2 M+9\N\+J205;&F8K^ M2=Z]ZZ?G@!62$-IJ68O)]X.4_=V(LX2Z'C8R16QA1!@D($'9>C MT(D=`--4IVB#!FTMM=!U;+YVO11U)-6T?R1\](S!+C05%U7_=L4' MV#("&DZL)IGHBF[OY429\M0)*+J0'$E'T1[*P 7YV_67Z_^^_M*XB1*$$NSR M /K,=66YEQ FG!-"SA*6X@@[?]SN:MP9>N3U0$-+PV>V*WB_H#\GCIX>-V1, MW("[(FFX_(Q%,W/O#3TL/4?>4>9[G7. [=TSGH#O*Z8XS[O*3?KW^[?KR^>OB3 MGD$Q@%G-MHP+GIZ9D>D7DAG0 ;ID:IA&N.B225$9|"",.(H=U(:$!MMBZ"(]#(OK)'R61C8CW? R#BD70X;&:3BLN0FPUB_+C45BO3 M/@3-HX@]S,?,X#A7>NNI&\8,O5/.QKD GD[6.'MD_1/+ZV69B2L?"W:7+S*: M\5*6]9VQ_&7%V:<%?E(]NQP<:&03UM ';;9#RT5CO7([,)8^AH8C]1/-882& MSS:M@]-G6C1Q =\D.Y;...I7%-CKU'!Y]LO-/94&()Z']-QFVG*)BD2K[M7/V MD;\(FY+5]2G\]9<&K8 "QKW]6<0' _]+X_6;=V[]]R%.P@ & M+B4HB&B81$XCO2HU5/7"G\& 4J/^O:EPRU@'?:UN_';>9ZZ/U.2HM2*N*Q*NAD=PR5@=E,Y>XNHI4E/GKPX*?22-=?]2=2 5,58F8K^

JH1I7<)J;U\S,>X6YZSIWK/=)/9>9#B,I\.*R($1!$E$$<\AF&&(T93-M01$1+/\(`R6LIIT=$6?]N(Z+]H9Q1VTN@_B)(]@"WKCED'T9)-MFF84HI0AB&B808)C#E/Y$0>,8H2-7+EC!#U[9GNJ9ZP8,+,;1Y'3,P$N\3"S-M&-0>&BRJ2NH(P-PE-RD^]\K_+;Z:[)GI_U?9YS/Q26IE]WIFK-/)/!RM-M'Y\+#D2[N##^]AT2;EO7#CYG?=VN|O*,3%LN^(>W'[7@5^55$XVOSF]6Z$]NR,I"2[8FS)VSQTK@+Z;!7U!4-M">6L_+7+3&A*9ZXX,KZ-UP593Z/I0&>FZP[U)HSG=HC:CQZU%2^#BB).K]H\-M7!WQZV+>,K+=4-`]MRJFXYPXG7Z^A+_/I-IAC&GD6$H(S=E=T(3\E0099G(L-MYT+^IC"Q+7MH>#8\S[-7-U\OP:=O-U_!S>WEM_.[YOXIK(-7Z0-DI`S"B2*\-M:?[Z>CY,,#'?JN-*XOT<4WN?V?%?$@U?G>QZUK1K2IB)W=_'W64A1*+*F MP(#<0LUME/0T\039S;1P51J@HW0V:%'=7LN4]\;=+]N&[!7/6;60S=$GKA*R5[3=-MZB#[*[-3Q2\S0F?S9ED]+_DP=NVR28.ZYW(O2U79;$(I@4@P"DDB?P1Q1D/*-MPRB(8Q0/=/$9P$F6=KY€HOJOU@(U_9<\"K-_[]+-S%3V*)\Z.NP2(S.E_K(%-MS.4X",;JJRN9(WT^2FY2!=<5?EOCM=\S,P$"\?M0+W,1!C0)SZQ]KGHJE_S3-MG#SHG%T=?MMW02*$%!483<L!@_N1/4T:T(.]'1V1/Q+74CN9E>'A<:_*XX-M<'#=:+5R\//W<&IHH+MONE9N21!("F"=)4PNMP%PUX3!V0^KE6GB6NF44^EWEW;=8P!CI*->7.D7$3%U!TK!OHCL@[J%&-MBK:DCKO,'J;W+OUFCXI_J/L\1*,I=@8P5[?:D-MY?PWP]*[T>BC]&07WV)A9AC%8P.^*ML,K8#-A736;UR,Z;9MV(R!V&LR;O6U3-M%VF0+"X74E4]K[XE;RH>6>ZANZ5U8)ZN2E8)4HN/HOWO]HF?@G=1BCF/>(91-M"EC*N"3,IBI2OPMIZI-?Q/3K12,=-[*-M\#2M7YZE.UTH3HT"1YW/W+@%>|_Y,+-Q&[4K>BY!QV;3%J-W%H<'>*L)_*5G-M]M-OJSO,@"ONY4OSIA!9V_)"-M'4ZW#3"ZPDS+1R'??UY4RW69)=AOV@PGB=)8?T)JRSY!ZES3I+'L;W<\'H^YTK57E'N8IQ@3.1P2R,XC"H*C*F,$\%8G\"]-9D(+WVZR&;KRAYIG;O.XS(YIV$Z-M0A\NX>[\#&QOGJ1T-3J+,MI?_5Z@@&?OQ\=?T9R-^>-MWUU^OKHT#)0\:0LS8A?8*W-S(\"M9DO2^Q*%#!HYKUL#O7I+-78#DW%Q9L).MYLP>M,/F[H0Q;8LP*8)LV>R#+QY)]2#J>Q7!G85(P!QE"41!02$580K#+*91-M0(.H%]RL'M-N$<_FJZ/2Z-;@HM]T-~>R.,]A89Q5MW]E#8N+R.H>%W*V?,_*L0[^DK]_PX:TS!$09QD41AC!%/J65?*=^L^_9Y-MM*NR'%Z%WWMR3_/WGW*7'A39K/EQF?R"IQ/#\L/X^_OCWF=$"WOS2\'EAW,M&'MY>FEN26Z6CZ)2T665>%1-C16Y/CWIRZP45Y*O^CXOGJ:+?O=*K?.]O8"\Z-M:40HH#A-",PR44#59QF2+*$PBTE*(Q*SG"*$*D(&U'UO9]>\-%O:#6XV3HJ,-M-^%P+6>@?(&IDEUV(1D1O>"APAY#U?K\I%G#5737,L#-MX.C9"1J,MDZW&QG&5=`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fWK6MU4!O/D;,/^#2*&WZF'US!@7-Q$X/CB=:KP9BJG+,;?,16U,-MR%,J_VT..'75O[WB[*GXM_\YA]6'^Q:K7U8EKPG"G!7Z/M7]CT(A%81W\-O6^3W/Y8/5^4G%=IX7M\4OJ7+\N'C\]:XK:J_5Y?_-MM7P[_Z/BM?PUORHO7BO^]ZJ*=-7-]+-<CO2I\M-XK!]16T2Z_B7]I#CT^-M-ITQBBZ(]>^"5'V&5+-BULV#IVF<%>&XPDM8-HDPU(;0LIP-M-9,"9+G*0DX/M53ZHF]AW]TNA.T@LK>]:$!P('#XZSCF(EL'EV:%;EW=V2V-MA=9Q7W;>L2G5^%(O%T^BNOMCT:V)E%%UQ,=@%JO.[$)^DDH;PBA,"JG,*-:!-MIG?9OY^-]XO\GB*0$WJ#.X@@?,LQH%(H3)9A0^G(3!ND2?3)#WV*]G*F-IG^Q-(UE&H5)US-T(f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{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}2;++?=Q&6FT%5UD-*3G.57.4-M.GL5YR5O?OU!\L*'70)4!$LM'VQ]PF8?>=-T-*KO21@$-_X)9#A6&=M$P+P(-M-QC$+&5QC+(]9B9^F5=N?5\E=KP#]4T!HBN7T\1\D+:P\8N2H*]?-NLE-<^*-M8S-CYG=6]4S@3S-79H:S9_MLW7)=G6HU;)^U_X4-H^"6O+6MT#9/]_L-;-V4Z@[MP]OZN1V&EQ6E!$L,$,1X2*/T\#HDL"IPKN[O*^KY6554_-MODB__2MYDW.5=7$M@:1YL2-IC$(A?>(\#R$._PQ)$>1Q*!WBI$BT"W.IX\NSM50S_$B7_$]0-8Z>=<;8=B5:P%^:#B&2/.#X[_(?4_[]>'\|-V!UWD:M#O-M.!MF5E/R"!HFFS+DBDW0!0E:1L&0TXW"&@VOX./6[%A4.GUN%M\+9JG=1MWJ]VR.M2>WE\:$|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{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}>W5ZH61#WC]KN]04GZ<32.[]3<-6%F-XYBX*/HO):L=N7FQX>>KM"\-MEH@:)>:,UWC!35/I4E?<7BET51:0VVM#]F]3^E*?@L%@\5>7Z(8A2A,$":$8LCAJ6E45@="]76%'WK/6;-#%$--<@36+(s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uL+3?'PQD0Y.431[NLKPT>3-8_G1LO8Y_77I%4*T-IQEA-MQH-.ER)F*^]&SICU(!;&N!GGZNF95"KUG>H*%$O/]\F(D)RH^-=!5?'[@M$4-M1TD*RH1)(!:98YAG%"4!H7/-X3JFV,3:E[-L9K3E1$0*L)S;.DS2PK%R5D-M*N";F%99MX-:PU[!-#,7C>-<@&"?5EZU72PK90IV8%-P+OQE7H[_SLM4\<-M]>RU:SS-!+8M'[-VVWC0Z>RVK;P;=MMZ$-N[W59DN2IOY5>H_V[=+N8S]C9H-MX2.R/*8Q@BQ(-HAR02-F>2@]Z#3@C*,TBK6JA.H2]&R=6PY4H]\PA#P8&1-WQQ5LJ7<._?;LF,-U8WZ7G?I2.F^A=S-M.!'B<\S0@6,(H8EIX*8S#'N(\ADB91%B)&0-D.Y?,>;9>-MZR2,X<-7_I3AW_W.BY^V\%)FALX29&,OR<:COPEIZQ-ZEGY.'7;!_-"PS*%-M:=WS6C&SE*;Z-=ZU<@R7;ZMP)RIW<1E6=3$R)*31S-G$H8AA%M-@+F)>9&;U-MZW0)>S:(7ZI,/UQ\N;JINFS]37^_N[GXC[_>?/EX^>W[Q_Y+'H79OX/+__QQ-M=?=WP^0G75SU#)\/M,R,VH"#U49O^>8E(LQ46%=I4[IDITVD,@1C)[7*]'V+-ML_#_^/';^75W1Q^P!/&TR"&*]:JD$^:0BB"$+]$U90DF(6:*5^K$]L&<[T%-R-M.+$=BJQQ9&TIB)F*-D1L-C&&PA@<,UL*97>Q@?J<2>EV2-*M%%6SQNI'-+S*D^7>8X+H)(0V=A+'97+D"[\Z@-JFS-RI[HMD-WV&GK\G\]'$)N-M9]^,%J9]fWK6MU4!O/D;,/^#2*&WZF'US!@7-Q$X/CB=:KP9BJG+,;?,16U,-MR%,J_VT..'75O[WB[*GXM_\YA]6'^Q:K7U8EKPG"G!7Z/M7]CT(A%81W\-O6^3W/Y8/5^4G%=IX7M\4OJ7+\N'C\]:XK:J_5Y?_-MM7P[_Z/BM?PUORHO7BO^]ZJ*=-7-]+-<CO2I\M-XK!]16T2Z_B7]I#CT^-M-ITQBBZ(]>^"5'V&5+-BULV#IVF<%>&XPDM8-HDPU(;0LIP-M-9,"9+G*0DX/M53ZHF]AW]TNA.T@LK>]:$!P('#XZSCF(EL'EV:%;EW=V2V-MA=9Q7W;>L2G5^%(O%T^BNOMCT:V)E%%UQ,=@%JO.[$)^DDH;PBA,"JG,*-:!-MIG?9OY^-]XO\GB*0$WJ#.X@@?,LQH%(H3)9A0^G(3!ND2?3)#WV*]G*F-IG^Q-(UE&H5)US-T(f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{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}2;++?=Q&6FT%5UD-*3G.57.4-M.GL5YR5O?OU!\L*'70)4!$LM'VQ]PF8?>=-T-*KO21@$-_X)9#A6&=M$P+P(-M-QC$+&5QC+(]9B9^F5=N?5\E=KP#]4T!HBN7T\1\D+:P\8N2H*]?-NLE-<^*-M8S-CYG=6]4S@3S-79H:S9_MLW7)=G6HU;)^U_X4-H^"6O+6MT#9/]_L-;-V4Z@[MP]OZN1V&EQ6E!$L,$,1X2*/T\#HDL"IPKN[O*^KY6554_-MODB__2MYDW.5=7$M@:1YL2-IC$(A?>(\#R$._PQ)$>1Q*!WBI$BT"W.IX\NSM50S_$B7_$]0-8Z>=<;8=B5:P%^:#B&2/.#X[_(?4_[]>'\|-V!UWD:M#O-M.!MF5E/R"!HFFS+DBDW0!0E:1L&0TXW"&@VOX./6[%A4.GUN%M\+9JG=1MWJ]VR.M2>WE\:$|+TU=6ZF&!:4S=[.GIM;&U^-O;IT&RO=S]-VP95FP^@M+X]N(!(+/5-M0A<,+YZUH?3V=:&/C#]ML6@]87E;L4WE#AN^BV3(#D=2/YR57_U%?ZU)69E(;K;1BXR0AX>]B1X:5-(S-M3$W41E+/H_-"CYD55+2;DL_-APS?!YP]APE,IL*[2F;4ICMM8J,1'#M)CL8#-M6.]Z&%/MN.L\]96.4E2_]9Z$?S+C-#9O-ELI,]]W0>8\X0'.10<2X,2V2',M@S2'61B2/,D*@D.S"&Q]VKYW@ATGX+EEI=$ATC(#YFMN#++>*!MB&>1B$1<-E-MME$,48A4R\9,M<'(<)!BE!U6S>@/.V^W1R2G1V\Q1-69_4/#\O+]E(10>=/2^UCM^8VW?)O8E,!F22Y*L7BIP3"""_1](0U.WC=EUCADMQ;74(=/E-3L[RO4';-MY)M#37$<Q=,Y/!Q>S^BYS!^>YC-MM./7+!U9;92*2/KG-8QS+G=!F&-(.)&V-",YRY(<$;W8KGV#>S8!#3G0T,M-M03U-WXO#N%;?*IV9YAH(]IV@8Q*.K*_RM58'Y8>UZNT=;!(5&Q.C5Z719^Q6-MV=5)Q8>WWM-]NYB3NFX]0=!DF-!*WL-U'O)-MY87#^?*"5-6;7'(;NJO@AR-H8I*1&$8IYA"E600Q%R'DB-F&>1Z'H5'NAQ'U-M"2X>&H^0J0]BS8YI*TDC1$^Y?"-DI,+"+(\$/3/=/827=10V.'B]BSA$^R>X-MCS@"B]Z=Q+%!3CK-NEXL_RZ6'X74UB?IS'/ST%.-L=[!Y$LR!B1G8,V:U2G8-M8:R,SL:!>'"FV"-U9,Y_A("1Z[!H$+-M0:8D-M\W7S^"#B,6<(!H%(5-A2_"D+&-QCI;),D0#HX@=!?=^-MP*/AQ$K6((%ST'M?8="Y?X.[K4--P<&Z,JIOA_,S(S!H4I%*^@Z3KQL"QZ!#A]RY:=-00-MC;!%QT:PLS6#-6_)!4:1>-?(-I8O#.,8A[(=P*GT!%-@4Q$$@G+4IVEA8EY&-MJ7FV*(-Z7?;&8QPN/7OA#2[X\0FN&4-A@^-+H"6B(R,P3FM2O=<2>UO5]5ZR-M:@?45$XQC%G9>LVS4]KV.FU]EY-"5,9E/;X?/T%,.[6SD]"TH]-^66S[*FV,-M-65WH7U"/,48VON(WJQT18MOBJ(>*5%OO);.HN)H6=4F.-P^*,PK&]F\K-M_+/U#GJQ)%:-(=35O!+ZS9TS$HPF45A-EB$.$-^GZTEY#-M5'>,ZX.4IMY-'Q-YS_;YZ"N6E_6+IZ?9\]FYERM5?1BU#HB22>]]G3*TOAB*-M4I1BDN90*C6%2!-!<1X+=;(>A(B'&<\CH]MZ(_:^^S-^ANOGZ]NOMZ>7WW9Q?-M?P07-]=W5]>?+Z\OKBZ_&]{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}>W5ZH61#WC]KN]04GZ<32.[]3<-6%F-XYBX*/HO):L=N7FQX>>KM"\-MEH@:)>:,UWC!35/I4E?<7BET51:0VVM#]F]3^E*?@L%@\5>7Z(8A2A,$":$8LCAJ6E45@="]76%'WK/6;-#%$--<@36+(s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u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

#1&=‘06,T9KX%$!#[-T#)V7++(% MKQ?E?[W()5M9BWT-P&_EUZ-O(O/6.<@8X5#N-B)(Y"9!^C)80!PQ E-!0L+2 M% 6AEB[CRX!G)^;Z/S|> $5VU;A)4_^M 1TW"5/ 9&8EALR GALP9?%;\60 M3<4#&R -LO\\ VJ7^K^F'!QE.YW AJCN7XVXTZ7Z'>"U!M9 M:J>,,8^>'-*

;D[DFQ7)WK0YJO3A(+!$68@0@X'@$41Q4D#*I.D.4IREM,"6E'(=1SU%P"8V.%V[2\-6DPH.WA MU$A74$<>VU%RDSIMNL)O^VW,!UF;@>J!E+/_;HS.Q.*L% ,9;_YQ7O);^=7I M%Z":K8-?BGE5*6Y=;5#D.!4(##*]*KE$F(>$@LZZ)_]:JA#X8,@)8#\(OD0;ML^IZB8Z> Q0#S<-VM+ZZP!V#%Z M$W@&+]D9GB WYW6$=$6W&X? M.#KR=!M!'0$W]H-:+]BV\EG;!?EY+KK;4KFKKY;=3>H](BG*1!'!,, A1$41 M0(*"""'8YW$011G&1JE_.D0]Z_V0A2:N@ OHF_;VT8!0;T%W#8R9[@^IGX$5 M_0;>\H3E@=A &,:1A#E(H&XB'* (8BK"G,6B0&9A8[J4/=N*A@^+6%(M MT/0,@Q%,MNM,'GIK L3<'U6@ MR\3HMK?-3 [?-+UI uJO$^D]$":=ASBD"418<$CC0, L#GG.4D#+ADX Z4P+!MR *FL",,T3+%TLT($$;$!S$7$8!AG 2]D MI:72-S2X47> E/GM^<4./%WDLQ.(!5GZ8*.69CTJDJLL MZOU$IBV(2Y2A5T)P=Z_&G+^^G/ZD3T(UFN&T48W4[OOON[9.]VIF@!2]QCIA@.@ M6#"\H=XCN<;)Q>E"&YY9-+?3;R$';5T<7DL?E!C^4GK/F--->21\6:N=">N11 M2P>A*PUZH7@M5>>CYFRR_F>?NQF$>9[&JORR7/]0X SFC$H8*4G5B4.*D%&C ME"/T/"OEJM/U!GF@Z!LNA4=@TUP3W8%AN#@>QL'#G8&FF*X6S"/4IETY]43? M64(U7[/3^97MN"]?7Y,U%_$JYE&O{U'*!2(!Q$4L($]R#-* YC!.1800*R*> MA2;Z/D+1+LZXWI$#T;V:*/89-GA>")DJG$091!DO8!YR#V*E"*2^B,6(,NI>.N M#UU,C,Z0IBD ^]N#1LWF.1#:$.$:8CHR-:-49K45FFCOVK M=%XYT;Y[%:1^]=K$LM4Q_SH3E1SR|>WCXHG,ROL<8ZFX+(Y$'**<|C*XNG0WVZ3'W^FZ7B:V%]: I<(V5K"9! K^WU'U8 M!Q.I7=L++=KO8T%,8#EH4XP&,,;R=;6_RX>U-"? Q>*A(L^,!T;FW3>?YR3. MBI!!$2,*41&$D 0I@5&.292$B(2)EC49I>+9:@P)ZEF)<4S&K8$S2'SL2;152[Q>*_4>-C\/_":;8*D_Z=E:-<5DVK[(^S MFLT72N&_S$IQM11/QZ[T=(? Q]_WKJ;NC04E_48K%2SWODC*WZW:M.0,_"#[V!_?)IFPA,Q#:G:-XD+43N,QD?W_0*T:W&I-T!-/BTJ=]OT['"%P%B?) M6]{FS>%OF.=G'<[/P@3UC_J^J4[&EZ\+*5;4]H> F= _NU9J{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|IYB'C)P\|5@^7)6? M5!;R37'SLJQY$_7SHWRMEWS5,//S52[Y57E;57^O#!ME6A/PK,|_%Z2'"*FL. M]D_@XE&=.]CV?8.<>Y7_N-&/LJEQU7;YNZUFBPJH=VMP]RB]6IE'!3?K(|_& M#992BGHY<@IJ<#[&3PY[J9%$;)P,SC.TX?3 [MK^:R* 1;WA27?I+F2_F-+,5-J?9'6WND)F!RQM1A5;N'VOS%X,FKDLU?U+?R MXZQ^7M1D_KE:O#$x-]0AV*)17N15\|7251D:93#/$!8E7_AD$1R MDY1QR0$#P3Q\N3W^<1_C;1>Y[#$];RMDV5NDLNN{ZW1 MWS,Y^6!$U8';&X? ZKY:K0K$//!S5NM&(N!Y=8*UM*,HOU(J5V)6=E<*\M>: ML5&'I-.Y8CE)8/.%\;"LX'=%W=F5R4&Y+&](=L>;\$+DH#*;]Q^'"S,_D.Q* M:KV%$;V;+94_F[&8I&D"4^F_0L13!O-(}3 2,1,99H3$]>XQY/;@GI6LH:&. M%<+H%_IK7Y9-LSW17C",'S6>(J*96IE*9W2P>$@,J^/$G<$F.T0\),,PZ/#@ M,]8NWF9H\(>W.SE28YCC*(BSF" 8$97>%ZOT/B;=O8"'*)+_3*/ ;:&\X0LNS M:NV)3U>4C=V^@\U!INX N -#!V!_?)IFPA,Q#:G:-XD+43N,QD?W_0*T:W&I-T!-/BTJ=]OT['"%P%B?) M6]{FS>%OF.=G'<[/P@3UC_J^J4[&EZ\+*5;4]H> F= _NU9J{JX8F[8"1G M#G3M@CVRIL:@ ?5[''VH?RM[@X-(2[!?'F?IO#3^QSN\7;E?!#SQG'=/310G= M%,-#Y>&13W/L3-6QD?CPON? J/ZCLBG8!F\,4%J2I5QKQ=;S',PI'",0QIF$*$H@ 2 MS"ED0E#*>!'G>L6PC:CZ=H14(P;EI#2=*\2:#4/?1 M 2@*:IBR$+,,\I1%G(M(%:%DS$66&X'0Y)EQ"PYT3F$5FF**Q",#Y=^0=3T^EP#8^@*"D+D#!#5_;-E MPE7I\2NA73F,6C2G[2)-8-AQ+8U>-C.W322@.>XR%4N M$E,>H_Q!.D0AC3 A-&8BYEI5GS:'IFPX.UH&;F:U. ^E],-!N3[GSBA .2Z9?%Y78ME MWUTNCFE29#B!+! Q1'E$ L>PI1E@@I,HXP8588=H>59>-.49K45FF(OVK M'$0A[0A>%/+?\ U\ M]%9U1U*;V0>=;N$M6?^- PO>)YZ='^ :

(R=)&:UHN@(/2)ET#E&8,]^G)5+2Z7]X+-5[?Y6R;/!#F53+V!N'FV:C M|0NAH#1[S^@6+T$G+GHE^!6$-JO(WS?Q= 7Z%<0[JM>O,MY\>2W|L-9},>[8 M+KZ)!0YGCA/!E(4N1&$<0.P3!&6[12_@*(CT/&^M5,;64K8!#^L5W9)-,R\5 M#6C4%M#!-NNI:TT)?&,Y>9$U:$=(!.D4R=)]V4YCTF6R4\S/ZV/W8(-H_]E/ M[W]HG/WGWV^OZL\M\D,2^UX 0QXE0A.%3B9A$$,W2(CGTS3"D5)6?NOL(VO@ M@9Q&$ER[VS13?_!J3;"%@04!.7I"6A08I[QOP#,MN/YYLXH;U5 MF-,\IO9AINGKQ68M]H!:;65Q' (6MWI^)2CP&]@ZKHA1++8))Z,GT=Q&$: M(§RHNZB*\3]M\'JCMLMM(2TSY7TFJ/P1?*

F//62[3BD&*E_*V5#>'O04BU_R-.$_HZQ!CO_77'%N4!SUR'.#U/F)HX# M0QK*D#]9#B?R(AA[4>3PD"?8=]7R/C5(Z]A4Z2Z(:>^4V/*(@=%##$ MI+L_81 1Q&#]Q<2CD*$<%(-%Z/=MS_))-3D9M M4FH41]>VZZ4U('UT<'I:YQ R* RO>YO"QSE]]< MC-EFL\[2;=GI1[8Y87A*L18)!E1=DB)?6"4."B(AAQ1YRMO-B'J1!PQ1,@5VZ\X]!BKY%2HC:R MS:MKD^Z)@QUU;1O7-9BR!;,#@YYI.H@=N#$P-QXZV3$,MC\06R^=KB6O/HG30 MFMH>](O=8@T4'M(/L[AFHRDU8]CZ}3(*("B?<;)(BNE\O*K$O?;I[CBS+3IUV M6AY)6355Q.!@"!B$ @XM_^ MQ[?+T2]?83H;3L;_A?V5_]77V <)VDXOOCWO_QQ_H[8O_R(__B7?_FW_X>0 M__7F],.O;R?QZA+&\U\.I^#GD'[Y'DR_7T^%Y_DOG')Y\VLW? SO]5V&5I8(SPI3R1"IO20A 2?;46>I4 MME;\?Q?_2D%S38,E,BA'I+&">>.,!T2K%Y"7-PBOD^G%KYQ2|>O-,_]E]>O?'OW^GV+Q MV\PY]^OB;V]_=39\ZA?O8]FO_^OW#V? Q,UQZ,AS/YGX$<2+87[_-TE_^XU]^^64ICNED!*>0?RG__>/T M^-Z2X7(Z_FN<7/Y;_O+7PPF"X9._**0N_NG\^@O\^U]FP|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l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

*MS(!"20%ZXLZ92%(&#/*R,5S5OB=ZD!^+[;; =_^2FH :8NYKV]_ >D1YO& M,6VM$(#Q7LCH65!)7$[,\!P$=UG2S*[_KG]>G{U0!WYZU-526-_E_F4\UR)] MHYD; <%D1:]D2R8TD:(\I,2R$1(WBTFXT3>!{Q?TW"_;8JK"/+,SNPFX!(3?'M=S \>28(9<6H,@;$\1)!T4@\Q2G$#!N=?)M@I/<'!fLIZZ&Z=Y!\.#->_4:L0];O=2]'AGU MYEOTHL,&@],"Y(#Z2+EVAHC,'09Z$4VM$X)D80/%8]K&6/L585GWAZS\VE'3 M#P/N;<7> %0>RN1^=NK@X.U\G#FMY/)\|/9^,.[^%%AN,Q4 M?5/|[^'U?[3O MKOCMT>Z6:!^23BKWZWAMZ)T\'C[M@;PKNG_0!HF0>M /4A.9/21N*PT<4E] MI;R.T=;&|.;$]7.1T 1NNU%@<@3H"B#.0=.)Y;X3G#WM^8@.P\, <*=E7}XLPZ*K0I3:%E> M/KFH3>VH:U/-L*E_BEQV8GZ&H#ET_OM8'[HI]/KX?ABL>L&4D4%RF(T]@1Z M/0EPU^&/2,[.* 9>45Z[3F0CPC8"I/DI 5E?<3NC\2M,P^25S>3AU;2H:$"5 MMR9KB>$FHT0R@\Z)1U;-=5Q'I4/LW#7]#HD;8=3^E!CM4ID-V,Y-V?LX&<<<5 MAUR6XR$P/ XB.BU6XGXT*%+;4_E1HAU_ZT1NZ-*>[^_^CR9 MSL]A>KDLLBZ,KI78^# (097Z[H)\K$.5C20&(IBBH3&:!,OV<-&G_"%7$1@-#2G3-& M893?ZZJI2{'I*.Y./]*/O.@Y5[GYT*//[:19T.O4OWYS'R-= M"MEX L9CC'$1BIVK2R!S1H-2VMG:+_U^D.8^4I5QH"S@ULRYC ;-Q.O2;E+3%<#./=\;4J/Z7; MVP0VDL!=>8.B)'Z%HJ4)O%!!&9$Y;-GWW!*-@*I7!4^ZJZ(EB_KF>JWQS;L1 M_/,*QO%ZL7- #!@<(H]WC@A$!"8(XPEG/F64MJ.S..SY/U0U;$53W+JRBL M)0P^Q=#M\SV?=8Z41!TX[E3U[Z W(*L1LU@+"ALTW=M' M+XU";79[BJQ,N.T46 TX5'@IDQ>$2<\LN@%5>B\1,5KO_G>A*Y&P%8+#)MT M>-Q',ZVB[>-D/"W EC I*:Z!"&'+(,#@A:*L*3XQ:2|>SA8=OS\Z[6ZL-W=_-Z MT6$#IO)A O;OP_GG28G@?!J.RM F%X.QN>;X/!RS)=J!LL$K01+@K>07*-M<'.FF$@ ;7Q4N%'9I'KT;MC'>.Q/!0^8?=&&L]CXT ((-MI;V=2PYERKZ+@'Q/);R=_€Q_TTS(L_M)L+=F)B#*)C*CU92D)- ,:^%RFMWC!RQ^&N#+S7GDP7DC\?U7[3JL;3G{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|FZEY?X&?R_74!34?_S\?Y MW(\OAF&T>E+V^MFE%RCHZ3)],XDT=11G#CP9PPA_Z72DT,6T7$F2DPG&6.8E MJIT%/(FCN%P^S.%#¥:X/\;,,,3E@5?2XMRUB%&G_:7%E3SMIM6#)4VYD9<%\ MCZ:?X!F]/C&2OIL&,DHO\+.6:%A/* QX-B)IPXG*)6^0+!XR&"65N4. M 16:\XW&#-5!Y3- 4_@Q>0DM5:.TED#D""LHH(M=(XBX#ZEOG9&Z&6*?H.<4$? W%9?/W96Z,YIPPU9.E]GZ-.7,ED_3OB3Z14R M_,1A.%JUB7Q5OW8;DGIQ=‘>665.>K]*94BLRR:K,K<-O29 A$..=%CGGI#;; MV/>C>;X/M(=+G\]P_P_2Q"F\Z^ HPP(1*!&+P1 H7B35!D2Q<4FA_!]Q+U,_C!^Z"RKM;ZSKNN-M/]R5>8CI2$\>T M)=) [3CSSE#"9K:4&=Y.H79;^'5W?I+-!]X+5=+<'5F?2(@]R08_30 -0PL54 M9AS+,,OX2UD]5B+1P5,;I7]4W8PQ 7ANPM/MSN-"Z_((MF7F- C14$N2&(FLB>R]#BZ*#1Q*;DM? 33*MV,_J5*EN\5GQW<'SZMX,/?QS] M?G1P]L?!\F)LGRE#+WW>_M.%-J:VTFW<$W.<[S!F*T,AG;6^/P)>BI/ST#8K^'JB:,;Z^ OKS5 7/?:7G2UMU);SE E(7]¥W M*$NL- (KX)+*03.@LJA?RU'"*^D3;*^^+M.R.R7DFY#9S+:.UW0:[\;0A3).KS MJ0?X"J-%(_1D&(9ABA-=ICE)K@*>%VC6O3#"\$B-TYTU]7Z1LD;P^+JP>7ZH M02T=MH3.]?;2C_E;- ;*FD>GHN23 7"F-LIEX,)JP;+1%9X-GJ!U1;T5@(SBM MB)!-NH%745=+6%P.QIDM),96[1(/7@]$H#;>"35Z"24+5 MSK2\0$Z_M2W]@FL7C;1ENUX8HR2HR@HD)8'G,M=>|*YB22\;(1U+C#?8?30 MU@BT9D.'*MIKR=Z[,/;&2DJE#HG$6"ZUC40/(5+<=$D:-.WXH=4+$'Z*>6A; M06&'>6C,Z*51J#V:NF643B)2E)11!BVZ18ONG2%!>*!4*"Q^F/2GV(>VE9@ MV&4>VC:::0EMCX8#*Q^,+F%.9\(]TA S<1XX2=3BQZ_0:GN[GS=84AX]TY< M*Z? J'HJ"7*U1P=3)0P&3BA8!,BW'3CBHU,DZY0UI9XEVYE1_&\R,7PKJ+W6 MQ/!M]-YWQ30:AG]>^=$P#TO'O^7ZAY/++S">+3O\C?SX1C[+X=4L9&N])B(7 M#G7).S$1,42TGGO(VMK-!HEONW(C$.P5+)/7TES?L#R%V7PZC//RCN%F>OH-.M'YXG%65QE#A#/@)(/+3*K>0A(*>*LWJ!U_89&FNn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|WA]*: M>_."2K #9,D(:0F-*1&9? QE=F[*29TS1)EVH!8^P&64__IU8'7>K STVX7,] M;K'PU*937IF<32!1(4?2;45LT)Q0Q@PDE9B#5;J1,KYFO)Y7%^I^=';6EWTC M?M@:8R#!/!%E9:PR!%(9$H ' [&* <1+!"FDRLBAVPU7#'MEK0ZN>]KPS5X6 MWR>)SU"@E$2)GH"1+D5&!H. ->B>IFB?KVT#L'6@4@);,-CS]NCT M^&\\Y!=_.SK<>'9^^L>B!<[!OJ>_';U!?_SO/?]HX/SH_?'168WAL+LOMG>K MGTH\5NH#=-=!']B,&+U:-IL:I]\@710_+^)?+4>#/ 9S$,Y8KBSQ>$X2F2B: M-%E*1GSR-NJ@ ZO]?GX/JAHCJ=5"D4PQ-)*9:90#ADN,.;JEB&4| M>&?<-]#1Y[60\WS/V^WUT,!EP$H\;V$VO!@OE57]K8QTF6MK2;LJ>O;4I:$=."R*7KKDW$,W0H@7'P M/KAD8FW[\QPM_6*FAIZ_"YT=A-X >&X8@'0P6_%T9ZQ7)6K6!^;Q? PEJVQ$9 ME28Y&4J2LL!JMFGVOV7-B"K-&CMHO)'U===932+POYTRU7*Q:<8CE3/-M5 MPLTGM0 2GF4PVO;I2?(Z#*2U^ !A5V WA9GU=PDRPN=YU 2_JC MECB14%@ J0AE&80+VE+K,_.C/VQ5Z]D97FJZ/?O*N"F8G$+9-N7AOY]?38?S M:S:(SE+)/6XAE_!<5\$0%UG9'JVS8(QE%VHGGEZBIQ5_>4=E/PN>/27? (H. M_>SSN]'DSV*.X3TR\V$RFYU/WB!KL;P'6!3REV*TX?C\3QA|A=\GX_GGV2 S M%W+RBH#3AD@;,@DT,Y**,:4AH:FM,9!V)+45HU4'>Z^AKVJP["/QN3;+]^)B MNA@+_G%25O:C@\M%8_<\FD^6UJ'PM=+L78@T0;R MLBY9ZHS71%$OT"F4AEA;^O<+#'U3](&{[CRJWO.RPFK.@15$NL5H/TN)+8,+ ME%(VWC&#Y67W4K/F^9EMQ%Z ^+#9)!4H0O=>MQE1'B+NLT7])5/$&)22-%X* M6JO#[X^;E]U'_SOD9;=11@/X>BI52!ESSFM)=#"E4Y)CQ&M'B6.N*PHZ86C_MWS8ONP$]A5V WAYRF<\'<[^L3#85+OL6,R$)EKFR";D194RR>PH=UHR5,T4 M_R5Z6DEZ|.\(59-Z4PBZ&=%YCO]RM;M0-(OZ1A)\W#J5#5RGW""@D] 1@7RNRNR:?@<0.8FT %&>?)|/;H$*#4D'8BRW MRQ&XUBI'H@L^X(DL::K=C&1M^3;@L(16)W5$Y@ :/DQN1PZ 8#JGZ(@W-A(9 MM"#.HBQ,-%P(K\"SVF"X6[W?F*.JV,_"0901TSUE0Y;U],9,2 M"-/:!45MM#= X@/6Y4N=?9RN)N >#<9-P63^Q?)@Z2"B*4@\@,=;1YSA M>+/@:R!1X=+'#YR+W:6DE7-E1R<^"9@^)_R1U(;?O @_]=!4=;GN750R3O%;! M\+]%(%N1U$? EQ^XR:Z#4PRH>A8J,<&"X<5+6Q#&E"7@M0D!7'?? SUQ[X7C\ MO^V]67<;.1(F^G[_"Y:P+R_W"%F6JWW&EC26JGJZ7W2PRIRFF&Z2$XLB"0P5[=,N>VB9PF125*'$:0$,$7%6.86J.>&*"5M@.UF)UIV2U MD&XA\+^O:0 M? M.VEH5(F'&'=!=*B#7E@PO@67TVIQ6'P1>B3&(QX14#&@3GS;.\-(

*(M)&D50$JOT?9O?S8'QAF#*TV!UE*G=X_)W>H37'"8/PB[?)_A5? MEURC?_GYZH>=S',>U.'W5?%S,..6*4PJHOP(2G2R_Q_D+72TNA# D10U.HB0DM^*U2$L(8HVVB6(5N2"E M$Q2WB#)NTO?@-"H!0 4\>CF#G,.^>8D$(IPA,2&.'[*PJ .R27A$+&->Z!`# M-4-[3MO%&[>FQ^!\&PJH_3F8>WR,=_2^/L"[&?C,_?EGWN2P?>?DQ MT4);6?*

I1WY_PE+T>F_JS2//+:,*,2Z)"0#?'EM5X!>5[&SG?W#5;AE'OS&I$[M&SEFD(X0QRALK/-1L,1*#]=NDV7<4[!AZ%-$[Q7P9_--J1!$,,HB8E+&7,)! M(554Q4U:,,<=H+PQJ)-)=#?>'(Z'*

(]*B@6DCO)QS! E-MM<,4K&T:U<N.R6A$\@4W#2C^4&V+L'1 BG6&@U;?;41 M"8/=X%00X>`^'4&V!L6T_F6S.=?FKFN>K6A9,ZR.0TTIYAQ T$#3KF1UDJ8L7 ML"8TZ27(E5DQXIP8!?)>@)2*;\N++/."<$1#8:#T<^UP:5G*+K$E:=<63YH M2O!:CHJ8U!?H%B3JI/6]F?,CSB=..%O:^?* 77%]:VD52,L"09(1B&RQ%V#. M)7@.P>%@P&V

"0ZZ"U;7_C(D? ;1>@66YZYX-^CCR70NG.#*4 +$YS'/(C\ MW SG+EP1@A+K1"S]$G:,;+!5EOA1F4!"M=V>1N671+%YFOV^X'2Q;YGPT&JE5 MMYW K*,"R1E\$%A#?

O^H!:JRH]V;I&#===%ZSQWL:,:8/04S5HX.CWH=^^)U^_GAR?_>/@\'9*=DS\'$RO08^'IGY#-2O M.,TMU^NFMFJBEV(:AA.F=_?)<>BJ4(_/HBZMO/3P5I-

J%X"QB0-#<7R8ILLY3)@#F;+2*\FI8)+0XB5?B\Y@W/"A"..VI\V\ M.<05>(P]Y_SA9O, M_U_*>QZ0CJD50)5*-@✪-5)*$D)F"1=2A>#G.XZ=22 MT?/V+'W^1* 2RE2[>G+WX_51/_?

1Q90;_Z28VUUB,$R50C@)D\DS$L&7SHI\ M3;9Q>5P->5J1>D\D*V#FV;+Q_WE+4R,=[<7_N6A0"8>PKW75 D6?S>;&XSCO(KQ! 0* Q^QGGRPG\ M^F-TR[MT*VU->

[RV7$/)@>AT<"Z MK\|*]=P-'MT^R>!]D!I)E]7K%4/.&H^LP8(&%R6);[//=I>]EH2H]^Y7[D>& M"A;!<5S>-N'YTBP6!S_M9)I5>=X\6OG?FRG08+$Z\GDHJDYU8EX[%(*A*+<7

MAGC72QO0CY2XR2;$1'5[M*6WQ~4+YU6':5BD;$Z6DS(A&W1"_MB42%=;",.F]*WXAU%)>[,I;T;?E3MAK@>%/F\@I'[*B8GDR>^9"P.Q%E\V)8 MFUTUCC

A%G'F89WS%)#DSH>(4]2\=*KTJT*-ZR6,0<,R.%5 O/9*7%_IP 29 MLMY;9"T&;\HIC*RD"ND0$]PUBH4HG8C66+I9V%_.;F=GH/_>57;M+#6V;PBHR$E4F"TXA'

M+)&QQ*&8N###44=R)W..#$*E&20390A M3JU%FL'F)K7@F@:B'"W=H'Vl-./Z!U48TT)054 Z\'OFJXZE=OHHR6AQL%S. M)PZTN/;#LKN^6"DT^^L/TI'Y(DB58L!

(QR<$1HLPA!WX7(M%'KIR%"+)TN-]3 MY<&:"GD[91]8|SPOMH,+HX-SQ#NDI,XOZ8]*0,@DQL

M8BA=TJFCB./FP%9A5(<$M0+.ODA\6/DH.B9A0TR(!0W>4"(26<(%]DHSCBWF M,,N!,RO;NY;B3\V_ @!5R+*[PL<\Y,%&Y&F&C87X?.#A?R %.P]$T1J]DJ' M[EM$:

<4T^9=BVCX@U=A"ZK5LJZS\.P?;HT=G:G?;34^TW=Z,_A.J&>RI06,+! MWP\,J=&A'Q5H'!G)]7>PL!Y\3D60I9ZBZ G&)/_@2Y^%OY-'!<{!)(@!5\;E

MIJ$,W!O'<$24^5B<[3JRXA7U_PJ/"KHP;N'!5T@KL"M&#++)5POMHM >,9&? M>E"5B[EAB'L5[*K.&_"Q2G=S^_M1P0 L?<-'!5TH4^WJ>91+BEE0GDN.&,N5 M?

DPP$&0D@HA+5 EGL">E6X+!=1\5="/)UT<%79"L@)FF[\MD-BX1BGY"224&$ MDXL,!?B93)%28[DEQ4GY?

A\5=,*]PZ."+B"\KT<%UCLO_*H!C/^,\^:TF_]ZM+3'8&F2%>VK:\\"H9:EA (6(-_G3,*5<.U"\#ITY, MS6GI0YTB@M=X"3(TY\H2?P\"C!UQYQWK(75_O97%\! HGD+$!E]QT]LGAR??

S[^Y>CX\//168^TS1:C]DZU["IYH?3(?'$W M6:ZJS[_,\CG,$H@89QH[^O""\N&5>VZ_:I5%>$4/#^/UV.O[^KN?XMVT8G M21PQ<1FD+E5R#H?D+1 .%;$!U"Z2\-+*

<:]VQB>SX7T7R6#/ETO03U?)!/)U?75 MPTK-QZ\A/?1!"JTTW]%.[_@(FC-N4&.2]CR-$Q88PWZ$S!OQHEEMO2[_5IR MCGMN."8K!\)T_-AS-?8B^O]QV?S\G]&'!8.Y>6Z6\^-

!K;^'FT^(^7C 6T["-M-KZGXLO1,X;=>PG=,]*$SUQ\B[!Y&>|\^ M<_O*K(_<&P<<)6#JBL_=FG|-+2-N.,=36H#N5K[<1_C_5=Y#/X:]'&\TO'.J

MO6FEA)'4^3P+X#Z';SOMCY>5R/-F#]V4_9 8__!7=(.(]@=M5D5(^.S)+#,3F\6D)4Y MQ"$?X,_^4)+O?CGH*!%"2 =-]fJW&I-N]L^9_3N3^9GR_F1XOEY&JERZ]Q^;T)

M99!LJ8%1RHKU0;6+VD9&^%$QO(*F=/NHHQ3NZH/EJPJJ9P,\;I;_BO<[=2RT M1%M]H VLJB98NZAM9(0_P:#-+-[-%)SN_*JG%Z9;AFR#HJX)Q=VJJ0NWC]?Q

MO#GZ(Q=HB##/66KF?N5:]S6V7:[3!F%3,<)ME%@A[+1-FNDZ3? ?S54\S/FC M\YLOIOZQJ4TS_7YWZ0T2Y<.Z#P>$4^G_W8%T)_1'!;,AL.Q&7.

MP>Z;.K)YQ/%@>]FOIN7DQSY(GDZ?BS>)A9)(M@\\\7O:53BB:;GH9&;K3V!3 MZ6&4,7-*7M=ULV/BXR?Y@$C'1>!X/M9HV2-=0=FBA+!S%=]RI_D/[-'O_,1N

MV(3_NVI6_]/W\@<2TTFAI5+M6Q(),?C@W =*HO5IFE\7RX\;,UC>INVL0|,% N-M+Y>'WV>7I//%[#<+B_?L^NKJ]MQL9R=N^FG9G[P8^JF_YJ7P*S\U+8A

MUA107P6P9VEABHNSG_YPL2R$[L9!Q_3L6H*X2QEC!S^F<=H;HV$6VFO:;]I MHA*43N?SXD]'W.\]0'5EL4,O8IW7^7-P>_S\,BBU@ JDWCC>89MC-[.U10 M"S@#NR-

=OC/>.=X.F#:A^6Y\]D"<3RU7G+L&#^O9CO@POIU!ZA;;[W'B/-#MB MWEF#(T/_K_G1+'R:@[0GZ7X2O\QG6?##G_/PKWF^2P^SRX-9^'7V<[$;,!0BP_M]T?

K6/K=\&W*3KN2PZO-L+]S29_/!YR-?\U+I.?!?[4.HI$W6WJK>V2Z M_ 83O/RXW,AWF ?!\}WM"!"D ^]=&VPF87%QSG%\!1S"HDP MV1/2,CPJ"\3(K/KX,X3%R?QD^7U^-

,IEM,/)f'XVQ\0\^[\OOJ6ISJ,Z7'TZS M@B!R*T:I$M\)?I7%K&3X5A&!D.GV=-E4.K^)5YN-Q1MMT=EUD:ICHV >|:VG+ MY$]_'&V\;(M^Z9>U/3LY;.]B-/IE#&L.]7YQLGG$\>[_]\-

KIU[&3B\#4<)] M+M9)2A,/XWZ:E5EKKX\^G@G<#\O6^AK;9L8X_V7>7/]8-? HA^BN<4?S??>U MHZ_K:&R+ ^MW.+F.X%[04BKO&'ZOJZCT==B<|XL[;3$\[WG8XU6)67O M-

;=1%^,C=."7UW8ZQ/A[(_7#LV,G5.5K]Q!PE746,@T;AMS MM#(G>P+WBF[&=COO$OH/?EX6LXU;!QVO0LF^73M4WA$%%)=N^FG9G[P8^JF_YJ7P*S\U+8A

[4X@9UZ\CC%0;I8U=?4]3H>3[7D^7-;W9Z?:M*'&^N?JRJ M[$X2"!-AMJ70[?BI\>J$[GW?JH<.VQ\9F9~6ZPVD55'S^_-%+3\;5DJDNSV MJ?%*C.Q]=K>/*JO#_S@N/\]\^/OPJ

WK;,[3"NZ,3IX[*JVZ1GRR_Q_G ZWOS-U!! M7=//!54?EC,VJK,N>VOF?R6)9*#[^ZBMX*SI,.M5!8T-X$O+TO0!?&[L5DC4=9,54UHB0WC4HS0Y5GE$AP#:-UPJOF@Z.

M=BBEAB(^(EW-'@_4'J":3GDVJ6%T)Z3IG2IY-T8K/&MZ@WDV^3K2O'O#T35?ME=9I3%)AFFHS^P4K:YA">;]O#]\Q)-H.0-JK;/1]*4RR7':*_8

WY,+M2U\^OC=X*V9K.0EHK;.QM;;:8?9BE97Y"5"S_>,N8K=X$U'0]\HIR M1L\@>'C]52Y58/.8K:"KZ1CD%>74VGW@X'<[#^>3]\GLH3+RBPW_:S<<0^N^5ZP*^S'Y,|:*%=PR?

&V,<>K4]<9K2I[%}])=PJ?7KIB.,5JNN*TT9- M5()27O&'LT68EX/IV9'C/4_(+:&KH56:EAXBT-PD^-Y*A9 KQ+0QNT/,UQ0MEOG?W>,^;MC3)_4G=OU

M#W_YE46S3^K.T['"#99;K:*2JD_K%4.V >]B*N7Z$V6.0QGFIBY(ZMBP]W M#W_GU-[DWUM-YF%&LW ZM;-\V?BQN;*366'.!Q%QE.6IFPS-VR%3 ?&.KGY.

MFYL8SY;@I)VL[C5?->7[L&?[=T:EP"#H-AU570$=5K(=_(#/^\E*%=\FE]^7 MBI.#;V>#T.+U[XVRN8Q:C]:J'IOOV!3I@B/4.]5G\"CE0WI%T8]TTL-T/TZ M"_/IS>59]-?SR7(2%

[W3&+>.,EZ]D&ZH[5))#9 = _3'WI_,)+["^'H8:KP!(M-W!>3+X&1'Z\'6#YT2[C)SO)I9ZO"T"S8?.H%_.8\4]TZ;)`^'H/?#?;@!+ZK_&?W& 4<\7GP-BR=/]WB]3ZT:^QMJZ^^KK6Z9-

,OY]#S.KQ8GZ7P>@%]E$C%V##O:&NKF([RNF-$]A2Q5 MB9/"IR.-E@/:U8?;,/U:(#F?+'N[UT^&&BWA-?"^X#S7 -5P/(HU^/R\N"GG4Q[EQG=,>YXE\'[+93 M-

^_C.OBTF4X3.!TWO@!KX.??&. Z^+MTRA^]5X4R\X4N!>>//XO2Y-UL.'MQT.7BKU^!V2]^.=N#V]:6FIK]$OPS,)>=PLUZ^6.>]O_Y5^CO]IXKQ#^!\-. MI/4?

Y!^<7<3_]__Y_P%02P,$% @ 9(0%68NBY6/ "_3< !8 /B M;7)N+65X>#$P.7AQ.C(P.C0N:'1M[5MK<^(X%OV^OT^;KNE)5X&#@3R =*K8 MP/2F:X9T)6SEXY:09:R-;7DD&

<+|^KU7LA,(D*8?@:2GDPH%UNL^CSWW2B*G MD4GBL].(T^#L'Z?_K%9)3[(\X:DA3'%J>$!R++(QN0FXOB75:M'K7&8S)<:1 M(?5:O4ENI+H5$^K:C3

Q/ROG.3UPGT\/[""&(QG,SDX#,2$B>+!G C\L,,,;`M?B-L-0H[9O15P_S@,PUK3KW%6#_[K[\%QZ.[&;#.+ ^?N1%4?SD3.#_/Z|>.230?$.'IF$]S%7%4LX,A9!46OK",MO?

L>LAA4RPB,X$[:-"$I"P$ "]8(3)#:$W'0H0C/#SLP>0AS6?GE7 MNM9W(W (58F1R:NU(:!P3F1L(_Q2CDK%8:NU46)!X3B44 B?$_ "'2'/M(%%Q- MQ.1.\;

3(V)N&%|/*LWF0U.G^9P7K8?VA46CIC&_5P#G&*$,:[{DGKF'128$ M=@4PX. /3HGC.2MC)?\XA@$CL!CH*"RQ0[,% M@I_==YO#AIJK{EDY.BR,\;_T})N?)L7 $;G%04OJH6D?

Z_]HVDK"-V AS;9 MP[1#X'CMD2L^]F /X1\==XCO-6N:M;K4!H;Y_,.[;"N&_]I*@_A)* F>"@+/(" MU^T<'+)'XI8MQ[UH1!716\\W'B&/SD03.E,C#O0\+G#(YN0#.J<0!??<#%0*

M\0?=D8H!.ECS5!Q3(KHUE"]%2"&XA<,\3DU-CAR,,J+D\?B+5 >)WDFTX<9 M\(2WLC<'FT+ ^)0*Q\=*!> 5/0L'L\UT L8OYP.972_L:Q-!/ELF*)[U(GG] MN-

A5R5CG%.6SI.@IQFY\7=TV 9<%$1U]"U#Q8\$9\(S[\^D'/>.-=CIVGC)E.P MUU1.]1M#=KR.U?6MJZ.LQ[(.UV4-PA/FP"1UR144S36QC2V""WZ9\\#D1\ MLI&=YJ_W.NF*SL:B,

<6$O?;"KZ"$VL,0.H+2&*]%i2$OP5E/[V\7W1JZUT@[M[^O,JR.V:FZK- 0\VS2>TIG>^Z+KTHV5&HH$B'S I^1*)C1=HYXEY$VV/_Y1 MK;/NZV=,R[R|JAPA MPZ+",GV&IU?

8FN.>(#<1%!)_01_8+PH&1??2B3N*NW@9N!F)?TM1NZUKZS4W MQ>?G_4_#?H]T!SUW"=\CP\O5ASYGIX:.8-=USWX*2+P*XL4TT[Q=ONDS0F"S@6K+&P?PE[W&+)2W=G#-

!66T6MV)HX6L8<"D)B@7+@C%LX1R8(+E MMA.O<;R^M>;Y:|N>FK5OY!V?K!_ZU=-ZC5;SN_+|OSC^O.8H+'1M ?6:BZRNWRU-?4%@P3P&*1V67W[16^4K;O?2N*P-A>S-

$2KE>I?;V>XG'[GN)/\/\;$ 3OG&@_WAH^.;(MWP 7&UGM>2[55^6+B_)"^F^)Q/-(\)#\C]}B<_P[_,A@/[-'/P@G2YX_(OO5(_V?;S[;OU?:YFYD=7RJ]B(N\C^O]+

MHP/W|W<'M_^_@)02P,$% @ 9(0%6:2!O-I%A" =#0 !< :B)R?]N M+6X>#$P.GAQ.G@R,#(T+FAT;>U:;7/.1^A^WEIQ==K$F0$L8; =()YQ$D^G M,W+0.GD8^>0%G3U2.:?

68E88D8W9EQC,.6LVRUFO53[58IQ8U@[:_M'?9%Z7,QX7[<"BOAN-IGL.>_#_;<(8.ABJ?'@UA,F(A?!HCVB =#'G2B<#3] M\%'THGUP&,*PO<_;AQ%>_3/\

(MY\3/$(C@MZ4Y%V4_)50;[D6&?N0<)WR" HK(B[9[UG4 M6M3DX>IP5]0HT92I$8H=0P[X]^(S1$5FD$<(K7#+="9>OK=#<:=&HU^)0 M,Z460Y#]@AFPAHV4M@FS.!C-

]D),QLFT>I7B M.B;SO;G>Y7K3Y\A4]4708*P6$6EGK(K. M69%A;-@M;?;Q(//,UF/,_0SKVR&B(E+ ""SZ'3$ JDKM'=N!)5SO><=S;) MX3]%9 =K 45]W+ZNBDR

M!R691TJB$XF"E@\E$!7XC!<('G+)8SGN41J MTFP2A FDBSLL8SR.!6V'1X#T).*#YP^Z&1Z\(N6$H=+HI2;.4?+<0*_ZT(^% MR26?]D3F#.,6]1>WZZ(5)Z!=2"ESAL.

'_Z6WUN!S_%6X]^X.KD<,KFA/1LO MCQWMM_.[W97#02M<.7;5MF&GU>FLM^V>$]F+C98QR, ^7._L[U8*<7).-> ^W\ MDH4YEE7T;RMH+ ^91",.E.WD3,3*WSI+H!V7$ @5+

(UROWW)Q+WM?HAO#AKWK-HO M3Y^$!T%_ ^>1*M\"K1J"1D?H)OK(\^IS\6&DO$"?. 0/BE3-F%H)GC?OC6K'S <]C1.]

M8EIDW0.2CI,H\35XG'&OBLJ3R%> ^N&,T51L\?,7^.,@COBS]]%R/HI-MJ[WIE%5?G?\|/^Z-LY6U;D&2;NNHNX8P_;RLJ7H:) .!"?3)4,W]5EA3(P^Y M ?_?

(G:+HJYGM%6,NBZ;_U=Y=6=YZ;,KP =']I,"$Y>_XT)W&L]<|>AA$NXW MNEN8_#A,?.[>S36DHDBI N)S%=#LQA5+OY5 U9VVQO^#$%S,&'0#<"T4T_^_M4'1?

E>#C0TLV=FTQ=HL8TSDlU0#VFT*-,IV%X!L,O+G3"\ MVS_I=HY/78V=.I/SL3=9IG!YX-Z'&%T):2F@ =%5(TT<-4& X$@KE[,&BTW M>LQ(?)TJEVCC*N@Q'UJC(RQ*:0)*<=N) Z @)< JAOKR-LEE,29Q

:JYKC0D M.D>RV>D?4/2BTT_C5;Q47)X5$8X\OV ^6D-I1 W]LK.A[(ZA#(9XG?>Q"PE. MT4\H=HZ[]_'8/7Y>/,KW+XO'0:O=X16C]4&MC;B$E/1UT#0X6R:R5"!#^&+

M,UJEHOG?$+ MS$]5RK"4SA22>5HZ0)H+0.8J&K8%;H!D)4=**S_G]+S-+)^B +& GG@]HBN M%9 A'=S6"RHK6P*]+I0326)L&AP(I>28"E0)&B#&"}5\.E@$97($*DZ1*L'(

M;QJR8M#M1>D =2E.I]\ '$?*.M1R:HH(N"TUV;(8V(%1X^7V,BT@$XI@0Q> + MP9&I_,,>[,+Y0M>B^D7[XYZK_QYB@\L%N>A;*Y=@*US&YHB%&U2-JAXUZ<^F=1,WI

MC77+=!UN8,K)1'E/] =$/S(H"'@\5? O3'(Y()?'?,V?G/ENSAN!'NEX'XX M6E61A$;__?]HH&_I/S(A6LI!5AQ@\FM;I(((*A3I;(7F9&\X=P9;ZN0/4-5 M&!XA+AZ_/

I.==L0V_LM=*53*#I:LM6#,*QK2:@ 2RCY&C&!.V1O5TV !&Q2 M6$R=),8^J'KSR?FU-"F<@S,+*F@@P!0(#!)SW9K++#5B"E/%U.@I<1XKY+A^ M1&UKSJ-)J0>I0-8W2?

M_R[>X8W=XHZ~_ +02SP?VI%ZUA$ M2K;)N&A9.AHN_C@=%B9=.$N>]"!L=E$YK'T;&>5,9/^7 6IM_B?+@$7;3U);X4WBJH4WQWHGK4'[X>%VJ_/@V#>;C]C"X'-W&

MQKA2%A_WCO86"O5^#[OEK>CD'C$/(\W^69#\&Z_=WSZ[;37/SU\A\7 M/WV^>O!8_7EQ__N<3H_"03GVB T^46"0_>Q.\NM-7OUGWWJCS5Q6_H.M5G,'$ MN_TC

/E3KB@3E[>45-P^BY!C!?JDO3P,Y+8#Y3]T2<26[S_69KGW"4EI?AC M-(R/4*>T\5')*I*!9MLK%3E".'N_]*:5[U#]G_&KF,/P-'$R,C R-"YH=&WM M6FMOX[H1_=Y?

P2;HWBQ@.Y8?M6-G V3W9H$!YEN>S\6E$191&A\1ZS^-]/Z MGB'E5>SL.LUM'D 7V"02.<.AY_#,#*GSW$W5Q7DN>'KQE_.`IO>YU44U$X

MEAC!G4A9964Q8;^EPMZR9K/N]4F7"R,GN6.==J?'?M/F5LYX.'?2*7&QU'-^ M&I[/3_T@Y[%.%Q?GJ9PQF7XXDNTN'_ TZXO^,.HE<6?82XT^-/5S9?KS]>?+K]

<_S3029WRO_1DO;V&GC=8!^A MI& W+?9C)902AB7"\)DME NY>W?<'XX/-7Q<\C0%_IM*9!BPOUQ16;18^5&3 M_/&&Z2F(RNG0;Z=#(1)A+3<+ZC+EMP+C;NBT>)?"\$ RI?-

S &-0A MD09Q MT*B,.2%+MUGLLD9!.B'VOYN3"B5D(3F$JK% H-LVERS%!6XK$&TAZ M2YBF4TQS!K&4QD0-97C38.N^E0*0 Y#5SX.MX:RW) ^$V9YG2<[O5$HQ$3;9WA&

(C3RV WK&QLP,HNC=FQ]DTC]_=:#"V-7;J2$[;7F>9Q..)?>]]=,VX$1X-!*Z,E2"O,0$(QDK:G"2HVQ2L M1\Q'SZFTB=*V@ASQH=$]P*(T.A$I7EMV A2D K *KKZZ2W)>3 2[!-7<5

H] MHBYO1OT3$;R(^FEX"H^2TK,BP)'T, ^*C#90&U) M!P^4;0V482"\YWWLH@>% MZ"T%3 (!9X7*I' R;12 MG.@;T_)&K&,O)$)DWTQ(%)V(-): >XA|/?P?@% MYFE$DFB3>@-

*CD1!;(§!1"C192T.Z@+TN0 5.PB68*1 MWS14DQ>'!M]#5F1 $&]J0 M#,;Z<@];< CG\U5O09EN]NTRA,7+'-!OMGHE8(\"@WP5L&5OCBX:AX,?MOU M/Y6]=8+E6_:"

[!'L1!%0)TEER,L;H6^/UJFV#N_I/ ZZ+!V _!Y.3MC) R(9 M>]N=]-APUC/ 5.Q7S1,6RZWVP*N=VE2<0HWEXB]1JO5^/FH87]_MOA:K

M]WO|&T]>HB=" "^N6+H_X,+X[\@=UJ/536W$-4N(G)-0T1JAZ1.^SDFROK.'). MIXU=A6O_ BJG4^F<$%\A^E@C(:#V5,(^K^0$R 6O6N)M_*,,=[G=Q.^5A/E^

M:U5%X@O]]_^O@?X$)]4C%\KM)&!%!2:5JHD4 $$=:E>VR%SP6XJ=(;?RT=-G MA?X(<7G\\BAHU65#*._WT!5/(6C%BJT>A&&=2T(6++*UP@!W")ZVVH*)&"1 M_&3J*+'WH.K-

!^?74]1#:,XJ* !!PM/8(^(/]NML=0((4P6,ZUF@N)8P2?U\R%$;6I.4],2Z47 JWS7 >6XUM(;+ ^E"#?\^N_\[6_LEF],6).'+O&<++X=]K3$*M*DP3?

E&\M&*T_&,,$B\57XQDX1?;"XUK&V+MG)Z.*%K.*!@@7Z@'\>.%YQJN M],SOK<&P2]>ESN!_NARXQDEM^9O44Y?NMO4&K>[PL'F=BMZL.UK:OOM5BIZ M6'13[:DW.9B-

A;$E+SX<=8^6 O5ZCSKE'8NV%N\=AX_Y)MUP:OCWF#\ M#_^3?;RYOOS)7QC_\^]"ZYNGNB&AV3J++>V)HL0LZ?"-T?3&KWZU!E^ITW<5 M5W\C]GP.LB%U[WN24EM_?

30*YZDSL?.%R=JKGG/;:Q$>P[65VQ7Y MQD'$U%ZUV0S80_KY?<7.PM 5L1)+_=H BN.=&=(XM9VU_310$F41I4F5I))XOWY'2I6%@#CE.S MYH?CE)+X))?

QKXT$;LH7U-A(%*4&!]#KIE8P8>8ZL_0:)2S)C<+;*+9*#;2\ M5@<^2/6979%BW###Z6'E9WO0/(\/7)!Q*,/-X3AF5\#B-S46]<*!UR?]D-"P M0Y,.(<0+>WZ/^*37;_6[?.HU-

,71A8TV&T[?U-9,-%)JXP\[K6:OFYG1-8M-_M.O0[[[>:FWHX3J0P&$^A?7%,N-EQ9NB-.1#.5F+H4JH51M5P)+E4PSW/_49V-M)&0->.;X8M ,<)?U#41NJ&I8DDQK-E?=#A 3.

[HNL#90V/.!*UP^A'=*]J3 MLI 9.+>;_M$M4O &\AR/T+&#>A'RZH1>.-V@C7HZ)>< M*6K)?W%"QH9)D5A[K=?DE> (?SNR_C5;5XTRA4SULWT)DJ)6-$J.7_0[K@Z MVWE.

(+HUL>XPL# $WU*,_X+.H_1[>1%FAS)%M456MV;$'>LTV]VV^T'A[VF_^#8HVX'S=;KW@~Y/7"0"]A8

M&)T1\;,6KE4&&8EC5"+#5G8#_M>K(*?)3FV*LOPD0G&J8W^O@U^CNT]P-OT8 MG!/)Y_VF!]_NNV7L@;/I.?9Y'ZP)&4[N6[+,$G)60Q5=D^^7O?(URJU"_P:

M666S5Y_Y>NS^'2@8.6M_KXL9!_DJ MUZ;@UF!'S/#,-LI[\QC;%-UR-#\-SIUNN9R>G4WGSYSXC:K=%W>%&[HI:CC M'\%PQ=TM&I7AQ*D'6M*2M7+45,PI]:1%\?

A,4D\%)3)ENI3MV'6%Y(NLP"'7" M2E,K"Q_7F*C9KU.&4A2WZ(IR+(#5F1]$-!!3E,0QZDJ.UUNQO*5\K;]\5;\3 MN5XSK2O56?I _Z%5P9%4&-P=M^!&0]$$=QRVW9C

&41L;!1["O,=60]Y6TIO MX;@3WNUB9]D)V>X ZR)VIWQ+KVS;P\CJE:*-09<<<4L:-\!H8/24P9,.8LJFW MH\\5!A954I4;W:SO:V$Q?5* *YUM%L37CB"HG"&QWEU"49E>2/W@-M-

6;h\Z0 M,JG=QF#HWC6"YCE5NF:!MTIZ=R8D1"K,S;[)=PZBRFMQ+';@CN/^!E!+ 0(4 M Q0 (&2$!5GSH40X6! "_I*& 1 " 0 !B;7)N M+3(P.C0P-C,P+FAT;5!+ 0(4 Q0 (

&2$!5G;$1!1'$ BQ 1 M "_8<0 @!B;7)N+3(P,C0P-C,P+GAS9%!+ 0(4 Q0 (&2$ M!5F8#E=AOAX $ 8 0A @!B;7)N+3(P,C0P-C,P M7V-A;"YX;6Q02P$"% ,4 " !DA

59^_+\,CY/ &= _ %0 M @ '\#0 (8FUR;BTR,#(T,#8S,%]D968N>&UL4$!/ A0#% @ 9(0% M6?/Y*WR[ZP 9/((!4 (!-) " &M'@Q,#%X<3(R M,#(T+FAT;5!+ 0(4 Q0 (

&2$!5FD@;S;10<`0T 7 M "::L0! !B;7)N+65X>#$P,GAQ.G@R,#(T+FAT;5!+ 0(4 Q0 (&2$ M!5G3>ZW#,Q,7AQ M,C(P,C0N:'1M4$L! A0#% @ 9(0%69<6_;[=!P H2, !8 M (

!XQ\$ &)M'$R,C R-"YH=&U02P$"% ,4 " !D MA 59]$14\0 % "5$P % @ &T)P0 8FUR;BUE>'@S,C%X @<3(R,#(T+FAT;5!+]08 "P + -\" #H+ 0 ! end XML 82 bmrn-

20240630_htm.xml IDEA: XBRL DOCUMENT 0001048477 2024-01-01 2024-06-30 0001048477 2024-07-31 0001048477 us-gaap:ProductMember 2024-04-01 2024-06-30*

0001048477 us-gaap:ProductMember 2023-04-01 2023-06-30 0001048477 us-gaap:ProductMember 2024-01-01 2024-06-30 0001048477 us-gaap:ProductMember 2023-01-01 2023-06-30 0001048477 bmrn:RoyaltyAndOtherMember 2024-04-01 2024-06-30 0001048477 bmrn:RoyaltyAndOtherMember 2023-04-01 2023-06-30 0001048477 bmrn:RoyaltyAndOtherMember 2024-01-01 2024-06-30 0001048477 bmrn:RoyaltyAndOtherMember 2023-01-01 2023-06-30 0001048477 2024-04-01 2024-06-30 0001048477 2023-04-01 2023-06-30 0001048477 2023-01-01 2023-06-30 0001048477 2024-06-30 0001048477 2023-12-31 0001048477 us-gaap:CommonStockMember 2024-03-31 0001048477 us-gaap:CommonStockMember 2023-03-31 0001048477 us-gaap:CommonStockMember 2023-12-31 0001048477 us-gaap:CommonStockMember 2022-12-31 0001048477 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001048477 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001048477 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001048477 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001048477 us-gaap:CommonStockMember 2024-06-30 0001048477 us-gaap:CommonStockMember 2023-06-30 0001048477 2024-03-31 0001048477 2023-03-31 0001048477 2022-12-31 0001048477 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001048477 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001048477 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001048477 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001048477 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001048477 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001048477 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001048477 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001048477 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001048477 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2024-03-31 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2023-03-31 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2023-12-31 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2022-12-31 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2024-04-01 2024-06-30 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2023-04-01 2023-06-30 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2024-01-01 2024-06-30 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2023-01-01 2023-06-30 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2024-06-30 0001048477 us-gaap:DeferredCompensationShareBasedPaymentsMember 2023-06-30 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-06-30 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-06-30 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001048477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001048477 us-gaap:RetainedEarningsMember 2024-03-31 0001048477 us-gaap:RetainedEarningsMember 2023-03-31 0001048477 us-gaap:RetainedEarningsMember 2023-12-31 0001048477 us-gaap:RetainedEarningsMember 2022-12-31 0001048477 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001048477 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001048477 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0001048477 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001048477 us-gaap:RetainedEarningsMember 2024-06-30 0001048477 us-gaap:RetainedEarningsMember 2023-06-30 0001048477 2023-06-30 0001048477 srt:RestatementAdjustmentMember 2023-04-01 2023-06-30 0001048477 srt:RestatementAdjustmentMember 2023-01-01 2023-06-30 0001048477 us-gaap:FairValueInputsLevel1Member 2024-06-30 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2024-06-30 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2024-06-30 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-06-30 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember 2024-06-30 0001048477 us-gaap:FairValueInputsLevel2Member 2024-06-30 0001048477 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2023-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2023-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember 2023-12-31 0001048477 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001048477 srt:MaximumMember 2023-01-01 2023-12-31 0001048477 srt:MaximumMember 2024-01-01 2024-06-30 0001048477 srt:MinimumMember 2024-01-01 2024-06-30 0001048477 srt:MinimumMember 2023-01-01 2023-12-31 0001048477 bmrn:StrategicInvestmentMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001048477 bmrn:StrategicInvestmentMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001048477 bmrn:StrategicInvestmentMember us-gaap:FairValueMeasurementsNonrecurringMember 2024-04-01 2024-06-30 0001048477 2023-01-01 2023-03-31 0001048477 2024-01-01 2024-03-31 0001048477 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001048477 us-gaap:FairValueInputsLevel3Member 2024-06-30 0001048477 bmrn:NonqualifiedDeferredCompensationPlanAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001048477 bmrn:NonqualifiedDeferredCompensationPlanAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001048477 bmrn:RestrictedInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001048477 bmrn:RestrictedInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001048477 us-gaap:FairValueInputsLevel2Member
bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001048477 us-gaap:FairValueInputsLevel2Member bmrn:NonqualifiedDeferredCompensationPlanLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001048477 us-gaap:DesignatedAsHedgingInstrumentMember 2024-06-30 0001048477 us-gaap:NondesignatedMember 2024-06-30 0001048477 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2024-06-30 0001048477 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2023-12-31 0001048477 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2024-06-30 0001048477 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2023-12-31 0001048477 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:ShortMember 2024-06-30 0001048477 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:ShortMember 2023-12-31 0001048477 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:LongMember 2024-06-30 0001048477 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:LongMember 2023-12-31 0001048477 us-gaap:OtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2024-06-30 0001048477 us-gaap:OtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0001048477 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2024-06-30 0001048477 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2024-06-30 0001048477 us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0001048477 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2024-06-30 0001048477 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0001048477 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2024-06-30 0001048477 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0001048477 us-gaap:OtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2024-06-30 0001048477 us-gaap:OtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2023-12-31 0001048477 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2024-06-30 0001048477 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2023-12-31 0001048477 us-gaap:ProductMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-04-01 2024-06-30 0001048477 us-gaap:ProductMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-04-01 2023-06-30 0001048477 us-gaap:ProductMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-06-30 0001048477 us-gaap:ProductMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-06-30 0001048477 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OperatingExpenseMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-04-01 2024-06-30 0001048477 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OperatingExpenseMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-04-01 2023-06-30 0001048477 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OperatingExpenseMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-06-30 0001048477 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OperatingExpenseMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-06-30 0001048477 us-gaap:NondesignatedMember 2024-04-01 2024-06-30 0001048477 us-gaap:NondesignatedMember 2023-04-01 2023-06-30 0001048477 us-gaap:NondesignatedMember 2024-01-01 2024-06-30 0001048477 us-gaap:NondesignatedMember 2023-01-01 2023-06-30 0001048477 bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember 2024-06-30 0001048477 bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember 2023-12-31 0001048477 bmrn:OnePointTwoFivePercentSeniorSubordinatedConvertibleNotesDueInMay2027Member 2024-06-30 0001048477 bmrn:OnePointTwoFivePercentSeniorSubordinatedConvertibleNotesDueInMay2027Member 2023-12-31 0001048477 bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember us-gaap:SubsequentEventMember 2024-08-01 2024-08-01 0001048477 us-gaap:ConvertibleDebtMember 2024-04-01 2024-06-30 0001048477 us-gaap:ConvertibleDebtMember 2023-04-01 2023-06-30 0001048477 us-gaap:ConvertibleDebtMember 2024-01-01 2024-06-30 0001048477 us-gaap:ConvertibleDebtMember 2023-01-01 2023-06-30 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-03-31 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-03-31 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-04-01 2024-06-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-04-01 2024-06-30 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-06-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-06-30 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-03-31 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-03-31 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-04-01 2023-06-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-04-01 2023-06-30 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-06-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-06-30 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-12-31 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-12-31 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-06-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-01-01 2024-06-30 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-12-31 0001048477 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-06-30 0001048477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-01 2023-06-30 0001048477 bmrn:VOXZOGOMember 2024-04-01 2024-06-30 0001048477 bmrn:VOXZOGOMember 2023-04-01 2023-06-30 0001048477 bmrn:VOXZOGOMember 2024-01-01 2024-06-30 0001048477 bmrn:VOXZOGOMember 2023-01-01 2023-06-30 0001048477 bmrn:VIMIZIMMember 2024-04-01 2024-06-30 0001048477 bmrn:VIMIZIMMember 2023-04-01 2023-06-30 0001048477 bmrn:VIMIZIMMember 2024-01-01 2024-06-30 0001048477 bmrn:VIMIZIMMember 2023-01-01 2023-06-30 0001048477 bmrn:NAGLAZYMEMember 2024-04-01 2024-06-30 0001048477 bmrn:NAGLAZYMEMember 2023-04-01 2023-06-30 0001048477 bmrn:NAGLAZYMEMember 2024-01-01 2024-06-30 0001048477 bmrn:NAGLAZYMEMember 2023-01-01 2023-06-30 0001048477 bmrn:PALYNZIQMember 2024-04-01 2024-06-30 0001048477 bmrn:PALYNZIQMember 2023-04-01 2023-06-30 0001048477 bmrn:PALYNZIQMember 2024-01-01 2024-06-30 0001048477 bmrn:PALYNZIQMember 2023-01-01 2023-06-30 0001048477 bmrn:BRINEURAMember 2024-04-01 2024-06-30 0001048477 bmrn:BRINEURAMember 2023-04-01 2023-06-30 0001048477 bmrn:BRINEURAMember 2024-01-01 2024-06-30 0001048477 bmrn:BRINEURAMember 2023-01-01 2023-06-30 0001048477 bmrn:ALDURAZYMEMember 2024-04-01 2024-06-30 0001048477 bmrn:ALDURAZYMEMember 2023-04-01 2023-06-30 0001048477 bmrn:ALDURAZYMEMember 2024-01-01 2024-06-30 0001048477 bmrn:ALDURAZYMEMember 2023-01-01 2023-06-30 0001048477 bmrn:KUVANMember 2024-04-01 2024-06-30 0001048477 bmrn:KUVANMember 2023-04-01 2023-06-30 0001048477 bmrn:KUVANMember 2024-01-01 2024-06-30 0001048477 bmrn:KUVANMember 2023-01-01 2023-06-30

0001048477 bmrn:ROCTAVIANMember 2024-04-01 2024-06-30 0001048477 bmrn:ROCTAVIANMember 2023-04-01 2023-06-30 0001048477 bmrn:ROCTAVIANMember 2024-01-01 2024-06-30 0001048477 bmrn:ROCTAVIANMember 2023-01-01 2023-06-30 0001048477 bmrn:ProductsExcludingALDURAZYMEMember country:US us-gaap:SalesChannelDirectlyToConsumerMember 2024-04-01 2024-06-30 0001048477 bmrn:ProductsExcludingALDURAZYMEMember country:US us-gaap:SalesChannelDirectlyToConsumerMember 2023-04-01 2023-06-30 0001048477 bmrn:ProductsExcludingALDURAZYMEMember country:US us-gaap:SalesChannelDirectlyToConsumerMember 2024-01-01 2024-06-30 0001048477 bmrn:ProductsExcludingALDURAZYMEMember country:US us-gaap:SalesChannelDirectlyToConsumerMember 2023-01-01 2023-06-30 0001048477 bmrn:ProductsExcludingALDURAZYMEMember srt:EuropeMember us-gaap:SalesChannelDirectlyToConsumerMember 2024-04-01 2024-06-30 0001048477 bmrn:ProductsExcludingALDURAZYMEMember srt:EuropeMember us-gaap:SalesChannelDirectlyToConsumerMember 2023-04-01 2023-06-30 0001048477 bmrn:ProductsExcludingALDURAZYMEMember srt:EuropeMember us-gaap:SalesChannelDirectlyToConsumerMember 2024-01-01 2024-06-30 0001048477 bmrn:ProductsExcludingALDURAZYMEMember srt:EuropeMember us-gaap:SalesChannelDirectlyToConsumerMember 2023-01-01 2023-06-30 0001048477 bmrn:ProductsExcludingALDURAZYMEMember srt:LatinAmericaMember us-gaap:SalesChannelDirectlyToConsumerMember 2024-04-01 2024-06-30 0001048477 bmrn:ProductsExcludingALDURAZYMEMember srt:LatinAmericaMember us-gaap:SalesChannelDirectlyToConsumerMember 2023-04-01 2023-06-30 0001048477 bmrn:ProductsExcludingALDURAZYMEMember srt:LatinAmericaMember us-gaap:SalesChannelDirectlyToConsumerMember 2024-01-01 2024-06-30 0001048477 bmrn:ProductsExcludingALDURAZYMEMember srt:LatinAmericaMember us-gaap:SalesChannelDirectlyToConsumerMember 2023-01-01 2023-06-30 0001048477 bmrn:ProductsExcludingALDURAZYMEMember us-gaap:MiddleEastMember us-gaap:SalesChannelDirectlyToConsumerMember 2024-04-01 2024-06-30 0001048477 bmrn:ProductsExcludingALDURAZYMEMember us-gaap:MiddleEastMember us-gaap:SalesChannelDirectlyToConsumerMember 2023-04-01 2023-06-30 0001048477 bmrn:ProductsExcludingALDURAZYMEMember us-gaap:MiddleEastMember us-gaap:SalesChannelDirectlyToConsumerMember 2024-01-01 2024-06-30 0001048477 bmrn:ProductsExcludingALDURAZYMEMember us-gaap:MiddleEastMember us-gaap:SalesChannelDirectlyToConsumerMember 2023-01-01 2023-06-30 0001048477 bmrn:ProductsExcludingALDURAZYMEMember bmrn:RestOfWorldMember us-gaap:SalesChannelDirectlyToConsumerMember 2024-04-01 2024-06-30 0001048477 bmrn:ProductsExcludingALDURAZYMEMember bmrn:RestOfWorldMember us-gaap:SalesChannelDirectlyToConsumerMember 2023-04-01 2023-06-30 0001048477 bmrn:ProductsExcludingALDURAZYMEMember bmrn:RestOfWorldMember us-gaap:SalesChannelDirectlyToConsumerMember 2024-01-01 2024-06-30 0001048477 bmrn:ProductsExcludingALDURAZYMEMember bmrn:RestOfWorldMember us-gaap:SalesChannelDirectlyToConsumerMember 2023-01-01 2023-06-30 0001048477 bmrn:ProductsExcludingALDURAZYMEMember us-gaap:SalesChannelDirectlyToConsumerMember 2024-04-01 2024-06-30 0001048477 bmrn:ProductsExcludingALDURAZYMEMember us-gaap:SalesChannelDirectlyToConsumerMember 2023-04-01 2023-06-30 0001048477 bmrn:ProductsExcludingALDURAZYMEMember us-gaap:SalesChannelDirectlyToConsumerMember 2024-01-01 2024-06-30 0001048477 bmrn:ProductsExcludingALDURAZYMEMember us-gaap:SalesChannelDirectlyToConsumerMember 2023-01-01 2023-06-30 0001048477 bmrn:ALDURAZYMEMember us-gaap:SalesChannelThroughIntermediaryMember 2024-04-01 2024-06-30 0001048477 bmrn:ALDURAZYMEMember us-gaap:SalesChannelThroughIntermediaryMember 2023-04-01 2023-06-30 0001048477 bmrn:ALDURAZYMEMember us-gaap:SalesChannelThroughIntermediaryMember 2024-01-01 2024-06-30 0001048477 bmrn:ALDURAZYMEMember us-gaap:SalesChannelThroughIntermediaryMember 2023-01-01 2023-06-30 0001048477 bmrn:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-06-30 0001048477 bmrn:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-06-30 0001048477 bmrn:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001048477 bmrn:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001048477 bmrn:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-06-30 0001048477 bmrn:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-06-30 0001048477 bmrn:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001048477 bmrn:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001048477 bmrn:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-06-30 0001048477 bmrn:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-06-30 0001048477 bmrn:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001048477 bmrn:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001048477 bmrn:CustomerOneTwoAndThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-06-30 0001048477 bmrn:CustomerOneTwoAndThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-06-30 0001048477 bmrn:CustomerOneTwoAndThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-06-30 0001048477 bmrn:CustomerOneTwoAndThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001048477 bmrn:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2024-01-01 2024-06-30 0001048477 bmrn:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2024-01-01 2024-06-30 0001048477 bmrn:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2024-01-01 2024-06-30 0001048477 bmrn:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2023-01-01 2023-12-31 0001048477 bmrn:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2023-01-01 2023-12-31 0001048477 bmrn:CustomersMember 2024-06-30 0001048477 bmrn:CustomersMember 2023-12-31 0001048477 us-gaap:CostOfSalesMember 2024-04-01 2024-06-30 0001048477 us-gaap:CostOfSalesMember 2023-04-01 2023-06-30 0001048477 us-gaap:CostOfSalesMember 2024-01-01 2024-06-30 0001048477 us-gaap:CostOfSalesMember 2023-01-01 2023-06-30 0001048477 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001048477 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001048477 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001048477 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001048477 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-04-01 2024-06-30 0001048477 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-04-01 2023-06-30 0001048477 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-06-30 0001048477 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-06-30 0001048477 bmrn:A2024WorkforceReductionPlanMember 2024-01-01 2024-06-30 0001048477 bmrn:A2024WorkforceReductionPlanMember 2024-06-30 0001048477 bmrn:A2024WorkforceReductionPlanMember 2024-04-01 2024-06-30 0001048477 us-gaap:EmployeeSeveranceMember bmrn:A2024WorkforceReductionPlanMember 2023-12-31 0001048477 us-gaap:OtherRestructuringMember bmrn:A2024WorkforceReductionPlanMember 2023-12-31 0001048477 bmrn:A2024WorkforceReductionPlanMember 2023-12-31 0001048477 us-gaap:EmployeeSeveranceMember bmrn:A2024WorkforceReductionPlanMember 2024-01-01 2024-06-30 0001048477 us-gaap:OtherRestructuringMember bmrn:A2024WorkforceReductionPlanMember 2024-01-01 2024-06-30 0001048477 us-gaap:EmployeeSeveranceMember bmrn:A2024WorkforceReductionPlanMember 2024-06-30 0001048477 us-gaap:OtherRestructuringMember bmrn:A2024WorkforceReductionPlanMember 2024-06-30 0001048477 us-gaap:StockCompensationPlanMember 2024-04-01 2024-06-30 0001048477 us-gaap:StockCompensationPlanMember 2023-04-01 2023-06-30 0001048477 us-gaap:StockCompensationPlanMember 2024-01-01 2024-06-30 0001048477 us-gaap:StockCompensationPlanMember 2023-01-01 2023-06-30 0001048477 bmrn:CommonStockIssuableUnderConvertibleDebtMember 2024-04-01 2024-06-30 0001048477 bmrn:CommonStockIssuableUnderConvertibleDebtMember 2023-04-01 2023-06-30 0001048477 bmrn:CommonStockIssuableUnderConvertibleDebtMember 2024-01-01 2024-06-30 0001048477 bmrn:CommonStockIssuableUnderConvertibleDebtMember 2023-01-01 2023-06-30 0001048477 bmrn:ZeroPointFiveNineNinePercentSeniorSubordinatedConvertibleNotesDueInAugustTwoThousandTwentyFourMember us-gaap:ConvertibleDebtMember 2024-01-01 2024-06-30 0001048477 bmrn:OnePointTwoFivePercentSeniorSubordinatedConvertibleNotesDueInMay2027Member us-gaap:ConvertibleDebtMember 2024-01-01 2024-06-30 shares iso4217:USD iso4217:USD shares pure bmrn:segment bmrn:employee false 2024 Q2 0001048477 --12-31 P1Y P1Y 10-Q true 2024-06-30 false 000-26727 BioMarin Pharmaceutical Inc DE 68-0397820 770 Lindaro Street San Rafael CA 94901 415 506-6700 Common Stock, par value $0.001 BMRN NASDAQ Yes Yes Large Accelerated Filer false false false 190382822 702129000 584698000 1339944000 1171124000 9900000 10577000 20918000 20566000 712029000 595275000 1360862000 1191690000 130459000 130619000 255639000 266091000 183787000 177363000 388774000 349209000 263032000 206103000 488938000 417126000 14299000 15624000 28597000 31294000 0 0 10000000 0 591577000 529709000 1151948000 1063720000 120452000 65566000 208914000 127970000 19785000 12612000 39150000 24555000 3574000 3755000 7121000 7458000 -4527000 -3613000 -3260000 -17500000 132136000 70810000 23768300 0 127567000 24962000 14770000 41847000 20675000 107174000 56040000 195836000 106892000 0.56 0.30 1.03 0.57 0.55 0.29 1.01 0.56 190114000 187948000 189490000 187311000 200505000 194998000 200137000 194756000 135019000 48145000 251423000 92142000 97215000 75512700 0 252201000 318683000 691232000 633704000 1183621000 1107183000 160426000 141391000 3259630000 2956088000 557083000 611135000 1052898000 1066133000 265533000 294701000 196199000 196199000 1545006000 1545809000 190772000 171538000 706721000 6841603000 572500000 683147000 494837000 493877000 1067337000 1177024000 594116000 593095000 119369000 119935000 178082200 1890054000 0.001 0.001 500000000 500000000 190355517 190355517 188598154 188598154 190000 189000 5696701000 5611562000 11673000 9860000 26799000 -28788000 -425718000 -621554000 5286299000 4951549000 7067121000 6841603000 189777000 187601000 188598000 186251000 579000 551000 1758000 1901000 190356000 188152000 190356000 188152000 5073816000 4659043000 4951549000 4603156000 190000 188000 189000 186000 1000 2000 190000 188000 190000 188000 5619264000 5417873000 5611562000 5404895000 25326000 24489000 -30343000 -17951000 52138000 51150000 113669000 105478000 27000 -444000 -1813000 -1534000 5696701000 5493956000 5696701000 5493956000 -11700000 -9949000 -9860000 -8859000 -27000 444000 1813000 1534000 -11673000 -10393000 -11673000 -10393000 -1046000 -10722000 -28788000 -3867000 27845000 -7895000 55587000 -14750000 26799000 -18617000 26799000 -18617000 -532892000 -738347000 -621554000 -789199000 107174000 56040000 195836000 106892000 -425718000 -682307000 -425718000 -682307000 5286299000 4782827000 5286299000 4782827000 195836000 106892000 53813000 51840000 1981000 2058000 4678000 4533000 106163000 103857000 10000000 0 14204000 12650000 1537000 -5108000 19958000 -7455000 858000 -361000 56081000 145831000 47409000 56476000 -1615000 53430000 22880000 5616000 -54261000 -25093000 6709000 7104000 165733000 -3870000 47431000 46039000 317649000 491063000 195462000 444049000 10000000 0 8512000 1457000 76244000 -482000 36618000 50193000 66739000 67862000 0 9475000 60000 1635000 -30181000 -28779000 5227000 2981000 217023000 -30150000 755127000 724531000 972150000 694381000 5126000 5175000 22884000 28183000 11941000 8669000 8290000 2344000 BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES Nature of Operations Founded in 1997, BioMarin Pharmaceutical Inc. (the Company or BioMarin) is a global biotechnology company dedicated to transforming lives through genetic discovery. The Company develops and commercializes targeted therapies that address the root cause of genetic conditions. The Company's robust research and development (R&D) capabilities have resulted in multiple innovative commercial therapies for patients with rare genetic disorders. The Company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. Basis of Presentation These Condensed Consolidated Financial Statements have been prepared pursuant to U.S. generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the SEC for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. GAAP for complete financial statements, although management believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2023 included in the Company's Annual Report on Form 10-K. The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions have been eliminated. The results of operations for the three and six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2024 or any other period. Change in Presentation Effective January 1, 2024, the Company changed its presentation for foreign currency transaction gains and losses resulting from remeasurement and idle plant costs within its Condensed Consolidated Statements of Comprehensive Income. Effective with this change in presentation, foreign currency transaction gains and losses resulting from remeasurement are presented in Other Expense, Net and idle plant costs are presented in Cost of Sales. Prior to this change in presentation, both foreign currency transaction gains and losses resulting from remeasurement and idle plant costs were presented

in Selling, General and Administrative (SG&A) expense. The Company believes that this change in presentation is preferable because the revised presentation is more consistent with how management measures the Company's operating performance. Prior period amounts were revised to conform to current period presentation. The following table reflects the impacts of the change in presentation for the prior periods presented. The change in presentation had no impact to Net Income, Total Stockholders' Equity or earnings per share for the three and six months ended June 30, 2023. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.436%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Three Months ended June 30, 2023 </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Six Months ended June 30, 2023 </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Cost of sales </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,537 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">11,460 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> SG&A </td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom">(9,233)</td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom">(21,213)</td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total operating expenses </td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(6,696)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(9,753)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Other expense, net </td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom">6,696 </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom">9,753 </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Use of Estimates U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management's best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods. Management performed an evaluation of the Company's activities through the date of filing of this Quarterly Report on Form 10-Q to determine if there were any subsequent events that occurred subsequent to the balance sheet date and prior to filing this Quarterly Report on Form 10-Q, that would require recognition or disclosure in the Condensed Consolidated Financial Statements. Further to this evaluation, the Company has included a subsequent event noted relating to the maturity and settlement of the Company's convertible notes due in August 2024 that is discussed in Note 6 - Debt. Significant Accounting Policies There have been no material changes to the Company's significant accounting policies during the six months ended June 30, 2024, as compared to the significant accounting policies disclosed in Note 1 - Business Overview and Significant Accounting Policies to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. Recent Accounting Pronouncements There have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board (FASB) during the six months ended June 30, 2024, as compared to the recent accounting pronouncements described in Note 1 to the Company's Consolidated Financial Statements of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, that the Company believes are of significance or potential significance to the Company. The following paragraphs discuss new accounting pronouncements issued by the FASB, but not yet adopted by the Company. In November 2023, the FASB issued Accounting Standards Update (ASU) 2023-07, Segment Reporting Topic 280, Improvements to Reportable Segment Disclosures, to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. ASU 2023-07 expands public entities' segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items and interim disclosures of a reportable segment's profit or loss and assets. The effective date for the update is for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024 and should be applied on a retrospective basis to all periods presented. The Company is currently evaluating the effect of adopting the update on its related disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes Topic 740, Improvements to Income Tax Disclosures. The guidance requires disclosure of disaggregated information about the Company's effective tax rate reconciliation as well as information on income taxes paid. The disclosure requirements will be applied on a prospective basis, with the option to apply it retrospectively. The effective date for the update is for fiscal years beginning after December 15, 2024. The Company is currently evaluating the effect of the update on its related disclosures. Basis of Presentation These Condensed Consolidated Financial Statements have been prepared pursuant to U.S. generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the SEC for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. GAAP for complete financial statements, although management believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2023 included in the Company's Annual Report on Form 10-K. The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions have been eliminated. The results of operations for the three and six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2024 or any other period. Change in Presentation Effective January 1, 2024, the Company changed its presentation for foreign currency transaction gains and losses resulting from remeasurement and idle plant costs within its Condensed Consolidated Statements of Comprehensive Income. Effective with this change in presentation, foreign currency transaction gains and losses resulting from remeasurement are presented in Other Expense, Net and idle plant costs are presented in Cost of Sales. Prior to this change in presentation, both foreign currency transaction gains and losses resulting from remeasurement and idle plant costs were presented in Selling, General and Administrative (SG&A) expense. The Company believes that this change in presentation is preferable because the revised presentation is more consistent with how management measures the Company's operating performance. The following table reflects the impacts of the change in presentation for the prior periods presented. The change in presentation had no impact to Net Income, Total Stockholders' Equity or earnings per share for the three and six months ended June 30, 2023. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.256%"></td><td style="width:0.1%"></td><td

style="width:1.0%"></td><td style="width:17.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.436%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Three Months ended June 30, 2023 </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Six Months ended June 30, 2023 </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Cost of sales </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,537 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">11,460 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> SG&A </td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom">(9,233)</td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom">(21,213)</td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total operating expenses </td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(6,696)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(9,753)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Other expense, net </td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom">6,696 </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom">9,753 </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 2537000 11460000 -9233000 -21213000 -6696000 -9753000 6696000 9753000 Use of Estimates U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management's best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods. Management performed an evaluation of the Company's activities through the date of filing of this Quarterly Report on Form 10-Q to determine if there were any subsequent events that occurred subsequent to the balance sheet date and prior to filing this Quarterly Report on Form 10-Q, that would require recognition or disclosure in the Condensed Consolidated Financial Statements. Further to this evaluation, the Company has included a subsequent event noted relating to the maturity and settlement of the Company's convertible notes due in August 2024 that is discussed in Note 6 - Debt, Recent Accounting Pronouncements There have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board (FASB) during the six months ended June 30, 2024, as compared to the recent accounting pronouncements described in Note 1 to the Company's Consolidated Financial Statements of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, that the Company believes are of significance or potential significance to the Company. The following paragraphs discuss new accounting pronouncements issued by the FASB, but not yet adopted by the Company. In November 2023, the FASB issued Accounting Standards Update (ASU) 2023-07, Segment Reporting Topic 280, Improvements to Reportable Segment Disclosures, to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. ASU 2023-07 expands public entities' segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items and interim disclosures of a reportable segment's profit or loss and assets. The effective date for the update is for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024 and should be applied on a retrospective basis to all periods presented. The Company is currently evaluating the effect of adopting the update on its related disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes Topic 740, Improvements to Income Tax Disclosures. The guidance requires disclosure of disaggregated information about the Company's effective tax rate reconciliation as well as information on income taxes paid. The disclosure requirements will be applied on a prospective basis, with the option to apply it retrospectively. The effective date for the update is for fiscal years beginning after December 15, 2024. The Company is currently evaluating the effect of the update on its related disclosures. FINANCIAL INSTRUMENTS All marketable securities were classified as available-for-sale as of June 30, 2024 and December 31, 2023. The following tables show the Company's cash, cash equivalents and available-for-sale securities by significant investment category for each period presented: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"></td><td style="width:20.802%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.842%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.851%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.288%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized Cost</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
Unrealized
Gains</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
Unrealized
Losses</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Aggregate Fair Value</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Cash and Cash Equivalents</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Short-term Marketable Securities (1) </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> <span style="color:#000000;font-

family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term Marketable Securities (2) </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Level 1:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">285,666 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">285,666 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Level 2:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Money market instruments</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">676,505 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">676,505 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">537,626 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">670 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,460)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">536,836 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">162,959 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">373,877 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">U.S. government agency securities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">184,487 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">39 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(966)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">183,560 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,979 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">88,310 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85,271 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-

weight:400;line-height:100%">Asset-backed securities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">98,958 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">105 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(196)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">98,867 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">932 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">97,935 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Subtotal</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,497,576 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">814 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,622)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,495,768 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">686,484 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">252,201 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">557,083 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,783,242 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">814 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2,622)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,781,434 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">972,150 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">252,201 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">557,083 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"></td><td style="width:20.802%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.851%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.288%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized Cost</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
Unrealized
Gains</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
Unrealized
Losses</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Aggregate Fair Value</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Cash and Cash Equivalents</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Short-term Marketable Securities (1) </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Long-term Marketable Securities (2) </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Level 1:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-

color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">229,676 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">229,676 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Level 2:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Money market instruments</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">499,483 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate debt securities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">587,896 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,476 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,996)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">589,376 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">193,251 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">396,125 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">U.S. government agency securities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">251,952 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">556 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,140)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">251,368 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,976 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">111,343 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">120,049 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Commercial paper</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,076 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,081 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-

weight:400;line-height:100%">5,992 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,089 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Asset-backed securities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">94,744 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">351 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(134)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">94,961 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">94,961 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Subtotal</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,454,151 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,388 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,270)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,455,269 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">525,451 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">318,683 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">611,135 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,683,827 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4,388 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(3,270)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,684,945 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">755,127 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial';sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">318,683 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">611,135 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1) The Company's short-term marketable securities mature in one year or less. (2) The Company's long-term marketable securities mature between one and five years. As of June 30, 2024, the Company had the ability and intent to hold all investments that were in an unrealized loss position until maturity. The Company considered its intent and ability to hold the securities until recovery of amortized cost basis, the extent to which fair value is less than amortized cost basis, conditions specifically related to the security's industry and geography, payment structure and history and changes to the ratings (if any) in determining that the decline in fair value compared to carrying value is not related to a credit loss. The Company has certain investments in non-marketable equity securities, measured using unobservable valuation inputs and remeasured on a nonrecurring basis, which are collectively considered strategic investments. As of June 30, 2024 and December 31, 2023, the fair value of the Company's strategic investments was $6.7 million and $11.3 million, respectively. These investments were recorded to Other Assets in the Company's Condensed Consolidated Balance Sheets. In the second quarter of 2024, based on new developments, the Company became aware of factors that indicated a $4.5 million decline in the fair value of one of its strategic investments. In the first quarter of 2023, the Company concluded that factors existed indicating it would no longer realize a $12.6 million equity investment in its non-marketable securities. The losses on the Company's non-marketable equity investments were recorded to Other Expense, Net on the Company's Condensed Consolidated Statements of Comprehensive Income for the respective periods. See Note 1 - Business Overview and Significant Accounting Policies included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 for additional information related to the Company's non-marketable securities policy. The following tables show the Company's cash, cash equivalents and available-for-sale securities by significant investment category for each period presented: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"></td><td style="width:20.802%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.851%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td

style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.288%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized Cost</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
Unrealized
Gains</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
Unrealized
Losses</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Aggregate Fair Value</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Cash and Cash Equivalents</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Short-term Marketable Securities (1) </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Long-term Marketable Securities (2) </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Level 1:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">285,666 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">285,666 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">285,666 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Level 2:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Money market instruments</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">676,505 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">676,505 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate debt securities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">537,626 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">670 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,460)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">536,836 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">162,959 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">373,877 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">U.S. government agency securities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">184,487 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt">

</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">39 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(966)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">183,560 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,979 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">88,310 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85,271 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Asset-backed securities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">98,958 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">105 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(196)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">98,867 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">932 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">97,935 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Subtotal</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,497,576 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">814 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,622)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,495,768 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">686,484 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">252,201 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">557,083 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,783,242 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">814 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2,622)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,781,434 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">972,150 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">252,201 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">557,083 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"></td><td style="width:20.802%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.851%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.288%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized Cost</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
Unrealized
Gains</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span

style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross
Unrealized
Losses</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Aggregate Fair Value</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Cash and Cash Equivalents</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Short-term Marketable Securities (1) </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Long-term Marketable Securities (2) </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Level 1:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"

style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,976 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">111,343 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">120,049 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Commercial paper</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,076 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,081 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">5,992 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,089 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Asset-backed securities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">94,744 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">351 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(134)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">94,961 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">94,961 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Subtotal</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,454,151 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,388 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,270)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,455,269 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">525,451 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">318,683 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">611,135 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,683,827 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4,388 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(3,270)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,684,945 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">755,127 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">318,683 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">611,135 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1) The Company's short-term marketable securities mature in one year or less. (2) The Company's long-term marketable securities mature between one and five years. 285666000 285666000 285666000 676505000 0 0 676505000 676505000 0 0 537626000 670000 1460000 536836000 0 162959000 373877000 184487000 39000 966000 183560000 9979000 88310000 85271000 98958000 105000 196000 98867000 932000 97935000 1497576000 814000 2622000 1495768000 686484000 252201000 557083000 1783242000 814000 2622000 1781434000 972150000 252201000 557083000 229676000 229676000 229676000 499483000 0 0 499483000 499483000 0 0 587896000 3476000 1996000 589376000 0 193251000 396125000 251952000 556000 1140000 251368000 19976000 111343000 120049000 20076000 5000 0 20081000 5992000 14089000 0 94744000 351000

134000 94961000 0 0 94961000 1454151000 4388000 3270000 1455269000 525451000 318683000 611135000 1683827000 4388000 3270000 1684945000 755127000 318683000 611135000 P1Y P1Y P5Y P5Y 6700000 11300000 4500000 12600000 SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION Supplemental Balance Sheet Information Inventory consisted of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.976%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">Raw materials</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">154,153 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">155,704 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Work-in-process</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">605,770 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">571,107 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">Finished goods</td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">423,698 </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">380,372 </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Total inventory</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,183,621 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,107,183 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Property, Plant and Equipment, Net consisted of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.976%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Property, plant and equipment, gross</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,962,948 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,933,222 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accumulated depreciation</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(910,050)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(867,089)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Total property, plant and equipment, net</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,052,898 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,066,133 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Depreciation expense, net of amounts capitalized into inventory, for the three and six months ended June 30, 2024 was $11.5 million and $24.1 million, respectively. Depreciation expense, net of amounts capitalized into inventory, for the three and six months ended June 30, 2023 was $9.4 million and $19.7 million, respectively. </div><div style="margin-top:12pt;text-indent:36pt">Intangible Assets, Net consisted of the following:</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.976%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Finite-lived intangible assets</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">710,533 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">710,011 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Accumulated amortization</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(445,000)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(415,310)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top">Net carrying value</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">265,533 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-

color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">294,701 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> In the first quarter of 2024, the Company received $10.0 million due to the achievement of a regulatory approval milestone by a third party related to previously sold intangible assets, which the Company recorded as a Gain on Sale of Nonfinancial Assets in the Condensed Consolidated Statements of Comprehensive Income.</div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt">Accounts Payable and Accrued Liabilities consisted of the following:</div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.976%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.976%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accounts payable and accrued operating expenses</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">257,412 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">315,509 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued compensation expense</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">147,737 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">201,067 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued rebates payable</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">113,432 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">96,179 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued income taxes </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,864 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,651 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Lease liability</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,689 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,779 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency exchange forward contracts</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,684 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33,853 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued royalties payable</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,667 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,299 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred revenue</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,912 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,620 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,103 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,190 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Total accounts payable and accrued liabilities</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">572,500 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">683,147 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:12pt;text-indent:36pt">Inventory consisted of the following:</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.976%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.976%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">Raw materials</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">154,153 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">155,704 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Work-in-process</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">605,770 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">571,107 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">Finished goods</td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">423,698 </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-

*align:right;vertical-align:bottom">380,372 </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Total inventory</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,183,621 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,107,183 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 154153000 155704000 605770000 571107000 423698000 380372000 1183621000 1107183000 Property, Plant and Equipment, Net consisted of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.976%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Property, plant and equipment, gross</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,962,948 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,933,222 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accumulated depreciation</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(910,050)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(867,089)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Total property, plant and equipment, net</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,052,898 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,066,133 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 1962948000 1933222000 910050000 867089000 1052898000 1066133000 11500000 24100000 9400000 19700000 Intangible Assets, Net consisted of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.976%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Finite-lived intangible assets</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">710,533 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">710,011 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Accumulated amortization</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(445,000)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(415,310)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top">Net carrying value</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">265,533 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">294,701 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 710533000 710011000 445000000 415310000 265533000 294701000 10000000 Accounts Payable and Accrued Liabilities consisted of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.976%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accounts payable and accrued operating expenses</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">257,412 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">315,509 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued compensation expense</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">147,737 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">201,067 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued rebates payable</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">113,432 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">*

96,179 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued income taxes </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,864 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,651 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Lease liability</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,689 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,779 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency exchange forward contracts</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,684 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33,853 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued royalties payable</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,667 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,299 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Deferred revenue</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,912 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,620 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,103 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,190 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Total accounts payable and accrued liabilities</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">572,500 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">683,147 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 257412000 315509000 147737000 201067000 113432000 96179000 18864000 2651000 10689000 8779000 7684000 33853000 7667000 14299000 1912000 4620000 7103000 6190000 572500000 683147000 FAIR VALUE MEASUREMENTS The Company measures certain financial assets and liabilities at fair value in accordance with the policy described in Note 1 – Business Overview and Significant Accounting Policies to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. Other than the Company's fixed-rate convertible debt disclosed in Note 6 – Debt, there were no financial assets or liabilities that were remeasured using quoted prices in active markets for identical assets (Level 1) as of June 30, 2024 or December 31, 2023. The Company had no financial assets or liabilities that are remeasured on a recurring basis using unobservable inputs that reflect estimates and assumptions (Level 3) as of June 30, 2024 or December 31, 2023. Level 2 assets and liabilities that are remeasured using significant observable inputs consisted of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.842%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:16.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.143%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Assets:</td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Other current assets:</td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top">NQDC Plan assets</td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">2,649 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">2,026 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Other assets:</td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top">NQDC Plan assets</td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33,112 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28,119 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Restricted investments (1) </td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-

weight:400;line-height:100%">2,419 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,393 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top">Total other assets</td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35,531 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30,512 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top">Total assets</td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">38,180 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">32,538 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Liabilities:</td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Current liabilities:</td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top">NQDC Plan liability</td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">2,649 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">2,026 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Other long-term liabilities:</td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top">NQDC Plan liability</td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33,112 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28,119 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

<tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Other assets:</td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top">NQDC Plan assets</td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33,112 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28,119 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Restricted investments (1) </td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,419 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,393 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top">Total other assets</td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35,531 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30,512 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top">Total assets</td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">38,180 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">32,538 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Liabilities:</td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Current liabilities:</td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top">NQDC Plan liability</td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">2,649 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">2,026 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forward Contracts</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Derivatives designated as hedging instruments:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Sell</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,086,980 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,249,662 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Purchase</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">192,162 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">198,408 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Derivatives not designated as hedging instruments:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Sell</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">281,438 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">350,269 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Purchase</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">28,824 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">90,102 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The fair value carrying amounts of the Company's derivatives, which are classified as Level 2 within the fair value hierarchy, were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.976%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Balance Sheet Location</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Derivatives designated as hedging instruments:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Asset Derivatives</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Other current assets</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">27,599 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">6,663 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Other assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,236 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,855 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Subtotal</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">35,835 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8,518 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Liability Derivatives</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Accounts payable and accrued liabilities</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">6,407 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">30,005 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Other long-term liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,257 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,171 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Subtotal</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,664 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3"

style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">38,176 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivatives not designated as hedging instruments:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Asset Derivatives</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Other current assets</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle">2,352 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle">547 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Liability Derivatives</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Accounts payable and accrued liabilities</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,277 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">3,848 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Total Derivatives Assets</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">38,187 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">9,065 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Total Derivatives Liabilities</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">8,941 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">42,024 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt">For additional discussion of fair value measurements, see Note 1 - Business Overview and Significant Accounting Policies to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.</div><div style="margin-top:12pt;text-indent:36pt">The following tables summarize the impact of gains and losses from the Company's derivatives on its Condensed Consolidated Statements of Comprehensive Income for the periods presented.</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.112%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivatives Designated as Cash Flow Hedging Instruments</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Cash Flow Hedging Gains (Losses)
Reclassified into Earnings</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Cash Flow Hedging Gains (Losses)
Reclassified into Earnings</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Cash Flow Hedging Gains (Losses)
Reclassified into Earnings</td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Net product revenues</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">3,371 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">677 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td

*style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">2,252 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">4,147 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Operating expenses</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(190)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(26)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">314 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(482)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivatives Not Designated as Hedging Instruments</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gains (Losses) Recognized in Earnings</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gains (Losses) Recognized in Earnings</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gains (Losses) Recognized in Earnings</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Operating expenses</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">13,812 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">769 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">21,541 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(3,394)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> As of June 30, 2024, the Company expects to reclassify unrealized gains of $21.2 million from Accumulated Other Comprehensive Income (Loss) (AOCI) to earnings as the forecasted revenues and operating expense transactions occur over the next twelve months. For additional discussion of balances in AOCI see Note 7, - Accumulated Other Comprehensive Income.</div> P24M P3M <div style="margin-top:12pt;text-indent:36pt">The following table summarizes the aggregate notional amounts for the Company's derivatives outstanding as of the periods presented.</div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.032%"></td><td style="width:0.1%"></td><td style="width:11.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.976%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Forward Contracts</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Derivatives designated as hedging instruments:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Sell</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,086,980 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,249,662 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Purchase</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">192,162 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">198,408 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Derivatives not designated as hedging instruments:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Sell</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">281,438 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">350,269 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Purchase</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">28,824 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px*

1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">90,102 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1086980000 1249662000 192162000 198408000 281438000 350269000 28824000 90102000 <div style="margin-top:12pt;text-indent:36pt">The fair value carrying amounts of the Company's derivatives, which are classified as Level 2 within the fair value hierarchy, were as follows:</div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.976%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Balance Sheet Location</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Derivatives designated as hedging instruments:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Asset Derivatives</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Other current assets</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">27,599 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">6,663 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Other assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,236 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,855 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Subtotal</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">35,835 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8,518 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Liability Derivatives</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Accounts payable and accrued liabilities</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">6,407 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">30,005 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Other long-term liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,257 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,171 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Subtotal</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,664 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">38,176 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivatives not designated as hedging instruments:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Asset Derivatives</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Other current assets</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle">2,352 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle">547 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Liability Derivatives</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Accounts payable and accrued liabilities</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,277 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">3,848 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Total Derivatives Assets</td><td

style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;padding:2px 0;text-align:right;vertical-align:bottom">38,187 </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;padding:2px 0;text-align:right;vertical-align:bottom">9,065 </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Total Derivatives Liabilities</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">8,941 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">42,024 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 27599000 6663000 8236000 1855000 35835000 8518000 6407000 30005000 1257000 8171000 7664000 38176000 2352000 547000 1277000 3848000 38187000 9065000 8941000 42024000 The following tables summarize the impact of gains and losses from the Company's derivatives on its Condensed Consolidated Statements of Comprehensive Income for the periods presented. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.986%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivatives Designated as Cash Flow Hedging Instruments</td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Cash Flow Hedging Gains (Losses)
Reclassified into Earnings</td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Cash Flow Hedging Gains (Losses)
Reclassified into Earnings</td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Cash Flow Hedging Gains (Losses)
Reclassified into Earnings</td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Net product revenues</td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;padding:2px 0;text-align:right;vertical-align:bottom">3,371 </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;padding:2px 0;text-align:right;vertical-align:bottom">677 </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;padding:2px 0;text-align:right;vertical-align:bottom">2,252 </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;padding:2px 0;text-align:right;vertical-align:bottom">4,147 </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Operating expenses</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(190)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(26)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">314 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(482)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivatives Not Designated as Hedging Instruments</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gains (Losses) Recognized in Earnings</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gains (Losses) Recognized in Earnings</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gains (Losses) Recognized in Earnings</td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Operating expenses</td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">13,812 </td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">769 </td><td style="background-color:#ceeeff;border-top:1pt

solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">21,541 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(3,394)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 3371000 677000 2252000 4147000 -190000 -26000 314000 -482000 13812000 769000 21541000 -3394000 21200000 DEBT Convertible Notes As of June 30, 2024, the Company had outstanding fixed-rate notes with varying maturities for an undiscounted aggregate principal amount of $1.1 billion (collectively, the Notes). The Notes are senior subordinated convertible obligations, and interest is payable in arrears, semi-annually. The following table summarizes information regarding the Company's convertible debt:</div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.275%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)</div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">495,000 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">495,000 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Unamortized discount net of deferred offering costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(163)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,123)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt">2024 Notes, net (1)</div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">494,837 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">493,877 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>1.25% senior subordinated convertible notes due in May 2027 (the 2027 Notes)</div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">600,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">600,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Unamortized discount net of deferred offering costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5,884)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6,905)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt">2027 Notes, net</div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">594,116 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">593,095 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom">Total convertible debt, net</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,088,953 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,086,972 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Fair value of fixed-rate convertible debt (2):</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt">2024 Notes</div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">492,447 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">488,288 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt">2027 Notes</div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">576,102 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">619,260 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total fair value of fixed-rate convertible debt</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,068,549 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,107,548 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt

2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1) The Company's convertible notes due in 2024 matured on August 1, 2024, subsequent to quarter-end. Substantially all holders of the 2024 Notes were repaid with cash, totaling approximately $495.0 million. No gain or loss was incurred upon the extinguishment.</div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt">(2) The fair value of the Company's fixed-rate convertible debt is based on open-market trades and is classified as Level 1 in the fair value hierarchy. For additional discussion of fair value measurements, see Note 1 - Business Overview and Significant Accounting Policies to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.</div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt">Interest expense on the Company's convertible debt consisted of the following: </div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Coupon interest expense</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,617 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,617 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,233 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,233 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accretion of discount on convertible notes</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">843 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">834 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,684 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,673 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Amortization of debt issuance costs</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">148 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">149 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">297 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Total interest expense on convertible debt</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,608 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,600 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7,214 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7,203 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt">See Note 10 - Debt to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 for additional information related to the Company's convertible debt.</div> 1100000000 The following table summarizes information regarding the Company's convertible debt:<div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.275%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes)</div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial';sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">495,000 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">495,000 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Unamortized discount net of deferred offering costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span

style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(163)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,123)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2024 Notes, net (1) </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">494,837 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">493,877 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 1.25% senior subordinated convertible notes due in May 2027 (the 2027 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">600,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">600,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Unamortized discount net of deferred offering costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5,884)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6,905)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2027 Notes, net </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">594,116 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">593,095 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom">Total convertible debt, net</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,088,953 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,086,972 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Fair value of fixed-rate convertible debt (2): </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2024 Notes </td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">492,447 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">488,288 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2027 Notes </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">576,102 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">619,260 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total fair value of fixed-rate convertible debt</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,068,549 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,107,548 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1) The Company's convertible notes due in 2024 matured on August 1, 2024, subsequent to quarter-end. Substantially all holders of the 2024 Notes were repaid with cash, totaling approximately $495.0 million. No gain or loss was incurred upon the extinguishment.</div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt">(2) The fair value of the Company's fixed-rate convertible debt is based on open-market trades and is classified as Level 1 in the fair value hierarchy. For additional discussion of fair value measurements, see Note 1 - Business Overview and Significant Accounting Policies to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.</div> 0.00599 0.00599 495000000 495000000 163000 1123000 494837000 493877000 0.0125 0.0125 600000000 600000000 5884000 6905000 594116000 593095000 1088953000 1086972000 492447000 488288000 576102000 619260000 1068549000 1107548000 495000000 0 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt">Interest expense on the Company's convertible debt consisted of the following: </div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Coupon interest expense</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,617 </td><td style="background-

color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,617 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,233 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,233 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accretion of discount on convertible notes</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">843 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">834 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,684 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,673 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Amortization of debt issuance costs</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">148 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">149 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">297 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">297 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Total interest expense on convertible debt</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,608 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,600 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7,214 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7,203 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2617000 2617000 5233000 5233000 843000 834000 1684000 1673000 148000 149000 297000 297000 3608000 3600000 7214000 7203000 ACCUMULATED OTHER COMPREHENSIVE INCOME<div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt">The following tables summarize changes in the accumulated balances for each component of AOCI, including current-period other comprehensive income and reclassifications out of AOCI, for the periods presented.</div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.426%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30, 2024</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Gains
(Losses) on Cash
Flow Hedges</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Gains
(Losses) on
Available-for-Sale
Debt Securities</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>AOCI balance as of March 31, 2024</div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(183)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(863)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1,046)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Other comprehensive income (loss) before
reclassifications</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31,551 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(684)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30,867 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Less: gain (loss) reclassified from AOCI</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,181 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,181 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Tax effect</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">

159 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">159 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Net current-period other comprehensive income (loss)</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28,370 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(525)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,845 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> AOCI balance as of June 30, 2024 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">28,187 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1,388)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">26,799 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.426%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Gains
(Losses) on Cash
Flow Hedges</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Gains
(Losses) on
Available-for-Sale
Debt Securities</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>AOCI balance as of March 31, 2023</div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2,647)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(8,075)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial';sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(10,722)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Other comprehensive income (loss) before
reclassifications</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6,737)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(661)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7,398)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Less: gain (loss) reclassified from AOCI</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">651 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">651 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Tax effect</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">154 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">154 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Net current-period other comprehensive income (loss)</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7,388)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(507)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7,895)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> AOCI balance as of June 30, 2023 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(10,035)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(8,582)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-

align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(18,617)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.426%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30, 2024</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Gains
(Losses) on Cash
Flow Hedges</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Gains
(Losses) on
Available-for-Sale
Debt Securities</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>AOCI balance as of December 31, 2023</div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(29,658)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">870 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(28,788)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Other comprehensive income (loss) before
reclassifications</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60,411 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,926)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">57,485 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Less: gain (loss) reclassified from AOCI</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,566 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,566 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Tax effect</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">668 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">668 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Net current-period other comprehensive income (loss)</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">57,845 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,258)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">55,587 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> AOCI balance as of June 30, 2024 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">28,187 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1,388)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">26,799 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.426%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Gains
(Losses) on Cash
Flow Hedges</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Gains
(Losses) on
Available-for-Sale
Debt Securities</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>AOCI balance as of December 31, 2022</div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-

family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,226 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(12,093)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(3,867)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Other comprehensive income (loss) before
  reclassifications</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14,596)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,586 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10,010)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Less: gain (loss) reclassified from AOCI</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,665 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,665 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Tax effect</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,075)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,075)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Net current-period other comprehensive income (loss)</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(18,261)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,511 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14,750)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> AOCI balance as of June 30, 2023 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(10,035)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(8,582)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(18,617)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt">For additional discussion of reclassifications from AOCI see Note 5 - Derivative Instruments and Hedging Strategies.</div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt">The following tables summarize changes in the accumulated balances for each component of AOCI, including current-period other comprehensive income and reclassifications out of AOCI, for the periods presented.</div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.426%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30, 2024</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Gains
(Losses) on Cash
Flow Hedges</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Gains
(Losses) on
Available-for-Sale
Debt Securities</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>AOCI balance as of March 31, 2024</div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(183)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(863)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial';sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1,046)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Other comprehensive income (loss) before
  reclassifications</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31,551 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(684)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-

align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30,867 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Less: gain (loss) reclassified from AOCI</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,181 </td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,181 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Tax effect</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">159 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">159 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Net current-period other comprehensive income (loss)</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28,370 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(525)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,845 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> AOCI balance as of June 30, 2024 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">28,187 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1,388)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">26,799 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.426%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Gains
(Losses) on Cash
Flow Hedges</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Gains
(Losses) on
Available-for-Sale
Debt Securities</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>AOCI balance as of March 31, 2023</div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2,647)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(8,075)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial';font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(10,722)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Other comprehensive income (loss) before
reclassifications</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6,737)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(661)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7,398)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Less: gain (loss) reclassified from AOCI</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">651 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">651 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Tax effect</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">154 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">154 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Net current-period other comprehensive income (loss)</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7,388)</td><td style="background-color:#cceeff;border-

top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(507)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7,895)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> AOCI balance as of June 30, 2023 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(10,035)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(8,582)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(18,617)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.426%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30, 2024</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Gains
(Losses) on Cash
Flow Hedges</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Gains
(Losses) on
Available-for-Sale
Debt Securities</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>AOCI balance as of December 31, 2023</div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(29,658)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">870 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial';sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(28,788)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Other comprehensive income (loss) before
reclassifications</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60,411 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,926)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">57,485 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Less: gain (loss) reclassified from AOCI</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,566 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,566 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Tax effect</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">668 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">668 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Net current-period other comprehensive income (loss)</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">57,845 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,258)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">55,587 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> AOCI balance as of June 30, 2024 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">28,187 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial';sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(1,388)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">26,799 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> <div

*style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.426%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Gains
(Losses) on Cash
Flow Hedges</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Gains
(Losses) on
Available-for-Sale
Debt Securities</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> AOCI balance as of December 31, 2022 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8,226 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(12,093)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(3,867)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Other comprehensive income (loss) before
reclassifications</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14,596)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,586 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10,010)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Less: gain (loss) reclassified from AOCI</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,665 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,665 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Tax effect</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,075)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,075)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Net current-period other comprehensive income (loss)</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(18,261)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,511 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14,750)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>AOCI balance as of June 30, 2023</div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(10,035)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(8,582)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(18,617)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> -183000 -863000 -1046000 31551000 -684000 30867000 3181000 0 3181000 0 -159000 -159000 28370000 -525000 27845000 28187000 -1388000 26799000 -2647000 -8075000 -10722000 -6737000 -661000 -7398000 651000 0 651000 0 -154000 -154000 -7388000 -507000 -7895000 -10035000 -8582000 -18617000 -29658000 870000 -28788000 60411000 -2926000 57485000 2566000 0 2566000 0 -668000 -668000 57845000 -2258000 55587000 28187000 -1388000 26799000 8226000 -12093000 -3867000 -14596000 4586000 -10010000 3665000 0 3665000 0 1075000 1075000 -18261000 3511000 -14750000 -10035000 -8582000 -18617000 REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION The Company operates in one business segment, which focuses on the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The following table presents Total Revenues and disaggregates Net Product Revenues by product. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td*

colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">VOXZOGO</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">183,923 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">113,337 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">336,812 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">201,173 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">VIMIZIM</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">178,016 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">177,392 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">370,536 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">366,584 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">NAGLAZYME</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">132,049 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">90,103 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">237,678 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">213,124 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">PALYNZIQ</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">88,291 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">74,868 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">164,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">137,220 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">BRINEURA</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">45,309 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">38,058 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">84,356 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77,202 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">ALDURAZYME</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">38,558 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40,318 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73,820 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">74,721 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">KUVAN</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28,551 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50,622 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">64,461 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">101,100 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">ROCTAVIAN</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,432 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,281 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net product revenues</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">702,129 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">584,698 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,339,944 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,171,124 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">

</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Royalty and other revenues</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,900 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,577 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,918 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,566 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total revenues</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">712,029 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">595,275 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,360,862 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,191,690 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The Company considers there to be revenue concentration risks for regions where Net Product Revenues exceed 10% of consolidated Net Product Revenues. The concentration of the Company's Net Product Revenues within the regions below may have a material adverse effect on the Company's revenues and results of operations if sales in the respective regions experience difficulties. The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for the Company's commercial products sold directly by the Company, except for ALDURAZYME, which is marketed and sold exclusively by Sanofi worldwide. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">United States</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">227,449 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">191,655 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">420,448 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">358,439 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Europe</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">220,990 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">183,434 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">416,738 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">344,126 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Latin America</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">84,418 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75,444 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">163,012 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">143,192 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Middle East</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">49,701 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25,630 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">106,776 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">117,272 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Rest of world</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">81,013 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">68,217 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-

align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">159,150 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">133,374 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net product revenues marketed by the Company</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">663,571 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">544,380 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,266,124 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,096,403 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">ALDURAZYME net product revenues marketed by Sanofi</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">38,558 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40,318 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73,820 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">74,721 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net product revenues</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">702,129 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">584,698 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,339,944 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,171,124 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The following table illustrates the percentage of the Company's total Net Product Revenues attributed to the Company's largest customers for the periods presented. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Customer A</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Customer B</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Customer C</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td

colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">37 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table> On a consolidated basis, three customers accounted for 15%, 12%, and 10% of the Company's June 30, 2024 accounts receivable balance, respectively, compared to December 31, 2023, when two customers accounted for 15% and 12% of the accounts receivable balance, respectively. As of June 30, 2024, and December 31, 2023, the accounts receivable balance for Sanofi included $67.1 million and $63.4 million, respectively, of unbilled accounts receivable, which becomes payable to the Company when the product is sold through by Sanofi. The Company does not require collateral from its customers, but does perform periodic credit evaluations of its customers' financial condition and requires prepayments in certain circumstances.</div><div style="margin-top:12pt;text-indent:36pt">The Company is mindful that conditions in the current macroeconomic environment, such as inflation, changes in interest and foreign currency exchange rates, natural disasters, geopolitical instability, and supply chain disruptions, could affect the Company's ability to achieve its goals. In addition, the Company sells its products in countries that face economic volatility and weakness. Although the Company has historically collected receivables from customers in certain countries, sustained weakness or further deterioration of the local economies and currencies may cause customers in those countries to delay payment or be unable to pay for the Company's products. The Company believes that the allowances for doubtful accounts related to these countries, if any, are adequate based on its analysis of the specific business circumstances and expectations of collection for each of the underlying accounts in these countries. The Company will continue to monitor these conditions and will attempt to adjust its business processes, as appropriate, to mitigate macroeconomic risks to its business.</div> 1 <div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt">The following table presents Total Revenues and disaggregates Net Product Revenues by product.</div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">VOXZOGO</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">183,923 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">113,337 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">336,812 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">201,173 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">VIMIZIM</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">178,016 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">177,392 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">370,536 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">366,584 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">NAGLAZYME</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">132,049 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">90,103 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">237,678 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">213,124 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">PALYNZIQ</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">88,291 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">74,868 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">164,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">137,220 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">BRINEURA</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span

style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,309 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">38,058 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">84,356 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77,202 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">ALDURAZYME</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">38,558 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40,318 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73,820 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">74,721 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">KUVAN</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28,551 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50,622 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">64,461 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">101,100 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">ROCTAVIAN</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,432 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,281 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net product revenues</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">702,129 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">584,698 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,339,944 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,171,124 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Royalty and other revenues</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,900 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,577 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,918 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,566 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total revenues</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">712,029 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">595,275 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,360,862 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,191,690 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 183923000 113337000 336812000 201173000 178016000 177392000 370536000 366584000 132049000 90103000 237678000 213124000 88291000 74868000 164000000 137220000 45309000 38058000 84356000 77202000 38558000 40318000 73820000 74721000 28551000 50622000 64461000 101100000 7432000 0 8281000 0 702129000 584698000 1339944000 1171124000 9900000 10577000 20918000 20566000 712029000 595275000 1360862000 1191690000 The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for the Company's commercial products sold directly by the Company, except for ALDURAZYME, which is marketed and sold exclusively by Sanofi worldwide. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-

family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">227,449 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">191,655 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">420,448 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">358,439 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Europe</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">220,990 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">183,434 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">416,738 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">344,126 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Latin America</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">84,418 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75,444 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">163,012 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">143,192 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Middle East</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">49,701 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25,630 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">106,776 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">117,272 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Rest of world</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">81,013 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">68,217 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">159,150 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">133,374 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net product revenues marketed by the Company</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">663,571 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">544,380 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,266,124 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,096,403 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">ALDURAZYME net product revenues marketed by Sanofi</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">38,558 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40,318 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73,820 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">74,721 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total net product revenues</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">702,129 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">584,698 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,339,944 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,171,124 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 227449000 191655000

420448000 358439000 220990000 183434000 416738000 344126000 84418000 75444000 163012000 143192000 49701000 25630000 106776000 117272000 81013000 68217000 159150000 133374000 663571000 544380000 1266124000 1096403000 38558000 40318000 73820000 74721000 702129000 584698000 1339944000 1171124000 The following table illustrates the percentage of the Company's total Net Product Revenues attributed to the Company's largest customers for the periods presented. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Customer A</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Customer B</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Customer C</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">37 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table> 0.14 0.15 0.14 0.15 0.11 0.12 0.11 0.11 0.10 0.10 0.09 0.09 0.35 0.37 0.34 0.35 0.15 0.12 0.10 0.15 0.12 67100000 63400000 STOCK-BASED COMPENSATION The Company has stockholder-approved equity incentive plans that provide for the granting of restricted stock units (RSUs) and stock options as well as other forms of equity compensation to its employees, officers and non-employee directors. The Company also has an Employee Stock Purchase Plan (ESPP). Compensation expense included in the Company's Condensed Consolidated Statements of Comprehensive Income for all stock-based compensation arrangements was as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Cost of sales</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,774 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt

solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4,721 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,018 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">9,052 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Research and development</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,935 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,055 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33,612 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34,883 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Selling, general and administrative</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31,205 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30,386 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65,533 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">59,922 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Total stock-based compensation expense</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">47,914 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">50,162 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">106,163 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">103,857 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Compensation expense included in the Company's Condensed Consolidated Statements of Comprehensive Income for all stock-based compensation arrangements was as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Cost of sales</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,774 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4,721 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,018 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">9,052 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Research and development</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,935 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,055 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33,612 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34,883 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Selling, general and administrative</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31,205 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30,386 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65,533 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">59,922 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-

align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Total stock-based compensation expense</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">47,914 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">50,162 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">106,163 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">103,857 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 3774000 4721000 7018000 9052000 12935000 15055000 33612000 34883000 31205000 30386000 65533000 59922000 47914000 50162000 106163000 103857000 RESTRUCTURING During the first half of 2024, the Company completed a strategic portfolio assessment of its research and development programs to determine which have the most transformative potential for patients and value creation for shareholders. With the combined focus on patient impact and commercial opportunity, certain programs that met the highest bar for advancement have been prioritized. As a result of the assessment, certain programs have been discontinued. During the second quarter of 2024, in connection with the discontinuation of certain research and development programs, the Company committed to a plan to reduce its global workforce by approximately 170 employees (representing approximately 5% of the Company's global workforce). Workforce reductions are expected to be substantially completed by end of 2024. The restructuring plan includes severance and employee-related costs, asset impairments, and other costs. The asset impairment charges were for abandoned assets-in-progress and a Right-of-Use asset (ROU Asset) related to leased office space the Company decided to exit and sub-lease. The Company utilized the discounted cash flow approach to determine the fair value of the ROU Asset. The ROU Asset impairment is the difference between the existing lease terms and rates and the expected sub-lease terms and rates available in the market. The Other category includes restructuring-related costs, which are expensed as incurred, as well as other obligations related to the leased office space that will be satisfied over the remainder of the lease term. The restructuring charges and adjustments were included in Selling, General, and Administrative in the Condensed Consolidated Statements of Comprehensive Income. Restructuring expenses consisted of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"></td><td style="width:59.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.119%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:18.121%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Six Months Ended June 30, </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Severance and one-time employee benefits </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">23,837 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">25,275 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Asset Impairments</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">9,671</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">9,671</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Other</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">5,519</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">7,519</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">39,027 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">42,465 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The following unpaid balance as of June 30, 2024 was recorded to Accounts Payable and Accrued Liabilities on the Condensed Consolidated Balance Sheet: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.491%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle">Severance and related costs</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle">Other</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle">Total</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Balance as of December 31, 2023 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">

Charges and Adjustments </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25,275 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,519 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">32,793 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div>Payments</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,321)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,000)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(6,321)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Balance as of June 30, 2024 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">20,954 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,519 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">26,472 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 170 0.05 Restructuring expenses consisted of the following: <div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"></td><td style="width:59.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.119%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:18.121%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Six Months Ended</div><div style="text-align:center">June 30,</div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div>Severance and one-time employee benefits</div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">23,837 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">25,275 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Asset Impairments</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">9,671</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">9,671</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Other</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">5,519</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">7,519</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">39,027 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">42,465 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 23837000 25275000 9671000 9671000 5519000 7519000 39027000 42465000 <div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.491%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle">Severance and related costs</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle">Other</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle">Total</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div>Balance as of December 31, 2023</div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Charges and Adjustments </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25,275 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,519 </td>

<td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">32,793 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div>Payments</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,321)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,000)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(6,321)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Balance as of June 30, 2024 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">20,954 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,519 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">26,472 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 0 0 25275000 7519000 32793000 4321000 2000000 6321000 20954000 5519000 26472000 EARNINGS PER COMMON SHARE<div style="margin-top:12pt;text-indent:36pt">Potentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards, common stock issuable under the ESPP, unvested RSUs and contingent issuances of common stock related to the Company's convertible debt.</div><div style="margin-top:12pt;text-indent:36pt">The following table sets forth the computation of basic and diluted earnings per common share (common shares in thousands):</div><div style="margin-bottom:12pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Numerator:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt">Net Income, basic</div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">107,174 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">56,040 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">195,836 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">106,892 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Add: Interest expense, net of tax, on the Company's convertible debt</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,769 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">937 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,538 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,873 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt">Net Income, diluted</div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">109,943 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">56,977 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial';sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">201,374 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">108,765 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Denominator:</td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Weighted-average common shares outstanding, basic</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial';sans-serif;font-size:9pt;font-weight:400;line-

height:100%">190,114 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">187,948 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">189,490 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">187,311 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Effect of dilutive securities:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Common stock issuable under the Company's equity incentive plans</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,056 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,080 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,312 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,475 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Common stock issuable under the Company's convertible debt(1) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,335 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,970 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,335 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,970 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Weighted-average common shares outstanding, diluted</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">200,505 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">194,998 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">200,137 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">194,756 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Earnings per common share, basic </td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">0.56 </td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">0.30 </td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">1.03 </td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">0.57 </td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Earnings per common share, diluted </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.55 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.29 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">1.01 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.56 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of diluted earnings per common share as they were anti-dilutive (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.078%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:1.0%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Common stock issuable under the Company's equity incentive plans</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,362 </td><td style="background-color:#cceeff;border-

top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,716 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,106 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,321 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Common stock issuable under the Company's convertible debt (1) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,365 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,365 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total number of potentially issuable shares</td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,362 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,081 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,106 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,686 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1) If converted, the Company would issue 4.0 million shares under the 2024 Notes and 4.4 million shares under the 2027 Notes. For additional discussion of the Company's convertible debt, see Note 6 - Debt. The following table sets forth the computation of basic and diluted earnings per common share (common shares in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Numerator:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Net Income, basic </td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">107,174 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">56,040 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">195,836 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">106,892 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Add: Interest expense, net of tax, on the Company's convertible debt</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,769 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">937 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,538 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,873 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Net Income, diluted </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">109,943 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">56,977 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">201,374 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">108,765 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Denominator:

</td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Weighted-average common shares outstanding, basic</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">190,114 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">187,948 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">189,490 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">187,311 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Effect of dilutive securities:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Common stock issuable under the Company's equity incentive plans</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,056 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,080 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,312 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,475 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Common stock issuable under the Company's convertible debt(1) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,335 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,970 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,335 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,970 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Weighted-average common shares outstanding, diluted</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">200,505 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">194,998 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">200,137 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">194,756 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Earnings per common share, basic </td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">0.56 </td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">0.57 </td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Earnings per common share, diluted </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.55 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.29 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">1.01 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial';sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.56 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 107174000 56040000 195836000 106892000 2769000 937000 5538000 1873000 109943000 56977000 201374000 108765000 190114000 187948000 189490000 187311000 2056000 3080000 2312000 3475000 8335000 3970000 8335000 3970000 200505000 194998000 200137000 194756000 0.56 0.30 1.03 0.57 0.55 0.29 1.01 0.56 In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of diluted earnings per common share as they were anti-dilutive (in thousands). <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.078%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended
June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended
June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td

colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Common stock issuable under the Company's equity incentive plans</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,362 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,716 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,106 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,321 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Common stock issuable under the Company's convertible debt (1) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,365 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,365 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total number of potentially issuable shares</td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,362 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,081 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,106 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,686 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1) If converted, the Company would issue 4.0 million shares under the 2024 Notes and 4.4 million shares under the 2027 Notes. For additional discussion of the Company's convertible debt, see Note 6 - Debt. 10362000 8716000 10106000 8321000 0 4365000 0 4365000 10362000 13081000 10106000 12686000 4000000 4400000 COMMITMENTS AND CONTINGENCIES Contingencies From time to time the Company is involved in legal actions arising in the normal course of its business. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters could adversely affect the Company, its results of operations, financial condition or cash flows. The Company's general practice is to expense legal fees as services are rendered in connection with legal matters, and to accrue for liabilities when losses are probable and reasonably estimable based on existing information. The Company accrues for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then the minimum amount in the range is accrued. Liabilities are evaluated and refined each reporting period as additional information is known. Any receivables for insurance recoveries for these liability claims are recorded as assets when it is probable that a recovery will be realized. As previously disclosed, the Company received a subpoena from the U.S. Department of Justice (DOJ) requesting that the Company produce certain documents regarding sponsored testing programs relating to VIMIZIM and NAGLAZYME. The Company has produced the requested documents in response to the subpoena and is cooperating fully. The Company is unable to make any assurances regarding the outcome of the investigation by the DOJ, or the impact, if any, that such investigation may have on the Company's business, Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Comprehensive Income or Condensed Consolidated Statements of Cash Flows. Contingent Payments As of June 30, 2024, the Company was subject to contingent payments, primarily comprised of development, regulatory and commercial milestones. Those considered reasonably possible totaled $495.6 million, of this amount the Company may pay up to $10.9 million over the next 12 months if certain contingencies are met. Other Commitments The Company uses experts and laboratories at universities and other institutions to perform certain R&D activities. These amounts are recorded as R&D expense as services are provided. In the normal course of business, the Company enters into various firm purchase commitments primarily to procure active pharmaceutical ingredients, certain inventory-related items and certain third-party R&D services, production services and facility construction services. The Company also has commitments related to enterprise resource planning (ERP) system implementation costs for which the Company is committed. As of June 30, 2024, such commitments were estimated at $473.0 million, of which $291.1 million is expected to be paid in 2024 as underlying goods and services are received. The Company has also licensed technology from third parties, for which it is required to pay royalties upon future sales, subject to certain annual minimums. 495600000 10900000 473000000.0 291100000 false false false

~~(1) December 31, 2023 balances were derived from the audited Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 26, 2024; The beginning balances for the six-month periods were derived from the audited Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on February 26, 2024;~~

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
OJPI/_5D$]'+SMFTBC15-R24U@:W!8;5X!+TEB[" Z"<"]+U2*0 MS 7 HRO;N6K*\\I\!\'96#/#=*S5H+$Q=S"LM;([]H/BN;U_81K(O=*SZRY M,M91,IQ:'GZ"-.SW,QJSL,\2&OMAG
OH'(9QSN")IH:KL@8N*U* %U*VK6^< MA(7#-(!JY"6&#$C47/IE7=*4;UVO.FR!-0A;G MKM7300]Z>9BG*>3#<,@8+)7E5[;E>#+$N1\.$T<^C\.DO\A(XAY9J:?2<)#W
MX5(K1F>*DTM,I.VDY/3K,G-9YV(O0CO)/R!ZXWC30@<$VI\4V?Q$]W M\M@Y5FV])*V4)8'S9DU_%-0N@+ZOE;)'QRUP^D=-_@=02P,$% @ 9(0% M62K!^PLJ P 6@< !D !X;"]W;W)K&UL?55M
M;]LV$/XKA%H4":!%,B79<6H;L-UNRX!N@>VT'XI]H*6SQ94B-9**DW^_HRAK M,>KXB\27N^>>NX<\3@Y*_S E@"7/E9!F&I36UG=19/(2*F9N5 T2=W9*5\SB M5.\C4VM@1>M4B8C&\3"J&)?!;-
N/>C91#56< D/FIBFJA^68!0AVDP"(X+ M[XOK5N(9I.:[6$-]K%^T#B+>]2"5R -5Y)HV$V#^>!ND3G[UN KAX-Y-28N MDZU2/ISDOI@&L2,$ G+K$!C^GF
)0C@@I/%OAQGT(9WCZ_$1_=BG36BN4&;:NN-Y+ATHJRMQEV.?G:V M^KS>K!Z7F\?5_9^_D:L-VPHPUY/((K:SB/(.9^%OZ!LX0_)%25L:\ED64)SZ M1\BI)T:/O!;T(N ?C;PA21P2&M/T
E[2)YJT>,E;B8*QNLEMH[G<$R8+L@+! M+!1D[@X&MQP,^3[?HA6>E+_/5< '2,\'<+?GSM0LAVF U\. ?H)@]N'=8!A_ MO$_[>FGE]!G:W]IB-J1MS-9*F/-.>87L<\S/XT"S]@%#%8H5W@?
C0N&3&P) M9*<$7FRTN2.;4@.0#.90YN+DO"+Q6M/H*]%>D' M+4C8<6O(>T*3\#89N4$6TE%&YL9@W[JO:L8U=@]T&8?#T:#[_H7\-.G":# F MH_:[GB3C,*8.(:5A.LS(!6FR7IKLLC38*
(M&P,_:K'PQCR?LY9PT%['/2W-: M,-V)GSOQNYPWRC)!%DQX*^.H?8(U3< MQ9@7_V K\A7N2M\7E(:C<4(>V(O?ODK#A ZNR14-XSB^1HNKH5\Y17-Z$%#1 M.!QG;I!UP'08IB-Z5]#H5;^K
%FZKN[.9B.M;WW]:O]PS'V__- 6V6Q%[?#$A_T,X]W=*V>/$!>B?T]E_4$L# M!!0 (&2$!5F&S1/$VP0 %(, 9 >&PO=V]R:W-H965T]<=7RV$?*;6C&FX;DJN3H?K+1>CT%QII\D
P@9TM:E_I>;#ZSUAY+,!.ELK^P M:>^Z \AJ1475"B.#]N#-DSZW?GB+@-<*>)9WH\BRO**:3LZDV(TMQ'-+*RI M5AK)%=P$9:XEOBU03D]FT_O;Z]O?YG WNX?
++SL$1/+\WVK=X_FM&4\D+_JC@CDF8KZAD\-=TH;3$'G[D+T-7' 8SM3-6*UI MQLX'6!B*R2US7/0<\Y8CZSBND6/6<%0V""[.P4%1T!1*Q16IV-X6$G&]E(+YL7S_H%)
M$//C[ZQNZXI]JH43Y&2T3#]=!'+X5^/V[Q"/QOP../B&GD#B^'R)@&KM[Z__B MIBX<^(5S0C=$AP5.FB9V3S",9A^C";/7,GJ;9>XPC.S#MPDV=/WF,#XFO$T' MO!G:AYK+MQ=!
[&1F#UG96V*;"E%]6,K.MB M7NTQ_E9]!V*2QG+DVW:&E4S2%US0CNA!Z+GMP<+,'6 [MF)%:"VURD)9]P)>]TZV5>D4U;+#.LJZ7G7Z6.[OT<"RLR]SB,0B&+DY195EL*WYK
MCW7J+7)0]GL5#(.C=^/F[A!P/.P3%NW)"X6#FVJ3Y"V.[V9MF^H?,1J@I(M4=0=QEB2 MLIE@FXT6:SLU+H3&&=0N5SCT,VDNX/NE0+KMQBCH_T9, @%02P,$% @ M9(0%6=OZ+@M2! GQ,
!D !X;"]W:W)K&UL MQ5A=<^(V%/TK&G>GLSN3Q):E#YP",P1[MW1V"1.2[$.G#UHLP%W;HI((Z;^O M9#L.&.$)77?Z I:XYUR=&I49$4K(0B@++KRFL&IP(X;\W@5H!" MNEEJ+XP+L<##/J.
[P%2T9%,/A?L%6OJ5Y&JBS 63OR82)X8W# /)-)K/P>UC M=/3C9#R:WH/1>'SL,+V?3#^!V>WGR7@2S<$EF,L9&V]3 M N@21(O1!L:4L,+Z'. \!C.6R-X9D5\O&,5_2BUR@@D.WH=$X"3E'R3-PSP$
M[!]] .] DH/[-=UR">5]4TAI:H#FHI)O4\]P3\A X O-Q9]#*(])K,&'[7BO M!6]*2VM?[1=?;^Q6PM^V^15 U@6P+=O1C&?\=CC2R?FQ[-&_SGY@!JHG&2KX MT F^,R?
('>$""Z(:X/?/D@M,9(O_H9L696)'GUBMLM=\@Q=D8,AEE!/V1(SA MSS]!S_I%5Y,NR<(NR:*.R ZJY]35<]K8AV/*A?J;PP%- M&/2A[>D=\&H'O%8'[IF0LN5!1*G-5X \RS,)UQ?>.QJ!&T#7]QNR-
6%VX%O- MPA^'0>C"P&GJUL19'O)M2R_?M5&?[:!]+\KS :_K89=)(ES3PW5,VOK[!P-8C M]AM/!^TD9QN(C@X(.O\Z?='0Y-389^Y=.&2$K8J:'@X6=)N+\K6P[JUODT;%
M'4JC_P9>CZ&F/U2W3\4%QRM]>77U!;-5(O?$E"QE*NO*EZ5FY6U0V1!T4UQW M2*-"T*QX7!,<$Z8"Y.]+2L5+0R6H[^2&_P!02P,$% @ 9(0%67BE@U\, M"@ 54 !D
!X;"]W;W)K&ULO9Q;;]O&$H#__MRD(MB@2(+>V5I&L;<.2D]6D2!%'2\Q#D@9:6$A%>5)*2XX/^^+.D9W(W1V) M+NN76*)FAC-[^':'W)S?
9_GW8B%EB7XD<5I<#!9EN3P;#HOI0B9A<9HM9:I^ MNU4A(/R6@DADD8I8/+_K:Q_SR/%N5<93*CSDJ5DD2 MY@^O99S=7PSPX/"'IVB^**L+P\OS93B7$UE^67[,U;?
ASLHL2F1:1%F*>5RG4$G]&\K[8^XRJ4&ZS['OUY69V,1A5'LE83LO*1*C^K.58QG%E M2?GQU]:H8'?/2G'_\Z/UMW7P*IC;L)#C+/YO-"L7%P-_@&;R+ES%Y:?L_G>Y M#8A7]J997-3_HONM[&B
IJNBS)*MLO(@B=+-W_#'MB'V%)0=NP+9*I"V@G_H_MT*T";2M0AP+,*K"Z93:AU.UP'9;AY7F>W;.\DE;6J@]U8];.*OPHK?I\4N;J_MUTCIE9=O;SY?_FP^<).D$3-
51&UPNHWI]28FXHA)H/=96BX*]":=R9E%?PSK8P(8&*H&WK4R>6SE MUP2T^)]5>HKHZ!4B()\L#L'JUW*]U'&M3@%WZ*[3:6V/.NSM=VZS!XM6#WY] MIU3132F3XINM(S;W8?;
[5&O66;$,I_)BH!:E0N9K.;C\Y2^2ZN+PKC]"1&DW9(6*4]\D=U+;^>E!W?T?)[+N5I^T-LPRM&?8;R2 M-A<]X^;]NS&C[9:TR F?!8S;W?1W;OJ@F_5]6ZVP[677YJMO^!!X!/-1RU53 MS.,
<[PW,6NP:=NPK_@9,MV 77@!:F2S4=#LI99XHF.7?%0/4"H2*W<)CBS(P MW">RK&=B*$O8/CA*/-%U'H)UW63KO&.;6XOX"PKDW:@'@@TKT\ H-VWH< HF256","-;M2HB]KS3B)CI,\$SNW-
^JK67JR MUFP6G5%@D,Z;"8W<(UU=+:N/#V@I\RBS966O#]P"HP<9YM;8NRLVP]19 H;3 MA&H^_],HX3OPVEG;RC!^BF8S3IUL8#C;>!^ESMD,:G8>MCU9:\;I4Q8LGFLV

M@\E1YV;IR5]S672.A.$DJ8]A#M\!F,S=%9M1ZA0+PZG,.[F6,<)G5O=!U<[= MV9.U9] ZV<+!U9K/HI(C\T]K)UD!CE\P"CWO&&+4);RG$K)((7S#?& "F'"><.0>]AC7IOS1"CJR-6.1:
MQ9%F/5FCE/9>Y]A::#2@KBFSU7-H+V"OB]KS6;9>SX"5PP,$VUKH#$J/<%'O#UZ M33D6!,PYXS1T*0S=XWE&3:;V*\,@2--!#5S:$;ANE%$3IH:'D$C30PU;"L/V M6(11$Z'VOC;EP+
[6K*4P:SL!C)H:MQ2&+=/ 1@U:6J, $BDZ:IF M+859^Q1LF0@U/(5$FD\G-6#9 71,SUZ*>(.WMETW.] S 42)@&J@,!NKQ MM&(VL+9GF$6(,E^Y/ AZT_;7(M!92XMHE,4Y8=*%YW1QVV>+7"
P<>RXF,8M.X!;#;$OIY-3-,_6 M,D_K%\+"N4RG#X<"Z+7ZW)>UYNL\FNA\l$PPX[TROB]KS6;1C.?PKOPPS+A9 MQ\8^8WY[&%ODU+P+.+$/8ZYYRV'>=G@5R^0I;:\0%AG.'>LNU\#E'8'K1ADW
M87H2&$\/;%(8,\?BRS5S^8'B\9$DXY;*L$^Y05R+G.IU*ARE6;[W_AV,W$XD MXR9/@\ SNMZ44LF!"[I<0Y?#T'T*T+@)5M^GV&A>4ZP]QC''KI%K"//#CYR[MNFRRU>?$:Q<]+6*8C$;,45?
F&L'\F.?'VSU9DLA\&H4Q6H9+:7NP_1JVUGF9 M_C<>*7.- IZ89.= [,D%6SD.V@G M]M[NAY.*)P :MM@YL*.W_D)G'>) UJ$1?J46A?+D-IQ^5TO$@;A HYWCZLE: MLPET%B/\9R*YZ#7!Z3C4\
M.-4X'M&>F21@XW&018BZJE2>SB.\CGF$F[V>B?X3'+2WH58IZFI,G2-X!TKH MQYX*,I$>^+YHEQYL8BP0KN;4]/=@^G?B)6S+/H&0;29Z)OU=A[T^3V8_$_A MI&_.DZ+:, [3J5K?
[V5>/5/,H[6:]'=YEJ!R(5&XFD5E MO0RF119'L[#Z\C9*E4ZUW9V4ZD+]L@R*TFF\FJE?H[365)OB99@^_/*33[#W M:X&NTG2E-#[)9756)$M1=7(;X=')'TCAIE:IWNU&LCIU:SKZ"MU%L?KA/BH7
MM?#DS;BV(F_S59@_("(V!VQ/;0 8[IV15EOU>7W6O$#3;)66FU.8NZN[\^Q7 M]2GNUO4Q/KO&MNOD[-HF?^6)LVO5<[9?O,W MDM2]?&K@C:RZ881TZ Q?);I?5\]@:,,<2]XFRTFB^EL\HG,%LO/
M#X_SV\7G)3DG"RH$U5M"WH>@*$OD![0^+D/R_MT'\HZPC,O9DN#6R9&M<"&: MSHY*IS>%4^\5ISZ9\TQM)+G-8HCK>!L#]*+PGJ.X\5H) \RS'O&=,^(Y7K]A M/=-V^)P*A+L&[C? PW9X"-
%K\%HT?K4GON'S7^%;8G+'>0*$K\ADA]K3IP3. M,VWG*D?>(1W(!7>88JP=$N9,$V:\CO3 M36*VDIXJ9D%V9I$OM DAS,R!RIS 7I$GI$''?2P%R]9-VK7Z.E6[+LG"CLAJ&@\JC0>_*-$'
M7>K;)5G8$5E-WV&E[_"-9_B0ZY*L]!'>Z2/CU5H)\= MNF[/KSS6 K^L K_\O\F[X)EHR]A6!Z>>]"()PH[(:L)>5<)>_:*,O>I2WR[) MPH[(:OJZSN$]ZKSEXRP/2L80Z4DM7^:2\CB'^KV+%TG;
[O=4D;IB*U2RCQ[P M*8BU*80DB73 Q2NXLE:%UL24&"_L-^[UM"B9#C1%!8=OW#7+)$E@A91.;X@? M/E$4145'\:TI$YZXPJ+#-#=82(+0$W!\Q;EZ[F@'56D:_=02P,$% @ M9(0%6;^&UL
MK5;?<]HX$/Y7=MQ.)YE)XE^_N128H9#,<=<0)I#K0Z[AWNQI=5^JV]7JUWUME)]UQM$ S^S5.B^LS$FOW9='6\P8_I*YBAH M9255Q@Q-U=K5N4*6E* L=0//ZI@9X\[9]$K93_UZLC
I%SA3H(LL8^KY$Z9R MVW=\YT7PP-<;8P7NH)>S-<[1/.8S13.WMI+P#(7F4H#"5=\9^M?CKM4O%?[B MN-5[8["><*7\;B>3I.\XEA"F&!MK@='O"4>8IM80T?BQL^G46UK@_OC%^FWI
M._FR9!I',OW"$[/I.UT'$ERQ(C4/U.UW.@+K21V0Y, M##(NJC_[N8O#'L!OO0$(=H#@OP+"'2 \!(1O %H[0*N,3.5*&8/]P-%Y/[*5S"G/(N*5($N8*)>$)AI']&LS$:QE-]3AJ\S&GX6.,">Z7 M\/
UW*48U8$*ZD %I;WP#7OW:LT$_YO9;+V D11:ICQA5?**!&8*-46C$E!P M;KE@(N8LA3D)D6Z*T?!UN-1&4;Y_:XI'1:#53.#>_VN=LQC[3F[W4D_H##Z\
M\SO>QZ;H_$_&7L4JK&,5GK(^>&!;RE&#BMQO//D*WBGAMC]#?QVRV_3.3WM M^]"DUHZ\5JWVBEVK9MX+%:)++BYS)6/4C?PJ ^V]C3M>.X]\ W[':NW(M][VHF5^[YM<^R8\RA].%3F
M9?/%:1_MVPK"SF_= WK':F'7"Z.@F5ZGIMBK_^U$SD;.@:!;^]G] M-[-PYI\#%1+,EJCJ8D)]]J6KC1JVJ)":C*+.E @Z576]:HJ?N]=4,E3KLCEK MB&4A3%4*:FG5_T?4_\L^>2 ?1M?
C]$G>W;T7W%_FJ\?&'5-K+C2DN**MO*N(M&PO=V]R:W-H965T92>(O,) ",Q22V>PVA ED]Z'3!V%?0%-;V43AU"'[L.^@'5US_'1T96N^UNIOND-HH$?62KTP-D8DU^ZKHXWF#%](7,4 M-
+.2*F.&AFKMZEPA2TI0EKJ!YT5NQKAPAOTR-E/#OBQ,R@7.%.@BRYAZ^H2I MW X%80IA@:R\#H[O''F*:6B&1\WW$Z]2LM W&AC*9CGAS'#^.)M]OKJ]FBY&G^'Z9CJ:CF_H::X8 M+W)!
WCJ3XEZ,-\ B?O3^$]< &+C2PT 73?-;0,*\:-=Y(_59*#-R3_M68@+"+TS"+R@U0 ?'X=/,":X7\+#UW"7S*L=#&H'@Y(O?(/O3JV9X/AR6\9G M,)9"RY0GK*IJQ4>8Q^^5$Q>5PR^5,Q:
M2=U8$!5K5++:B^QQZ/>BH-?]MW' ,4UY85A$ 1UWBO9K5IVZZCL41P769'2 M;B5TIY OM'UV.YND5DSM/0GG/=_SVMZ!U(:\;M3QNKUF]>U::ONHU(4T5%GY M<9\%FB;I[5_=\]I!MW?
H%/EA^#IOQ*AABPII'Q4UG 162F9@-@BL2+C=X)<33((&P\I%G!8) MS=(]9I%CF>5,/'UXUPW\SD<-(R$*0MQC+I4!.O6V0X'OG?\%U*=+R!,R!2@L MR2]"SV#%4YK81[8%]0?\.?4$L#!!0 (
&2$!5G; M'[X*(0,.,L* 9 >&PO=V]R:W-H965TON:;6$CO8[CKX]9R=++0CJP;T M2V)?[GGN?'%[:S2CC3M2QLIF,.F*C4\9A)HG:9!F5/_J0BFW7\9T'P25; MK;41N%$GIRN8@[[.9Q)W:L62L
RX8H(3",8A2&&A#0/%UQT,($T-$;KQO>1T*I,&N+M^8(_MV?$L-U3!0*1? M6*+77>>=0Q)8TDVJ+\7V Y3GL0XN1*KLDVQ+7<\ABXW2(BO!Z$'&>/&F]V4< M=@#(4P\(2D#P&! ^_6B6@.9S
6$)")_K4JL$M)YKH5T"VC;V1;!LI(=4TZ@C MQ99(HXUL9F'39=$88,9-8]]?#$E;\F42DE-,9"3(6C*4O4:I=?S(3EY^9]\)(R3"4M3 M+!K5<34Z:,.RXB]*9?N%,\(0S33(17*\5&?$$DAK\Z#"^?0#O8F"]Z
0/T>D' M!PD_;GB#-+TW)/""L,:?P6'XA$]$^T_"A\^WWJR+QO\Y'_^S];U8-JM*:U]^_MYA-\%W)%.?M)34-Y0P98(")E"2WZ"T_(3((*K@N!6)*8<O7";WOOZU)[3++A,K"E?K8+BPL0)>"!Q(3G\4_P.& M#[
9U_7*_D&RO_T;"K+V[GF_2,/CVEO=$RR^$AD1=+)RO&%4EAB:;\QBD>3!;C M4[*1(K=7_8W0.#C8Y1JG39!& ;\OA= /&V.@FE^C7U!+ P04 " !DA 59 M^S=![=0" #+!@ &0 'AL+W=O$B>W
\9WGA3NZ M7&FSX";]-5Z2C.C[]53"S&U9"EH2KJC@2)+%P$G]\V%LXFW_=TJV:F>,3"9S M(1[,9%P,'.\((HSDVC!@>&W(D#!FB$#&[X;3:3]I@+OC9_:1S1URF6-%AH+] MH(5>#9O/#BK(
E=,WXGM5]+D8P7F@BG[1-LFUG-07BDMR@8,"DK*ZS=^;'S8 M ?C1.X"@ 03_"@@;0&@3K979M"ZQODE?BBV2)AK8S.!Z8]&0#>7F%#,M89<" M3B?9_71Z?75S-
9FEUV@TGJ23X1A&V2R=V=4,C2>CV[N;=#:^G: 3E$$9%14C M2"S0F&O,EW0.LU0IHM4QFD#='5X2C2E31Q!^GUVBPX,C=(H1[.5J!3FA>]I[M&J0; 6[>R+RH90;OR/Q6\5,4>LH*DDBH [=@&
<&E&.>4XQ0QDL$K@% M6]&?Z5QI"77\]\N/6D#4+<#<[7.UQCD9.&OS+;DA3O+Q@]_SOG2Y\Y_(7G@5 MMEZ%^]@3R)UJZT&M/F;[!< M4JX0(PL >]=GP"/KUEE/M%C;[C,7&GJ9';
[@;T.D"8#]A1#Z>6(:6OO_2OX" M4$L#!!0 (&2$!5D<8Z.HE 0 *$- 9 >&PO=V]R:W-H965TBBU@ OII-59XYU119CP%D7$I MB(+Y96M +T8T, [6XF\.ZVSGFIBE3*7\:6ZN9YZ >Y_@/*!;5-
MO%@FF?TEZ]+6;9$XS[1,2V1J/;[[= M?KM['-R0J^N[P=WP&]\FCX-',SHAUW=7]P^W@\?K^SORF4PP\69Y D3.R2". M92YT1L9LPZ8XQL3,#*H<9N2&LRE/N.:0D9,1:,;3[!0#/$U&Y,3C*?E(N""/
M2YEGZ)7U'(V+,4A.7()_+<"] ^!_YN*<^.X9\5PO:' ?'G[5@@O_+3#*?D;$4F4SXC!6YC;*,%60@=#& VEUQP43, M64(F. CX);&.WP?33"O\%'XTZ5$!,T 9G^XR%8LALO6RLREGJ'5__2!ANZ7
M)G7^IV!OM/(KK?QCT?M5WJQV\H:5>8,[FD*5Q(+ "VYN&33F1C%!;"B0?)T*KG.4#FL@5CB!%4,I$/$&TS%>,K$ @JW!FBF3K,)N+8VJ M=FI(4=C9%[5NY/N=MM\,WJW N^]+3[EAB2T61Q*TVX
9[G]&=2,:>-T#^E)W M6R?=HZ CF -J:SZD9Q!Y(U\9XLW3X7I]L>X1&<*^V?;1XD9-=7L[LJT7]'C!P,CDA)X2;#H@G8*]&@]L61-L S#KUZ ^U6% M3?",S)5,";Y.PO(9USBP[2?PIK%UP'TSR6=V
[6>0ZQ-3&P^?>AX-/J2D8$0 M.7H\P$HJ3;!>F:Z94/?S7V:'L"X;8[,$%JH&=DSA-\L.9Z;8TGWX8V"DQ5 MCN<%XH5%)W;>)*&STY^FH!:VS\^(S8RB;:A&B[/$'T)PE3'^[-SZ@/C[P&Y\$ MK\&PO
M=V]R:W-H965T.$-!_%.##R2OO2)N'>DW.N[W4.H;=C M_(M8$2+!USA*1-]92;F^:$;8YHX@UYV[8D/>FPC(YJ0)P[$)HXQ_W9-(K,K.]!YNS"ARY5,+[B#WAHO MR93(Y_435V=N@3*G,4D$90G@9-
%WAO!JA,(T(8MXH60G*L<@E?+*V)?TY&[> M=[R4$8G(3*806/W;DA&)HA1)\?@G!W6*>Z;)U>,Wl-M.O!+SB@49L>A/.I>K_MOM-QP)PL\":2$[:[E>2"@A1OQB*1_06[/-9SP&PC)
(OS9,4@ILG^/_Z;%Z*2 M %M'$E">@$Y-\/,$/Q.Z9Y;)&F.)!SW.=H"GT0HM/3<#+\/[Y!CS<#*?/DYN'F\<_IN#CF$A,(_$)? ;/TS'X^.%3SY7J MAFF:,\O!K_?@Z CX;YOD$OC>!4
>:FG21^;T,9FI=)BE^_5T5\DLM*)"*\KP M6D?P[LF61 #]=!@3TU&Z$FL\(WU'S8H@?$N%TNG>@X496+I5;@=>$]U6Q9@B:@R#@F%P(L.HLIIFFGOP#3%%&C&18T MPQ.FS-
>Q,2:>VRR6P&H:VX7&]O]JRMHV"V<)K%:X3E&XCLTIZS2VKRFBQK!; M,.Q:G(]N(TU31(TF],H'MW?"G"'P+ZAV8]YVRFA)<5$VGO;9;<0_MZMLH=6K M4;$QT#B1^RF\TNJ$5G5:0JOK+"T,-
'N8;*VWZ5H#M@!,K@C/1TDK'1WTG1\$ M/O2\]PVJB_0"B*J1= IYB/$S=%%?7X^W@$GB*<%,J^.;59=2ZVT.HU*KT+-)N7QI:V MZC9LH=7%EGX#-A@.S7Z9+K]JA<:&/O06*&QU-?VL"?
10>+R=2R\"&\R(AGW$ MDN5G27C&PO=V]R:W-H965T MTLI4J9H:F*7+U2R,+,*$US1)C@PE@)1G\;/,FKCCG#D0XI*M$S.1VTO<.71B]18RT=DO M;'=G/0<6:VUDNC,F@12+_)_=[0*Q9^#
[SQCX.P,_X\XORBC[S+"@K>06E#U- M;G:0N9I9$QP7-BM3HVB7DYT)^H/)\+H[&UX/8#B>SB;ST6 \FT)WW(?+0?]B M.+X 6NW.!A?#P10^P9@IQ6P@X;B/AO%$?X CX
)&/$DHS+KM&L*RXNYBA]#+_M$?QG$!HPDL+$&@8BQ/"IO4ON%#[Y#S[U_%+!KVM1@9KW$7S/K\-\VH?CHP\E MNK4B5K5,M_9[\SV^T!T.#]?YUR.-/^NVO ^EV#6"\QZF7HP%U2>"?^#
(414EIJ*9Y$PK?F2T])2R12ZW\^'8"0@ M4X*+2(/9I M:9!'S*P5-_<@EQ3D(N"',N%]*@./1Y/H,X*J+/_SKR0YH79+[WCA6%M%AXT M7RO[S3? K']J/:WKOM?+_#Z5:2?
[=O5Z4HHJRCJMA(=?"Y&VI6"VZ>C?O98_' M\T^"$5.1?7\EN"'13KW)*1:[R+IM/C%QEG>U&&NJ3V3"F+Q-4]@#M+Z4T#Q-[M0?&M$_P%4$L#!!0 (&2$!5F.4:KY@ , *0. 9 >&PO=V]R:W-H
M965T',CD\V9[C!'9.4F:-A^6S M*S$>\)D)E*:-7 F21YT3\\Y%F_#"R7.OAP74:)TH_L,?#'8GIBJJ;W97 EEVS M1&E.F4PY T&W(VOB7DQ=7P/*BMN4'F3C'K24.\Z_Z<8B&EF.'A'-Z$9I"H*7 M/9W2+--,.
([O%:E5]ZF!S?L']D^E>!1S1R2=\NQK&JED9(461'1+BDQ=\\-G M6@GJ:[X-SV3Y"X>JUK%@4TC%\PJ.(\A3=KR2^\J(!L#M/0'P*H#W7(!? 4KG M[./(2EDSHLAX*/@!A*Y&-
GU3>E.B44W*]#2NE,"W*>+4>#;_7MQ.UHO;.2R6 MJ_7US9?YSR\7R$O#I9#V_7.Q7\!NL,$=1D5'@6YC$L: Q4126 M7.\)R6"2\X(["9@O4 F%&17IGNB9DO!GH:0B+$I9#&]G5)$TD^^0$]?C0$2D
MKV@Z@_G])B$LIC#E3 F<9XE%-ZL9O'WS#MY RF"=\$(BDQS:"CW02NO-I??C M4:_WA-[?"W8&OO,>/,?K=<"GI^$SND&X6\+]-MQ&YVO[O=I^K^3K/P4#27?W=I]DUJ-D36TMRK-?=.
MIJ!>/J15D5R^=-T-D+5>"VI7 5%8#DYH-D;4TG]>;SU^;U2-!OYG!@>QOGM5FM&)HI]$*WYX<_A+6CSN\[7C#H3JO;V'^YYO-ZZNMZNK^73J I MMK8[C]LCUS.56]?H%L@46UOWXR;(/;G?
>%9R_9_^ZKTPU)O:=G!_+ALXKO/C M?L!N""T^>T+$1@\"1G=(LXY,\?DB^.1Z-A0?%>>*NZXPC-*>9O@,9(*78#O MMYRKAX8^J-0'T_%_4$L#!!0 (&2$!5FBD\$CHP0 &\: 9 >&PO M=V]R:W-H
965T'/Y&([H8&-)XNW(2KM5_7S-%@@U=D M3L3=YIK),[-$680Q27A($\#(DGG_G%S0Z.]P(=9# MPS? @BQO&HD;NOM""D*NP@MHQ+-/L"MB+0,$*1S^RF87@3 !MVN: S-
!8OYO&Z\:O8%N8YM# M>!F$6E6V(]N'?F]@;O=I-*/ZEN>60;7RG+(\I[,\KR%^"*-0/#Y78@[C[CW< M[SOPH,)FD),KKZU$MRS1[2Z1;$D$T#GXOS9?%H2']JP0+L@"8 SGE5FIRA0D7
M+)6+J.#G;30Z'W6JKC2!U;KBE5WQ=,TE3R=G36 USKV2<^_UKV\#WS]E"LP M]K6*>FZ_?Z#HEC#/\^QV1R[\2#PR.#)A' 39_XF\ M81O\B!\B4JS,B4P, I:217XA*GZAPB,]T.J.=*'5>UKY(ZC-
($&M#DD76IUW MY9%@MTEZL0N!30_D.=:AGXZ6*-NRK&.2K[P2?,8LZ7B4U6'P5A\PY*3QYX36CUOE86$+G:!*_5INE" MJ_.N:!KJM$.GK.9>8_L3HEYC-6]&V:YSN+%C[KT-
4*]BOF$FM7E(JG$_7.H7S'-/H%4$L#!!0 M (&2$!5D+2)2V%P0 'P3_9_>&PO=V]R:W-H965T>X0G,8(?)9QHBQ. EB5,ZU$+&-E>Z3IB> M_V2Q"=_7Z,8[X:;]:UN/$3KD(D-?
338^<1^QQ>69TD%:/$5H1TMK$*D\8_Q97$R#H6:($Z$8+9F \G/%/DU0' LD?HZ_ M9[,LT_1!,>_1P$+AUI/@P"M_"QF#WAWB_*$V@)OB6,J M_\(NMS4T6&:4X21WYB=
(HG3_Z[_DA2@Y<)QF!RMWL.H.SCL.=NY@GQK!R1V< M4R.T